yourlist:M201910226746803381A1F0E0DB47453E0216320D05F99EJ	Entry	Entry name	Status	Protein names	Gene names	Organism	Length	Annotation	Features	Keywords	Miscellaneous [CC]	Subcellular location [CC]	Protein families	Gene ontology (biological process)	Gene ontology (cellular component)	Gene ontology (GO)	Gene ontology (molecular function)	yourlist:M201910226746803381A1F0E0DB47453E0216320D05F7E2K
CD44	P16070	CD44_HUMAN	reviewed	CD44 antigen (CDw44) (Epican) (Extracellular matrix receptor III) (ECMR-III) (GP90 lymphocyte homing/adhesion receptor) (HUTCH-I) (Heparan sulfate proteoglycan) (Hermes antigen) (Hyaluronate receptor) (Phagocytic glycoprotein 1) (PGP-1) (Phagocytic glycoprotein I) (PGP-I) (CD antigen CD44)	CD44 LHR MDU2 MDU3 MIC4	Homo sapiens (Human)	742	5 out of 5	Alternative sequence (23); Beta strand (13); Binding site (4); Chain (1); Compositional bias (1); Disulfide bond (3); Domain (1); Glycosylation (9); Helix (4); Modified residue (4); Natural variant (5); Region (2); Sequence conflict (13); Signal peptide (1); Topological domain (2); Transmembrane (1); Turn (1)	3D-structure;Alternative splicing;Blood group antigen;Cell adhesion;Cell membrane;Cell projection;Complete proteome;Direct protein sequencing;Disulfide bond;Glycoprotein;Membrane;Phosphoprotein;Polymorphism;Proteoglycan;Receptor;Reference proteome;Signal;Transmembrane;Transmembrane helix		SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:22726066, ECO:0000269|PubMed:23589287}; Single-pass type I membrane protein {ECO:0000255}. Cell projection, microvillus {ECO:0000250|UniProtKB:P15379}. Note=Colocalizes with actin in membrane protrusions at wounding edges. Co-localizes with RDX, EZR and MSN in microvilli. Localizes to cholesterol-rich membrane-bound lipid raft domains. {ECO:0000250|UniProtKB:P15379, ECO:0000269|PubMed:23589287}.		cartilage development [GO:0051216]; cell adhesion [GO:0007155]; cell-cell adhesion [GO:0098609]; cell-matrix adhesion [GO:0007160]; cell migration [GO:0016477]; cellular response to fibroblast growth factor stimulus [GO:0044344]; extracellular matrix disassembly [GO:0022617]; extracellular matrix organization [GO:0030198]; hyaluronan catabolic process [GO:0030214]; inflammatory response [GO:0006954]; interferon-gamma-mediated signaling pathway [GO:0060333]; leukocyte migration [GO:0050900]; monocyte aggregation [GO:0070487]; negative regulation of apoptotic process [GO:0043066]; negative regulation of cysteine-type endopeptidase activity involved in apoptotic process [GO:0043154]; negative regulation of DNA damage response, signal transduction by p53 class mediator [GO:0043518]; negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator [GO:1902166]; neutrophil degranulation [GO:0043312]; positive regulation of ERK1 and ERK2 cascade [GO:0070374]; positive regulation of heterotypic cell-cell adhesion [GO:0034116]; positive regulation of monocyte aggregation [GO:1900625]; positive regulation of peptidyl-serine phosphorylation [GO:0033138]; positive regulation of peptidyl-tyrosine phosphorylation [GO:0050731]; regulation of lamellipodium morphogenesis [GO:2000392]; T cell activation [GO:0042110]; wound healing, spreading of cells [GO:0044319]	apical plasma membrane [GO:0016324]; basolateral plasma membrane [GO:0016323]; cell projection [GO:0042995]; cell surface [GO:0009986]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; focal adhesion [GO:0005925]; Golgi apparatus [GO:0005794]; integral component of plasma membrane [GO:0005887]; lamellipodium membrane [GO:0031258]; macrophage migration inhibitory factor receptor complex [GO:0035692]; microvillus [GO:0005902]; plasma membrane [GO:0005886]; secretory granule membrane [GO:0030667]	apical plasma membrane [GO:0016324]; basolateral plasma membrane [GO:0016323]; cell projection [GO:0042995]; cell surface [GO:0009986]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; focal adhesion [GO:0005925]; Golgi apparatus [GO:0005794]; integral component of plasma membrane [GO:0005887]; lamellipodium membrane [GO:0031258]; macrophage migration inhibitory factor receptor complex [GO:0035692]; microvillus [GO:0005902]; plasma membrane [GO:0005886]; secretory granule membrane [GO:0030667]; collagen binding [GO:0005518]; hyaluronic acid binding [GO:0005540]; transmembrane signaling receptor activity [GO:0004888]; cartilage development [GO:0051216]; cell adhesion [GO:0007155]; cell migration [GO:0016477]; cell-cell adhesion [GO:0098609]; cell-matrix adhesion [GO:0007160]; cellular response to fibroblast growth factor stimulus [GO:0044344]; extracellular matrix disassembly [GO:0022617]; extracellular matrix organization [GO:0030198]; hyaluronan catabolic process [GO:0030214]; inflammatory response [GO:0006954]; interferon-gamma-mediated signaling pathway [GO:0060333]; leukocyte migration [GO:0050900]; monocyte aggregation [GO:0070487]; negative regulation of apoptotic process [GO:0043066]; negative regulation of cysteine-type endopeptidase activity involved in apoptotic process [GO:0043154]; negative regulation of DNA damage response, signal transduction by p53 class mediator [GO:0043518]; negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator [GO:1902166]; neutrophil degranulation [GO:0043312]; positive regulation of ERK1 and ERK2 cascade [GO:0070374]; positive regulation of heterotypic cell-cell adhesion [GO:0034116]; positive regulation of monocyte aggregation [GO:1900625]; positive regulation of peptidyl-serine phosphorylation [GO:0033138]; positive regulation of peptidyl-tyrosine phosphorylation [GO:0050731]; regulation of lamellipodium morphogenesis [GO:2000392]; T cell activation [GO:0042110]; wound healing, spreading of cells [GO:0044319]	collagen binding [GO:0005518]; hyaluronic acid binding [GO:0005540]; transmembrane signaling receptor activity [GO:0004888]	CD44
SLC7A11	Q9UPY5	XCT_HUMAN	reviewed	Cystine/glutamate transporter (Amino acid transport system xc-) (Calcium channel blocker resistance protein CCBR1) (Solute carrier family 7 member 11) (xCT)	SLC7A11	Homo sapiens (Human)	501	5 out of 5	Chain (1); Glycosylation (1); Modified residue (1); Topological domain (13); Transmembrane (12)	Amino-acid transport;Complete proteome;Disulfide bond;Glycoprotein;Membrane;Phosphoprotein;Reference proteome;Transmembrane;Transmembrane helix;Transport		SUBCELLULAR LOCATION: Membrane {ECO:0000269|PubMed:15151999}; Multi-pass membrane protein {ECO:0000269|PubMed:15151999}.	Amino acid-polyamine-organocation (APC) superfamily, L-type amino acid transporter (LAT) (TC 2.A.3.8) family	adult behavior [GO:0030534]; amino acid transport [GO:0006865]; cellular response to oxidative stress [GO:0034599]; dipeptide import across plasma membrane [GO:0140206]; glutamate homeostasis [GO:0090461]; glutathione metabolic process [GO:0006749]; glutathione transmembrane transport [GO:0034775]; lens fiber cell differentiation [GO:0070306]; leukocyte migration [GO:0050900]; L-glutamate import across plasma membrane [GO:0098712]; limb development [GO:0060173]; lung alveolus development [GO:0048286]; modulation of chemical synaptic transmission [GO:0050804]; negative regulation of oxidative stress-induced neuron death [GO:1903204]; platelet aggregation [GO:0070527]; regulation of AMPA glutamate receptor clustering [GO:1904717]; regulation of cell population proliferation [GO:0042127]; regulation of cysteine metabolic process [GO:1901494]; regulation of glutamate metabolic process [GO:2000211]; regulation of glutathione biosynthetic process [GO:1903786]; regulation of melanin biosynthetic process [GO:0048021]; regulation of neutrophil apoptotic process [GO:0033029]; regulation of protein transport [GO:0051223]; response to nicotine [GO:0035094]; response to organic cyclic compound [GO:0014070]; response to redox state [GO:0051775]; response to toxic substance [GO:0009636]; striatum development [GO:0021756]; ventricular system development [GO:0021591]; visual learning [GO:0008542]	astrocyte projection [GO:0097449]; brush border membrane [GO:0031526]; cell surface [GO:0009986]; cytoskeleton [GO:0005856]; integral component of membrane [GO:0016021]; plasma membrane [GO:0005886]; rough endoplasmic reticulum [GO:0005791]	astrocyte projection [GO:0097449]; brush border membrane [GO:0031526]; cell surface [GO:0009986]; cytoskeleton [GO:0005856]; integral component of membrane [GO:0016021]; plasma membrane [GO:0005886]; rough endoplasmic reticulum [GO:0005791]; cystine:glutamate antiporter activity [GO:0015327]; L-amino acid transmembrane transporter activity [GO:0015179]; adult behavior [GO:0030534]; amino acid transport [GO:0006865]; cellular response to oxidative stress [GO:0034599]; dipeptide import across plasma membrane [GO:0140206]; glutamate homeostasis [GO:0090461]; glutathione metabolic process [GO:0006749]; glutathione transmembrane transport [GO:0034775]; L-glutamate import across plasma membrane [GO:0098712]; lens fiber cell differentiation [GO:0070306]; leukocyte migration [GO:0050900]; limb development [GO:0060173]; lung alveolus development [GO:0048286]; modulation of chemical synaptic transmission [GO:0050804]; negative regulation of oxidative stress-induced neuron death [GO:1903204]; platelet aggregation [GO:0070527]; regulation of AMPA glutamate receptor clustering [GO:1904717]; regulation of cell population proliferation [GO:0042127]; regulation of cysteine metabolic process [GO:1901494]; regulation of glutamate metabolic process [GO:2000211]; regulation of glutathione biosynthetic process [GO:1903786]; regulation of melanin biosynthetic process [GO:0048021]; regulation of neutrophil apoptotic process [GO:0033029]; regulation of protein transport [GO:0051223]; response to nicotine [GO:0035094]; response to organic cyclic compound [GO:0014070]; response to redox state [GO:0051775]; response to toxic substance [GO:0009636]; striatum development [GO:0021756]; ventricular system development [GO:0021591]; visual learning [GO:0008542]	cystine:glutamate antiporter activity [GO:0015327]; L-amino acid transmembrane transporter activity [GO:0015179]	
ACSS2	Q9NR19	ACSA_HUMAN	reviewed	Acetyl-coenzyme A synthetase, cytoplasmic (EC 6.2.1.1) (Acetate--CoA ligase) (Acetyl-CoA synthetase) (ACS) (AceCS) (Acetyl-CoA synthetase 1) (AceCS1) (Acyl-CoA synthetase short-chain family member 2) (Acyl-activating enzyme) (Propionate--CoA ligase) (EC 6.2.1.17)	ACSS2 ACAS2	Homo sapiens (Human)	701	5 out of 5	Alternative sequence (1); Binding site (5); Chain (1); Modified residue (8); Nucleotide binding (2); Region (1); Sequence conflict (3)	ATP-binding;Acetylation;Alternative splicing;Complete proteome;Cytoplasm;Ligase;Nucleotide-binding;Phosphoprotein;Reference proteome		SUBCELLULAR LOCATION: Cytoplasm, cytosol {ECO:0000269|PubMed:10843999, ECO:0000269|PubMed:28003429}.	ATP-dependent AMP-binding enzyme family	acetate biosynthetic process [GO:0019413]; acetyl-CoA biosynthetic process from acetate [GO:0019427]; ethanol oxidation [GO:0006069]; lipid biosynthetic process [GO:0008610]; propionate biosynthetic process [GO:0019542]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; intracellular membrane-bounded organelle [GO:0043231]; mitochondrial matrix [GO:0005759]; nucleoplasm [GO:0005654]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; intracellular membrane-bounded organelle [GO:0043231]; mitochondrial matrix [GO:0005759]; nucleoplasm [GO:0005654]; acetate-CoA ligase activity [GO:0003987]; AMP binding [GO:0016208]; ATP binding [GO:0005524]; propionate-CoA ligase activity [GO:0050218]; acetate biosynthetic process [GO:0019413]; acetyl-CoA biosynthetic process from acetate [GO:0019427]; ethanol oxidation [GO:0006069]; lipid biosynthetic process [GO:0008610]; propionate biosynthetic process [GO:0019542]	acetate-CoA ligase activity [GO:0003987]; AMP binding [GO:0016208]; ATP binding [GO:0005524]; propionate-CoA ligase activity [GO:0050218]	ACSS2
ACSS1	Q9NUB1	ACS2L_HUMAN	reviewed	Acetyl-coenzyme A synthetase 2-like, mitochondrial (EC 6.2.1.1) (Acetate--CoA ligase 2) (Acetyl-CoA synthetase 2) (AceCS2) (Acyl-CoA synthetase short-chain family member 1) (Propionate--CoA ligase) (EC 6.2.1.17)	ACSS1 ACAS2L KIAA1846	Homo sapiens (Human)	689	5 out of 5	Alternative sequence (5); Binding site (5); Chain (1); Compositional bias (1); Erroneous initiation (1); Frameshift (1); Modified residue (2); Mutagenesis (1); Natural variant (1); Nucleotide binding (2); Region (1); Sequence caution (1); Sequence conflict (2); Transit peptide (1)	3D-structure;ATP-binding;Acetylation;Alternative splicing;Complete proteome;Direct protein sequencing;Ligase;Mitochondrion;Nucleotide-binding;Polymorphism;Reference proteome;Transit peptide		SUBCELLULAR LOCATION: Mitochondrion matrix {ECO:0000269|PubMed:16788062}.	ATP-dependent AMP-binding enzyme family	acetate biosynthetic process [GO:0019413]; acetyl-CoA biosynthetic process [GO:0006085]; acetyl-CoA biosynthetic process from acetate [GO:0019427]; ethanol oxidation [GO:0006069]; propionate biosynthetic process [GO:0019542]	mitochondrial matrix [GO:0005759]	mitochondrial matrix [GO:0005759]; acetate-CoA ligase activity [GO:0003987]; AMP binding [GO:0016208]; ATP binding [GO:0005524]; propionate-CoA ligase activity [GO:0050218]; acetate biosynthetic process [GO:0019413]; acetyl-CoA biosynthetic process [GO:0006085]; acetyl-CoA biosynthetic process from acetate [GO:0019427]; ethanol oxidation [GO:0006069]; propionate biosynthetic process [GO:0019542]	acetate-CoA ligase activity [GO:0003987]; AMP binding [GO:0016208]; ATP binding [GO:0005524]; propionate-CoA ligase activity [GO:0050218]	ACSS1
HMOX1	P09601	HMOX1_HUMAN	reviewed	Heme oxygenase 1 (HO-1) (EC 1.14.14.18)	HMOX1 HO HO1	Homo sapiens (Human)	288	5 out of 5	Beta strand (1); Binding site (3); Chain (1); Helix (15); Metal binding (1); Modified residue (1); Mutagenesis (1); Natural variant (2); Turn (1)	3D-structure;Apoptosis;Complete proteome;Endoplasmic reticulum;Heme;Iron;Membrane;Metal-binding;Microsome;Oxidoreductase;Phosphoprotein;Polymorphism;Reference proteome		SUBCELLULAR LOCATION: Microsome {ECO:0000269|PubMed:22419571}. Endoplasmic reticulum membrane {ECO:0000269|PubMed:22419571}; Peripheral membrane protein {ECO:0000269|PubMed:22419571}; Cytoplasmic side {ECO:0000269|PubMed:22419571}.	Heme oxygenase family	angiogenesis [GO:0001525]; cell death [GO:0008219]; cellular iron ion homeostasis [GO:0006879]; cellular response to arsenic-containing substance [GO:0071243]; cellular response to cadmium ion [GO:0071276]; cellular response to cisplatin [GO:0072719]; cellular response to heat [GO:0034605]; cellular response to hypoxia [GO:0071456]; cellular response to nutrient [GO:0031670]; cytokine-mediated signaling pathway [GO:0019221]; endothelial cell proliferation [GO:0001935]; erythrocyte homeostasis [GO:0034101]; excretion [GO:0007588]; heme catabolic process [GO:0042167]; heme oxidation [GO:0006788]; intracellular signal transduction [GO:0035556]; intrinsic apoptotic signaling pathway in response to DNA damage [GO:0008630]; iron ion homeostasis [GO:0055072]; liver regeneration [GO:0097421]; low-density lipoprotein particle clearance [GO:0034383]; negative regulation of DNA binding [GO:0043392]; negative regulation of DNA-binding transcription factor activity [GO:0043433]; negative regulation of epithelial cell apoptotic process [GO:1904036]; negative regulation of extrinsic apoptotic signaling pathway via death domain receptors [GO:1902042]; negative regulation of leukocyte migration [GO:0002686]; negative regulation of macroautophagy [GO:0016242]; negative regulation of mast cell cytokine production [GO:0032764]; negative regulation of mast cell degranulation [GO:0043305]; negative regulation of muscle cell apoptotic process [GO:0010656]; negative regulation of neuron apoptotic process [GO:0043524]; negative regulation of smooth muscle cell proliferation [GO:0048662]; negative regulation of vascular smooth muscle cell proliferation [GO:1904706]; positive regulation of angiogenesis [GO:0045766]; positive regulation of apoptotic process [GO:0043065]; positive regulation of blood vessel diameter [GO:0097755]; positive regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis [GO:1903589]; positive regulation of cell migration involved in sprouting angiogenesis [GO:0090050]; positive regulation of chemokine biosynthetic process [GO:0045080]; positive regulation of I-kappaB kinase/NF-kappaB signaling [GO:0043123]; positive regulation of macroautophagy [GO:0016239]; positive regulation of smooth muscle cell proliferation [GO:0048661]; protein homooligomerization [GO:0051260]; regulation of angiogenesis [GO:0045765]; regulation of blood pressure [GO:0008217]; regulation of DNA-binding transcription factor activity [GO:0051090]; regulation of transcription from RNA polymerase II promoter in response to iron [GO:0034395]; regulation of transcription from RNA polymerase II promoter in response to oxidative stress [GO:0043619]; response to estrogen [GO:0043627]; response to hydrogen peroxide [GO:0042542]; response to nicotine [GO:0035094]; response to oxidative stress [GO:0006979]; small GTPase mediated signal transduction [GO:0007264]; smooth muscle hyperplasia [GO:0014806]; wound healing involved in inflammatory response [GO:0002246]	caveola [GO:0005901]; cytosol [GO:0005829]; endoplasmic reticulum [GO:0005783]; endoplasmic reticulum membrane [GO:0005789]; extracellular space [GO:0005615]; membrane [GO:0016020]; nucleolus [GO:0005730]; nucleus [GO:0005634]; perinuclear region of cytoplasm [GO:0048471]	caveola [GO:0005901]; cytosol [GO:0005829]; endoplasmic reticulum [GO:0005783]; endoplasmic reticulum membrane [GO:0005789]; extracellular space [GO:0005615]; membrane [GO:0016020]; nucleolus [GO:0005730]; nucleus [GO:0005634]; perinuclear region of cytoplasm [GO:0048471]; enzyme binding [GO:0019899]; heme binding [GO:0020037]; heme oxygenase (decyclizing) activity [GO:0004392]; metal ion binding [GO:0046872]; phospholipase D activity [GO:0004630]; protein homodimerization activity [GO:0042803]; angiogenesis [GO:0001525]; cell death [GO:0008219]; cellular iron ion homeostasis [GO:0006879]; cellular response to arsenic-containing substance [GO:0071243]; cellular response to cadmium ion [GO:0071276]; cellular response to cisplatin [GO:0072719]; cellular response to heat [GO:0034605]; cellular response to hypoxia [GO:0071456]; cellular response to nutrient [GO:0031670]; cytokine-mediated signaling pathway [GO:0019221]; endothelial cell proliferation [GO:0001935]; erythrocyte homeostasis [GO:0034101]; excretion [GO:0007588]; heme catabolic process [GO:0042167]; heme oxidation [GO:0006788]; intracellular signal transduction [GO:0035556]; intrinsic apoptotic signaling pathway in response to DNA damage [GO:0008630]; iron ion homeostasis [GO:0055072]; liver regeneration [GO:0097421]; low-density lipoprotein particle clearance [GO:0034383]; negative regulation of DNA binding [GO:0043392]; negative regulation of DNA-binding transcription factor activity [GO:0043433]; negative regulation of epithelial cell apoptotic process [GO:1904036]; negative regulation of extrinsic apoptotic signaling pathway via death domain receptors [GO:1902042]; negative regulation of leukocyte migration [GO:0002686]; negative regulation of macroautophagy [GO:0016242]; negative regulation of mast cell cytokine production [GO:0032764]; negative regulation of mast cell degranulation [GO:0043305]; negative regulation of muscle cell apoptotic process [GO:0010656]; negative regulation of neuron apoptotic process [GO:0043524]; negative regulation of smooth muscle cell proliferation [GO:0048662]; negative regulation of vascular smooth muscle cell proliferation [GO:1904706]; positive regulation of angiogenesis [GO:0045766]; positive regulation of apoptotic process [GO:0043065]; positive regulation of blood vessel diameter [GO:0097755]; positive regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis [GO:1903589]; positive regulation of cell migration involved in sprouting angiogenesis [GO:0090050]; positive regulation of chemokine biosynthetic process [GO:0045080]; positive regulation of I-kappaB kinase/NF-kappaB signaling [GO:0043123]; positive regulation of macroautophagy [GO:0016239]; positive regulation of smooth muscle cell proliferation [GO:0048661]; protein homooligomerization [GO:0051260]; regulation of angiogenesis [GO:0045765]; regulation of blood pressure [GO:0008217]; regulation of DNA-binding transcription factor activity [GO:0051090]; regulation of transcription from RNA polymerase II promoter in response to iron [GO:0034395]; regulation of transcription from RNA polymerase II promoter in response to oxidative stress [GO:0043619]; response to estrogen [GO:0043627]; response to hydrogen peroxide [GO:0042542]; response to nicotine [GO:0035094]; response to oxidative stress [GO:0006979]; small GTPase mediated signal transduction [GO:0007264]; smooth muscle hyperplasia [GO:0014806]; wound healing involved in inflammatory response [GO:0002246]	enzyme binding [GO:0019899]; heme binding [GO:0020037]; heme oxygenase (decyclizing) activity [GO:0004392]; metal ion binding [GO:0046872]; phospholipase D activity [GO:0004630]; protein homodimerization activity [GO:0042803]	HMOX1
HIF1A	Q16665	HIF1A_HUMAN	reviewed	Hypoxia-inducible factor 1-alpha (HIF-1-alpha) (HIF1-alpha) (ARNT-interacting protein) (Basic-helix-loop-helix-PAS protein MOP1) (Class E basic helix-loop-helix protein 78) (bHLHe78) (Member of PAS protein 1) (PAS domain-containing protein 8)	HIF1A BHLHE78 MOP1 PASD8	Homo sapiens (Human)	826	5 out of 5	Alternative sequence (3); Beta strand (9); Chain (1); Compositional bias (1); Cross-link (5); Domain (4); Helix (9); Modified residue (12); Motif (1); Mutagenesis (28); Natural variant (3); Region (9); Sequence conflict (1); Turn (3)	3D-structure;Acetylation;Activator;Alternative splicing;Complete proteome;Cytoplasm;DNA-binding;Direct protein sequencing;Hydroxylation;Isopeptide bond;Nucleus;Phosphoprotein;Polymorphism;Reference proteome;Repeat;S-nitrosylation;Transcription;Transcription regulation;Ubl conjugation		SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:9822602}. Nucleus {ECO:0000269|PubMed:22009797, ECO:0000269|PubMed:9822602}. Nucleus speckle {ECO:0000250|UniProtKB:Q61221}. Note=Colocalizes with HIF3A in the nucleus and speckles (By similarity). Cytoplasmic in normoxia, nuclear translocation in response to hypoxia (PubMed:9822602). {ECO:0000250|UniProtKB:Q61221}.		angiogenesis [GO:0001525]; axonal transport of mitochondrion [GO:0019896]; B-1 B cell homeostasis [GO:0001922]; cardiac ventricle morphogenesis [GO:0003208]; cartilage development [GO:0051216]; cellular iron ion homeostasis [GO:0006879]; cellular response to hypoxia [GO:0071456]; cellular response to interleukin-1 [GO:0071347]; cerebral cortex development [GO:0021987]; collagen metabolic process [GO:0032963]; connective tissue replacement involved in inflammatory response wound healing [GO:0002248]; cytokine-mediated signaling pathway [GO:0019221]; digestive tract morphogenesis [GO:0048546]; dopaminergic neuron differentiation [GO:0071542]; elastin metabolic process [GO:0051541]; embryonic hemopoiesis [GO:0035162]; embryonic placenta development [GO:0001892]; epithelial cell differentiation involved in mammary gland alveolus development [GO:0061030]; epithelial to mesenchymal transition [GO:0001837]; glucose homeostasis [GO:0042593]; heart looping [GO:0001947]; hemoglobin biosynthetic process [GO:0042541]; hypoxia-inducible factor-1alpha signaling pathway [GO:0097411]; intestinal epithelial cell maturation [GO:0060574]; iris morphogenesis [GO:0061072]; lactate metabolic process [GO:0006089]; lactation [GO:0007595]; mRNA transcription by RNA polymerase II [GO:0042789]; muscle cell cellular homeostasis [GO:0046716]; negative regulation of bone mineralization [GO:0030502]; negative regulation of gene expression [GO:0010629]; negative regulation of growth [GO:0045926]; negative regulation of mesenchymal cell apoptotic process [GO:2001054]; negative regulation of oxidative stress-induced neuron intrinsic apoptotic signaling pathway [GO:1903377]; negative regulation of reactive oxygen species metabolic process [GO:2000378]; negative regulation of thymocyte apoptotic process [GO:0070244]; negative regulation of TOR signaling [GO:0032007]; neural crest cell migration [GO:0001755]; neural fold elevation formation [GO:0021502]; outflow tract morphogenesis [GO:0003151]; oxygen homeostasis [GO:0032364]; positive regulation of angiogenesis [GO:0045766]; positive regulation of autophagy of mitochondrion [GO:1903599]; positive regulation of blood vessel endothelial cell migration [GO:0043536]; positive regulation of chemokine-mediated signaling pathway [GO:0070101]; positive regulation of chemokine production [GO:0032722]; positive regulation of endothelial cell proliferation [GO:0001938]; positive regulation of epithelial cell migration [GO:0010634]; positive regulation of erythrocyte differentiation [GO:0045648]; positive regulation of gene expression [GO:0010628]; positive regulation of glycolytic process [GO:0045821]; positive regulation of hormone biosynthetic process [GO:0046886]; positive regulation of insulin secretion involved in cellular response to glucose stimulus [GO:0035774]; positive regulation of macroautophagy [GO:0016239]; positive regulation of neuroblast proliferation [GO:0002052]; positive regulation of nitric-oxide synthase activity [GO:0051000]; positive regulation of pri-miRNA transcription by RNA polymerase II [GO:1902895]; positive regulation of receptor biosynthetic process [GO:0010870]; positive regulation of transcription, DNA-templated [GO:0045893]; positive regulation of transcription by RNA polymerase II [GO:0045944]; positive regulation of transcription from RNA polymerase II promoter in response to hypoxia [GO:0061419]; positive regulation of vascular endothelial growth factor production [GO:0010575]; positive regulation of vascular endothelial growth factor receptor signaling pathway [GO:0030949]; post-translational protein modification [GO:0043687]; protein deubiquitination [GO:0016579]; protein ubiquitination [GO:0016567]; regulation of aerobic respiration [GO:1903715]; regulation of gene expression [GO:0010468]; regulation of transcription, DNA-templated [GO:0006355]; regulation of transcription by RNA polymerase II [GO:0006357]; regulation of transcription from RNA polymerase II promoter in response to hypoxia [GO:0061418]; regulation of transcription from RNA polymerase II promoter in response to oxidative stress [GO:0043619]; regulation of transforming growth factor beta2 production [GO:0032909]; response to hypoxia [GO:0001666]; response to iron ion [GO:0010039]; response to muscle activity [GO:0014850]; retina vasculature development in camera-type eye [GO:0061298]; signal transduction [GO:0007165]; transcription by RNA polymerase II [GO:0006366]; vascular endothelial growth factor production [GO:0010573]; visual learning [GO:0008542]	axon cytoplasm [GO:1904115]; cytoplasm [GO:0005737]; cytosol [GO:0005829]; motile cilium [GO:0031514]; nuclear body [GO:0016604]; nuclear chromatin [GO:0000790]; nuclear speck [GO:0016607]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; protein-containing complex [GO:0032991]; RNA polymerase II transcription factor complex [GO:0090575]; transcription factor complex [GO:0005667]	axon cytoplasm [GO:1904115]; cytoplasm [GO:0005737]; cytosol [GO:0005829]; motile cilium [GO:0031514]; nuclear body [GO:0016604]; nuclear chromatin [GO:0000790]; nuclear speck [GO:0016607]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; protein-containing complex [GO:0032991]; RNA polymerase II transcription factor complex [GO:0090575]; transcription factor complex [GO:0005667]; DNA-binding transcription activator activity, RNA polymerase II-specific [GO:0001228]; DNA-binding transcription factor activity [GO:0003700]; DNA-binding transcription factor activity, RNA polymerase II-specific [GO:0000981]; E-box binding [GO:0070888]; enzyme binding [GO:0019899]; histone acetyltransferase binding [GO:0035035]; histone deacetylase binding [GO:0042826]; Hsp90 protein binding [GO:0051879]; nuclear hormone receptor binding [GO:0035257]; p53 binding [GO:0002039]; protein domain specific binding [GO:0019904]; protein heterodimerization activity [GO:0046982]; protein kinase binding [GO:0019901]; RNA polymerase II regulatory region sequence-specific DNA binding [GO:0000977]; transcription factor binding [GO:0008134]; ubiquitin protein ligase binding [GO:0031625]; angiogenesis [GO:0001525]; axonal transport of mitochondrion [GO:0019896]; B-1 B cell homeostasis [GO:0001922]; cardiac ventricle morphogenesis [GO:0003208]; cartilage development [GO:0051216]; cellular iron ion homeostasis [GO:0006879]; cellular response to hypoxia [GO:0071456]; cellular response to interleukin-1 [GO:0071347]; cerebral cortex development [GO:0021987]; collagen metabolic process [GO:0032963]; connective tissue replacement involved in inflammatory response wound healing [GO:0002248]; cytokine-mediated signaling pathway [GO:0019221]; digestive tract morphogenesis [GO:0048546]; dopaminergic neuron differentiation [GO:0071542]; elastin metabolic process [GO:0051541]; embryonic hemopoiesis [GO:0035162]; embryonic placenta development [GO:0001892]; epithelial cell differentiation involved in mammary gland alveolus development [GO:0061030]; epithelial to mesenchymal transition [GO:0001837]; glucose homeostasis [GO:0042593]; heart looping [GO:0001947]; hemoglobin biosynthetic process [GO:0042541]; hypoxia-inducible factor-1alpha signaling pathway [GO:0097411]; intestinal epithelial cell maturation [GO:0060574]; iris morphogenesis [GO:0061072]; lactate metabolic process [GO:0006089]; lactation [GO:0007595]; mRNA transcription by RNA polymerase II [GO:0042789]; muscle cell cellular homeostasis [GO:0046716]; negative regulation of bone mineralization [GO:0030502]; negative regulation of gene expression [GO:0010629]; negative regulation of growth [GO:0045926]; negative regulation of mesenchymal cell apoptotic process [GO:2001054]; negative regulation of oxidative stress-induced neuron intrinsic apoptotic signaling pathway [GO:1903377]; negative regulation of reactive oxygen species metabolic process [GO:2000378]; negative regulation of thymocyte apoptotic process [GO:0070244]; negative regulation of TOR signaling [GO:0032007]; neural crest cell migration [GO:0001755]; neural fold elevation formation [GO:0021502]; outflow tract morphogenesis [GO:0003151]; oxygen homeostasis [GO:0032364]; positive regulation of angiogenesis [GO:0045766]; positive regulation of autophagy of mitochondrion [GO:1903599]; positive regulation of blood vessel endothelial cell migration [GO:0043536]; positive regulation of chemokine production [GO:0032722]; positive regulation of chemokine-mediated signaling pathway [GO:0070101]; positive regulation of endothelial cell proliferation [GO:0001938]; positive regulation of epithelial cell migration [GO:0010634]; positive regulation of erythrocyte differentiation [GO:0045648]; positive regulation of gene expression [GO:0010628]; positive regulation of glycolytic process [GO:0045821]; positive regulation of hormone biosynthetic process [GO:0046886]; positive regulation of insulin secretion involved in cellular response to glucose stimulus [GO:0035774]; positive regulation of macroautophagy [GO:0016239]; positive regulation of neuroblast proliferation [GO:0002052]; positive regulation of nitric-oxide synthase activity [GO:0051000]; positive regulation of pri-miRNA transcription by RNA polymerase II [GO:1902895]; positive regulation of receptor biosynthetic process [GO:0010870]; positive regulation of transcription by RNA polymerase II [GO:0045944]; positive regulation of transcription from RNA polymerase II promoter in response to hypoxia [GO:0061419]; positive regulation of transcription, DNA-templated [GO:0045893]; positive regulation of vascular endothelial growth factor production [GO:0010575]; positive regulation of vascular endothelial growth factor receptor signaling pathway [GO:0030949]; post-translational protein modification [GO:0043687]; protein deubiquitination [GO:0016579]; protein ubiquitination [GO:0016567]; regulation of aerobic respiration [GO:1903715]; regulation of gene expression [GO:0010468]; regulation of transcription by RNA polymerase II [GO:0006357]; regulation of transcription from RNA polymerase II promoter in response to hypoxia [GO:0061418]; regulation of transcription from RNA polymerase II promoter in response to oxidative stress [GO:0043619]; regulation of transcription, DNA-templated [GO:0006355]; regulation of transforming growth factor beta2 production [GO:0032909]; response to hypoxia [GO:0001666]; response to iron ion [GO:0010039]; response to muscle activity [GO:0014850]; retina vasculature development in camera-type eye [GO:0061298]; signal transduction [GO:0007165]; transcription by RNA polymerase II [GO:0006366]; vascular endothelial growth factor production [GO:0010573]; visual learning [GO:0008542]	DNA-binding transcription activator activity, RNA polymerase II-specific [GO:0001228]; DNA-binding transcription factor activity [GO:0003700]; DNA-binding transcription factor activity, RNA polymerase II-specific [GO:0000981]; E-box binding [GO:0070888]; enzyme binding [GO:0019899]; histone acetyltransferase binding [GO:0035035]; histone deacetylase binding [GO:0042826]; Hsp90 protein binding [GO:0051879]; nuclear hormone receptor binding [GO:0035257]; p53 binding [GO:0002039]; protein domain specific binding [GO:0019904]; protein heterodimerization activity [GO:0046982]; protein kinase binding [GO:0019901]; RNA polymerase II regulatory region sequence-specific DNA binding [GO:0000977]; transcription factor binding [GO:0008134]; ubiquitin protein ligase binding [GO:0031625]	HIF1A
NFE2L2	Q16236	NF2L2_HUMAN	reviewed	Nuclear factor erythroid 2-related factor 2 (NF-E2-related factor 2) (NFE2-related factor 2) (Nrf-2) (HEBP1) (Nuclear factor, erythroid derived 2, like 2)	NFE2L2 NRF2	Homo sapiens (Human)	605	5 out of 5	Alternative sequence (2); Chain (1); Domain (1); Erroneous initiation (2); Glycosylation (6); Helix (4); Modified residue (4); Motif (2); Mutagenesis (9); Natural variant (7); Region (3); Sequence conflict (4); Turn (1)	3D-structure;Acetylation;Activator;Alternative splicing;Complete proteome;Cytoplasm;DNA-binding;Disease mutation;Glycation;Glycoprotein;Host-virus interaction;Nucleus;Phosphoprotein;Polymorphism;Reference proteome;Transcription;Transcription regulation;Ubl conjugation		SUBCELLULAR LOCATION: Cytoplasm, cytosol {ECO:0000269|PubMed:11035812, ECO:0000269|PubMed:15601839, ECO:0000269|PubMed:21196497}. Nucleus {ECO:0000255|PROSITE-ProRule:PRU00978, ECO:0000269|PubMed:11035812, ECO:0000269|PubMed:15601839, ECO:0000269|PubMed:21196497}. Note=Cytosolic under unstressed conditions: ubiquitinated and degraded by the BCR(KEAP1) E3 ubiquitin ligase complex (PubMed:15601839, PubMed:21196497). Translocates into the nucleus upon induction by electrophilic agents that inactivate the BCR(KEAP1) E3 ubiquitin ligase complex (PubMed:21196497). {ECO:0000269|PubMed:15601839, ECO:0000269|PubMed:21196497}.	BZIP family, CNC subfamily	aflatoxin catabolic process [GO:0046223]; aging [GO:0007568]; cell redox homeostasis [GO:0045454]; cellular response to angiotensin [GO:1904385]; cellular response to fluid shear stress [GO:0071498]; cellular response to glucose starvation [GO:0042149]; cellular response to hydrogen peroxide [GO:0070301]; cellular response to laminar fluid shear stress [GO:0071499]; cellular response to oxidative stress [GO:0034599]; cellular response to tumor necrosis factor [GO:0071356]; endoplasmic reticulum unfolded protein response [GO:0030968]; inflammatory response [GO:0006954]; negative regulation of cardiac muscle cell apoptotic process [GO:0010667]; negative regulation of endothelial cell apoptotic process [GO:2000352]; negative regulation of hematopoietic stem cell differentiation [GO:1902037]; negative regulation of hydrogen peroxide-induced cell death [GO:1903206]; negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway [GO:1902176]; negative regulation of vascular associated smooth muscle cell migration [GO:1904753]; PERK-mediated unfolded protein response [GO:0036499]; positive regulation of angiogenesis [GO:0045766]; positive regulation of blood coagulation [GO:0030194]; positive regulation of blood vessel endothelial cell migration [GO:0043536]; positive regulation of ER-associated ubiquitin-dependent protein catabolic process [GO:1903071]; positive regulation of gene expression [GO:0010628]; positive regulation of glucose import [GO:0046326]; positive regulation of glutathione biosynthetic process [GO:1903788]; positive regulation of neuron projection development [GO:0010976]; positive regulation of reactive oxygen species metabolic process [GO:2000379]; positive regulation of transcription, DNA-templated [GO:0045893]; positive regulation of transcription by RNA polymerase II [GO:0045944]; positive regulation of transcription from RNA polymerase II promoter in response to hypoxia [GO:0061419]; positive regulation of transcription from RNA polymerase II promoter in response to oxidative stress [GO:0036091]; positive regulation of transcription from RNA polymerase II promoter in response to stress [GO:0036003]; proteasomal ubiquitin-independent protein catabolic process [GO:0010499]; proteasome-mediated ubiquitin-dependent protein catabolic process [GO:0043161]; protein ubiquitination [GO:0016567]; regulation of embryonic development [GO:0045995]; regulation of removal of superoxide radicals [GO:2000121]; regulation of transcription from RNA polymerase II promoter in response to copper ion [GO:0061396]; transcription by RNA polymerase II [GO:0006366]; viral process [GO:0016032]	centrosome [GO:0005813]; cytoplasm [GO:0005737]; cytosol [GO:0005829]; Golgi apparatus [GO:0005794]; nuclear chromatin [GO:0000790]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; plasma membrane [GO:0005886]; protein-DNA complex [GO:0032993]	centrosome [GO:0005813]; cytoplasm [GO:0005737]; cytosol [GO:0005829]; Golgi apparatus [GO:0005794]; nuclear chromatin [GO:0000790]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; plasma membrane [GO:0005886]; protein-DNA complex [GO:0032993]; DNA binding [GO:0003677]; DNA-binding transcription activator activity, RNA polymerase II-specific [GO:0001228]; DNA-binding transcription factor activity [GO:0003700]; DNA-binding transcription factor activity, RNA polymerase II-specific [GO:0000981]; protein domain specific binding [GO:0019904]; RNA polymerase II activating transcription factor binding [GO:0001102]; RNA polymerase II distal enhancer sequence-specific DNA binding [GO:0000980]; transcription cofactor binding [GO:0001221]; transcription regulatory region DNA binding [GO:0044212]; transcription regulatory region sequence-specific DNA binding [GO:0000976]; aflatoxin catabolic process [GO:0046223]; aging [GO:0007568]; cell redox homeostasis [GO:0045454]; cellular response to angiotensin [GO:1904385]; cellular response to fluid shear stress [GO:0071498]; cellular response to glucose starvation [GO:0042149]; cellular response to hydrogen peroxide [GO:0070301]; cellular response to laminar fluid shear stress [GO:0071499]; cellular response to oxidative stress [GO:0034599]; cellular response to tumor necrosis factor [GO:0071356]; endoplasmic reticulum unfolded protein response [GO:0030968]; inflammatory response [GO:0006954]; negative regulation of cardiac muscle cell apoptotic process [GO:0010667]; negative regulation of endothelial cell apoptotic process [GO:2000352]; negative regulation of hematopoietic stem cell differentiation [GO:1902037]; negative regulation of hydrogen peroxide-induced cell death [GO:1903206]; negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway [GO:1902176]; negative regulation of vascular associated smooth muscle cell migration [GO:1904753]; PERK-mediated unfolded protein response [GO:0036499]; positive regulation of angiogenesis [GO:0045766]; positive regulation of blood coagulation [GO:0030194]; positive regulation of blood vessel endothelial cell migration [GO:0043536]; positive regulation of ER-associated ubiquitin-dependent protein catabolic process [GO:1903071]; positive regulation of gene expression [GO:0010628]; positive regulation of glucose import [GO:0046326]; positive regulation of glutathione biosynthetic process [GO:1903788]; positive regulation of neuron projection development [GO:0010976]; positive regulation of reactive oxygen species metabolic process [GO:2000379]; positive regulation of transcription by RNA polymerase II [GO:0045944]; positive regulation of transcription from RNA polymerase II promoter in response to hypoxia [GO:0061419]; positive regulation of transcription from RNA polymerase II promoter in response to oxidative stress [GO:0036091]; positive regulation of transcription from RNA polymerase II promoter in response to stress [GO:0036003]; positive regulation of transcription, DNA-templated [GO:0045893]; proteasomal ubiquitin-independent protein catabolic process [GO:0010499]; proteasome-mediated ubiquitin-dependent protein catabolic process [GO:0043161]; protein ubiquitination [GO:0016567]; regulation of embryonic development [GO:0045995]; regulation of removal of superoxide radicals [GO:2000121]; regulation of transcription from RNA polymerase II promoter in response to copper ion [GO:0061396]; transcription by RNA polymerase II [GO:0006366]; viral process [GO:0016032]	DNA binding [GO:0003677]; DNA-binding transcription activator activity, RNA polymerase II-specific [GO:0001228]; DNA-binding transcription factor activity [GO:0003700]; DNA-binding transcription factor activity, RNA polymerase II-specific [GO:0000981]; protein domain specific binding [GO:0019904]; RNA polymerase II activating transcription factor binding [GO:0001102]; RNA polymerase II distal enhancer sequence-specific DNA binding [GO:0000980]; transcription cofactor binding [GO:0001221]; transcription regulatory region DNA binding [GO:0044212]; transcription regulatory region sequence-specific DNA binding [GO:0000976]	NFE2L2
SQSTM1	Q13501	SQSTM_HUMAN	reviewed	Sequestosome-1 (EBI3-associated protein of 60 kDa) (EBIAP) (p60) (Phosphotyrosine-independent ligand for the Lck SH2 domain of 62 kDa) (Ubiquitin-binding protein p62)	SQSTM1 ORCA OSIL	Homo sapiens (Human)	440	5 out of 5	Alternative sequence (1); Beta strand (13); Chain (1); Compositional bias (1); Cross-link (4); Domain (2); Helix (6); Initiator methionine (2); Modified residue (21); Motif (2); Mutagenesis (28); Natural variant (50); Region (8); Sequence conflict (1); Turn (4); Zinc finger (1)	3D-structure;Acetylation;Alternative splicing;Amyotrophic lateral sclerosis;Apoptosis;Autophagy;Complete proteome;Cytoplasm;Cytoplasmic vesicle;Differentiation;Direct protein sequencing;Disease mutation;Endoplasmic reticulum;Endosome;Immunity;Isopeptide bond;Lysosome;Metal-binding;Neurodegeneration;Nucleus;Phosphoprotein;Polymorphism;Reference proteome;Ubl conjugation;Zinc;Zinc-finger		SUBCELLULAR LOCATION: Cytoplasm, cytosol {ECO:0000269|PubMed:20168092, ECO:0000269|PubMed:22792322}. Late endosome. Lysosome. Cytoplasmic vesicle, autophagosome. Nucleus. Endoplasmic reticulum. Nucleus, PML body {ECO:0000269|PubMed:20168092}. Cytoplasm, myofibril, sarcomere {ECO:0000250}. Note=In cardiac muscle, localizes to the sarcomeric band (By similarity). Commonly found in inclusion bodies containing polyubiquitinated protein aggregates. In neurodegenerative diseases, detected in Lewy bodies in Parkinson disease, neurofibrillary tangles in Alzheimer disease, and HTT aggregates in Huntington disease. In protein aggregate diseases of the liver, found in large amounts in Mallory bodies of alcoholic and nonalcoholic steatohepatitis, hyaline bodies in hepatocellular carcinoma, and in SERPINA1 aggregates. Enriched in Rosenthal fibers of pilocytic astrocytoma. In the cytoplasm, observed in both membrane-free ubiquitin-containing protein aggregates (sequestosomes) and membrane-surrounded autophagosomes. Colocalizes with TRIM13 in the perinuclear endoplasmic reticulum. Co-localizes with TRIM5 in cytoplasmic bodies. When nuclear export is blocked by treatment with leptomycin B, accumulates in PML bodies. {ECO:0000269|PubMed:20168092}.		aggrephagy [GO:0035973]; apoptotic process [GO:0006915]; autophagy [GO:0006914]; autophagy of mitochondrion [GO:0000422]; cell differentiation [GO:0030154]; endosomal transport [GO:0016197]; endosome organization [GO:0007032]; immune system process [GO:0002376]; interleukin-1-mediated signaling pathway [GO:0070498]; intracellular signal transduction [GO:0035556]; macroautophagy [GO:0016236]; mitochondrion organization [GO:0007005]; mitophagy [GO:0000423]; negative regulation of apoptotic process [GO:0043066]; negative regulation of transcription by RNA polymerase II [GO:0000122]; positive regulation of apoptotic process [GO:0043065]; positive regulation of long-term synaptic potentiation [GO:1900273]; positive regulation of protein localization to plasma membrane [GO:1903078]; positive regulation of protein phosphorylation [GO:0001934]; positive regulation of transcription by RNA polymerase II [GO:0045944]; protein heterooligomerization [GO:0051291]; protein localization [GO:0008104]; protein localization to perinuclear region of cytoplasm [GO:1905719]; regulation of I-kappaB kinase/NF-kappaB signaling [GO:0043122]; regulation of mitochondrion organization [GO:0010821]; regulation of protein complex stability [GO:0061635]; regulation of Ras protein signal transduction [GO:0046578]; response to ischemia [GO:0002931]; response to mitochondrial depolarisation [GO:0098780]; selective autophagy [GO:0061912]; ubiquitin-dependent protein catabolic process [GO:0006511]	aggresome [GO:0016235]; amphisome [GO:0044753]; autolysosome [GO:0044754]; autophagosome [GO:0005776]; cytoplasm [GO:0005737]; cytosol [GO:0005829]; endoplasmic reticulum [GO:0005783]; extracellular exosome [GO:0070062]; inclusion body [GO:0016234]; intracellular membrane-bounded organelle [GO:0043231]; late endosome [GO:0005770]; Lewy body [GO:0097413]; mitochondrion [GO:0005739]; nucleoplasm [GO:0005654]; P-body [GO:0000932]; phagophore assembly site [GO:0000407]; PML body [GO:0016605]; sarcomere [GO:0030017]; sperm midpiece [GO:0097225]	aggresome [GO:0016235]; amphisome [GO:0044753]; autolysosome [GO:0044754]; autophagosome [GO:0005776]; cytoplasm [GO:0005737]; cytosol [GO:0005829]; endoplasmic reticulum [GO:0005783]; extracellular exosome [GO:0070062]; inclusion body [GO:0016234]; intracellular membrane-bounded organelle [GO:0043231]; late endosome [GO:0005770]; Lewy body [GO:0097413]; mitochondrion [GO:0005739]; nucleoplasm [GO:0005654]; P-body [GO:0000932]; phagophore assembly site [GO:0000407]; PML body [GO:0016605]; sarcomere [GO:0030017]; sperm midpiece [GO:0097225]; enzyme binding [GO:0019899]; identical protein binding [GO:0042802]; ionotropic glutamate receptor binding [GO:0035255]; K63-linked polyubiquitin modification-dependent protein binding [GO:0070530]; protein homodimerization activity [GO:0042803]; protein kinase binding [GO:0019901]; protein kinase C binding [GO:0005080]; protein serine/threonine kinase activity [GO:0004674]; receptor tyrosine kinase binding [GO:0030971]; SH2 domain binding [GO:0042169]; ubiquitin binding [GO:0043130]; ubiquitin protein ligase binding [GO:0031625]; zinc ion binding [GO:0008270]; aggrephagy [GO:0035973]; apoptotic process [GO:0006915]; autophagy [GO:0006914]; autophagy of mitochondrion [GO:0000422]; cell differentiation [GO:0030154]; endosomal transport [GO:0016197]; endosome organization [GO:0007032]; immune system process [GO:0002376]; interleukin-1-mediated signaling pathway [GO:0070498]; intracellular signal transduction [GO:0035556]; macroautophagy [GO:0016236]; mitochondrion organization [GO:0007005]; mitophagy [GO:0000423]; negative regulation of apoptotic process [GO:0043066]; negative regulation of transcription by RNA polymerase II [GO:0000122]; positive regulation of apoptotic process [GO:0043065]; positive regulation of long-term synaptic potentiation [GO:1900273]; positive regulation of protein localization to plasma membrane [GO:1903078]; positive regulation of protein phosphorylation [GO:0001934]; positive regulation of transcription by RNA polymerase II [GO:0045944]; protein heterooligomerization [GO:0051291]; protein localization [GO:0008104]; protein localization to perinuclear region of cytoplasm [GO:1905719]; regulation of I-kappaB kinase/NF-kappaB signaling [GO:0043122]; regulation of mitochondrion organization [GO:0010821]; regulation of protein complex stability [GO:0061635]; regulation of Ras protein signal transduction [GO:0046578]; response to ischemia [GO:0002931]; response to mitochondrial depolarisation [GO:0098780]; selective autophagy [GO:0061912]; ubiquitin-dependent protein catabolic process [GO:0006511]	enzyme binding [GO:0019899]; identical protein binding [GO:0042802]; ionotropic glutamate receptor binding [GO:0035255]; K63-linked polyubiquitin modification-dependent protein binding [GO:0070530]; protein homodimerization activity [GO:0042803]; protein kinase binding [GO:0019901]; protein kinase C binding [GO:0005080]; protein serine/threonine kinase activity [GO:0004674]; receptor tyrosine kinase binding [GO:0030971]; SH2 domain binding [GO:0042169]; ubiquitin binding [GO:0043130]; ubiquitin protein ligase binding [GO:0031625]; zinc ion binding [GO:0008270]	SQSTM1
NQO1	P15559	NQO1_HUMAN	reviewed	NAD(P)H dehydrogenase [quinone] 1 (EC 1.6.5.2) (Azoreductase) (DT-diaphorase) (DTD) (Menadione reductase) (NAD(P)H:quinone oxidoreductase 1) (Phylloquinone reductase) (Quinone reductase 1) (QR1)	NQO1 DIA4 NMOR1	Homo sapiens (Human)	274	5 out of 5	Alternative sequence (2); Beta strand (11); Binding site (4); Chain (1); Cross-link (2); Helix (17); Mass spectrometry (1); Modified residue (1); Natural variant (3); Nucleotide binding (3); Region (1); Sequence conflict (1); Turn (5)	3D-structure;Alternative splicing;Complete proteome;Cytoplasm;FAD;Flavoprotein;Isopeptide bond;NAD;NADP;Oxidoreductase;Phosphoprotein;Polymorphism;Reference proteome;Ubl conjugation	MISCELLANEOUS: Quinone reductase accepts electrons from both NADH and NADPH with equal efficiency.	SUBCELLULAR LOCATION: Cytoplasm.	NAD(P)H dehydrogenase (quinone) family	aging [GO:0007568]; cellular response to hydrogen peroxide [GO:0070301]; cellular response to metal ion [GO:0071248]; negative regulation of apoptotic process [GO:0043066]; negative regulation of catalytic activity [GO:0043086]; nitric oxide biosynthetic process [GO:0006809]; positive regulation of neuron apoptotic process [GO:0043525]; regulation of cellular amino acid metabolic process [GO:0006521]; response to electrical stimulus [GO:0051602]; response to estradiol [GO:0032355]; response to ethanol [GO:0045471]; response to hydrogen sulfide [GO:1904880]; response to nitrogen compound [GO:1901698]; response to nutrient [GO:0007584]; response to toxic substance [GO:0009636]; synaptic transmission, cholinergic [GO:0007271]; xenobiotic metabolic process [GO:0006805]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; dendrite [GO:0030425]; neuronal cell body [GO:0043025]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; dendrite [GO:0030425]; neuronal cell body [GO:0043025]; cytochrome-b5 reductase activity, acting on NAD(P)H [GO:0004128]; electron transfer activity [GO:0009055]; identical protein binding [GO:0042802]; NAD(P)H dehydrogenase (quinone) activity [GO:0003955]; oxidoreductase activity [GO:0016491]; RNA binding [GO:0003723]; superoxide dismutase activity [GO:0004784]; aging [GO:0007568]; cellular response to hydrogen peroxide [GO:0070301]; cellular response to metal ion [GO:0071248]; negative regulation of apoptotic process [GO:0043066]; negative regulation of catalytic activity [GO:0043086]; nitric oxide biosynthetic process [GO:0006809]; positive regulation of neuron apoptotic process [GO:0043525]; regulation of cellular amino acid metabolic process [GO:0006521]; response to electrical stimulus [GO:0051602]; response to estradiol [GO:0032355]; response to ethanol [GO:0045471]; response to hydrogen sulfide [GO:1904880]; response to nitrogen compound [GO:1901698]; response to nutrient [GO:0007584]; response to toxic substance [GO:0009636]; synaptic transmission, cholinergic [GO:0007271]; xenobiotic metabolic process [GO:0006805]	cytochrome-b5 reductase activity, acting on NAD(P)H [GO:0004128]; electron transfer activity [GO:0009055]; identical protein binding [GO:0042802]; NAD(P)H dehydrogenase (quinone) activity [GO:0003955]; oxidoreductase activity [GO:0016491]; RNA binding [GO:0003723]; superoxide dismutase activity [GO:0004784]	NQO1
PFKP	Q01813	PFKAP_HUMAN	reviewed	ATP-dependent 6-phosphofructokinase, platelet type (ATP-PFK) (PFK-P) (EC 2.7.1.11) (6-phosphofructokinase type C) (Phosphofructo-1-kinase isozyme C) (PFK-C) (Phosphohexokinase)	PFKP PFKF	Homo sapiens (Human)	784	5 out of 5	Active site (1); Alternative sequence (1); Beta strand (33); Binding site (9); Chain (1); Glycosylation (1); Helix (37); Metal binding (1); Modified residue (11); Nucleotide binding (2); Region (9); Sequence conflict (4); Turn (7)	3D-structure;ATP-binding;Acetylation;Allosteric enzyme;Alternative splicing;Complete proteome;Cytoplasm;Glycolysis;Glycoprotein;Kinase;Magnesium;Metal-binding;Nucleotide-binding;Phosphoprotein;Reference proteome;Transferase	MISCELLANEOUS: In human PFK exists as a system of 3 types of subunits, PFKM (muscle), PFKL (liver) and PFKP (platelet) isoenzymes.	SUBCELLULAR LOCATION: Cytoplasm {ECO:0000255|HAMAP-Rule:MF_03184}.	Phosphofructokinase type A (PFKA) family, ATP-dependent PFK group I subfamily, Eukaryotic two domain clade 'E' sub-subfamily	canonical glycolysis [GO:0061621]; cellular response to leukemia inhibitory factor [GO:1990830]; fructose 1,6-bisphosphate metabolic process [GO:0030388]; fructose 6-phosphate metabolic process [GO:0006002]; glucose catabolic process [GO:0006007]; protein homotetramerization [GO:0051289]	6-phosphofructokinase complex [GO:0005945]; cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; membrane [GO:0016020]; nucleus [GO:0005634]	6-phosphofructokinase complex [GO:0005945]; cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; membrane [GO:0016020]; nucleus [GO:0005634]; 6-phosphofructokinase activity [GO:0003872]; AMP binding [GO:0016208]; ATP binding [GO:0005524]; cadherin binding [GO:0045296]; fructose-6-phosphate binding [GO:0070095]; identical protein binding [GO:0042802]; metal ion binding [GO:0046872]; monosaccharide binding [GO:0048029]; protein-containing complex binding [GO:0044877]; canonical glycolysis [GO:0061621]; cellular response to leukemia inhibitory factor [GO:1990830]; fructose 1,6-bisphosphate metabolic process [GO:0030388]; fructose 6-phosphate metabolic process [GO:0006002]; glucose catabolic process [GO:0006007]; protein homotetramerization [GO:0051289]	6-phosphofructokinase activity [GO:0003872]; AMP binding [GO:0016208]; ATP binding [GO:0005524]; cadherin binding [GO:0045296]; fructose-6-phosphate binding [GO:0070095]; identical protein binding [GO:0042802]; metal ion binding [GO:0046872]; monosaccharide binding [GO:0048029]; protein-containing complex binding [GO:0044877]	PFKP
PKM	P14618	KPYM_HUMAN	reviewed	Pyruvate kinase PKM (EC 2.7.1.40) (Cytosolic thyroid hormone-binding protein) (CTHBP) (Opa-interacting protein 3) (OIP-3) (Pyruvate kinase 2/3) (Pyruvate kinase muscle isozyme) (Thyroid hormone-binding protein 1) (THBP1) (Tumor M2-PK) (p58)	PKM OIP3 PK2 PK3 PKM2	Homo sapiens (Human)	531	5 out of 5	Alternative sequence (2); Beta strand (29); Binding site (12); Chain (1); Cross-link (4); Erroneous initiation (1); Helix (25); Initiator methionine (1); Metal binding (6); Modified residue (26); Mutagenesis (4); Natural variant (1); Nucleotide binding (1); Region (4); Sequence conflict (10); Site (2); Turn (9)	3D-structure;ATP-binding;Acetylation;Allosteric enzyme;Alternative splicing;Complete proteome;Cytoplasm;Direct protein sequencing;Glycolysis;Hydroxylation;Isopeptide bond;Kinase;Magnesium;Metal-binding;Methylation;Nucleotide-binding;Nucleus;Phosphoprotein;Polymorphism;Potassium;Pyruvate;Reference proteome;Transferase;Ubl conjugation	MISCELLANEOUS: There are 4 isozymes of pyruvate kinase in mammals (L, R, M1, M2) encoded by 2 different genes: PKLR and PKM. The L and R isozymes are generated from the PKLR by differential splicing of RNA; the M1 and M2 forms are produced from the PKM gene by differential splicing. L type is major isozyme in the liver, R is found in red cells, M1 is the main form in muscle, heart and brain, and M2 is found in early fetal tissues as well as in most cancer cells.	SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:25263439}. Nucleus. Note=Translocates to the nucleus in response to different apoptotic stimuli. Nuclear translocation is sufficient to induce cell death that is caspase independent, isoform-specific and independent of its enzymatic activity.	Pyruvate kinase family	animal organ regeneration [GO:0031100]; ATP biosynthetic process [GO:0006754]; canonical glycolysis [GO:0061621]; cellular response to insulin stimulus [GO:0032869]; glycolytic process [GO:0006096]; liver development [GO:0001889]; neutrophil degranulation [GO:0043312]; positive regulation of sprouting angiogenesis [GO:1903672]; programmed cell death [GO:0012501]; protein homotetramerization [GO:0051289]; pyruvate biosynthetic process [GO:0042866]; response to gravity [GO:0009629]; response to hypoxia [GO:0001666]; response to muscle inactivity [GO:0014870]; response to nutrient [GO:0007584]; skeletal muscle tissue regeneration [GO:0043403]	cilium [GO:0005929]; collagen-containing extracellular matrix [GO:0062023]; cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; extracellular vesicle [GO:1903561]; ficolin-1-rich granule lumen [GO:1904813]; mitochondrion [GO:0005739]; nucleus [GO:0005634]; pyruvate kinase complex [GO:1902912]; secretory granule lumen [GO:0034774]; vesicle [GO:0031982]	cilium [GO:0005929]; collagen-containing extracellular matrix [GO:0062023]; cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; extracellular vesicle [GO:1903561]; ficolin-1-rich granule lumen [GO:1904813]; mitochondrion [GO:0005739]; nucleus [GO:0005634]; pyruvate kinase complex [GO:1902912]; secretory granule lumen [GO:0034774]; vesicle [GO:0031982]; ADP binding [GO:0043531]; ATP binding [GO:0005524]; cadherin binding [GO:0045296]; identical protein binding [GO:0042802]; kinase activity [GO:0016301]; magnesium ion binding [GO:0000287]; MHC class II protein complex binding [GO:0023026]; potassium ion binding [GO:0030955]; pyruvate kinase activity [GO:0004743]; RNA binding [GO:0003723]; thyroid hormone binding [GO:0070324]; animal organ regeneration [GO:0031100]; ATP biosynthetic process [GO:0006754]; canonical glycolysis [GO:0061621]; cellular response to insulin stimulus [GO:0032869]; glycolytic process [GO:0006096]; liver development [GO:0001889]; neutrophil degranulation [GO:0043312]; positive regulation of sprouting angiogenesis [GO:1903672]; programmed cell death [GO:0012501]; protein homotetramerization [GO:0051289]; pyruvate biosynthetic process [GO:0042866]; response to gravity [GO:0009629]; response to hypoxia [GO:0001666]; response to muscle inactivity [GO:0014870]; response to nutrient [GO:0007584]; skeletal muscle tissue regeneration [GO:0043403]	ADP binding [GO:0043531]; ATP binding [GO:0005524]; cadherin binding [GO:0045296]; identical protein binding [GO:0042802]; kinase activity [GO:0016301]; magnesium ion binding [GO:0000287]; MHC class II protein complex binding [GO:0023026]; potassium ion binding [GO:0030955]; pyruvate kinase activity [GO:0004743]; RNA binding [GO:0003723]; thyroid hormone binding [GO:0070324]	PKM
PFKL	P17858	PFKAL_HUMAN	reviewed	ATP-dependent 6-phosphofructokinase, liver type (ATP-PFK) (PFK-L) (EC 2.7.1.11) (6-phosphofructokinase type B) (Phosphofructo-1-kinase isozyme B) (PFK-B) (Phosphohexokinase)	PFKL	Homo sapiens (Human)	780	5 out of 5	Active site (1); Alternative sequence (1); Binding site (9); Chain (1); Glycosylation (1); Initiator methionine (1); Metal binding (1); Modified residue (4); Mutagenesis (2); Natural variant (3); Nucleotide binding (2); Region (9); Sequence conflict (14)	ATP-binding;Acetylation;Allosteric enzyme;Alternative splicing;Complete proteome;Cytoplasm;Direct protein sequencing;Glycolysis;Glycoprotein;Kinase;Magnesium;Metal-binding;Nucleotide-binding;Phosphoprotein;Polymorphism;Reference proteome;Transferase	MISCELLANEOUS: In human PFK exists as a system of 3 types of subunits, PFKM (muscle), PFKL (liver) and PFKP (platelet) isoenzymes.; MISCELLANEOUS: Glycosylation may play a role in cancer cell proliferation: inhibition of 6-phosphofructokinase activity and subsequent redirection of the glucose flux through the oxidative pentose phosphate pathway confers a selective growth advantage on cancer cells. Moreover GlcNAcylation is observed in multiple cancer cell lines and tissue samples and GlcNAcylation leads to larger xenografts tunors in mice (PubMed:22923583). {ECO:0000305|PubMed:22923583}.	SUBCELLULAR LOCATION: Cytoplasm {ECO:0000255|HAMAP-Rule:MF_03184}.	Phosphofructokinase type A (PFKA) family, ATP-dependent PFK group I subfamily, Eukaryotic two domain clade 'E' sub-subfamily	canonical glycolysis [GO:0061621]; fructose 1,6-bisphosphate metabolic process [GO:0030388]; fructose 6-phosphate metabolic process [GO:0006002]; glucose catabolic process [GO:0006007]; glycolytic process [GO:0006096]; negative regulation of insulin secretion [GO:0046676]; neutrophil degranulation [GO:0043312]; protein homotetramerization [GO:0051289]; response to glucose [GO:0009749]	6-phosphofructokinase complex [GO:0005945]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; ficolin-1-rich granule lumen [GO:1904813]; membrane [GO:0016020]; secretory granule lumen [GO:0034774]	6-phosphofructokinase complex [GO:0005945]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; ficolin-1-rich granule lumen [GO:1904813]; membrane [GO:0016020]; secretory granule lumen [GO:0034774]; 6-phosphofructokinase activity [GO:0003872]; AMP binding [GO:0016208]; ATP binding [GO:0005524]; fructose binding [GO:0070061]; fructose-6-phosphate binding [GO:0070095]; identical protein binding [GO:0042802]; kinase binding [GO:0019900]; metal ion binding [GO:0046872]; monosaccharide binding [GO:0048029]; canonical glycolysis [GO:0061621]; fructose 1,6-bisphosphate metabolic process [GO:0030388]; fructose 6-phosphate metabolic process [GO:0006002]; glucose catabolic process [GO:0006007]; glycolytic process [GO:0006096]; negative regulation of insulin secretion [GO:0046676]; neutrophil degranulation [GO:0043312]; protein homotetramerization [GO:0051289]; response to glucose [GO:0009749]	6-phosphofructokinase activity [GO:0003872]; AMP binding [GO:0016208]; ATP binding [GO:0005524]; fructose-6-phosphate binding [GO:0070095]; fructose binding [GO:0070061]; identical protein binding [GO:0042802]; kinase binding [GO:0019900]; metal ion binding [GO:0046872]; monosaccharide binding [GO:0048029]	PFKL
PKLR	P30613	KPYR_HUMAN	reviewed	Pyruvate kinase PKLR (EC 2.7.1.40) (Pyruvate kinase 1) (Pyruvate kinase isozymes L/R) (R-type/L-type pyruvate kinase) (Red cell/liver pyruvate kinase)	PKLR PK1 PKL	Homo sapiens (Human)	574	5 out of 5	Alternative sequence (1); Beta strand (24); Binding site (9); Chain (1); Erroneous gene model prediction (1); Helix (27); Metal binding (6); Modified residue (5); Natural variant (108); Nucleotide binding (1); Region (2); Sequence conflict (2); Site (1); Turn (4)	3D-structure;ATP-binding;Allosteric enzyme;Alternative splicing;Complete proteome;Disease mutation;Glycolysis;Hereditary hemolytic anemia;Kinase;Magnesium;Metal-binding;Nucleotide-binding;Phosphoprotein;Polymorphism;Potassium;Pyruvate;Reference proteome;Transferase	MISCELLANEOUS: There are 4 isozymes of pyruvate kinase in mammals: L, R, M1 and M2. L type is major isozyme in the liver, R is found in red cells, M1 is the main form in muscle, heart and brain, and M2 is found in early fetal tissues.		Pyruvate kinase family	ATP biosynthetic process [GO:0006754]; canonical glycolysis [GO:0061621]; cellular response to epinephrine stimulus [GO:0071872]; cellular response to insulin stimulus [GO:0032869]; glycolytic process [GO:0006096]; pyruvate biosynthetic process [GO:0042866]; response to ATP [GO:0033198]; response to cAMP [GO:0051591]; response to glucose [GO:0009749]; response to heat [GO:0009408]; response to hypoxia [GO:0001666]; response to lithium ion [GO:0010226]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; ATP binding [GO:0005524]; kinase activity [GO:0016301]; magnesium ion binding [GO:0000287]; potassium ion binding [GO:0030955]; pyruvate kinase activity [GO:0004743]; ATP biosynthetic process [GO:0006754]; canonical glycolysis [GO:0061621]; cellular response to epinephrine stimulus [GO:0071872]; cellular response to insulin stimulus [GO:0032869]; glycolytic process [GO:0006096]; pyruvate biosynthetic process [GO:0042866]; response to ATP [GO:0033198]; response to cAMP [GO:0051591]; response to glucose [GO:0009749]; response to heat [GO:0009408]; response to hypoxia [GO:0001666]; response to lithium ion [GO:0010226]	ATP binding [GO:0005524]; kinase activity [GO:0016301]; magnesium ion binding [GO:0000287]; potassium ion binding [GO:0030955]; pyruvate kinase activity [GO:0004743]	PKLR
PFKM	P08237	PFKAM_HUMAN	reviewed	ATP-dependent 6-phosphofructokinase, muscle type (ATP-PFK) (PFK-M) (EC 2.7.1.11) (6-phosphofructokinase type A) (Phosphofructo-1-kinase isozyme A) (PFK-A) (Phosphohexokinase)	PFKM PFKX	Homo sapiens (Human)	780	5 out of 5	Active site (1); Alternative sequence (2); Binding site (9); Chain (1); Glycosylation (1); Initiator methionine (1); Metal binding (1); Modified residue (5); Natural variant (11); Nucleotide binding (2); Region (9); Sequence conflict (2)	3D-structure;ATP-binding;Acetylation;Allosteric enzyme;Alternative splicing;Complete proteome;Cytoplasm;Disease mutation;Glycogen storage disease;Glycolysis;Glycoprotein;Kinase;Magnesium;Metal-binding;Nucleotide-binding;Phosphoprotein;Reference proteome;Transferase	MISCELLANEOUS: In human PFK exists as a system of 3 types of subunits, PFKM (muscle), PFKL (liver) and PFKP (platelet) isoenzymes.	SUBCELLULAR LOCATION: Cytoplasm {ECO:0000255|HAMAP-Rule:MF_03184}.	Phosphofructokinase type A (PFKA) family, ATP-dependent PFK group I subfamily, Eukaryotic two domain clade 'E' sub-subfamily	canonical glycolysis [GO:0061621]; fructose 1,6-bisphosphate metabolic process [GO:0030388]; fructose 6-phosphate metabolic process [GO:0006002]; glucose catabolic process [GO:0006007]; glycolytic process [GO:0006096]; glycolytic process through fructose-6-phosphate [GO:0061615]; muscle cell cellular homeostasis [GO:0046716]; positive regulation of transcription by RNA polymerase II [GO:0045944]; protein homotetramerization [GO:0051289]	6-phosphofructokinase complex [GO:0005945]; apical plasma membrane [GO:0016324]; cytosol [GO:0005829]; membrane [GO:0016020]; nucleus [GO:0005634]	6-phosphofructokinase complex [GO:0005945]; apical plasma membrane [GO:0016324]; cytosol [GO:0005829]; membrane [GO:0016020]; nucleus [GO:0005634]; 6-phosphofructokinase activity [GO:0003872]; AMP binding [GO:0016208]; ATP binding [GO:0005524]; fructose binding [GO:0070061]; fructose-6-phosphate binding [GO:0070095]; identical protein binding [GO:0042802]; kinase binding [GO:0019900]; metal ion binding [GO:0046872]; monosaccharide binding [GO:0048029]; protein C-terminus binding [GO:0008022]; canonical glycolysis [GO:0061621]; fructose 1,6-bisphosphate metabolic process [GO:0030388]; fructose 6-phosphate metabolic process [GO:0006002]; glucose catabolic process [GO:0006007]; glycolytic process [GO:0006096]; glycolytic process through fructose-6-phosphate [GO:0061615]; muscle cell cellular homeostasis [GO:0046716]; positive regulation of transcription by RNA polymerase II [GO:0045944]; protein homotetramerization [GO:0051289]	6-phosphofructokinase activity [GO:0003872]; AMP binding [GO:0016208]; ATP binding [GO:0005524]; fructose-6-phosphate binding [GO:0070095]; fructose binding [GO:0070061]; identical protein binding [GO:0042802]; kinase binding [GO:0019900]; metal ion binding [GO:0046872]; monosaccharide binding [GO:0048029]; protein C-terminus binding [GO:0008022]	PFKM
CAT	P04040	CATA_HUMAN	reviewed	Catalase (EC 1.11.1.6)	CAT	Homo sapiens (Human)	527	5 out of 5	Active site (2); Beta strand (18); Chain (1); Helix (21); Initiator methionine (1); Metal binding (1); Modified residue (14); Sequence conflict (9); Turn (7)	3D-structure;Acetylation;Complete proteome;Direct protein sequencing;Heme;Hydrogen peroxide;Iron;Metal-binding;Mitogen;NADP;Oxidoreductase;Peroxidase;Peroxisome;Phosphoprotein;Reference proteome		SUBCELLULAR LOCATION: Peroxisome.	Catalase family	aerobic respiration [GO:0009060]; aging [GO:0007568]; cellular response to growth factor stimulus [GO:0071363]; cellular response to oxidative stress [GO:0034599]; cholesterol metabolic process [GO:0008203]; hemoglobin metabolic process [GO:0020027]; hydrogen peroxide catabolic process [GO:0042744]; negative regulation of apoptotic process [GO:0043066]; negative regulation of NF-kappaB transcription factor activity [GO:0032088]; neutrophil degranulation [GO:0043312]; osteoblast differentiation [GO:0001649]; positive regulation of cell division [GO:0051781]; positive regulation of NF-kappaB transcription factor activity [GO:0051092]; positive regulation of phosphatidylinositol 3-kinase signaling [GO:0014068]; protein homotetramerization [GO:0051289]; protein targeting to peroxisome [GO:0006625]; protein tetramerization [GO:0051262]; response to activity [GO:0014823]; response to cadmium ion [GO:0046686]; response to estradiol [GO:0032355]; response to ethanol [GO:0045471]; response to fatty acid [GO:0070542]; response to hydrogen peroxide [GO:0042542]; response to hyperoxia [GO:0055093]; response to hypoxia [GO:0001666]; response to inactivity [GO:0014854]; response to insulin [GO:0032868]; response to L-ascorbic acid [GO:0033591]; response to lead ion [GO:0010288]; response to light intensity [GO:0009642]; response to ozone [GO:0010193]; response to phenylpropanoid [GO:0080184]; response to reactive oxygen species [GO:0000302]; response to vitamin A [GO:0033189]; response to vitamin E [GO:0033197]; triglyceride metabolic process [GO:0006641]; ureteric bud development [GO:0001657]; UV protection [GO:0009650]	cytosol [GO:0005829]; endoplasmic reticulum [GO:0005783]; extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; ficolin-1-rich granule lumen [GO:1904813]; focal adhesion [GO:0005925]; Golgi apparatus [GO:0005794]; intracellular membrane-bounded organelle [GO:0043231]; lysosome [GO:0005764]; membrane [GO:0016020]; mitochondrial intermembrane space [GO:0005758]; peroxisomal matrix [GO:0005782]; peroxisomal membrane [GO:0005778]; peroxisome [GO:0005777]; plasma membrane [GO:0005886]; secretory granule lumen [GO:0034774]	cytosol [GO:0005829]; endoplasmic reticulum [GO:0005783]; extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; ficolin-1-rich granule lumen [GO:1904813]; focal adhesion [GO:0005925]; Golgi apparatus [GO:0005794]; intracellular membrane-bounded organelle [GO:0043231]; lysosome [GO:0005764]; membrane [GO:0016020]; mitochondrial intermembrane space [GO:0005758]; peroxisomal matrix [GO:0005782]; peroxisomal membrane [GO:0005778]; peroxisome [GO:0005777]; plasma membrane [GO:0005886]; secretory granule lumen [GO:0034774]; aminoacylase activity [GO:0004046]; antioxidant activity [GO:0016209]; catalase activity [GO:0004096]; enzyme binding [GO:0019899]; heme binding [GO:0020037]; identical protein binding [GO:0042802]; metal ion binding [GO:0046872]; NADP binding [GO:0050661]; oxidoreductase activity, acting on peroxide as acceptor [GO:0016684]; protein homodimerization activity [GO:0042803]; signaling receptor binding [GO:0005102]; aerobic respiration [GO:0009060]; aging [GO:0007568]; cellular response to growth factor stimulus [GO:0071363]; cellular response to oxidative stress [GO:0034599]; cholesterol metabolic process [GO:0008203]; hemoglobin metabolic process [GO:0020027]; hydrogen peroxide catabolic process [GO:0042744]; negative regulation of apoptotic process [GO:0043066]; negative regulation of NF-kappaB transcription factor activity [GO:0032088]; neutrophil degranulation [GO:0043312]; osteoblast differentiation [GO:0001649]; positive regulation of cell division [GO:0051781]; positive regulation of NF-kappaB transcription factor activity [GO:0051092]; positive regulation of phosphatidylinositol 3-kinase signaling [GO:0014068]; protein homotetramerization [GO:0051289]; protein targeting to peroxisome [GO:0006625]; protein tetramerization [GO:0051262]; response to activity [GO:0014823]; response to cadmium ion [GO:0046686]; response to estradiol [GO:0032355]; response to ethanol [GO:0045471]; response to fatty acid [GO:0070542]; response to hydrogen peroxide [GO:0042542]; response to hyperoxia [GO:0055093]; response to hypoxia [GO:0001666]; response to inactivity [GO:0014854]; response to insulin [GO:0032868]; response to L-ascorbic acid [GO:0033591]; response to lead ion [GO:0010288]; response to light intensity [GO:0009642]; response to ozone [GO:0010193]; response to phenylpropanoid [GO:0080184]; response to reactive oxygen species [GO:0000302]; response to vitamin A [GO:0033189]; response to vitamin E [GO:0033197]; triglyceride metabolic process [GO:0006641]; ureteric bud development [GO:0001657]; UV protection [GO:0009650]	aminoacylase activity [GO:0004046]; antioxidant activity [GO:0016209]; catalase activity [GO:0004096]; enzyme binding [GO:0019899]; heme binding [GO:0020037]; identical protein binding [GO:0042802]; metal ion binding [GO:0046872]; NADP binding [GO:0050661]; oxidoreductase activity, acting on peroxide as acceptor [GO:0016684]; protein homodimerization activity [GO:0042803]; signaling receptor binding [GO:0005102]	CAT
CAT	Q6IB77	GLYAT_HUMAN	reviewed	Glycine N-acyltransferase (EC 2.3.1.13) (Acyl-CoA:glycine N-acyltransferase) (AAc) (Aralkyl acyl-CoA N-acyltransferase) (Aralkyl acyl-CoA:amino acid N-acyltransferase) (Benzoyl-coenzyme A:glycine N-acyltransferase) (Glycine N-benzoyltransferase) (EC 2.3.1.71) (HRP-1(CLP))	GLYAT ACGNAT CAT GAT	Homo sapiens (Human)	296	5 out of 5	Alternative sequence (2); Chain (1); Erroneous initiation (2); Modified residue (12); Natural variant (2)	Acetylation;Acyltransferase;Alternative splicing;Complete proteome;Detoxification;Mitochondrion;Polymorphism;Reference proteome;Transferase		SUBCELLULAR LOCATION: Mitochondrion {ECO:0000269|PubMed:22475485}.	Glycine N-acyltransferase family	acyl-CoA metabolic process [GO:0006637]; benzoyl-CoA metabolic process [GO:1901787]; glycine metabolic process [GO:0006544]; monocarboxylic acid metabolic process [GO:0032787]; response to toxic substance [GO:0009636]; xenobiotic metabolic process [GO:0006805]	mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]	mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]; glycine N-acyltransferase activity [GO:0047961]; glycine N-benzoyltransferase activity [GO:0047962]; transferase activity, transferring acyl groups [GO:0016746]; acyl-CoA metabolic process [GO:0006637]; benzoyl-CoA metabolic process [GO:1901787]; glycine metabolic process [GO:0006544]; monocarboxylic acid metabolic process [GO:0032787]; response to toxic substance [GO:0009636]; xenobiotic metabolic process [GO:0006805]	glycine N-acyltransferase activity [GO:0047961]; glycine N-benzoyltransferase activity [GO:0047962]; transferase activity, transferring acyl groups [GO:0016746]	CAT
PNPLA3	Q9NST1	PLPL3_HUMAN	reviewed	1-acylglycerol-3-phosphate O-acyltransferase PNPLA3 (EC 2.3.1.51) (Acylglycerol transacylase) (Adiponutrin) (ADPN) (Calcium-independent phospholipase A2-epsilon) (iPLA2-epsilon) (Lysophosphatidic acid acyltransferase) (Patatin-like phospholipase domain-containing protein 3) (EC 3.1.1.3)	PNPLA3 ADPN C22orf20	Homo sapiens (Human)	481	5 out of 5	Active site (2); Alternative sequence (1); Chain (1); Domain (1); Glycosylation (2); Motif (3); Mutagenesis (4); Natural variant (9); Topological domain (2); Transmembrane (1)	Acyltransferase;Alternative splicing;Complete proteome;Disease mutation;Glycoprotein;Hydrolase;Lipid biosynthesis;Lipid droplet;Lipid metabolism;Membrane;Obesity;Phospholipid biosynthesis;Phospholipid metabolism;Polymorphism;Reference proteome;Signal-anchor;Transferase;Transmembrane;Transmembrane helix		SUBCELLULAR LOCATION: Membrane {ECO:0000269|PubMed:15364929, ECO:0000269|PubMed:22560221}; Single-pass type II membrane protein {ECO:0000269|PubMed:15364929}. Lipid droplet {ECO:0000269|PubMed:20034933, ECO:0000269|PubMed:22560221}.		acylglycerol acyl-chain remodeling [GO:0036155]; glycerophospholipid metabolic process [GO:0006650]; lipid droplet organization [GO:0034389]; lipid homeostasis [GO:0055088]; long-chain fatty acid metabolic process [GO:0001676]; phosphatidic acid biosynthetic process [GO:0006654]; triglyceride acyl-chain remodeling [GO:0036153]; triglyceride biosynthetic process [GO:0019432]; triglyceride catabolic process [GO:0019433]	cytoplasm [GO:0005737]; endoplasmic reticulum membrane [GO:0005789]; integral component of membrane [GO:0016021]; lipid droplet [GO:0005811]; membrane [GO:0016020]	cytoplasm [GO:0005737]; endoplasmic reticulum membrane [GO:0005789]; integral component of membrane [GO:0016021]; lipid droplet [GO:0005811]; membrane [GO:0016020]; 1-acylglycerol-3-phosphate O-acyltransferase activity [GO:0003841]; diolein transacylation activity [GO:0051265]; long-chain fatty acyl-CoA binding [GO:0036042]; lysophosphatidic acid acyltransferase activity [GO:0042171]; lysophosphatidic acid binding [GO:0035727]; mono-olein transacylation activity [GO:0051264]; phospholipase A2 activity [GO:0004623]; triglyceride lipase activity [GO:0004806]; acylglycerol acyl-chain remodeling [GO:0036155]; glycerophospholipid metabolic process [GO:0006650]; lipid droplet organization [GO:0034389]; lipid homeostasis [GO:0055088]; long-chain fatty acid metabolic process [GO:0001676]; phosphatidic acid biosynthetic process [GO:0006654]; triglyceride acyl-chain remodeling [GO:0036153]; triglyceride biosynthetic process [GO:0019432]; triglyceride catabolic process [GO:0019433]	1-acylglycerol-3-phosphate O-acyltransferase activity [GO:0003841]; diolein transacylation activity [GO:0051265]; long-chain fatty acyl-CoA binding [GO:0036042]; lysophosphatidic acid acyltransferase activity [GO:0042171]; lysophosphatidic acid binding [GO:0035727]; mono-olein transacylation activity [GO:0051264]; phospholipase A2 activity [GO:0004623]; triglyceride lipase activity [GO:0004806]	PNPLA3
PCSK9	Q8NBP7	PCSK9_HUMAN	reviewed	Proprotein convertase subtilisin/kexin type 9 (EC 3.4.21.-) (Neural apoptosis-regulated convertase 1) (NARC-1) (Proprotein convertase 9) (PC9) (Subtilisin/kexin-like protease PC9)	PCSK9 NARC1 PSEC0052	Homo sapiens (Human)	692	5 out of 5	Active site (3); Alternative sequence (3); Beta strand (52); Chain (1); Disulfide bond (11); Domain (2); Frameshift (1); Glycosylation (1); Helix (15); Modified residue (3); Mutagenesis (3); Natural variant (41); Propeptide (1); Region (1); Sequence conflict (1); Signal peptide (1); Site (2); Turn (6)	3D-structure;Alternative splicing;Apoptosis;Autocatalytic cleavage;Calcium;Cholesterol metabolism;Complete proteome;Cytoplasm;Direct protein sequencing;Disease mutation;Disulfide bond;Endoplasmic reticulum;Endosome;Glycoprotein;Golgi apparatus;Hydrolase;Lipid metabolism;Lysosome;Phosphoprotein;Polymorphism;Protease;Reference proteome;Secreted;Serine protease;Signal;Steroid metabolism;Sterol metabolism;Sulfation;Zymogen		SUBCELLULAR LOCATION: Cytoplasm. Secreted. Endosome. Lysosome. Cell surface. Endoplasmic reticulum. Golgi apparatus. Note=Autocatalytic cleavage is required to transport it from the endoplasmic reticulum to the Golgi apparatus and for the secretion of the mature protein. Localizes to the endoplasmic reticulum in the absence of LDLR and colocalizes to the cell surface and to the endosomes/lysosomes in the presence of LDLR. The sorting to the cell surface and endosomes is required in order to fully promote LDLR degradation.	Peptidase S8 family	apoptotic process [GO:0006915]; cellular protein metabolic process [GO:0044267]; cellular response to insulin stimulus [GO:0032869]; cellular response to starvation [GO:0009267]; cholesterol homeostasis [GO:0042632]; cholesterol metabolic process [GO:0008203]; kidney development [GO:0001822]; lipoprotein metabolic process [GO:0042157]; liver development [GO:0001889]; low-density lipoprotein particle clearance [GO:0034383]; low-density lipoprotein particle receptor catabolic process [GO:0032802]; lysosomal transport [GO:0007041]; negative regulation of low-density lipoprotein particle clearance [GO:0010989]; negative regulation of low-density lipoprotein particle receptor binding [GO:1905596]; negative regulation of low-density lipoprotein receptor activity [GO:1905598]; negative regulation of receptor-mediated endocytosis involved in cholesterol transport [GO:1905601]; negative regulation of receptor recycling [GO:0001920]; negative regulation of sodium ion transmembrane transporter activity [GO:2000650]; neurogenesis [GO:0022008]; neuron differentiation [GO:0030182]; phospholipid metabolic process [GO:0006644]; positive regulation of low-density lipoprotein particle receptor catabolic process [GO:0032805]; positive regulation of neuron apoptotic process [GO:0043525]; positive regulation of receptor internalization [GO:0002092]; post-translational protein modification [GO:0043687]; protein autoprocessing [GO:0016540]; regulation of neuron apoptotic process [GO:0043523]; regulation of signaling receptor activity [GO:0010469]; triglyceride metabolic process [GO:0006641]	cell surface [GO:0009986]; COPII-coated ER to Golgi transport vesicle [GO:0030134]; cytoplasm [GO:0005737]; early endosome [GO:0005769]; endolysosome membrane [GO:0036020]; endoplasmic reticulum [GO:0005783]; endoplasmic reticulum lumen [GO:0005788]; extracellular region [GO:0005576]; extracellular space [GO:0005615]; extrinsic component of external side of plasma membrane [GO:0031232]; Golgi apparatus [GO:0005794]; late endosome [GO:0005770]; lysosomal membrane [GO:0005765]; lysosome [GO:0005764]; PCSK9-AnxA2 complex [GO:1990667]; PCSK9-LDLR complex [GO:1990666]; perinuclear region of cytoplasm [GO:0048471]; plasma membrane [GO:0005886]; rough endoplasmic reticulum [GO:0005791]	cell surface [GO:0009986]; COPII-coated ER to Golgi transport vesicle [GO:0030134]; cytoplasm [GO:0005737]; early endosome [GO:0005769]; endolysosome membrane [GO:0036020]; endoplasmic reticulum [GO:0005783]; endoplasmic reticulum lumen [GO:0005788]; extracellular region [GO:0005576]; extracellular space [GO:0005615]; extrinsic component of external side of plasma membrane [GO:0031232]; Golgi apparatus [GO:0005794]; late endosome [GO:0005770]; lysosomal membrane [GO:0005765]; lysosome [GO:0005764]; PCSK9-AnxA2 complex [GO:1990667]; PCSK9-LDLR complex [GO:1990666]; perinuclear region of cytoplasm [GO:0048471]; plasma membrane [GO:0005886]; rough endoplasmic reticulum [GO:0005791]; apolipoprotein binding [GO:0034185]; apolipoprotein receptor binding [GO:0034190]; low-density lipoprotein particle binding [GO:0030169]; low-density lipoprotein particle receptor binding [GO:0050750]; protein self-association [GO:0043621]; receptor inhibitor activity [GO:0030547]; RNA binding [GO:0003723]; serine-type endopeptidase activity [GO:0004252]; sodium channel inhibitor activity [GO:0019871]; very-low-density lipoprotein particle binding [GO:0034189]; very-low-density lipoprotein particle receptor binding [GO:0070326]; apoptotic process [GO:0006915]; cellular protein metabolic process [GO:0044267]; cellular response to insulin stimulus [GO:0032869]; cellular response to starvation [GO:0009267]; cholesterol homeostasis [GO:0042632]; cholesterol metabolic process [GO:0008203]; kidney development [GO:0001822]; lipoprotein metabolic process [GO:0042157]; liver development [GO:0001889]; low-density lipoprotein particle clearance [GO:0034383]; low-density lipoprotein particle receptor catabolic process [GO:0032802]; lysosomal transport [GO:0007041]; negative regulation of low-density lipoprotein particle clearance [GO:0010989]; negative regulation of low-density lipoprotein particle receptor binding [GO:1905596]; negative regulation of low-density lipoprotein receptor activity [GO:1905598]; negative regulation of receptor recycling [GO:0001920]; negative regulation of receptor-mediated endocytosis involved in cholesterol transport [GO:1905601]; negative regulation of sodium ion transmembrane transporter activity [GO:2000650]; neurogenesis [GO:0022008]; neuron differentiation [GO:0030182]; phospholipid metabolic process [GO:0006644]; positive regulation of low-density lipoprotein particle receptor catabolic process [GO:0032805]; positive regulation of neuron apoptotic process [GO:0043525]; positive regulation of receptor internalization [GO:0002092]; post-translational protein modification [GO:0043687]; protein autoprocessing [GO:0016540]; regulation of neuron apoptotic process [GO:0043523]; regulation of signaling receptor activity [GO:0010469]; triglyceride metabolic process [GO:0006641]	apolipoprotein binding [GO:0034185]; apolipoprotein receptor binding [GO:0034190]; low-density lipoprotein particle binding [GO:0030169]; low-density lipoprotein particle receptor binding [GO:0050750]; protein self-association [GO:0043621]; receptor inhibitor activity [GO:0030547]; RNA binding [GO:0003723]; serine-type endopeptidase activity [GO:0004252]; sodium channel inhibitor activity [GO:0019871]; very-low-density lipoprotein particle binding [GO:0034189]; very-low-density lipoprotein particle receptor binding [GO:0070326]	PCSK9
FASN	P49327	FAS_HUMAN	reviewed	Fatty acid synthase (EC 2.3.1.85) [Includes: [Acyl-carrier-protein] S-acetyltransferase (EC 2.3.1.38); [Acyl-carrier-protein] S-malonyltransferase (EC 2.3.1.39); 3-oxoacyl-[acyl-carrier-protein] synthase (EC 2.3.1.41); 3-oxoacyl-[acyl-carrier-protein] reductase (EC 1.1.1.100); 3-hydroxyacyl-[acyl-carrier-protein] dehydratase (EC 4.2.1.59); Enoyl-[acyl-carrier-protein] reductase (EC 1.3.1.39); Oleoyl-[acyl-carrier-protein] hydrolase (EC 3.1.2.14)]	FASN FAS	Homo sapiens (Human)	2511	5 out of 5	Active site (5); Beta strand (76); Chain (1); Cross-link (1); Domain (1); Erroneous initiation (2); Helix (103); Modified residue (26); Natural variant (4); Nucleotide binding (2); Region (5); Sequence caution (1); Sequence conflict (20); Turn (19)	3D-structure;Acetylation;Complete proteome;Cytoplasm;Direct protein sequencing;Fatty acid biosynthesis;Fatty acid metabolism;Hydrolase;Isopeptide bond;Lipid biosynthesis;Lipid metabolism;Lyase;Multifunctional enzyme;NAD;NADP;Oxidoreductase;Phosphopantetheine;Phosphoprotein;Polymorphism;Pyridoxal phosphate;Reference proteome;Transferase;Ubl conjugation	MISCELLANEOUS: The relatively low beta-ketoacyl synthase activity may be attributable to the low 4'-phosphopantetheine content of the protein.	SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:17081065}. Melanosome {ECO:0000269|PubMed:17081065}. Note=Identified by mass spectrometry in melanosome fractions from stage I to stage IV.		acetyl-CoA metabolic process [GO:0006084]; cellular response to interleukin-4 [GO:0071353]; establishment of endothelial intestinal barrier [GO:0090557]; ether lipid biosynthetic process [GO:0008611]; fatty acid biosynthetic process [GO:0006633]; fatty acid metabolic process [GO:0006631]; fatty-acyl-CoA biosynthetic process [GO:0046949]; mammary gland development [GO:0030879]; monocyte differentiation [GO:0030224]; neutrophil differentiation [GO:0030223]; osteoblast differentiation [GO:0001649]; positive regulation of cellular metabolic process [GO:0031325]; regulation of cholesterol biosynthetic process [GO:0045540]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]; glycogen granule [GO:0042587]; Golgi apparatus [GO:0005794]; melanosome [GO:0042470]; membrane [GO:0016020]; plasma membrane [GO:0005886]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]; glycogen granule [GO:0042587]; Golgi apparatus [GO:0005794]; melanosome [GO:0042470]; membrane [GO:0016020]; plasma membrane [GO:0005886]; (3R)-hydroxymyristoyl-[acyl-carrier-protein] dehydratase activity [GO:0008659]; 3-hydroxyoctanoyl-[acyl-carrier-protein] dehydratase activity [GO:0047451]; 3-oxo-glutaryl-[acp] methyl ester reductase activity [GO:0102131]; 3-oxo-pimeloyl-[acp] methyl ester reductase activity [GO:0102132]; 3-oxoacyl-[acyl-carrier-protein] reductase (NADPH) activity [GO:0004316]; 3-oxoacyl-[acyl-carrier-protein] synthase activity [GO:0004315]; [acyl-carrier-protein] S-acetyltransferase activity [GO:0004313]; [acyl-carrier-protein] S-malonyltransferase activity [GO:0004314]; cadherin binding [GO:0045296]; drug binding [GO:0008144]; enoyl-[acyl-carrier-protein] reductase (NADPH, A-specific) activity [GO:0047117]; myristoyl-[acyl-carrier-protein] hydrolase activity [GO:0016295]; NADPH binding [GO:0070402]; oleoyl-[acyl-carrier-protein] hydrolase activity [GO:0004320]; palmitoyl-[acyl-carrier-protein] hydrolase activity [GO:0016296]; phosphopantetheine binding [GO:0031177]; protein homodimerization activity [GO:0042803]; RNA binding [GO:0003723]; acetyl-CoA metabolic process [GO:0006084]; cellular response to interleukin-4 [GO:0071353]; establishment of endothelial intestinal barrier [GO:0090557]; ether lipid biosynthetic process [GO:0008611]; fatty acid biosynthetic process [GO:0006633]; fatty acid metabolic process [GO:0006631]; fatty-acyl-CoA biosynthetic process [GO:0046949]; mammary gland development [GO:0030879]; monocyte differentiation [GO:0030224]; neutrophil differentiation [GO:0030223]; osteoblast differentiation [GO:0001649]; positive regulation of cellular metabolic process [GO:0031325]; regulation of cholesterol biosynthetic process [GO:0045540]	(3R)-hydroxymyristoyl-[acyl-carrier-protein] dehydratase activity [GO:0008659]; [acyl-carrier-protein] S-acetyltransferase activity [GO:0004313]; [acyl-carrier-protein] S-malonyltransferase activity [GO:0004314]; 3-hydroxyoctanoyl-[acyl-carrier-protein] dehydratase activity [GO:0047451]; 3-oxoacyl-[acyl-carrier-protein] reductase (NADPH) activity [GO:0004316]; 3-oxoacyl-[acyl-carrier-protein] synthase activity [GO:0004315]; 3-oxo-glutaryl-[acp] methyl ester reductase activity [GO:0102131]; 3-oxo-pimeloyl-[acp] methyl ester reductase activity [GO:0102132]; cadherin binding [GO:0045296]; drug binding [GO:0008144]; enoyl-[acyl-carrier-protein] reductase (NADPH, A-specific) activity [GO:0047117]; myristoyl-[acyl-carrier-protein] hydrolase activity [GO:0016295]; NADPH binding [GO:0070402]; oleoyl-[acyl-carrier-protein] hydrolase activity [GO:0004320]; palmitoyl-[acyl-carrier-protein] hydrolase activity [GO:0016296]; phosphopantetheine binding [GO:0031177]; protein homodimerization activity [GO:0042803]; RNA binding [GO:0003723]	FASN
FPGS	Q05932	FOLC_HUMAN	reviewed	Folylpolyglutamate synthase, mitochondrial (EC 6.3.2.17) (Folylpoly-gamma-glutamate synthetase) (FPGS) (Tetrahydrofolylpolyglutamate synthase) (Tetrahydrofolate synthase)	FPGS	Homo sapiens (Human)	587	5 out of 5	Alternative sequence (3); Binding site (2); Chain (1); Erroneous initiation (1); Metal binding (3); Modified residue (2); Natural variant (7); Nucleotide binding (1); Sequence conflict (1); Transit peptide (1)	ATP-binding;Acetylation;Alternative initiation;Alternative splicing;Complete proteome;Cytoplasm;Ligase;Magnesium;Membrane;Metal-binding;Mitochondrion;Mitochondrion inner membrane;Nucleotide-binding;One-carbon metabolism;Phosphoprotein;Polymorphism;Reference proteome;Transit peptide		SUBCELLULAR LOCATION: Isoform 1: Mitochondrion inner membrane {ECO:0000269|PubMed:16169100}. Mitochondrion matrix {ECO:0000269|PubMed:16169100, ECO:0000269|PubMed:8408020, ECO:0000269|PubMed:8662720}.; SUBCELLULAR LOCATION: Isoform 2: Cytoplasm {ECO:0000269|PubMed:8662720}.	Folylpolyglutamate synthase family	animal organ regeneration [GO:0031100]; brain development [GO:0007420]; cell population proliferation [GO:0008283]; folic acid-containing compound biosynthetic process [GO:0009396]; folic acid-containing compound metabolic process [GO:0006760]; folic acid metabolic process [GO:0046655]; glutamate metabolic process [GO:0006536]; liver development [GO:0001889]; nucleobase-containing compound metabolic process [GO:0006139]; one-carbon metabolic process [GO:0006730]; tetrahydrofolylpolyglutamate biosynthetic process [GO:0046901]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; mitochondrial inner membrane [GO:0005743]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; mitochondrial inner membrane [GO:0005743]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]; ATP binding [GO:0005524]; metal ion binding [GO:0046872]; tetrahydrofolylpolyglutamate synthase activity [GO:0004326]; animal organ regeneration [GO:0031100]; brain development [GO:0007420]; cell population proliferation [GO:0008283]; folic acid metabolic process [GO:0046655]; folic acid-containing compound biosynthetic process [GO:0009396]; folic acid-containing compound metabolic process [GO:0006760]; glutamate metabolic process [GO:0006536]; liver development [GO:0001889]; nucleobase-containing compound metabolic process [GO:0006139]; one-carbon metabolic process [GO:0006730]; tetrahydrofolylpolyglutamate biosynthetic process [GO:0046901]	ATP binding [GO:0005524]; metal ion binding [GO:0046872]; tetrahydrofolylpolyglutamate synthase activity [GO:0004326]	FPGS
GGH	Q92820	GGH_HUMAN	reviewed	Gamma-glutamyl hydrolase (EC 3.4.19.9) (Conjugase) (GH) (Gamma-Glu-X carboxypeptidase)	GGH	Homo sapiens (Human)	318	5 out of 5	Active site (2); Beta strand (11); Chain (1); Domain (1); Glycosylation (4); Helix (12); Mutagenesis (4); Natural variant (3); Signal peptide (1); Turn (4)	3D-structure;Complete proteome;Glycoprotein;Hydrolase;Lysosome;Polymorphism;Reference proteome;Secreted;Signal		SUBCELLULAR LOCATION: Secreted, extracellular space {ECO:0000305}. Lysosome {ECO:0000269|PubMed:12643545}. Melanosome {ECO:0000269|PubMed:12643545}. Note=While its intracellular location is primarily the lysosome, most of the enzyme activity is secreted. Identified by mass spectrometry in melanosome fractions from stage I to stage IV. {ECO:0000269|PubMed:12643545}.	Peptidase C26 family	neutrophil degranulation [GO:0043312]; response to ethanol [GO:0045471]; response to insulin [GO:0032868]; response to zinc ion [GO:0010043]; tetrahydrofolylpolyglutamate metabolic process [GO:0046900]	azurophil granule lumen [GO:0035578]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; extracellular space [GO:0005615]; melanosome [GO:0042470]; nucleus [GO:0005634]; specific granule lumen [GO:0035580]; tertiary granule lumen [GO:1904724]; vacuole [GO:0005773]	azurophil granule lumen [GO:0035578]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; extracellular space [GO:0005615]; melanosome [GO:0042470]; nucleus [GO:0005634]; specific granule lumen [GO:0035580]; tertiary granule lumen [GO:1904724]; vacuole [GO:0005773]; exopeptidase activity [GO:0008238]; gamma-glutamyl-peptidase activity [GO:0034722]; omega peptidase activity [GO:0008242]; neutrophil degranulation [GO:0043312]; response to ethanol [GO:0045471]; response to insulin [GO:0032868]; response to zinc ion [GO:0010043]; tetrahydrofolylpolyglutamate metabolic process [GO:0046900]	exopeptidase activity [GO:0008238]; gamma-glutamyl-peptidase activity [GO:0034722]; omega peptidase activity [GO:0008242]	GGH
MTR	Q99707	METH_HUMAN	reviewed	Methionine synthase (EC 2.1.1.13) (5-methyltetrahydrofolate--homocysteine methyltransferase) (Vitamin-B12 dependent methionine synthase) (MS)	MTR	Homo sapiens (Human)	1265	5 out of 5	Alternative sequence (1); Beta strand (24); Binding site (10); Chain (1); Domain (5); Helix (48); Metal binding (4); Modified residue (1); Mutagenesis (2); Natural variant (8); Region (3); Turn (5)	3D-structure;Alternative splicing;Amino-acid biosynthesis;Cobalamin;Cobalt;Complete proteome;Cytoplasm;Disease mutation;Metal-binding;Methionine biosynthesis;Methyltransferase;Phosphoprotein;Polymorphism;Reference proteome;Repeat;S-adenosyl-L-methionine;Transferase;Zinc	MISCELLANEOUS: L-homocysteine is bound via the zinc atom. {ECO:0000250}.	SUBCELLULAR LOCATION: Cytoplasm.	Vitamin-B12 dependent methionine synthase family	axon regeneration [GO:0031103]; cellular response to nitric oxide [GO:0071732]; cobalamin metabolic process [GO:0009235]; methionine biosynthetic process [GO:0009086]; methylation [GO:0032259]; nervous system development [GO:0007399]; pteridine-containing compound metabolic process [GO:0042558]; response to axon injury [GO:0048678]; sulfur amino acid metabolic process [GO:0000096]	cytosol [GO:0005829]	cytosol [GO:0005829]; cobalamin binding [GO:0031419]; methionine synthase activity [GO:0008705]; zinc ion binding [GO:0008270]; axon regeneration [GO:0031103]; cellular response to nitric oxide [GO:0071732]; cobalamin metabolic process [GO:0009235]; methionine biosynthetic process [GO:0009086]; methylation [GO:0032259]; nervous system development [GO:0007399]; pteridine-containing compound metabolic process [GO:0042558]; response to axon injury [GO:0048678]; sulfur amino acid metabolic process [GO:0000096]	cobalamin binding [GO:0031419]; methionine synthase activity [GO:0008705]; zinc ion binding [GO:0008270]	MTR
MTHFS	P49914	MTHFS_HUMAN	reviewed	5-formyltetrahydrofolate cyclo-ligase (EC 6.3.3.2) (5,10-methenyl-tetrahydrofolate synthetase) (MTHFS) (Methenyl-THF synthetase)	MTHFS	Homo sapiens (Human)	203	5 out of 5	Alternative sequence (1); Beta strand (9); Binding site (3); Chain (1); Frameshift (1); Helix (8); Initiator methionine (1); Metal binding (2); Modified residue (1); Mutagenesis (6); Natural variant (4); Nucleotide binding (2); Region (1); Sequence conflict (2); Turn (2)	3D-structure;ATP-binding;Acetylation;Alternative splicing;Complete proteome;Cytoplasm;Disease mutation;Epilepsy;Folate-binding;Ligase;Magnesium;Metal-binding;Nucleotide-binding;Polymorphism;Reference proteome		SUBCELLULAR LOCATION: Cytoplasm.	5-formyltetrahydrofolate cyclo-ligase family	folic acid catabolic process [GO:0046657]; folic acid-containing compound biosynthetic process [GO:0009396]; folic acid metabolic process [GO:0046655]; formate metabolic process [GO:0015942]; glutamate metabolic process [GO:0006536]; tetrahydrofolate interconversion [GO:0035999]; tetrahydrofolate metabolic process [GO:0046653]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]; 5-formyltetrahydrofolate cyclo-ligase activity [GO:0030272]; ATP binding [GO:0005524]; folic acid binding [GO:0005542]; metal ion binding [GO:0046872]; folic acid catabolic process [GO:0046657]; folic acid metabolic process [GO:0046655]; folic acid-containing compound biosynthetic process [GO:0009396]; formate metabolic process [GO:0015942]; glutamate metabolic process [GO:0006536]; tetrahydrofolate interconversion [GO:0035999]; tetrahydrofolate metabolic process [GO:0046653]	5-formyltetrahydrofolate cyclo-ligase activity [GO:0030272]; ATP binding [GO:0005524]; folic acid binding [GO:0005542]; metal ion binding [GO:0046872]	MTHFS
ATIC	P31939	PUR9_HUMAN	reviewed	Bifunctional purine biosynthesis protein PURH [Cleaved into: Bifunctional purine biosynthesis protein PURH, N-terminally processed] [Includes: Phosphoribosylaminoimidazolecarboxamide formyltransferase (EC 2.1.2.3) (5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase) (AICAR transformylase); IMP cyclohydrolase (EC 3.5.4.10) (ATIC) (IMP synthase) (Inosinicase)]	ATIC PURH OK/SW-cl.86	Homo sapiens (Human)	592	5 out of 5	Active site (2); Alternative sequence (1); Beta strand (25); Binding site (6); Chain (2); Domain (1); Helix (28); Initiator methionine (1); Modified residue (2); Natural variant (2); Nucleotide binding (5); Region (1); Sequence conflict (1); Site (1); Turn (5)	3D-structure;Acetylation;Alternative splicing;Complete proteome;Direct protein sequencing;Disease mutation;Epilepsy;Hydrolase;Multifunctional enzyme;Polymorphism;Purine biosynthesis;Reference proteome;Transferase			PurH family	'de novo' IMP biosynthetic process [GO:0006189]; animal organ regeneration [GO:0031100]; brainstem development [GO:0003360]; cellular response to interleukin-7 [GO:0098761]; cerebellum development [GO:0021549]; cerebral cortex development [GO:0021987]; dihydrofolate metabolic process [GO:0046452]; nucleobase-containing compound metabolic process [GO:0006139]; nucleoside metabolic process [GO:0009116]; purine ribonucleoside monophosphate biosynthetic process [GO:0009168]; response to inorganic substance [GO:0010035]; tetrahydrofolate biosynthetic process [GO:0046654]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]; membrane [GO:0016020]; plasma membrane [GO:0005886]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]; membrane [GO:0016020]; plasma membrane [GO:0005886]; cadherin binding [GO:0045296]; IMP cyclohydrolase activity [GO:0003937]; phosphoribosylaminoimidazolecarboxamide formyltransferase activity [GO:0004643]; protein homodimerization activity [GO:0042803]; 'de novo' IMP biosynthetic process [GO:0006189]; animal organ regeneration [GO:0031100]; brainstem development [GO:0003360]; cellular response to interleukin-7 [GO:0098761]; cerebellum development [GO:0021549]; cerebral cortex development [GO:0021987]; dihydrofolate metabolic process [GO:0046452]; nucleobase-containing compound metabolic process [GO:0006139]; nucleoside metabolic process [GO:0009116]; purine ribonucleoside monophosphate biosynthetic process [GO:0009168]; response to inorganic substance [GO:0010035]; tetrahydrofolate biosynthetic process [GO:0046654]	cadherin binding [GO:0045296]; IMP cyclohydrolase activity [GO:0003937]; phosphoribosylaminoimidazolecarboxamide formyltransferase activity [GO:0004643]; protein homodimerization activity [GO:0042803]	ATIC
AMT	P48728	GCST_HUMAN	reviewed	Aminomethyltransferase, mitochondrial (EC 2.1.2.10) (Glycine cleavage system T protein) (GCVT)	AMT GCST	Homo sapiens (Human)	403	5 out of 5	Alternative sequence (3); Beta strand (20); Binding site (3); Chain (1); Helix (13); Mutagenesis (1); Natural variant (11); Sequence conflict (1); Transit peptide (1); Turn (3)	3D-structure;Alternative splicing;Aminotransferase;Complete proteome;Disease mutation;Mitochondrion;Reference proteome;Transferase;Transit peptide		SUBCELLULAR LOCATION: Mitochondrion {ECO:0000305|PubMed:16051266}.	GcvT family	glycine catabolic process [GO:0006546]; glycine decarboxylation via glycine cleavage system [GO:0019464]	mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]; nucleoplasm [GO:0005654]	mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]; nucleoplasm [GO:0005654]; aminomethyltransferase activity [GO:0004047]; transaminase activity [GO:0008483]; glycine catabolic process [GO:0006546]; glycine decarboxylation via glycine cleavage system [GO:0019464]	aminomethyltransferase activity [GO:0004047]; transaminase activity [GO:0008483]	AMT
GART	P22102	PUR2_HUMAN	reviewed	Trifunctional purine biosynthetic protein adenosine-3 [Includes: Phosphoribosylamine--glycine ligase (EC 6.3.4.13) (Glycinamide ribonucleotide synthetase) (GARS) (Phosphoribosylglycinamide synthetase); Phosphoribosylformylglycinamidine cyclo-ligase (EC 6.3.3.1) (AIR synthase) (AIRS) (Phosphoribosyl-aminoimidazole synthetase); Phosphoribosylglycinamide formyltransferase (EC 2.1.2.2) (5'-phosphoribosylglycinamide transformylase) (GAR transformylase) (GART)]	GART PGFT PRGS	Homo sapiens (Human)	1010	5 out of 5	Active site (1); Alternative sequence (1); Beta strand (41); Binding site (2); Chain (1); Domain (1); Helix (41); Initiator methionine (1); Metal binding (2); Modified residue (7); Natural variant (5); Nucleotide binding (1); Region (6); Site (1); Turn (9)	3D-structure;ATP-binding;Acetylation;Alternative splicing;Complete proteome;Ligase;Manganese;Metal-binding;Multifunctional enzyme;Nucleotide-binding;Phosphoprotein;Polymorphism;Purine biosynthesis;Reference proteome;Transferase			GARS family; AIR synthase family; GART family	'de novo' IMP biosynthetic process [GO:0006189]; brainstem development [GO:0003360]; cerebellum development [GO:0021549]; cerebral cortex development [GO:0021987]; glycine metabolic process [GO:0006544]; purine nucleobase biosynthetic process [GO:0009113]; purine nucleotide biosynthetic process [GO:0006164]; purine ribonucleoside monophosphate biosynthetic process [GO:0009168]; response to inorganic substance [GO:0010035]; response to organic substance [GO:0010033]; tetrahydrofolate biosynthetic process [GO:0046654]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]; ATP binding [GO:0005524]; metal ion binding [GO:0046872]; phosphoribosylamine-glycine ligase activity [GO:0004637]; phosphoribosylformylglycinamidine cyclo-ligase activity [GO:0004641]; phosphoribosylglycinamide formyltransferase activity [GO:0004644]; 'de novo' IMP biosynthetic process [GO:0006189]; brainstem development [GO:0003360]; cerebellum development [GO:0021549]; cerebral cortex development [GO:0021987]; glycine metabolic process [GO:0006544]; purine nucleobase biosynthetic process [GO:0009113]; purine nucleotide biosynthetic process [GO:0006164]; purine ribonucleoside monophosphate biosynthetic process [GO:0009168]; response to inorganic substance [GO:0010035]; response to organic substance [GO:0010033]; tetrahydrofolate biosynthetic process [GO:0046654]	ATP binding [GO:0005524]; metal ion binding [GO:0046872]; phosphoribosylamine-glycine ligase activity [GO:0004637]; phosphoribosylformylglycinamidine cyclo-ligase activity [GO:0004641]; phosphoribosylglycinamide formyltransferase activity [GO:0004644]	GART
GPX7	Q96SL4	GPX7_HUMAN	reviewed	Glutathione peroxidase 7 (GPx-7) (GSHPx-7) (EC 1.11.1.9) (CL683)	GPX7 GPX6 UNQ469/PRO828	Homo sapiens (Human)	187	5 out of 5	Active site (1); Beta strand (7); Chain (1); Erroneous translation (1); Helix (7); Sequence conflict (1); Signal peptide (1)	3D-structure;Complete proteome;Oxidoreductase;Peroxidase;Reference proteome;Secreted;Signal		SUBCELLULAR LOCATION: Secreted {ECO:0000305}.	Glutathione peroxidase family	cellular response to oxidative stress [GO:0034599]	endoplasmic reticulum [GO:0005783]; endoplasmic reticulum lumen [GO:0005788]; extracellular region [GO:0005576]	endoplasmic reticulum [GO:0005783]; endoplasmic reticulum lumen [GO:0005788]; extracellular region [GO:0005576]; catalase activity [GO:0004096]; glutathione peroxidase activity [GO:0004602]; peroxidase activity [GO:0004601]; cellular response to oxidative stress [GO:0034599]	catalase activity [GO:0004096]; glutathione peroxidase activity [GO:0004602]; peroxidase activity [GO:0004601]	GPX7
GPX8	Q8TED1	GPX8_HUMAN	reviewed	Probable glutathione peroxidase 8 (GPx-8) (GSHPx-8) (EC 1.11.1.9)	GPX8 UNQ847/PRO1785	Homo sapiens (Human)	209	3 out of 5	Active site (1); Beta strand (7); Chain (1); Helix (7); Modified residue (1); Natural variant (1); Transmembrane (1); Turn (1)	3D-structure;Acetylation;Complete proteome;Membrane;Oxidoreductase;Peroxidase;Polymorphism;Reference proteome;Transmembrane;Transmembrane helix		SUBCELLULAR LOCATION: Membrane {ECO:0000305}; Single-pass membrane protein {ECO:0000305}.	Glutathione peroxidase family	cellular response to oxidative stress [GO:0034599]	endoplasmic reticulum lumen [GO:0005788]; integral component of membrane [GO:0016021]	endoplasmic reticulum lumen [GO:0005788]; integral component of membrane [GO:0016021]; glutathione peroxidase activity [GO:0004602]; peroxidase activity [GO:0004601]; cellular response to oxidative stress [GO:0034599]	glutathione peroxidase activity [GO:0004602]; peroxidase activity [GO:0004601]	GPX8
GPX4	P36969	GPX4_HUMAN	reviewed	Phospholipid hydroperoxide glutathione peroxidase (PHGPx) (EC 1.11.1.12) (Glutathione peroxidase 4) (GPx-4) (GSHPx-4)	GPX4	Homo sapiens (Human)	197	5 out of 5	Active site (1); Alternative sequence (1); Beta strand (10); Chain (1); Helix (9); Modified residue (1); Mutagenesis (2); Natural variant (3); Non-standard residue (1); Transit peptide (1); Turn (2)	3D-structure;Alternative initiation;Complete proteome;Cytoplasm;Developmental protein;Dwarfism;Mitochondrion;Oxidoreductase;Peroxidase;Phosphoprotein;Polymorphism;Reference proteome;Selenocysteine;Transit peptide		SUBCELLULAR LOCATION: Isoform Mitochondrial: Mitochondrion {ECO:0000250|UniProtKB:O70325}.; SUBCELLULAR LOCATION: Isoform Cytoplasmic: Cytoplasm {ECO:0000250|UniProtKB:O70325}.	Glutathione peroxidase family	aging [GO:0007568]; chromatin organization [GO:0006325]; glutathione metabolic process [GO:0006749]; lipoxygenase pathway [GO:0019372]; long-chain fatty acid biosynthetic process [GO:0042759]; multicellular organism development [GO:0007275]; negative regulation of ferroptosis [GO:0110076]; oxidation-reduction process [GO:0055114]; phospholipid metabolic process [GO:0006644]; protein polymerization [GO:0051258]; regulation of inflammatory response [GO:0050727]; response to estradiol [GO:0032355]; response to oxidative stress [GO:0006979]; spermatogenesis [GO:0007283]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]; mitochondrion [GO:0005739]; nuclear envelope [GO:0005635]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; protein-containing complex [GO:0032991]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]; mitochondrion [GO:0005739]; nuclear envelope [GO:0005635]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; protein-containing complex [GO:0032991]; glutathione peroxidase activity [GO:0004602]; identical protein binding [GO:0042802]; peroxidase activity [GO:0004601]; phospholipid-hydroperoxide glutathione peroxidase activity [GO:0047066]; selenium binding [GO:0008430]; aging [GO:0007568]; chromatin organization [GO:0006325]; glutathione metabolic process [GO:0006749]; lipoxygenase pathway [GO:0019372]; long-chain fatty acid biosynthetic process [GO:0042759]; multicellular organism development [GO:0007275]; negative regulation of ferroptosis [GO:0110076]; oxidation-reduction process [GO:0055114]; phospholipid metabolic process [GO:0006644]; protein polymerization [GO:0051258]; regulation of inflammatory response [GO:0050727]; response to estradiol [GO:0032355]; response to oxidative stress [GO:0006979]; spermatogenesis [GO:0007283]	glutathione peroxidase activity [GO:0004602]; identical protein binding [GO:0042802]; peroxidase activity [GO:0004601]; phospholipid-hydroperoxide glutathione peroxidase activity [GO:0047066]; selenium binding [GO:0008430]	GPX4
GPX2	P18283	GPX2_HUMAN	reviewed	Glutathione peroxidase 2 (GPx-2) (GSHPx-2) (EC 1.11.1.9) (Gastrointestinal glutathione peroxidase) (Glutathione peroxidase-gastrointestinal) (GPx-GI) (GSHPx-GI) (Glutathione peroxidase-related protein 2) (GPRP-2)	GPX2	Homo sapiens (Human)	190	5 out of 5	Active site (1); Beta strand (8); Chain (1); Helix (9); Natural variant (4); Non-standard residue (1); Sequence conflict (2); Turn (1)	3D-structure;Complete proteome;Cytoplasm;Oxidoreductase;Peroxidase;Polymorphism;Reference proteome;Selenocysteine		SUBCELLULAR LOCATION: Cytoplasm. Note=Mainly cytoplasmic.	Glutathione peroxidase family	cellular response to oxidative stress [GO:0034599]	cytoplasm [GO:0005737]; cytosol [GO:0005829]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; electron transfer activity [GO:0009055]; glutathione peroxidase activity [GO:0004602]; peroxidase activity [GO:0004601]; cellular response to oxidative stress [GO:0034599]	electron transfer activity [GO:0009055]; glutathione peroxidase activity [GO:0004602]; peroxidase activity [GO:0004601]	GPX2
GPX3	P22352	GPX3_HUMAN	reviewed	Glutathione peroxidase 3 (GPx-3) (GSHPx-3) (EC 1.11.1.9) (Extracellular glutathione peroxidase) (Plasma glutathione peroxidase) (GPx-P) (GSHPx-P)	GPX3 GPXP	Homo sapiens (Human)	226	5 out of 5	Active site (1); Beta strand (9); Chain (1); Helix (9); Natural variant (1); Non-standard residue (1); Signal peptide (1); Turn (1)	3D-structure;Complete proteome;Direct protein sequencing;Oxidoreductase;Peroxidase;Polymorphism;Reference proteome;Secreted;Selenocysteine;Signal		SUBCELLULAR LOCATION: Secreted.	Glutathione peroxidase family	cellular response to oxidative stress [GO:0034599]; hydrogen peroxide catabolic process [GO:0042744]; protein homotetramerization [GO:0051289]; response to lipid hydroperoxide [GO:0006982]	extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; extracellular space [GO:0005615]	extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; extracellular space [GO:0005615]; glutathione peroxidase activity [GO:0004602]; peroxidase activity [GO:0004601]; selenium binding [GO:0008430]; transcription factor binding [GO:0008134]; cellular response to oxidative stress [GO:0034599]; hydrogen peroxide catabolic process [GO:0042744]; protein homotetramerization [GO:0051289]; response to lipid hydroperoxide [GO:0006982]	glutathione peroxidase activity [GO:0004602]; peroxidase activity [GO:0004601]; selenium binding [GO:0008430]; transcription factor binding [GO:0008134]	GPX3
GPX5	O75715	GPX5_HUMAN	reviewed	Epididymal secretory glutathione peroxidase (EC 1.11.1.9) (Epididymis-specific glutathione peroxidase-like protein) (EGLP) (Glutathione peroxidase 5) (GPx-5) (GSHPx-5)	GPX5	Homo sapiens (Human)	221	5 out of 5	Active site (1); Alternative sequence (1); Beta strand (10); Chain (1); Helix (10); Natural variant (2); Signal peptide (1); Turn (1)	3D-structure;Alternative splicing;Complete proteome;Oxidoreductase;Peroxidase;Polymorphism;Reference proteome;Secreted;Signal		SUBCELLULAR LOCATION: Secreted.	Glutathione peroxidase family	cellular response to oxidative stress [GO:0034599]; hydrogen peroxide catabolic process [GO:0042744]; lipid metabolic process [GO:0006629]	extracellular region [GO:0005576]; extracellular space [GO:0005615]	extracellular region [GO:0005576]; extracellular space [GO:0005615]; glutathione peroxidase activity [GO:0004602]; peroxidase activity [GO:0004601]; selenium binding [GO:0008430]; cellular response to oxidative stress [GO:0034599]; hydrogen peroxide catabolic process [GO:0042744]; lipid metabolic process [GO:0006629]	glutathione peroxidase activity [GO:0004602]; peroxidase activity [GO:0004601]; selenium binding [GO:0008430]	GPX5
GPX1	P07203	GPX1_HUMAN	reviewed	Glutathione peroxidase 1 (GPx-1) (GSHPx-1) (EC 1.11.1.9) (Cellular glutathione peroxidase)	GPX1	Homo sapiens (Human)	203	5 out of 5	Active site (1); Alternative sequence (2); Beta strand (7); Chain (1); Helix (10); Modified residue (9); Natural variant (5); Non-standard residue (1); Sequence conflict (1); Site (1); Turn (1)	3D-structure;Acetylation;Alternative splicing;Complete proteome;Cytoplasm;Oxidoreductase;Peroxidase;Phosphoprotein;Polymorphism;Reference proteome;Selenocysteine		SUBCELLULAR LOCATION: Cytoplasm.	Glutathione peroxidase family	angiogenesis involved in wound healing [GO:0060055]; blood vessel endothelial cell migration [GO:0043534]; cell redox homeostasis [GO:0045454]; cellular response to oxidative stress [GO:0034599]; endothelial cell development [GO:0001885]; fat cell differentiation [GO:0045444]; glutathione metabolic process [GO:0006749]; heart contraction [GO:0060047]; hydrogen peroxide catabolic process [GO:0042744]; interaction with symbiont [GO:0051702]; lipoxygenase pathway [GO:0019372]; myoblast proliferation [GO:0051450]; negative regulation of cysteine-type endopeptidase activity involved in apoptotic process [GO:0043154]; negative regulation of extrinsic apoptotic signaling pathway via death domain receptors [GO:1902042]; negative regulation of inflammatory response to antigenic stimulus [GO:0002862]; negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway [GO:1902176]; negative regulation of release of cytochrome c from mitochondria [GO:0090201]; positive regulation of protein kinase B signaling [GO:0051897]; positive regulation of supramolecular fiber organization [GO:1902905]; protein oxidation [GO:0018158]; purine nucleotide catabolic process [GO:0006195]; regulation of gene expression, epigenetic [GO:0040029]; regulation of mammary gland epithelial cell proliferation [GO:0033599]; regulation of proteasomal protein catabolic process [GO:0061136]; response to gamma radiation [GO:0010332]; response to hydrogen peroxide [GO:0042542]; response to hydroperoxide [GO:0033194]; response to selenium ion [GO:0010269]; response to symbiotic bacterium [GO:0009609]; response to xenobiotic stimulus [GO:0009410]; sensory perception of sound [GO:0007605]; skeletal muscle fiber development [GO:0048741]; skeletal muscle tissue regeneration [GO:0043403]; temperature homeostasis [GO:0001659]; triglyceride metabolic process [GO:0006641]; UV protection [GO:0009650]; vasodilation [GO:0042311]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]; glutathione peroxidase activity [GO:0004602]; peroxidase activity [GO:0004601]; SH3 domain binding [GO:0017124]; angiogenesis involved in wound healing [GO:0060055]; blood vessel endothelial cell migration [GO:0043534]; cell redox homeostasis [GO:0045454]; cellular response to oxidative stress [GO:0034599]; endothelial cell development [GO:0001885]; fat cell differentiation [GO:0045444]; glutathione metabolic process [GO:0006749]; heart contraction [GO:0060047]; hydrogen peroxide catabolic process [GO:0042744]; interaction with symbiont [GO:0051702]; lipoxygenase pathway [GO:0019372]; myoblast proliferation [GO:0051450]; negative regulation of cysteine-type endopeptidase activity involved in apoptotic process [GO:0043154]; negative regulation of extrinsic apoptotic signaling pathway via death domain receptors [GO:1902042]; negative regulation of inflammatory response to antigenic stimulus [GO:0002862]; negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway [GO:1902176]; negative regulation of release of cytochrome c from mitochondria [GO:0090201]; positive regulation of protein kinase B signaling [GO:0051897]; positive regulation of supramolecular fiber organization [GO:1902905]; protein oxidation [GO:0018158]; purine nucleotide catabolic process [GO:0006195]; regulation of gene expression, epigenetic [GO:0040029]; regulation of mammary gland epithelial cell proliferation [GO:0033599]; regulation of proteasomal protein catabolic process [GO:0061136]; response to gamma radiation [GO:0010332]; response to hydrogen peroxide [GO:0042542]; response to hydroperoxide [GO:0033194]; response to selenium ion [GO:0010269]; response to symbiotic bacterium [GO:0009609]; response to xenobiotic stimulus [GO:0009410]; sensory perception of sound [GO:0007605]; skeletal muscle fiber development [GO:0048741]; skeletal muscle tissue regeneration [GO:0043403]; temperature homeostasis [GO:0001659]; triglyceride metabolic process [GO:0006641]; UV protection [GO:0009650]; vasodilation [GO:0042311]	glutathione peroxidase activity [GO:0004602]; peroxidase activity [GO:0004601]; SH3 domain binding [GO:0017124]	GPX1
GCLC	P48506	GSH1_HUMAN	reviewed	Glutamate--cysteine ligase catalytic subunit (EC 6.3.2.2) (GCS heavy chain) (Gamma-ECS) (Gamma-glutamylcysteine synthetase)	GCLC GLCL GLCLC	Homo sapiens (Human)	637	5 out of 5	Chain (1); Modified residue (3); Natural variant (5)	ATP-binding;Acetylation;Complete proteome;Disease mutation;Glutathione biosynthesis;Hereditary hemolytic anemia;Ligase;Nucleotide-binding;Phosphoprotein;Polymorphism;Reference proteome			Glutamate--cysteine ligase type 3 family	aging [GO:0007568]; cell redox homeostasis [GO:0045454]; cellular response to fibroblast growth factor stimulus [GO:0044344]; cellular response to follicle-stimulating hormone stimulus [GO:0071372]; cellular response to glucose stimulus [GO:0071333]; cellular response to hepatocyte growth factor stimulus [GO:0035729]; cellular response to insulin stimulus [GO:0032869]; cellular response to mechanical stimulus [GO:0071260]; cellular response to thyroxine stimulus [GO:0097069]; cysteine metabolic process [GO:0006534]; glutamate metabolic process [GO:0006536]; glutathione biosynthetic process [GO:0006750]; L-ascorbic acid metabolic process [GO:0019852]; negative regulation of apoptotic process [GO:0043066]; negative regulation of extrinsic apoptotic signaling pathway [GO:2001237]; negative regulation of hepatic stellate cell activation [GO:2000490]; negative regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathway [GO:1901029]; negative regulation of neuron apoptotic process [GO:0043524]; negative regulation of protein ubiquitination [GO:0031397]; negative regulation of transcription, DNA-templated [GO:0045892]; positive regulation of proteasomal ubiquitin-dependent protein catabolic process [GO:0032436]; regulation of blood vessel diameter [GO:0097746]; regulation of mitochondrial depolarization [GO:0051900]; response to activity [GO:0014823]; response to arsenic-containing substance [GO:0046685]; response to cadmium ion [GO:0046686]; response to heat [GO:0009408]; response to hormone [GO:0009725]; response to human chorionic gonadotropin [GO:0044752]; response to interleukin-1 [GO:0070555]; response to nitrosative stress [GO:0051409]; response to nutrient [GO:0007584]; response to oxidative stress [GO:0006979]; response to xenobiotic stimulus [GO:0009410]	cytosol [GO:0005829]; glutamate-cysteine ligase complex [GO:0017109]; mitochondrion [GO:0005739]	cytosol [GO:0005829]; glutamate-cysteine ligase complex [GO:0017109]; mitochondrion [GO:0005739]; ADP binding [GO:0043531]; ATP binding [GO:0005524]; coenzyme binding [GO:0050662]; glutamate binding [GO:0016595]; glutamate-cysteine ligase activity [GO:0004357]; magnesium ion binding [GO:0000287]; protein heterodimerization activity [GO:0046982]; aging [GO:0007568]; cell redox homeostasis [GO:0045454]; cellular response to fibroblast growth factor stimulus [GO:0044344]; cellular response to follicle-stimulating hormone stimulus [GO:0071372]; cellular response to glucose stimulus [GO:0071333]; cellular response to hepatocyte growth factor stimulus [GO:0035729]; cellular response to insulin stimulus [GO:0032869]; cellular response to mechanical stimulus [GO:0071260]; cellular response to thyroxine stimulus [GO:0097069]; cysteine metabolic process [GO:0006534]; glutamate metabolic process [GO:0006536]; glutathione biosynthetic process [GO:0006750]; L-ascorbic acid metabolic process [GO:0019852]; negative regulation of apoptotic process [GO:0043066]; negative regulation of extrinsic apoptotic signaling pathway [GO:2001237]; negative regulation of hepatic stellate cell activation [GO:2000490]; negative regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathway [GO:1901029]; negative regulation of neuron apoptotic process [GO:0043524]; negative regulation of protein ubiquitination [GO:0031397]; negative regulation of transcription, DNA-templated [GO:0045892]; positive regulation of proteasomal ubiquitin-dependent protein catabolic process [GO:0032436]; regulation of blood vessel diameter [GO:0097746]; regulation of mitochondrial depolarization [GO:0051900]; response to activity [GO:0014823]; response to arsenic-containing substance [GO:0046685]; response to cadmium ion [GO:0046686]; response to heat [GO:0009408]; response to hormone [GO:0009725]; response to human chorionic gonadotropin [GO:0044752]; response to interleukin-1 [GO:0070555]; response to nitrosative stress [GO:0051409]; response to nutrient [GO:0007584]; response to oxidative stress [GO:0006979]; response to xenobiotic stimulus [GO:0009410]	ADP binding [GO:0043531]; ATP binding [GO:0005524]; coenzyme binding [GO:0050662]; glutamate binding [GO:0016595]; glutamate-cysteine ligase activity [GO:0004357]; magnesium ion binding [GO:0000287]; protein heterodimerization activity [GO:0046982]	GCLC
GCLM	P48507	GSH0_HUMAN	reviewed	Glutamate--cysteine ligase regulatory subunit (GCS light chain) (Gamma-ECS regulatory subunit) (Gamma-glutamylcysteine synthetase regulatory subunit) (Glutamate--cysteine ligase modifier subunit)	GCLM GLCLR	Homo sapiens (Human)	274	5 out of 5	Alternative sequence (1); Chain (1); Modified residue (1); Natural variant (1)	Acetylation;Alternative splicing;Complete proteome;Glutathione biosynthesis;Polymorphism;Reference proteome			Aldo/keto reductase family, Glutamate--cysteine ligase light chain subfamily	aging [GO:0007568]; apoptotic mitochondrial changes [GO:0008637]; cellular response to fibroblast growth factor stimulus [GO:0044344]; cellular response to follicle-stimulating hormone stimulus [GO:0071372]; cellular response to glucose stimulus [GO:0071333]; cellular response to hepatocyte growth factor stimulus [GO:0035729]; cellular response to leukemia inhibitory factor [GO:1990830]; cellular response to thyroxine stimulus [GO:0097069]; cysteine metabolic process [GO:0006534]; glutamate metabolic process [GO:0006536]; glutathione biosynthetic process [GO:0006750]; hepatic stellate cell activation [GO:0035733]; negative regulation of extrinsic apoptotic signaling pathway [GO:2001237]; negative regulation of neuron apoptotic process [GO:0043524]; positive regulation of glutamate-cysteine ligase activity [GO:0035229]; regulation of blood vessel diameter [GO:0097746]; regulation of mitochondrial depolarization [GO:0051900]; response to activity [GO:0014823]; response to drug [GO:0042493]; response to human chorionic gonadotropin [GO:0044752]; response to nitrosative stress [GO:0051409]; response to nutrient [GO:0007584]; response to oxidative stress [GO:0006979]	cytosol [GO:0005829]; glutamate-cysteine ligase complex [GO:0017109]	cytosol [GO:0005829]; glutamate-cysteine ligase complex [GO:0017109]; enzyme regulator activity [GO:0030234]; glutamate-cysteine ligase activity [GO:0004357]; glutamate-cysteine ligase catalytic subunit binding [GO:0035226]; protein heterodimerization activity [GO:0046982]; aging [GO:0007568]; apoptotic mitochondrial changes [GO:0008637]; cellular response to fibroblast growth factor stimulus [GO:0044344]; cellular response to follicle-stimulating hormone stimulus [GO:0071372]; cellular response to glucose stimulus [GO:0071333]; cellular response to hepatocyte growth factor stimulus [GO:0035729]; cellular response to leukemia inhibitory factor [GO:1990830]; cellular response to thyroxine stimulus [GO:0097069]; cysteine metabolic process [GO:0006534]; glutamate metabolic process [GO:0006536]; glutathione biosynthetic process [GO:0006750]; hepatic stellate cell activation [GO:0035733]; negative regulation of extrinsic apoptotic signaling pathway [GO:2001237]; negative regulation of neuron apoptotic process [GO:0043524]; positive regulation of glutamate-cysteine ligase activity [GO:0035229]; regulation of blood vessel diameter [GO:0097746]; regulation of mitochondrial depolarization [GO:0051900]; response to activity [GO:0014823]; response to drug [GO:0042493]; response to human chorionic gonadotropin [GO:0044752]; response to nitrosative stress [GO:0051409]; response to nutrient [GO:0007584]; response to oxidative stress [GO:0006979]	enzyme regulator activity [GO:0030234]; glutamate-cysteine ligase activity [GO:0004357]; glutamate-cysteine ligase catalytic subunit binding [GO:0035226]; protein heterodimerization activity [GO:0046982]	GCLM
GSS	P48637	GSHB_HUMAN	reviewed	Glutathione synthetase (GSH synthetase) (GSH-S) (EC 6.3.2.3) (Glutathione synthase)	GSS	Homo sapiens (Human)	474	5 out of 5	Alternative sequence (1); Beta strand (23); Binding site (9); Chain (1); Helix (23); Initiator methionine (1); Metal binding (3); Modified residue (2); Natural variant (16); Nucleotide binding (2); Region (4); Turn (2)	3D-structure;ATP-binding;Acetylation;Alternative splicing;Complete proteome;Direct protein sequencing;Disease mutation;Glutathione biosynthesis;Hereditary hemolytic anemia;Ligase;Magnesium;Metal-binding;Nucleotide-binding;Phosphoprotein;Polymorphism;Reference proteome			Eukaryotic GSH synthase family	aging [GO:0007568]; cellular amino acid metabolic process [GO:0006520]; glutathione biosynthetic process [GO:0006750]; nervous system development [GO:0007399]; response to amino acid [GO:0043200]; response to cadmium ion [GO:0046686]; response to nutrient levels [GO:0031667]; response to oxidative stress [GO:0006979]; response to tumor necrosis factor [GO:0034612]; response to xenobiotic stimulus [GO:0009410]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]; ATP binding [GO:0005524]; glutathione binding [GO:0043295]; glutathione synthase activity [GO:0004363]; glycine binding [GO:0016594]; identical protein binding [GO:0042802]; magnesium ion binding [GO:0000287]; protein homodimerization activity [GO:0042803]; aging [GO:0007568]; cellular amino acid metabolic process [GO:0006520]; glutathione biosynthetic process [GO:0006750]; nervous system development [GO:0007399]; response to amino acid [GO:0043200]; response to cadmium ion [GO:0046686]; response to nutrient levels [GO:0031667]; response to oxidative stress [GO:0006979]; response to tumor necrosis factor [GO:0034612]; response to xenobiotic stimulus [GO:0009410]	ATP binding [GO:0005524]; glutathione binding [GO:0043295]; glutathione synthase activity [GO:0004363]; glycine binding [GO:0016594]; identical protein binding [GO:0042802]; magnesium ion binding [GO:0000287]; protein homodimerization activity [GO:0042803]	GSS
GSR	P00390	GSHR_HUMAN	reviewed	Glutathione reductase, mitochondrial (GR) (GRase) (EC 1.8.1.7)	GSR GLUR GRD1	Homo sapiens (Human)	522	5 out of 5	Active site (1); Alternative sequence (3); Beta strand (25); Chain (1); Disulfide bond (2); Erroneous initiation (1); Helix (17); Modified residue (1); Natural variant (6); Nucleotide binding (1); Transit peptide (1); Turn (4)	3D-structure;Acetylation;Alternative initiation;Alternative splicing;Complete proteome;Cytoplasm;Direct protein sequencing;Disulfide bond;FAD;Flavoprotein;Mitochondrion;NADP;Oxidoreductase;Polymorphism;Redox-active center;Reference proteome;Transit peptide	MISCELLANEOUS: The active site is a redox-active disulfide bond.	SUBCELLULAR LOCATION: Isoform Mitochondrial: Mitochondrion.; SUBCELLULAR LOCATION: Isoform Cytoplasmic: Cytoplasm.	Class-I pyridine nucleotide-disulfide oxidoreductase family	cell redox homeostasis [GO:0045454]; cellular response to oxidative stress [GO:0034599]; glutathione metabolic process [GO:0006749]; nucleobase-containing small molecule interconversion [GO:0015949]	cytosol [GO:0005829]; external side of plasma membrane [GO:0009897]; extracellular exosome [GO:0070062]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]	cytosol [GO:0005829]; external side of plasma membrane [GO:0009897]; extracellular exosome [GO:0070062]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]; electron transfer activity [GO:0009055]; flavin adenine dinucleotide binding [GO:0050660]; glutathione-disulfide reductase activity [GO:0004362]; NADP binding [GO:0050661]; cell redox homeostasis [GO:0045454]; cellular response to oxidative stress [GO:0034599]; glutathione metabolic process [GO:0006749]; nucleobase-containing small molecule interconversion [GO:0015949]	electron transfer activity [GO:0009055]; flavin adenine dinucleotide binding [GO:0050660]; glutathione-disulfide reductase activity [GO:0004362]; NADP binding [GO:0050661]	GSR
GLS	O94925	GLSK_HUMAN	reviewed	Glutaminase kidney isoform, mitochondrial (GLS) (EC 3.5.1.2) (K-glutaminase) (L-glutamine amidohydrolase) [Cleaved into: Glutaminase kidney isoform, mitochondrial 68 kDa chain; Glutaminase kidney isoform, mitochondrial 65 kDa chain]	GLS GLS1 KIAA0838	Homo sapiens (Human)	669	5 out of 5	Alternative sequence (3); Beta strand (15); Binding site (7); Chain (2); Erroneous initiation (1); Helix (29); Modified residue (4); Mutagenesis (10); Natural variant (5); Region (1); Repeat (2); Sequence conflict (4); Site (1); Transit peptide (1); Turn (6)	3D-structure;ANK repeat;Acetylation;Alternative splicing;Cataract;Complete proteome;Cytoplasm;Direct protein sequencing;Disease mutation;Epilepsy;Hydrolase;Mitochondrion;Phosphoprotein;Polymorphism;Reference proteome;Repeat;Transit peptide		SUBCELLULAR LOCATION: Isoform 1: Mitochondrion {ECO:0000250|UniProtKB:P13264}. Cytoplasm, cytosol {ECO:0000269|PubMed:22228304}. Note=The 74-kDa cytosolic precursor is translocated into the mitochondria and processed via a 72-kDa intermediate to yield the mature 68- and 65-kDa subunits. {ECO:0000250|UniProtKB:P13264}.; SUBCELLULAR LOCATION: Isoform 3: Mitochondrion {ECO:0000269|PubMed:22228304}.; SUBCELLULAR LOCATION: Glutaminase kidney isoform, mitochondrial 68 kDa chain: Mitochondrion matrix {ECO:0000250|UniProtKB:P13264}. Note=Produced by the proteolytic processing of the 74-kDa cytosolic precursor. {ECO:0000250|UniProtKB:P13264}.; SUBCELLULAR LOCATION: Glutaminase kidney isoform, mitochondrial 65 kDa chain: Mitochondrion matrix {ECO:0000250|UniProtKB:P13264}. Note=Produced by the proteolytic processing of the 74-kDa cytosolic precursor. {ECO:0000250|UniProtKB:P13264}.	Glutaminase family	cellular amino acid biosynthetic process [GO:0008652]; chemical synaptic transmission [GO:0007268]; glutamate biosynthetic process [GO:0006537]; glutamate homeostasis [GO:0090461]; glutamate secretion [GO:0014047]; glutamine catabolic process [GO:0006543]; protein homotetramerization [GO:0051289]; regulation of respiratory gaseous exchange by nervous system process [GO:0002087]; suckling behavior [GO:0001967]	cytosol [GO:0005829]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]	cytosol [GO:0005829]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]; glutaminase activity [GO:0004359]; cellular amino acid biosynthetic process [GO:0008652]; chemical synaptic transmission [GO:0007268]; glutamate biosynthetic process [GO:0006537]; glutamate homeostasis [GO:0090461]; glutamate secretion [GO:0014047]; glutamine catabolic process [GO:0006543]; protein homotetramerization [GO:0051289]; regulation of respiratory gaseous exchange by nervous system process [GO:0002087]; suckling behavior [GO:0001967]	glutaminase activity [GO:0004359]	GLS
GGCT	O75223	GGCT_HUMAN	reviewed	Gamma-glutamylcyclotransferase (EC 4.3.2.9) (Cytochrome c-releasing factor 21)	GGCT C7orf24 CRF21	Homo sapiens (Human)	188	5 out of 5	Active site (1); Alternative sequence (4); Beta strand (6); Binding site (1); Chain (1); Helix (8); Modified residue (1); Mutagenesis (4); Region (1); Turn (1)	3D-structure;Alternative splicing;Complete proteome;Lyase;Phosphoprotein;Reference proteome			Gamma-glutamylcyclotransferase family	glutathione biosynthetic process [GO:0006750]; release of cytochrome c from mitochondria [GO:0001836]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]; gamma-glutamylcyclotransferase activity [GO:0003839]; protein homodimerization activity [GO:0042803]; glutathione biosynthetic process [GO:0006750]; release of cytochrome c from mitochondria [GO:0001836]	gamma-glutamylcyclotransferase activity [GO:0003839]; protein homodimerization activity [GO:0042803]	GGCT
GLRX2	Q9NS18	GLRX2_HUMAN	reviewed	Glutaredoxin-2, mitochondrial	GLRX2 GRX2 CGI-133	Homo sapiens (Human)	164	5 out of 5	Alternative sequence (1); Beta strand (5); Binding site (3); Chain (1); Disulfide bond (1); Domain (1); Erroneous initiation (1); Frameshift (1); Helix (7); Metal binding (2); Modified residue (2); Mutagenesis (4); Natural variant (2); Transit peptide (1)	2Fe-2S;3D-structure;Alternative splicing;Complete proteome;Disulfide bond;Electron transport;Glutathionylation;Iron;Iron-sulfur;Metal-binding;Mitochondrion;Nucleus;Phosphoprotein;Polymorphism;Redox-active center;Reference proteome;Transit peptide;Transport	MISCELLANEOUS: The absence of GLRX2 dramatically sensitizes cells to cell death induced by doxorubicin/adriamycin and phenylarsine oxide.	SUBCELLULAR LOCATION: Isoform 1: Mitochondrion.; SUBCELLULAR LOCATION: Isoform 2: Nucleus.	Glutaredoxin family	aging [GO:0007568]; apoptotic process [GO:0006915]; cell differentiation [GO:0030154]; cell redox homeostasis [GO:0045454]; cellular response to superoxide [GO:0071451]; DNA protection [GO:0042262]; glutathione metabolic process [GO:0006749]; regulation of signal transduction [GO:0009966]; regulation of transcription, DNA-templated [GO:0006355]; response to hydrogen peroxide [GO:0042542]; response to organic substance [GO:0010033]; response to redox state [GO:0051775]; response to temperature stimulus [GO:0009266]	dendrite [GO:0030425]; intracellular membrane-bounded organelle [GO:0043231]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]; neuronal cell body [GO:0043025]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]	dendrite [GO:0030425]; intracellular membrane-bounded organelle [GO:0043231]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]; neuronal cell body [GO:0043025]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; 2 iron, 2 sulfur cluster binding [GO:0051537]; arsenate reductase (glutaredoxin) activity [GO:0008794]; electron transfer activity [GO:0009055]; glutathione disulfide oxidoreductase activity [GO:0015038]; metal ion binding [GO:0046872]; protein disulfide isomerase activity [GO:0003756]; protein disulfide oxidoreductase activity [GO:0015035]; aging [GO:0007568]; apoptotic process [GO:0006915]; cell differentiation [GO:0030154]; cell redox homeostasis [GO:0045454]; cellular response to superoxide [GO:0071451]; DNA protection [GO:0042262]; glutathione metabolic process [GO:0006749]; regulation of signal transduction [GO:0009966]; regulation of transcription, DNA-templated [GO:0006355]; response to hydrogen peroxide [GO:0042542]; response to organic substance [GO:0010033]; response to redox state [GO:0051775]; response to temperature stimulus [GO:0009266]	2 iron, 2 sulfur cluster binding [GO:0051537]; arsenate reductase (glutaredoxin) activity [GO:0008794]; electron transfer activity [GO:0009055]; glutathione disulfide oxidoreductase activity [GO:0015038]; metal ion binding [GO:0046872]; protein disulfide isomerase activity [GO:0003756]; protein disulfide oxidoreductase activity [GO:0015035]	GLRX2
GSTO2	Q9H4Y5	GSTO2_HUMAN	reviewed	Glutathione S-transferase omega-2 (GSTO-2) (EC 2.5.1.18) (Glutathione S-transferase omega 2-2) (GSTO 2-2) (Glutathione-dependent dehydroascorbate reductase) (EC 1.8.5.1) (Monomethylarsonic acid reductase) (MMA(V) reductase) (EC 1.20.4.2)	GSTO2	Homo sapiens (Human)	243	5 out of 5	Active site (1); Alternative sequence (2); Beta strand (6); Binding site (2); Chain (1); Domain (2); Helix (13); Mutagenesis (1); Natural variant (2); Region (1); Sequence conflict (1); Turn (1)	3D-structure;Alternative splicing;Complete proteome;Oxidoreductase;Polymorphism;Reference proteome;Transferase			GST superfamily, Omega family	cellular response to arsenic-containing substance [GO:0071243]; glutathione derivative biosynthetic process [GO:1901687]; L-ascorbic acid metabolic process [GO:0019852]; oxidation-reduction process [GO:0055114]; xenobiotic metabolic process [GO:0006805]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]; glutathione dehydrogenase (ascorbate) activity [GO:0045174]; glutathione transferase activity [GO:0004364]; identical protein binding [GO:0042802]; methylarsonate reductase activity [GO:0050610]; oxidoreductase activity [GO:0016491]; cellular response to arsenic-containing substance [GO:0071243]; glutathione derivative biosynthetic process [GO:1901687]; L-ascorbic acid metabolic process [GO:0019852]; oxidation-reduction process [GO:0055114]; xenobiotic metabolic process [GO:0006805]	glutathione dehydrogenase (ascorbate) activity [GO:0045174]; glutathione transferase activity [GO:0004364]; identical protein binding [GO:0042802]; methylarsonate reductase activity [GO:0050610]; oxidoreductase activity [GO:0016491]	GSTO2
GGT5	P36269	GGT5_HUMAN	reviewed	Glutathione hydrolase 5 proenzyme (EC 3.4.19.13) (Gamma-glutamyl transpeptidase-related enzyme) (GGT-rel) (Gamma-glutamyltransferase 5) (GGT 5) (EC 2.3.2.2) (Gamma-glutamyltransferase-like activity 1) (Gamma-glutamyltranspeptidase 5) (Leukotriene-C4 hydrolase) (EC 3.4.19.14) [Cleaved into: Glutathione hydrolase 5 heavy chain; Glutathione hydrolase 5 light chain]	GGT5 GGTLA1	Homo sapiens (Human)	586	5 out of 5	Active site (1); Alternative sequence (2); Binding site (3); Chain (2); Frameshift (1); Glycosylation (6); Natural variant (4); Region (1); Sequence conflict (2); Topological domain (2); Transmembrane (1)	Acyltransferase;Alternative splicing;Complete proteome;Glutathione biosynthesis;Glycoprotein;Hydrolase;Leukotriene biosynthesis;Membrane;Polymorphism;Protease;Reference proteome;Signal-anchor;Transferase;Transmembrane;Transmembrane helix;Zymogen		SUBCELLULAR LOCATION: Membrane {ECO:0000250}; Single-pass type II membrane protein {ECO:0000250}.	Gamma-glutamyltransferase family	cellular amino acid metabolic process [GO:0006520]; fatty acid metabolic process [GO:0006631]; glutathione biosynthetic process [GO:0006750]; glutathione catabolic process [GO:0006751]; inflammatory response [GO:0006954]; leukotriene D4 biosynthetic process [GO:1901750]; leukotriene metabolic process [GO:0006691]; proteolysis [GO:0006508]; response to estradiol [GO:0032355]; response to lipopolysaccharide [GO:0032496]; response to tumor necrosis factor [GO:0034612]; spermatogenesis [GO:0007283]	integral component of membrane [GO:0016021]; intrinsic component of plasma membrane [GO:0031226]; plasma membrane [GO:0005886]	integral component of membrane [GO:0016021]; intrinsic component of plasma membrane [GO:0031226]; plasma membrane [GO:0005886]; glutathione hydrolase activity [GO:0036374]; hypoglycin A gamma-glutamyl transpeptidase activity [GO:0102953]; leukotriene C4 gamma-glutamyl transferase activity [GO:0103068]; leukotriene-C(4) hydrolase [GO:0002951]; peptidyltransferase activity [GO:0000048]; cellular amino acid metabolic process [GO:0006520]; fatty acid metabolic process [GO:0006631]; glutathione biosynthetic process [GO:0006750]; glutathione catabolic process [GO:0006751]; inflammatory response [GO:0006954]; leukotriene D4 biosynthetic process [GO:1901750]; leukotriene metabolic process [GO:0006691]; proteolysis [GO:0006508]; response to estradiol [GO:0032355]; response to lipopolysaccharide [GO:0032496]; response to tumor necrosis factor [GO:0034612]; spermatogenesis [GO:0007283]	glutathione hydrolase activity [GO:0036374]; hypoglycin A gamma-glutamyl transpeptidase activity [GO:0102953]; leukotriene-C(4) hydrolase [GO:0002951]; leukotriene C4 gamma-glutamyl transferase activity [GO:0103068]; peptidyltransferase activity [GO:0000048]	GGT5
GGT1	P19440	GGT1_HUMAN	reviewed	Glutathione hydrolase 1 proenzyme (EC 3.4.19.13) (Gamma-glutamyltransferase 1) (Gamma-glutamyltranspeptidase 1) (GGT 1) (EC 2.3.2.2) (Leukotriene-C4 hydrolase) (EC 3.4.19.14) (CD antigen CD224) [Cleaved into: Glutathione hydrolase 1 heavy chain; Glutathione hydrolase 1 light chain]	GGT1 GGT	Homo sapiens (Human)	569	5 out of 5	Active site (1); Alternative sequence (3); Beta strand (20); Binding site (3); Chain (2); Disulfide bond (2); Erroneous initiation (1); Glycosylation (7); Helix (24); Mutagenesis (22); Natural variant (6); Region (1); Sequence conflict (6); Topological domain (2); Transmembrane (1); Turn (6)	3D-structure;Acyltransferase;Alternative promoter usage;Alternative splicing;Cell membrane;Complete proteome;Direct protein sequencing;Disulfide bond;Glutathione biosynthesis;Glycoprotein;Hydrolase;Membrane;Mental retardation;Polymorphism;Protease;Reference proteome;Sialic acid;Signal-anchor;Transferase;Transmembrane;Transmembrane helix;Zymogen	MISCELLANEOUS: Cys-454 was thought to bind the gamma-glutamyl moiety, but mutagenesis of this residue had no effect on activity.; MISCELLANEOUS: Chloride ions bound in the active site cavity may contribute to stabilize the protein fold.	SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:23682772, ECO:0000269|PubMed:8095045}; Single-pass type II membrane protein {ECO:0000269|PubMed:23682772, ECO:0000269|PubMed:8095045}.	Gamma-glutamyltransferase family	cellular amino acid metabolic process [GO:0006520]; cysteine biosynthetic process [GO:0019344]; fatty acid metabolic process [GO:0006631]; glutamate metabolic process [GO:0006536]; glutathione biosynthetic process [GO:0006750]; glutathione catabolic process [GO:0006751]; leukotriene D4 biosynthetic process [GO:1901750]; leukotriene metabolic process [GO:0006691]; peptide modification [GO:0031179]; proteolysis [GO:0006508]; regulation of immune system process [GO:0002682]; regulation of inflammatory response [GO:0050727]; response to estradiol [GO:0032355]; response to lipopolysaccharide [GO:0032496]; response to tumor necrosis factor [GO:0034612]; spermatogenesis [GO:0007283]; xenobiotic metabolic process [GO:0006805]; zymogen activation [GO:0031638]	extracellular exosome [GO:0070062]; extracellular space [GO:0005615]; integral component of membrane [GO:0016021]; plasma membrane [GO:0005886]	extracellular exosome [GO:0070062]; extracellular space [GO:0005615]; integral component of membrane [GO:0016021]; plasma membrane [GO:0005886]; glutathione hydrolase activity [GO:0036374]; hypoglycin A gamma-glutamyl transpeptidase activity [GO:0102953]; leukotriene C4 gamma-glutamyl transferase activity [GO:0103068]; leukotriene-C(4) hydrolase [GO:0002951]; peptidyltransferase activity [GO:0000048]; cellular amino acid metabolic process [GO:0006520]; cysteine biosynthetic process [GO:0019344]; fatty acid metabolic process [GO:0006631]; glutamate metabolic process [GO:0006536]; glutathione biosynthetic process [GO:0006750]; glutathione catabolic process [GO:0006751]; leukotriene D4 biosynthetic process [GO:1901750]; leukotriene metabolic process [GO:0006691]; peptide modification [GO:0031179]; proteolysis [GO:0006508]; regulation of immune system process [GO:0002682]; regulation of inflammatory response [GO:0050727]; response to estradiol [GO:0032355]; response to lipopolysaccharide [GO:0032496]; response to tumor necrosis factor [GO:0034612]; spermatogenesis [GO:0007283]; xenobiotic metabolic process [GO:0006805]; zymogen activation [GO:0031638]	glutathione hydrolase activity [GO:0036374]; hypoglycin A gamma-glutamyl transpeptidase activity [GO:0102953]; leukotriene-C(4) hydrolase [GO:0002951]; leukotriene C4 gamma-glutamyl transferase activity [GO:0103068]; peptidyltransferase activity [GO:0000048]	GGT1
GLRX3	O76003	GLRX3_HUMAN	reviewed	Glutaredoxin-3 (PKC-interacting cousin of thioredoxin) (PICOT) (PKC-theta-interacting protein) (PKCq-interacting protein) (Thioredoxin-like protein 2)	GLRX3 PICOT TXNL2 HUSSY-22	Homo sapiens (Human)	335	5 out of 5	Beta strand (15); Chain (1); Domain (3); Helix (16); Initiator methionine (1); Metal binding (2); Modified residue (3); Mutagenesis (4); Natural variant (2); Sequence conflict (3); Turn (2)	3D-structure;Acetylation;Complete proteome;Cytoplasm;Direct protein sequencing;Iron;Iron-sulfur;Metal-binding;Phosphoprotein;Polymorphism;Reference proteome;Repeat	MISCELLANEOUS: Silencing of Grx3 in HeLa cells decreases the activities of several cytosolic Fe/S proteins, such as ACO1, a major component of post-transcriptional iron regulation. As a consequence, Grx3-depleted cells show decreased levels of ferritin and increased levels of transferrin receptor, features characteristic of cellular iron starvation (PubMed:23615448). {ECO:0000305|PubMed:23615448}.	SUBCELLULAR LOCATION: Cytoplasm, cytosol {ECO:0000305|PubMed:27519415}. Cytoplasm, cell cortex {ECO:0000269|PubMed:10636891}. Cytoplasm, myofibril, sarcomere, Z line {ECO:0000250|UniProtKB:Q9CQM9}. Note=Under the plasma membrane (By similarity). After PMA stimulation, GLRX3 and PRKCQ/PKC-theta translocate to a more extended submembrane area (By similarity). In the Z line, found associated with CSRP3 (By similarity). {ECO:0000250|UniProtKB:Q9CQM9}.		[2Fe-2S] cluster assembly [GO:0044571]; cell redox homeostasis [GO:0045454]; cellular iron ion homeostasis [GO:0006879]; negative regulation of cardiac muscle hypertrophy [GO:0010614]; protein maturation by iron-sulfur cluster transfer [GO:0097428]; regulation of the force of heart contraction [GO:0002026]	cell cortex [GO:0005938]; cytosol [GO:0005829]; dendrite [GO:0030425]; nucleus [GO:0005634]; Z disc [GO:0030018]	cell cortex [GO:0005938]; cytosol [GO:0005829]; dendrite [GO:0030425]; nucleus [GO:0005634]; Z disc [GO:0030018]; electron transfer activity [GO:0009055]; identical protein binding [GO:0042802]; iron-sulfur cluster binding [GO:0051536]; metal ion binding [GO:0046872]; protein disulfide oxidoreductase activity [GO:0015035]; protein kinase C binding [GO:0005080]; RNA binding [GO:0003723]; [2Fe-2S] cluster assembly [GO:0044571]; cell redox homeostasis [GO:0045454]; cellular iron ion homeostasis [GO:0006879]; negative regulation of cardiac muscle hypertrophy [GO:0010614]; protein maturation by iron-sulfur cluster transfer [GO:0097428]; regulation of the force of heart contraction [GO:0002026]	electron transfer activity [GO:0009055]; identical protein binding [GO:0042802]; iron-sulfur cluster binding [GO:0051536]; metal ion binding [GO:0046872]; protein disulfide oxidoreductase activity [GO:0015035]; protein kinase C binding [GO:0005080]; RNA binding [GO:0003723]	GLRX3
GGT7	Q9UJ14	GGT7_HUMAN	reviewed	Glutathione hydrolase 7 (EC 3.4.19.13) (Gamma-glutamyltransferase 7) (GGT 7) (EC 2.3.2.2) (Gamma-glutamyltransferase-like 3) (Gamma-glutamyltransferase-like 5) (Gamma-glutamyltranspeptidase 7) [Cleaved into: Glutathione hydrolase 7 heavy chain; Glutathione hydrolase 7 light chain]	GGT7 GGTL3 GGTL5	Homo sapiens (Human)	662	5 out of 5	Alternative sequence (8); Chain (2); Erroneous initiation (1); Glycosylation (10); Modified residue (4); Sequence conflict (1); Topological domain (2); Transmembrane (1)	Acyltransferase;Alternative splicing;Complete proteome;Glutathione biosynthesis;Glycoprotein;Hydrolase;Membrane;Phosphoprotein;Reference proteome;Signal-anchor;Transferase;Transmembrane;Transmembrane helix;Zymogen		SUBCELLULAR LOCATION: Membrane {ECO:0000250}; Single-pass type II membrane protein {ECO:0000250}.	Gamma-glutamyltransferase family	glutathione biosynthetic process [GO:0006750]; glutathione catabolic process [GO:0006751]; leukotriene D4 biosynthetic process [GO:1901750]; negative regulation of response to oxidative stress [GO:1902883]	integral component of membrane [GO:0016021]; plasma membrane [GO:0005886]	integral component of membrane [GO:0016021]; plasma membrane [GO:0005886]; glutathione hydrolase activity [GO:0036374]; hypoglycin A gamma-glutamyl transpeptidase activity [GO:0102953]; leukotriene C4 gamma-glutamyl transferase activity [GO:0103068]; peptidyltransferase activity [GO:0000048]; glutathione biosynthetic process [GO:0006750]; glutathione catabolic process [GO:0006751]; leukotriene D4 biosynthetic process [GO:1901750]; negative regulation of response to oxidative stress [GO:1902883]	glutathione hydrolase activity [GO:0036374]; hypoglycin A gamma-glutamyl transpeptidase activity [GO:0102953]; leukotriene C4 gamma-glutamyl transferase activity [GO:0103068]; peptidyltransferase activity [GO:0000048]	GGT7
GGT2	P36268	GGT2_HUMAN	reviewed	Inactive glutathione hydrolase 2 (Gamma-glutamyltransferase 2) (Inactive gamma-glutamyltranspeptidase 2) (GGT 2)	GGT2	Homo sapiens (Human)	569	5 out of 5	Active site (1); Alternative sequence (2); Binding site (3); Chain (1); Glycosylation (2); Mutagenesis (2); Region (1); Signal peptide (1)	Alternative splicing;Complete proteome;Cytoplasm;Endoplasmic reticulum;Glycoprotein;Reference proteome;Signal		SUBCELLULAR LOCATION: Cytoplasm, perinuclear region {ECO:0000269|PubMed:23682772}. Endoplasmic reticulum {ECO:0000269|PubMed:23682772}. Note=Co-localizes with calnexin in the endoplasmic reticulum.	Gamma-glutamyltransferase family	glutathione catabolic process [GO:0006751]; leukotriene D4 biosynthetic process [GO:1901750]; peptide modification [GO:0031179]; regulation of immune system process [GO:0002682]; regulation of inflammatory response [GO:0050727]; response to estradiol [GO:0032355]; response to lipopolysaccharide [GO:0032496]; response to tumor necrosis factor [GO:0034612]; spermatogenesis [GO:0007283]	endoplasmic reticulum [GO:0005783]; extracellular exosome [GO:0070062]; perinuclear region of cytoplasm [GO:0048471]; plasma membrane [GO:0005886]	endoplasmic reticulum [GO:0005783]; extracellular exosome [GO:0070062]; perinuclear region of cytoplasm [GO:0048471]; plasma membrane [GO:0005886]; glutathione hydrolase activity [GO:0036374]; peptidyltransferase activity [GO:0000048]; glutathione catabolic process [GO:0006751]; leukotriene D4 biosynthetic process [GO:1901750]; peptide modification [GO:0031179]; regulation of immune system process [GO:0002682]; regulation of inflammatory response [GO:0050727]; response to estradiol [GO:0032355]; response to lipopolysaccharide [GO:0032496]; response to tumor necrosis factor [GO:0034612]; spermatogenesis [GO:0007283]	glutathione hydrolase activity [GO:0036374]; peptidyltransferase activity [GO:0000048]	GGT2
GSTM1	P09488	GSTM1_HUMAN	reviewed	Glutathione S-transferase Mu 1 (EC 2.5.1.18) (GST HB subunit 4) (GST class-mu 1) (GSTM1-1) (GSTM1a-1a) (GSTM1b-1b) (GTH4)	GSTM1 GST1	Homo sapiens (Human)	218	5 out of 5	Alternative sequence (1); Beta strand (7); Binding site (2); Chain (1); Domain (2); Helix (9); Initiator methionine (1); Modified residue (2); Mutagenesis (6); Natural variant (2); Region (4); Sequence conflict (2); Turn (2)	3D-structure;Alternative splicing;Complete proteome;Cytoplasm;Direct protein sequencing;Phosphoprotein;Polymorphism;Reference proteome;Transferase		SUBCELLULAR LOCATION: Cytoplasm.	GST superfamily, Mu family	cellular detoxification of nitrogen compound [GO:0070458]; glutathione derivative biosynthetic process [GO:1901687]; glutathione metabolic process [GO:0006749]; nitrobenzene metabolic process [GO:0018916]; xenobiotic catabolic process [GO:0042178]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; intercellular bridge [GO:0045171]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; intercellular bridge [GO:0045171]; enzyme binding [GO:0019899]; glutathione binding [GO:0043295]; glutathione transferase activity [GO:0004364]; protein homodimerization activity [GO:0042803]; cellular detoxification of nitrogen compound [GO:0070458]; glutathione derivative biosynthetic process [GO:1901687]; glutathione metabolic process [GO:0006749]; nitrobenzene metabolic process [GO:0018916]; xenobiotic catabolic process [GO:0042178]	enzyme binding [GO:0019899]; glutathione binding [GO:0043295]; glutathione transferase activity [GO:0004364]; protein homodimerization activity [GO:0042803]	GSTM1
GSTM5	P46439	GSTM5_HUMAN	reviewed	Glutathione S-transferase Mu 5 (EC 2.5.1.18) (GST class-mu 5) (GSTM5-5)	GSTM5	Homo sapiens (Human)	218	5 out of 5	Binding site (1); Chain (1); Domain (2); Natural variant (2); Region (4); Sequence conflict (1)	Complete proteome;Cytoplasm;Polymorphism;Reference proteome;Transferase		SUBCELLULAR LOCATION: Cytoplasm.	GST superfamily, Mu family	glutathione derivative biosynthetic process [GO:1901687]; glutathione metabolic process [GO:0006749]	cytosol [GO:0005829]; intercellular bridge [GO:0045171]	cytosol [GO:0005829]; intercellular bridge [GO:0045171]; glutathione transferase activity [GO:0004364]; identical protein binding [GO:0042802]; glutathione derivative biosynthetic process [GO:1901687]; glutathione metabolic process [GO:0006749]	glutathione transferase activity [GO:0004364]; identical protein binding [GO:0042802]	GSTM5
GSTM3	P21266	GSTM3_HUMAN	reviewed	Glutathione S-transferase Mu 3 (EC 2.5.1.18) (GST class-mu 3) (GSTM3-3) (hGSTM3-3)	GSTM3 GST5	Homo sapiens (Human)	225	5 out of 5	Beta strand (8); Binding site (1); Chain (1); Cross-link (2); Domain (2); Helix (11); Mutagenesis (4); Natural variant (1); Region (4); Sequence conflict (1)	3D-structure;Complete proteome;Cytoplasm;Direct protein sequencing;Isopeptide bond;Polymorphism;Reference proteome;Transferase;Ubl conjugation		SUBCELLULAR LOCATION: Cytoplasm.	GST superfamily, Mu family	cellular detoxification of nitrogen compound [GO:0070458]; establishment of blood-nerve barrier [GO:0008065]; glutathione derivative biosynthetic process [GO:1901687]; glutathione metabolic process [GO:0006749]; nitrobenzene metabolic process [GO:0018916]; response to estrogen [GO:0043627]; xenobiotic catabolic process [GO:0042178]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; intercellular bridge [GO:0045171]; nucleus [GO:0005634]; sperm fibrous sheath [GO:0035686]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; intercellular bridge [GO:0045171]; nucleus [GO:0005634]; sperm fibrous sheath [GO:0035686]; enzyme binding [GO:0019899]; glutathione binding [GO:0043295]; glutathione transferase activity [GO:0004364]; identical protein binding [GO:0042802]; protein homodimerization activity [GO:0042803]; cellular detoxification of nitrogen compound [GO:0070458]; establishment of blood-nerve barrier [GO:0008065]; glutathione derivative biosynthetic process [GO:1901687]; glutathione metabolic process [GO:0006749]; nitrobenzene metabolic process [GO:0018916]; response to estrogen [GO:0043627]; xenobiotic catabolic process [GO:0042178]	enzyme binding [GO:0019899]; glutathione binding [GO:0043295]; glutathione transferase activity [GO:0004364]; identical protein binding [GO:0042802]; protein homodimerization activity [GO:0042803]	GSTM3
GSTO1	P78417	GSTO1_HUMAN	reviewed	Glutathione S-transferase omega-1 (GSTO-1) (EC 2.5.1.18) (Glutathione S-transferase omega 1-1) (GSTO 1-1) (Glutathione-dependent dehydroascorbate reductase) (EC 1.8.5.1) (Monomethylarsonic acid reductase) (MMA(V) reductase) (EC 1.20.4.2) (S-(Phenacyl)glutathione reductase) (SPG-R)	GSTO1 GSTTLP28	Homo sapiens (Human)	241	5 out of 5	Active site (1); Alternative sequence (2); Beta strand (7); Binding site (2); Chain (1); Domain (2); Erroneous initiation (1); Helix (14); Initiator methionine (1); Modified residue (6); Mutagenesis (1); Natural variant (6); Region (1); Turn (2)	3D-structure;Acetylation;Alternative splicing;Complete proteome;Cytoplasm;Direct protein sequencing;Oxidoreductase;Phosphoprotein;Polymorphism;Reference proteome;Transferase		SUBCELLULAR LOCATION: Cytoplasm, cytosol {ECO:0000269|PubMed:11511179}.	GST superfamily, Omega family	cellular response to arsenic-containing substance [GO:0071243]; glutathione derivative biosynthetic process [GO:1901687]; interleukin-12-mediated signaling pathway [GO:0035722]; L-ascorbic acid metabolic process [GO:0019852]; methylation [GO:0032259]; negative regulation of ryanodine-sensitive calcium-release channel activity [GO:0060315]; oxidation-reduction process [GO:0055114]; positive regulation of ryanodine-sensitive calcium-release channel activity [GO:0060316]; positive regulation of skeletal muscle contraction by regulation of release of sequestered calcium ion [GO:0014810]; regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ion [GO:0010881]; regulation of release of sequestered calcium ion into cytosol by sarcoplasmic reticulum [GO:0010880]; xenobiotic catabolic process [GO:0042178]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; glutathione dehydrogenase (ascorbate) activity [GO:0045174]; glutathione transferase activity [GO:0004364]; methylarsonate reductase activity [GO:0050610]; oxidoreductase activity [GO:0016491]; cellular response to arsenic-containing substance [GO:0071243]; glutathione derivative biosynthetic process [GO:1901687]; interleukin-12-mediated signaling pathway [GO:0035722]; L-ascorbic acid metabolic process [GO:0019852]; methylation [GO:0032259]; negative regulation of ryanodine-sensitive calcium-release channel activity [GO:0060315]; oxidation-reduction process [GO:0055114]; positive regulation of ryanodine-sensitive calcium-release channel activity [GO:0060316]; positive regulation of skeletal muscle contraction by regulation of release of sequestered calcium ion [GO:0014810]; regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ion [GO:0010881]; regulation of release of sequestered calcium ion into cytosol by sarcoplasmic reticulum [GO:0010880]; xenobiotic catabolic process [GO:0042178]	glutathione dehydrogenase (ascorbate) activity [GO:0045174]; glutathione transferase activity [GO:0004364]; methylarsonate reductase activity [GO:0050610]; oxidoreductase activity [GO:0016491]	GSTO1
GGT6	Q6P531	GGT6_HUMAN	reviewed	Glutathione hydrolase 6 (EC 3.4.19.13) (Gamma-glutamyltransferase 6) (GGT 6) (EC 2.3.2.2) (Gamma-glutamyltranspeptidase 6) [Cleaved into: Glutathione hydrolase 6 heavy chain; Glutathione hydrolase 6 light chain]	GGT6	Homo sapiens (Human)	493	5 out of 5	Alternative sequence (1); Chain (2); Compositional bias (1); Glycosylation (2); Natural variant (2); Topological domain (2); Transmembrane (1)	Acyltransferase;Alternative splicing;Complete proteome;Glutathione biosynthesis;Glycoprotein;Hydrolase;Membrane;Polymorphism;Reference proteome;Signal-anchor;Transferase;Transmembrane;Transmembrane helix;Zymogen		SUBCELLULAR LOCATION: Membrane {ECO:0000250}; Single-pass type II membrane protein {ECO:0000250}.	Gamma-glutamyltransferase family	glutathione biosynthetic process [GO:0006750]; leukotriene D4 biosynthetic process [GO:1901750]	extracellular exosome [GO:0070062]; integral component of membrane [GO:0016021]	extracellular exosome [GO:0070062]; integral component of membrane [GO:0016021]; glutathione hydrolase activity [GO:0036374]; hypoglycin A gamma-glutamyl transpeptidase activity [GO:0102953]; leukotriene C4 gamma-glutamyl transferase activity [GO:0103068]; glutathione biosynthetic process [GO:0006750]; leukotriene D4 biosynthetic process [GO:1901750]	glutathione hydrolase activity [GO:0036374]; hypoglycin A gamma-glutamyl transpeptidase activity [GO:0102953]; leukotriene C4 gamma-glutamyl transferase activity [GO:0103068]	GGT6
GSTM4	Q03013	GSTM4_HUMAN	reviewed	Glutathione S-transferase Mu 4 (EC 2.5.1.18) (GST class-mu 4) (GST-Mu2) (GSTM4-4)	GSTM4	Homo sapiens (Human)	218	5 out of 5	Alternative sequence (3); Beta strand (5); Binding site (1); Chain (1); Domain (2); Helix (9); Natural variant (6); Region (4); Sequence conflict (3); Turn (2)	3D-structure;Alternative splicing;Complete proteome;Cytoplasm;Direct protein sequencing;Polymorphism;Reference proteome;Transferase		SUBCELLULAR LOCATION: Cytoplasm.	GST superfamily, Mu family	glutathione derivative biosynthetic process [GO:1901687]; glutathione metabolic process [GO:0006749]; long-chain fatty acid biosynthetic process [GO:0042759]; nitrobenzene metabolic process [GO:0018916]; xenobiotic catabolic process [GO:0042178]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; intercellular bridge [GO:0045171]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; intercellular bridge [GO:0045171]; enzyme binding [GO:0019899]; glutathione binding [GO:0043295]; glutathione transferase activity [GO:0004364]; protein homodimerization activity [GO:0042803]; glutathione derivative biosynthetic process [GO:1901687]; glutathione metabolic process [GO:0006749]; long-chain fatty acid biosynthetic process [GO:0042759]; nitrobenzene metabolic process [GO:0018916]; xenobiotic catabolic process [GO:0042178]	enzyme binding [GO:0019899]; glutathione binding [GO:0043295]; glutathione transferase activity [GO:0004364]; protein homodimerization activity [GO:0042803]	GSTM4
GSTA4	O15217	GSTA4_HUMAN	reviewed	Glutathione S-transferase A4 (EC 2.5.1.18) (GST class-alpha member 4) (Glutathione S-transferase A4-4)	GSTA4	Homo sapiens (Human)	222	5 out of 5	Alternative sequence (1); Beta strand (6); Binding site (2); Chain (1); Domain (2); Helix (11); Modified residue (1); Mutagenesis (2); Natural variant (2); Region (2); Turn (2)	3D-structure;Acetylation;Alternative splicing;Complete proteome;Cytoplasm;Polymorphism;Reference proteome;Transferase		SUBCELLULAR LOCATION: Cytoplasm.	GST superfamily, Alpha family	glutathione derivative biosynthetic process [GO:1901687]; glutathione metabolic process [GO:0006749]; xenobiotic metabolic process [GO:0006805]	cytosol [GO:0005829]	cytosol [GO:0005829]; glutathione transferase activity [GO:0004364]; identical protein binding [GO:0042802]; protein homodimerization activity [GO:0042803]; glutathione derivative biosynthetic process [GO:1901687]; glutathione metabolic process [GO:0006749]; xenobiotic metabolic process [GO:0006805]	glutathione transferase activity [GO:0004364]; identical protein binding [GO:0042802]; protein homodimerization activity [GO:0042803]	GSTA4
GLRX	P35754	GLRX1_HUMAN	reviewed	Glutaredoxin-1 (Thioltransferase-1) (TTase-1)	GLRX GRX	Homo sapiens (Human)	106	5 out of 5	Beta strand (4); Chain (1); Disulfide bond (2); Domain (1); Helix (5); Initiator methionine (1); Modified residue (2); Natural variant (1); Sequence conflict (1); Turn (1)	3D-structure;Acetylation;Complete proteome;Cytoplasm;Direct protein sequencing;Disulfide bond;Electron transport;Polymorphism;Redox-active center;Reference proteome;Transport		SUBCELLULAR LOCATION: Cytoplasm.	Glutaredoxin family	cell redox homeostasis [GO:0045454]; nucleobase-containing small molecule interconversion [GO:0015949]; positive regulation of membrane potential [GO:0045838]; positive regulation of sodium ion transmembrane transporter activity [GO:2000651]; protein deglutathionylation [GO:0080058]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]; nucleus [GO:0005634]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]; nucleus [GO:0005634]; electron transfer activity [GO:0009055]; glutathione disulfide oxidoreductase activity [GO:0015038]; glutathione oxidoreductase activity [GO:0097573]; protein N-terminus binding [GO:0047485]; cell redox homeostasis [GO:0045454]; nucleobase-containing small molecule interconversion [GO:0015949]; positive regulation of membrane potential [GO:0045838]; positive regulation of sodium ion transmembrane transporter activity [GO:2000651]; protein deglutathionylation [GO:0080058]	electron transfer activity [GO:0009055]; glutathione disulfide oxidoreductase activity [GO:0015038]; glutathione oxidoreductase activity [GO:0097573]; protein N-terminus binding [GO:0047485]	GLRX
GSTA3	Q16772	GSTA3_HUMAN	reviewed	Glutathione S-transferase A3 (EC 2.5.1.18) (GST class-alpha member 3) (Glutathione S-transferase A3-3)	GSTA3	Homo sapiens (Human)	222	5 out of 5	Beta strand (5); Binding site (2); Chain (1); Domain (2); Erroneous initiation (2); Helix (11); Initiator methionine (1); Modified residue (2); Natural variant (5); Region (2); Sequence conflict (3); Turn (2)	3D-structure;Acetylation;Complete proteome;Cytoplasm;Polymorphism;Reference proteome;Transferase		SUBCELLULAR LOCATION: Cytoplasm.	GST superfamily, Alpha family	glutathione derivative biosynthetic process [GO:1901687]; glutathione metabolic process [GO:0006749]; xenobiotic metabolic process [GO:0006805]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]; glutathione transferase activity [GO:0004364]; glutathione derivative biosynthetic process [GO:1901687]; glutathione metabolic process [GO:0006749]; xenobiotic metabolic process [GO:0006805]	glutathione transferase activity [GO:0004364]	GSTA3
OPLAH	O14841	OPLA_HUMAN	reviewed	5-oxoprolinase (EC 3.5.2.9) (5-oxo-L-prolinase) (5-OPase) (Pyroglutamase)	OPLAH	Homo sapiens (Human)	1288	4 out of 5	Chain (1); Frameshift (2); Modified residue (2); Natural variant (1); Sequence conflict (1)	ATP-binding;Complete proteome;Hydrolase;Nucleotide-binding;Phosphoprotein;Polymorphism;Reference proteome			Oxoprolinase family	glutathione biosynthetic process [GO:0006750]; glutathione metabolic process [GO:0006749]	cytosol [GO:0005829]	cytosol [GO:0005829]; 5-oxoprolinase (ATP-hydrolyzing) activity [GO:0017168]; ATP binding [GO:0005524]; glutathione biosynthetic process [GO:0006750]; glutathione metabolic process [GO:0006749]	5-oxoprolinase (ATP-hydrolyzing) activity [GO:0017168]; ATP binding [GO:0005524]	OPLAH
GLRX5	Q86SX6	GLRX5_HUMAN	reviewed	Glutaredoxin-related protein 5, mitochondrial (Monothiol glutaredoxin-5)	GLRX5 C14orf87	Homo sapiens (Human)	157	5 out of 5	Beta strand (5); Binding site (2); Chain (1); Compositional bias (3); Domain (1); Erroneous initiation (1); Helix (5); Metal binding (1); Modified residue (2); Natural variant (4); Region (2); Transit peptide (1); Turn (1)	2Fe-2S;3D-structure;Complete proteome;Disease mutation;Iron;Iron-sulfur;Metal-binding;Mitochondrion;Phosphoprotein;Polymorphism;Redox-active center;Reference proteome;Transit peptide		SUBCELLULAR LOCATION: Mitochondrion matrix {ECO:0000269|PubMed:20364084}.	Glutaredoxin family, Monothiol subfamily	cell redox homeostasis [GO:0045454]; hemopoiesis [GO:0030097]; protein lipoylation [GO:0009249]; small molecule metabolic process [GO:0044281]	dendrite [GO:0030425]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]; neuronal cell body [GO:0043025]; nucleus [GO:0005634]	dendrite [GO:0030425]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]; neuronal cell body [GO:0043025]; nucleus [GO:0005634]; 2 iron, 2 sulfur cluster binding [GO:0051537]; electron transfer activity [GO:0009055]; metal ion binding [GO:0046872]; protein disulfide oxidoreductase activity [GO:0015035]; cell redox homeostasis [GO:0045454]; hemopoiesis [GO:0030097]; protein lipoylation [GO:0009249]; small molecule metabolic process [GO:0044281]	2 iron, 2 sulfur cluster binding [GO:0051537]; electron transfer activity [GO:0009055]; metal ion binding [GO:0046872]; protein disulfide oxidoreductase activity [GO:0015035]	GLRX5
GSTA5	Q7RTV2	GSTA5_HUMAN	reviewed	Glutathione S-transferase A5 (EC 2.5.1.18) (GST class-alpha member 5) (Glutathione S-transferase A5-5)	GSTA5	Homo sapiens (Human)	222	4 out of 5	Binding site (2); Chain (1); Domain (2); Initiator methionine (1); Modified residue (2); Natural variant (1); Region (2)	Acetylation;Complete proteome;Cytoplasm;Polymorphism;Reference proteome;Transferase		SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}.	GST superfamily, Alpha family	glutathione metabolic process [GO:0006749]; xenobiotic metabolic process [GO:0006805]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]; glutathione transferase activity [GO:0004364]; glutathione metabolic process [GO:0006749]; xenobiotic metabolic process [GO:0006805]	glutathione transferase activity [GO:0004364]	GSTA5
GSTK1	Q9Y2Q3	GSTK1_HUMAN	reviewed	Glutathione S-transferase kappa 1 (EC 2.5.1.18) (GST 13-13) (GST class-kappa) (GSTK1-1) (hGSTK1) (Glutathione S-transferase subunit 13)	GSTK1 HDCMD47P	Homo sapiens (Human)	226	5 out of 5	Alternative sequence (3); Beta strand (6); Binding site (2); Chain (1); Helix (11); Modified residue (10); Region (2); Sequence conflict (5); Turn (2)	3D-structure;Acetylation;Alternative splicing;Complete proteome;Peroxisome;Reference proteome;Transferase		SUBCELLULAR LOCATION: Peroxisome {ECO:0000269|PubMed:14742434}.	GST superfamily, Kappa family	epithelial cell differentiation [GO:0030855]; glutathione derivative biosynthetic process [GO:1901687]; glutathione metabolic process [GO:0006749]; protein targeting to peroxisome [GO:0006625]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]; intracellular [GO:0005622]; membrane [GO:0016020]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]; peroxisomal matrix [GO:0005782]; peroxisome [GO:0005777]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]; intracellular [GO:0005622]; membrane [GO:0016020]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]; peroxisomal matrix [GO:0005782]; peroxisome [GO:0005777]; glutathione peroxidase activity [GO:0004602]; glutathione transferase activity [GO:0004364]; protein disulfide oxidoreductase activity [GO:0015035]; epithelial cell differentiation [GO:0030855]; glutathione derivative biosynthetic process [GO:1901687]; glutathione metabolic process [GO:0006749]; protein targeting to peroxisome [GO:0006625]	glutathione peroxidase activity [GO:0004602]; glutathione transferase activity [GO:0004364]; protein disulfide oxidoreductase activity [GO:0015035]	GSTK1
GSTM2	P28161	GSTM2_HUMAN	reviewed	Glutathione S-transferase Mu 2 (EC 2.5.1.18) (GST class-mu 2) (GSTM2-2)	GSTM2 GST4	Homo sapiens (Human)	218	5 out of 5	Alternative sequence (1); Beta strand (8); Binding site (2); Chain (1); Domain (2); Helix (9); Modified residue (2); Mutagenesis (1); Natural variant (1); Region (4); Sequence conflict (3); Site (1); Turn (4)	3D-structure;Alternative splicing;Complete proteome;Cytoplasm;Direct protein sequencing;Phosphoprotein;Polymorphism;Reference proteome;Transferase		SUBCELLULAR LOCATION: Cytoplasm.	GST superfamily, Mu family	cellular detoxification of nitrogen compound [GO:0070458]; cellular response to caffeine [GO:0071313]; glutathione derivative biosynthetic process [GO:1901687]; glutathione metabolic process [GO:0006749]; linoleic acid metabolic process [GO:0043651]; negative regulation of ryanodine-sensitive calcium-release channel activity [GO:0060315]; nitrobenzene metabolic process [GO:0018916]; positive regulation of ryanodine-sensitive calcium-release channel activity [GO:0060316]; regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ion [GO:0010881]; regulation of release of sequestered calcium ion into cytosol by sarcoplasmic reticulum [GO:0010880]; regulation of skeletal muscle contraction by regulation of release of sequestered calcium ion [GO:0014809]; relaxation of cardiac muscle [GO:0055119]; xenobiotic catabolic process [GO:0042178]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; intercellular bridge [GO:0045171]; sarcoplasmic reticulum [GO:0016529]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; intercellular bridge [GO:0045171]; sarcoplasmic reticulum [GO:0016529]; enzyme binding [GO:0019899]; glutathione binding [GO:0043295]; glutathione peroxidase activity [GO:0004602]; glutathione transferase activity [GO:0004364]; protein homodimerization activity [GO:0042803]; signaling receptor binding [GO:0005102]; cellular detoxification of nitrogen compound [GO:0070458]; cellular response to caffeine [GO:0071313]; glutathione derivative biosynthetic process [GO:1901687]; glutathione metabolic process [GO:0006749]; linoleic acid metabolic process [GO:0043651]; negative regulation of ryanodine-sensitive calcium-release channel activity [GO:0060315]; nitrobenzene metabolic process [GO:0018916]; positive regulation of ryanodine-sensitive calcium-release channel activity [GO:0060316]; regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ion [GO:0010881]; regulation of release of sequestered calcium ion into cytosol by sarcoplasmic reticulum [GO:0010880]; regulation of skeletal muscle contraction by regulation of release of sequestered calcium ion [GO:0014809]; relaxation of cardiac muscle [GO:0055119]; xenobiotic catabolic process [GO:0042178]	enzyme binding [GO:0019899]; glutathione binding [GO:0043295]; glutathione peroxidase activity [GO:0004602]; glutathione transferase activity [GO:0004364]; protein homodimerization activity [GO:0042803]; signaling receptor binding [GO:0005102]	GSTM2
GSTA1	P08263	GSTA1_HUMAN	reviewed	Glutathione S-transferase A1 (EC 2.5.1.18) (13-hydroperoxyoctadecadienoate peroxidase) (EC 1.11.1.-) (Androst-5-ene-3,17-dione isomerase) (EC 5.3.3.-) (GST HA subunit 1) (GST class-alpha member 1) (GST-epsilon) (GSTA1-1) (GTH1) [Cleaved into: Glutathione S-transferase A1, N-terminally processed]	GSTA1	Homo sapiens (Human)	222	5 out of 5	Beta strand (5); Binding site (2); Chain (2); Domain (2); Helix (11); Initiator methionine (1); Modified residue (3); Mutagenesis (3); Natural variant (3); Region (2); Sequence conflict (5); Turn (2)	3D-structure;Acetylation;Complete proteome;Cytoplasm;Direct protein sequencing;Isomerase;Oxidoreductase;Peroxidase;Polymorphism;Reference proteome;Transferase		SUBCELLULAR LOCATION: Cytoplasm.	GST superfamily, Alpha family	epithelial cell differentiation [GO:0030855]; glutathione derivative biosynthetic process [GO:1901687]; glutathione metabolic process [GO:0006749]; linoleic acid metabolic process [GO:0043651]; prostaglandin metabolic process [GO:0006693]; xenobiotic metabolic process [GO:0006805]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]; glutathione peroxidase activity [GO:0004602]; glutathione transferase activity [GO:0004364]; steroid delta-isomerase activity [GO:0004769]; epithelial cell differentiation [GO:0030855]; glutathione derivative biosynthetic process [GO:1901687]; glutathione metabolic process [GO:0006749]; linoleic acid metabolic process [GO:0043651]; prostaglandin metabolic process [GO:0006693]; xenobiotic metabolic process [GO:0006805]	glutathione peroxidase activity [GO:0004602]; glutathione transferase activity [GO:0004364]; steroid delta-isomerase activity [GO:0004769]	GSTA1
GSTA2	P09210	GSTA2_HUMAN	reviewed	Glutathione S-transferase A2 (EC 2.5.1.18) (GST HA subunit 2) (GST class-alpha member 2) (GST-gamma) (GSTA2-2) (GTH2)	GSTA2 GST2	Homo sapiens (Human)	222	5 out of 5	Beta strand (6); Binding site (2); Chain (1); Domain (2); Helix (11); Initiator methionine (1); Modified residue (2); Natural variant (4); Region (2); Sequence conflict (5); Turn (3)	3D-structure;Acetylation;Complete proteome;Cytoplasm;Direct protein sequencing;Polymorphism;Reference proteome;Transferase		SUBCELLULAR LOCATION: Cytoplasm.	GST superfamily, Alpha family	epithelial cell differentiation [GO:0030855]; glutathione derivative biosynthetic process [GO:1901687]; glutathione metabolic process [GO:0006749]; interleukin-12-mediated signaling pathway [GO:0035722]; xenobiotic metabolic process [GO:0006805]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]; glutathione transferase activity [GO:0004364]; epithelial cell differentiation [GO:0030855]; glutathione derivative biosynthetic process [GO:1901687]; glutathione metabolic process [GO:0006749]; interleukin-12-mediated signaling pathway [GO:0035722]; xenobiotic metabolic process [GO:0006805]	glutathione transferase activity [GO:0004364]	GSTA2
MTHFD2	P13995	MTDC_HUMAN	reviewed	Bifunctional methylenetetrahydrofolate dehydrogenase/cyclohydrolase, mitochondrial [Includes: NAD-dependent methylenetetrahydrofolate dehydrogenase (EC 1.5.1.15); Methenyltetrahydrofolate cyclohydrolase (EC 3.5.4.9)]	MTHFD2 NMDMC	Homo sapiens (Human)	350	5 out of 5	Alternative sequence (1); Beta strand (12); Binding site (1); Chain (1); Cross-link (1); Erroneous initiation (4); Helix (12); Modified residue (1); Mutagenesis (10); Nucleotide binding (1); Region (3); Sequence conflict (2); Transit peptide (1); Turn (3)	3D-structure;Acetylation;Alternative splicing;Complete proteome;Hydrolase;Isopeptide bond;Magnesium;Mitochondrion;Multifunctional enzyme;NAD;NADP;One-carbon metabolism;Oxidoreductase;Reference proteome;Transit peptide;Ubl conjugation	MISCELLANEOUS: This NAD-dependent bifunctional enzyme has very different kinetic properties than the larger NADP-dependent trifunctional enzyme and is unique in that it requires formation of an enzyme-magnesium complex to allow binding of NAD.	SUBCELLULAR LOCATION: Mitochondrion.	Tetrahydrofolate dehydrogenase/cyclohydrolase family	folic acid metabolic process [GO:0046655]; tetrahydrofolate interconversion [GO:0035999]; tetrahydrofolate metabolic process [GO:0046653]	extracellular space [GO:0005615]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]	extracellular space [GO:0005615]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]; magnesium ion binding [GO:0000287]; methenyltetrahydrofolate cyclohydrolase activity [GO:0004477]; methylenetetrahydrofolate dehydrogenase (NAD+) activity [GO:0004487]; methylenetetrahydrofolate dehydrogenase (NADP+) activity [GO:0004488]; phosphate ion binding [GO:0042301]; folic acid metabolic process [GO:0046655]; tetrahydrofolate interconversion [GO:0035999]; tetrahydrofolate metabolic process [GO:0046653]	magnesium ion binding [GO:0000287]; methenyltetrahydrofolate cyclohydrolase activity [GO:0004477]; methylenetetrahydrofolate dehydrogenase (NAD+) activity [GO:0004487]; methylenetetrahydrofolate dehydrogenase (NADP+) activity [GO:0004488]; phosphate ion binding [GO:0042301]	MTHFD2
MTHFD1	P11586	C1TC_HUMAN	reviewed	C-1-tetrahydrofolate synthase, cytoplasmic (C1-THF synthase) [Cleaved into: C-1-tetrahydrofolate synthase, cytoplasmic, N-terminally processed] [Includes: Methylenetetrahydrofolate dehydrogenase (EC 1.5.1.5); Methenyltetrahydrofolate cyclohydrolase (EC 3.5.4.9); Formyltetrahydrofolate synthetase (EC 6.3.4.3)]	MTHFD1 MTHFC MTHFD	Homo sapiens (Human)	935	5 out of 5	Beta strand (9); Binding site (1); Chain (2); Helix (12); Initiator methionine (1); Modified residue (4); Mutagenesis (8); Natural variant (11); Nucleotide binding (2); Region (5); Turn (3)	3D-structure;ATP-binding;Acetylation;Amino-acid biosynthesis;Complete proteome;Cytoplasm;Direct protein sequencing;Disease mutation;Histidine biosynthesis;Hydrolase;Ligase;Methionine biosynthesis;Multifunctional enzyme;NADP;Nucleotide-binding;One-carbon metabolism;Oxidoreductase;Phosphoprotein;Polymorphism;Purine biosynthesis;Reference proteome		SUBCELLULAR LOCATION: Cytoplasm.	Tetrahydrofolate dehydrogenase/cyclohydrolase family; Formate--tetrahydrofolate ligase family	10-formyltetrahydrofolate biosynthetic process [GO:0009257]; embryonic neurocranium morphogenesis [GO:0048702]; embryonic viscerocranium morphogenesis [GO:0048703]; folic acid metabolic process [GO:0046655]; heart development [GO:0007507]; histidine biosynthetic process [GO:0000105]; methionine biosynthetic process [GO:0009086]; methionine metabolic process [GO:0006555]; neural tube closure [GO:0001843]; one-carbon metabolic process [GO:0006730]; purine nucleobase biosynthetic process [GO:0009113]; purine nucleotide biosynthetic process [GO:0006164]; serine family amino acid biosynthetic process [GO:0009070]; serine family amino acid metabolic process [GO:0009069]; somite development [GO:0061053]; tetrahydrofolate interconversion [GO:0035999]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; membrane [GO:0016020]; mitochondrion [GO:0005739]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; membrane [GO:0016020]; mitochondrion [GO:0005739]; ATP binding [GO:0005524]; formate-tetrahydrofolate ligase activity [GO:0004329]; methenyltetrahydrofolate cyclohydrolase activity [GO:0004477]; methylenetetrahydrofolate dehydrogenase (NAD+) activity [GO:0004487]; methylenetetrahydrofolate dehydrogenase (NADP+) activity [GO:0004488]; methylenetetrahydrofolate dehydrogenase [NAD(P)+] activity [GO:0004486]; 10-formyltetrahydrofolate biosynthetic process [GO:0009257]; embryonic neurocranium morphogenesis [GO:0048702]; embryonic viscerocranium morphogenesis [GO:0048703]; folic acid metabolic process [GO:0046655]; heart development [GO:0007507]; histidine biosynthetic process [GO:0000105]; methionine biosynthetic process [GO:0009086]; methionine metabolic process [GO:0006555]; neural tube closure [GO:0001843]; one-carbon metabolic process [GO:0006730]; purine nucleobase biosynthetic process [GO:0009113]; purine nucleotide biosynthetic process [GO:0006164]; serine family amino acid biosynthetic process [GO:0009070]; serine family amino acid metabolic process [GO:0009069]; somite development [GO:0061053]; tetrahydrofolate interconversion [GO:0035999]	ATP binding [GO:0005524]; formate-tetrahydrofolate ligase activity [GO:0004329]; methenyltetrahydrofolate cyclohydrolase activity [GO:0004477]; methylenetetrahydrofolate dehydrogenase (NAD+) activity [GO:0004487]; methylenetetrahydrofolate dehydrogenase (NADP+) activity [GO:0004488]; methylenetetrahydrofolate dehydrogenase [NAD(P)+] activity [GO:0004486]	MTHFD1
MTHFD1L	Q6UB35	C1TM_HUMAN	reviewed	Monofunctional C1-tetrahydrofolate synthase, mitochondrial (EC 6.3.4.3) (Formyltetrahydrofolate synthetase)	MTHFD1L FTHFSDC1	Homo sapiens (Human)	978	5 out of 5	Alternative sequence (2); Chain (1); Compositional bias (1); Erroneous initiation (2); Modified residue (4); Natural variant (1); Nucleotide binding (1); Region (2); Sequence conflict (2); Transit peptide (1)	ATP-binding;Acetylation;Alternative splicing;Complete proteome;Direct protein sequencing;Ligase;Mitochondrion;Nucleotide-binding;One-carbon metabolism;Phosphoprotein;Polymorphism;Reference proteome;Transit peptide	MISCELLANEOUS: May participate in the progression of colorectal cancer by conferring growth advantage. Could be a new molecular target for cancer therapy.	SUBCELLULAR LOCATION: Mitochondrion {ECO:0000269|PubMed:12937168}.	Tetrahydrofolate dehydrogenase/cyclohydrolase family; Formate--tetrahydrofolate ligase family	10-formyltetrahydrofolate biosynthetic process [GO:0009257]; embryonic neurocranium morphogenesis [GO:0048702]; embryonic viscerocranium morphogenesis [GO:0048703]; folic acid-containing compound metabolic process [GO:0006760]; folic acid metabolic process [GO:0046655]; formate metabolic process [GO:0015942]; neural tube closure [GO:0001843]; purine nucleobase biosynthetic process [GO:0009113]; tetrahydrofolate interconversion [GO:0035999]	cytoplasm [GO:0005737]; membrane [GO:0016020]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]	cytoplasm [GO:0005737]; membrane [GO:0016020]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]; ATP binding [GO:0005524]; formate-tetrahydrofolate ligase activity [GO:0004329]; methylenetetrahydrofolate dehydrogenase (NADP+) activity [GO:0004488]; protein homodimerization activity [GO:0042803]; 10-formyltetrahydrofolate biosynthetic process [GO:0009257]; embryonic neurocranium morphogenesis [GO:0048702]; embryonic viscerocranium morphogenesis [GO:0048703]; folic acid metabolic process [GO:0046655]; folic acid-containing compound metabolic process [GO:0006760]; formate metabolic process [GO:0015942]; neural tube closure [GO:0001843]; purine nucleobase biosynthetic process [GO:0009113]; tetrahydrofolate interconversion [GO:0035999]	ATP binding [GO:0005524]; formate-tetrahydrofolate ligase activity [GO:0004329]; methylenetetrahydrofolate dehydrogenase (NADP+) activity [GO:0004488]; protein homodimerization activity [GO:0042803]	MTHFD1L
MTHFD2L	Q9H903	MTD2L_HUMAN	reviewed	Probable bifunctional methylenetetrahydrofolate dehydrogenase/cyclohydrolase 2 (NADP-dependent methylenetetrahydrofolate dehydrogenase 2-like protein) (MTHFD2-like) [Includes: NAD-dependent methylenetetrahydrofolate dehydrogenase (EC 1.5.1.15); Methenyltetrahydrofolate cyclohydrolase (EC 3.5.4.9)]	MTHFD2L	Homo sapiens (Human)	347	5 out of 5	Alternative sequence (5); Binding site (1); Chain (1); Erroneous initiation (1); Nucleotide binding (1); Region (3); Sequence caution (1)	Alternative splicing;Amino-acid biosynthesis;Complete proteome;Histidine biosynthesis;Hydrolase;Magnesium;Membrane;Methionine biosynthesis;Mitochondrion;Mitochondrion inner membrane;Multifunctional enzyme;NAD;One-carbon metabolism;Oxidoreductase;Purine biosynthesis;Reference proteome		SUBCELLULAR LOCATION: Mitochondrion inner membrane {ECO:0000250}; Peripheral membrane protein {ECO:0000250}; Matrix side {ECO:0000250}.	Tetrahydrofolate dehydrogenase/cyclohydrolase family	10-formyltetrahydrofolate metabolic process [GO:0009256]; folic acid metabolic process [GO:0046655]; histidine biosynthetic process [GO:0000105]; methionine biosynthetic process [GO:0009086]; purine nucleotide biosynthetic process [GO:0006164]; tetrahydrofolate interconversion [GO:0035999]	mitochondrial inner membrane [GO:0005743]; mitochondrial matrix [GO:0005759]	mitochondrial inner membrane [GO:0005743]; mitochondrial matrix [GO:0005759]; methenyltetrahydrofolate cyclohydrolase activity [GO:0004477]; methylenetetrahydrofolate dehydrogenase (NAD+) activity [GO:0004487]; methylenetetrahydrofolate dehydrogenase (NADP+) activity [GO:0004488]; 10-formyltetrahydrofolate metabolic process [GO:0009256]; folic acid metabolic process [GO:0046655]; histidine biosynthetic process [GO:0000105]; methionine biosynthetic process [GO:0009086]; purine nucleotide biosynthetic process [GO:0006164]; tetrahydrofolate interconversion [GO:0035999]	methenyltetrahydrofolate cyclohydrolase activity [GO:0004477]; methylenetetrahydrofolate dehydrogenase (NAD+) activity [GO:0004487]; methylenetetrahydrofolate dehydrogenase (NADP+) activity [GO:0004488]	MTHFD2L
MTHFR	P42898	MTHR_HUMAN	reviewed	Methylenetetrahydrofolate reductase (EC 1.5.1.20)	MTHFR	Homo sapiens (Human)	656	5 out of 5	Active site (1); Alternative sequence (1); Beta strand (18); Binding site (8); Chain (1); Helix (28); Natural variant (65); Nucleotide binding (5); Turn (2)	3D-structure;Allosteric enzyme;Alternative splicing;Complete proteome;Disease mutation;FAD;Flavoprotein;NADP;Oxidoreductase;Polymorphism;Reference proteome;Schizophrenia			Methylenetetrahydrofolate reductase family	folic acid metabolic process [GO:0046655]; heterochromatin maintenance [GO:0070829]; homocysteine metabolic process [GO:0050667]; methionine biosynthetic process [GO:0009086]; methionine metabolic process [GO:0006555]; neural tube closure [GO:0001843]; regulation of histone methylation [GO:0031060]; response to amino acid [GO:0043200]; response to folic acid [GO:0051593]; response to hypoxia [GO:0001666]; response to interleukin-1 [GO:0070555]; response to vitamin B2 [GO:0033274]; S-adenosylmethionine metabolic process [GO:0046500]; tetrahydrofolate interconversion [GO:0035999]	cytosol [GO:0005829]; synapse [GO:0045202]	cytosol [GO:0005829]; synapse [GO:0045202]; FAD binding [GO:0071949]; flavin adenine dinucleotide binding [GO:0050660]; methylenetetrahydrofolate reductase (NAD(P)H) activity [GO:0004489]; modified amino acid binding [GO:0072341]; NADP binding [GO:0050661]; protein-containing complex binding [GO:0044877]; folic acid metabolic process [GO:0046655]; heterochromatin maintenance [GO:0070829]; homocysteine metabolic process [GO:0050667]; methionine biosynthetic process [GO:0009086]; methionine metabolic process [GO:0006555]; neural tube closure [GO:0001843]; regulation of histone methylation [GO:0031060]; response to amino acid [GO:0043200]; response to folic acid [GO:0051593]; response to hypoxia [GO:0001666]; response to interleukin-1 [GO:0070555]; response to vitamin B2 [GO:0033274]; S-adenosylmethionine metabolic process [GO:0046500]; tetrahydrofolate interconversion [GO:0035999]	FAD binding [GO:0071949]; flavin adenine dinucleotide binding [GO:0050660]; methylenetetrahydrofolate reductase (NAD(P)H) activity [GO:0004489]; modified amino acid binding [GO:0072341]; NADP binding [GO:0050661]; protein-containing complex binding [GO:0044877]	MTHFR
DHFR2	Q86XF0	DYR2_HUMAN	reviewed	Dihydrofolate reductase 2, mitochondrial (Dihydrofolate reductase, mitochondrial) (EC 1.5.1.3) (Dihydrofolate reductase-like protein 1)	DHFR2 DHFRL1 DHFRP4	Homo sapiens (Human)	187	5 out of 5	Binding site (2); Chain (1); Domain (1); Natural variant (1); Nucleotide binding (4); Region (1)	Complete proteome;Membrane;Mitochondrion;Mitochondrion inner membrane;NADP;One-carbon metabolism;Oxidoreductase;Polymorphism;Reference proteome	MISCELLANEOUS: Humans have acquired two dihydrofolate reductase enzymes during their evolution, DHFR and DHFR2. In contrast to human, mice and brown rats have just one. {ECO:0000269|PubMed:25980602}.	SUBCELLULAR LOCATION: Mitochondrion {ECO:0000269|PubMed:21876184, ECO:0000269|PubMed:21876188}. Mitochondrion matrix {ECO:0000269|PubMed:21876188}. Mitochondrion inner membrane {ECO:0000269|PubMed:21876188}.	Dihydrofolate reductase family	dihydrofolate metabolic process [GO:0046452]; folic acid metabolic process [GO:0046655]; one-carbon metabolic process [GO:0006730]; tetrahydrofolate biosynthetic process [GO:0046654]; tetrahydrofolate metabolic process [GO:0046653]; thymidine biosynthetic process [GO:0046105]	mitochondrial inner membrane [GO:0005743]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]	mitochondrial inner membrane [GO:0005743]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]; dihydrofolate reductase activity [GO:0004146]; mRNA binding [GO:0003729]; NADP binding [GO:0050661]; dihydrofolate metabolic process [GO:0046452]; folic acid metabolic process [GO:0046655]; one-carbon metabolic process [GO:0006730]; tetrahydrofolate biosynthetic process [GO:0046654]; tetrahydrofolate metabolic process [GO:0046653]; thymidine biosynthetic process [GO:0046105]	dihydrofolate reductase activity [GO:0004146]; mRNA binding [GO:0003729]; NADP binding [GO:0050661]	DHFR2
DHFR	P00374	DYR_HUMAN	reviewed	Dihydrofolate reductase (EC 1.5.1.3)	DHFR	Homo sapiens (Human)	187	5 out of 5	Alternative sequence (1); Beta strand (15); Binding site (3); Chain (1); Domain (1); Helix (5); Mutagenesis (8); Natural variant (2); Nucleotide binding (4); Region (1); Sequence conflict (1); Turn (2)	3D-structure;Alternative splicing;Complete proteome;Cytoplasm;Disease mutation;Methotrexate resistance;Mitochondrion;NADP;One-carbon metabolism;Oxidoreductase;RNA-binding;Reference proteome		SUBCELLULAR LOCATION: Mitochondrion {ECO:0000250|UniProtKB:P00375}. Cytoplasm {ECO:0000250|UniProtKB:P00375}.	Dihydrofolate reductase family	axon regeneration [GO:0031103]; dihydrofolate metabolic process [GO:0046452]; folic acid metabolic process [GO:0046655]; negative regulation of translation [GO:0017148]; one-carbon metabolic process [GO:0006730]; oxidation-reduction process [GO:0055114]; positive regulation of nitric-oxide synthase activity [GO:0051000]; regulation of removal of superoxide radicals [GO:2000121]; regulation of transcription involved in G1/S transition of mitotic cell cycle [GO:0000083]; response to methotrexate [GO:0031427]; tetrahydrobiopterin biosynthetic process [GO:0006729]; tetrahydrofolate biosynthetic process [GO:0046654]; tetrahydrofolate metabolic process [GO:0046653]	cytosol [GO:0005829]; mitochondrion [GO:0005739]	cytosol [GO:0005829]; mitochondrion [GO:0005739]; dihydrofolate reductase activity [GO:0004146]; drug binding [GO:0008144]; folic acid binding [GO:0005542]; methotrexate binding [GO:0051870]; mRNA binding [GO:0003729]; NADP binding [GO:0050661]; NADPH binding [GO:0070402]; sequence-specific mRNA binding [GO:1990825]; translation repressor activity, mRNA regulatory element binding [GO:0000900]; axon regeneration [GO:0031103]; dihydrofolate metabolic process [GO:0046452]; folic acid metabolic process [GO:0046655]; negative regulation of translation [GO:0017148]; one-carbon metabolic process [GO:0006730]; oxidation-reduction process [GO:0055114]; positive regulation of nitric-oxide synthase activity [GO:0051000]; regulation of removal of superoxide radicals [GO:2000121]; regulation of transcription involved in G1/S transition of mitotic cell cycle [GO:0000083]; response to methotrexate [GO:0031427]; tetrahydrobiopterin biosynthetic process [GO:0006729]; tetrahydrofolate biosynthetic process [GO:0046654]; tetrahydrofolate metabolic process [GO:0046653]	dihydrofolate reductase activity [GO:0004146]; drug binding [GO:0008144]; folic acid binding [GO:0005542]; methotrexate binding [GO:0051870]; mRNA binding [GO:0003729]; NADP binding [GO:0050661]; NADPH binding [GO:0070402]; sequence-specific mRNA binding [GO:1990825]; translation repressor activity, mRNA regulatory element binding [GO:0000900]	DHFR
GLUD1	P00367	DHE3_HUMAN	reviewed	Glutamate dehydrogenase 1, mitochondrial (GDH 1) (EC 1.4.1.3)	GLUD1 GLUD	Homo sapiens (Human)	558	5 out of 5	Active site (1); Alternative sequence (3); Beta strand (18); Binding site (12); Chain (1); Helix (23); Modified residue (54); Mutagenesis (3); Natural variant (13); Nucleotide binding (1); Transit peptide (1); Turn (6)	3D-structure;ADP-ribosylation;ATP-binding;Acetylation;Alternative splicing;Complete proteome;Direct protein sequencing;Disease mutation;GTP-binding;Mitochondrion;NADP;Nucleotide-binding;Oxidoreductase;Phosphoprotein;Reference proteome;Transit peptide		SUBCELLULAR LOCATION: Mitochondrion matrix.	Glu/Leu/Phe/Val dehydrogenases family	cellular amino acid biosynthetic process [GO:0008652]; glutamate biosynthetic process [GO:0006537]; glutamate catabolic process [GO:0006538]; glutamine metabolic process [GO:0006541]; positive regulation of insulin secretion [GO:0032024]; substantia nigra development [GO:0021762]; tricarboxylic acid metabolic process [GO:0072350]	cytoplasm [GO:0005737]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]	cytoplasm [GO:0005737]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]; ADP binding [GO:0043531]; ATP binding [GO:0005524]; glutamate dehydrogenase (NAD+) activity [GO:0004352]; glutamate dehydrogenase [NAD(P)+] activity [GO:0004353]; GTP binding [GO:0005525]; identical protein binding [GO:0042802]; leucine binding [GO:0070728]; NAD+ binding [GO:0070403]; cellular amino acid biosynthetic process [GO:0008652]; glutamate biosynthetic process [GO:0006537]; glutamate catabolic process [GO:0006538]; glutamine metabolic process [GO:0006541]; positive regulation of insulin secretion [GO:0032024]; substantia nigra development [GO:0021762]; tricarboxylic acid metabolic process [GO:0072350]	ADP binding [GO:0043531]; ATP binding [GO:0005524]; glutamate dehydrogenase (NAD+) activity [GO:0004352]; glutamate dehydrogenase [NAD(P)+] activity [GO:0004353]; GTP binding [GO:0005525]; identical protein binding [GO:0042802]; leucine binding [GO:0070728]; NAD+ binding [GO:0070403]	GLUD1
GLUD2	P49448	DHE4_HUMAN	reviewed	Glutamate dehydrogenase 2, mitochondrial (GDH 2) (EC 1.4.1.3)	GLUD2 GLUDP1	Homo sapiens (Human)	558	5 out of 5	Active site (1); Beta strand (15); Binding site (1); Chain (1); Helix (21); Modified residue (1); Natural variant (1); Sequence conflict (2); Transit peptide (1); Turn (4)	3D-structure;ADP-ribosylation;Complete proteome;Mitochondrion;NADP;Oxidoreductase;Polymorphism;Reference proteome;Transit peptide		SUBCELLULAR LOCATION: Mitochondrion matrix {ECO:0000269|PubMed:22709669}.	Glu/Leu/Phe/Val dehydrogenases family	glutamate biosynthetic process [GO:0006537]; glutamate catabolic process [GO:0006538]; glutamate metabolic process [GO:0006536]; oxidation-reduction process [GO:0055114]	mitochondrion [GO:0005739]	mitochondrion [GO:0005739]; ADP binding [GO:0043531]; glutamate dehydrogenase (NAD+) activity [GO:0004352]; glutamate dehydrogenase [NAD(P)+] activity [GO:0004353]; GTP binding [GO:0005525]; leucine binding [GO:0070728]; glutamate biosynthetic process [GO:0006537]; glutamate catabolic process [GO:0006538]; glutamate metabolic process [GO:0006536]; oxidation-reduction process [GO:0055114]	ADP binding [GO:0043531]; glutamate dehydrogenase (NAD+) activity [GO:0004352]; glutamate dehydrogenase [NAD(P)+] activity [GO:0004353]; GTP binding [GO:0005525]; leucine binding [GO:0070728]	GLUD2
ALDH3B1	P43353	AL3B1_HUMAN	reviewed	Aldehyde dehydrogenase family 3 member B1 (EC 1.2.1.28) (EC 1.2.1.5) (EC 1.2.1.7) (Aldehyde dehydrogenase 7)	ALDH3B1 ALDH7	Homo sapiens (Human)	468	5 out of 5	Active site (2); Alternative sequence (1); Chain (1); Lipidation (2); Modified residue (2); Nucleotide binding (1); Propeptide (1)	Acetylation;Alternative splicing;Cell membrane;Complete proteome;Lipoprotein;Membrane;Methylation;NAD;Oxidoreductase;Palmitate;Prenylation;Reference proteome		SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:23721920}; Lipid-anchor {ECO:0000269|PubMed:23721920}. Note=Primarily in the plasma membrane as well as in some punctate structures in the cytoplasm.	Aldehyde dehydrogenase family	alcohol metabolic process [GO:0006066]; aldehyde catabolic process [GO:0046185]; cellular response to oxidative stress [GO:0034599]; ethanol catabolic process [GO:0006068]; lipid metabolic process [GO:0006629]; neutrophil degranulation [GO:0043312]; oxidation-reduction process [GO:0055114]; sphingolipid biosynthetic process [GO:0030148]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; plasma membrane [GO:0005886]; secretory granule membrane [GO:0030667]; specific granule membrane [GO:0035579]; vesicle [GO:0031982]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; plasma membrane [GO:0005886]; secretory granule membrane [GO:0030667]; specific granule membrane [GO:0035579]; vesicle [GO:0031982]; 3-chloroallyl aldehyde dehydrogenase activity [GO:0004028]; aldehyde dehydrogenase [NAD(P)+] activity [GO:0004030]; benzaldehyde dehydrogenase (NAD+) activity [GO:0018479]; benzaldehyde dehydrogenase (NADP+) activity [GO:0018477]; alcohol metabolic process [GO:0006066]; aldehyde catabolic process [GO:0046185]; cellular response to oxidative stress [GO:0034599]; ethanol catabolic process [GO:0006068]; lipid metabolic process [GO:0006629]; neutrophil degranulation [GO:0043312]; oxidation-reduction process [GO:0055114]; sphingolipid biosynthetic process [GO:0030148]	3-chloroallyl aldehyde dehydrogenase activity [GO:0004028]; aldehyde dehydrogenase [NAD(P)+] activity [GO:0004030]; benzaldehyde dehydrogenase (NAD+) activity [GO:0018479]; benzaldehyde dehydrogenase (NADP+) activity [GO:0018477]	ALDH3B1
ALDH18A1	P54886	P5CS_HUMAN	reviewed	Delta-1-pyrroline-5-carboxylate synthase (P5CS) (Aldehyde dehydrogenase family 18 member A1) [Includes: Glutamate 5-kinase (GK) (EC 2.7.2.11) (Gamma-glutamyl kinase); Gamma-glutamyl phosphate reductase (GPR) (EC 1.2.1.41) (Glutamate-5-semialdehyde dehydrogenase) (Glutamyl-gamma-semialdehyde dehydrogenase)]	ALDH18A1 GSAS P5CS PYCS	Homo sapiens (Human)	795	5 out of 5	Alternative sequence (1); Beta strand (15); Binding site (3); Chain (1); Erroneous initiation (2); Helix (19); Modified residue (3); Natural variant (17); Nucleotide binding (2); Region (2); Sequence conflict (7); Turn (4)	3D-structure;ATP-binding;Alternative splicing;Amino-acid biosynthesis;Complete proteome;Disease mutation;Hereditary spastic paraplegia;Kinase;Membrane;Mental retardation;Mitochondrion;Mitochondrion inner membrane;Multifunctional enzyme;NADP;Neurodegeneration;Nucleotide-binding;Oxidoreductase;Polymorphism;Proline biosynthesis;Reference proteome;Transferase		SUBCELLULAR LOCATION: Mitochondrion inner membrane {ECO:0000269|PubMed:26297558, ECO:0000269|PubMed:26320891}.	Glutamate 5-kinase family; Gamma-glutamyl phosphate reductase family	cellular amino acid biosynthetic process [GO:0008652]; citrulline biosynthetic process [GO:0019240]; glutamate metabolic process [GO:0006536]; L-proline biosynthetic process [GO:0055129]; ornithine biosynthetic process [GO:0006592]; proline biosynthetic process [GO:0006561]	cytosol [GO:0005829]; mitochondrial inner membrane [GO:0005743]; mitochondrion [GO:0005739]	cytosol [GO:0005829]; mitochondrial inner membrane [GO:0005743]; mitochondrion [GO:0005739]; ATP binding [GO:0005524]; glutamate 5-kinase activity [GO:0004349]; glutamate-5-semialdehyde dehydrogenase activity [GO:0004350]; identical protein binding [GO:0042802]; RNA binding [GO:0003723]; cellular amino acid biosynthetic process [GO:0008652]; citrulline biosynthetic process [GO:0019240]; glutamate metabolic process [GO:0006536]; L-proline biosynthetic process [GO:0055129]; ornithine biosynthetic process [GO:0006592]; proline biosynthetic process [GO:0006561]	ATP binding [GO:0005524]; glutamate 5-kinase activity [GO:0004349]; glutamate-5-semialdehyde dehydrogenase activity [GO:0004350]; identical protein binding [GO:0042802]; RNA binding [GO:0003723]	ALDH18A1
ALDH3A2	P51648	AL3A2_HUMAN	reviewed	Aldehyde dehydrogenase family 3 member A2 (EC 1.2.1.3) (EC 1.2.1.94) (Aldehyde dehydrogenase 10) (Fatty aldehyde dehydrogenase) (Microsomal aldehyde dehydrogenase)	ALDH3A2 ALDH10 FALDH	Homo sapiens (Human)	485	5 out of 5	Active site (2); Alternative sequence (1); Beta strand (17); Chain (1); Helix (23); Modified residue (1); Mutagenesis (6); Natural variant (27); Nucleotide binding (1); Topological domain (1); Transmembrane (1); Turn (5)	3D-structure;Alternative splicing;Complete proteome;Direct protein sequencing;Disease mutation;Endoplasmic reticulum;Fatty acid metabolism;Ichthyosis;Lipid metabolism;Membrane;Mental retardation;Microsome;NAD;Oxidoreductase;Phosphoprotein;Reference proteome;Transmembrane;Transmembrane helix		SUBCELLULAR LOCATION: Microsome membrane {ECO:0000269|PubMed:9133646}; Single-pass membrane protein {ECO:0000305|PubMed:25047030, ECO:0000305|PubMed:9133646}. Endoplasmic reticulum membrane {ECO:0000305|PubMed:9133646}; Single-pass membrane protein {ECO:0000305|PubMed:25047030, ECO:0000305|PubMed:9133646}; Cytoplasmic side {ECO:0000250|UniProtKB:P30839}.	Aldehyde dehydrogenase family	cellular aldehyde metabolic process [GO:0006081]; central nervous system development [GO:0007417]; epidermis development [GO:0008544]; fatty acid alpha-oxidation [GO:0001561]; hexadecanal metabolic process [GO:0046458]; oxidation-reduction process [GO:0055114]; peripheral nervous system development [GO:0007422]; phytol metabolic process [GO:0033306]; sesquiterpenoid metabolic process [GO:0006714]; sphingolipid biosynthetic process [GO:0030148]	endoplasmic reticulum membrane [GO:0005789]; integral component of membrane [GO:0016021]; intracellular membrane-bounded organelle [GO:0043231]; peroxisomal membrane [GO:0005778]; peroxisome [GO:0005777]	endoplasmic reticulum membrane [GO:0005789]; integral component of membrane [GO:0016021]; intracellular membrane-bounded organelle [GO:0043231]; peroxisomal membrane [GO:0005778]; peroxisome [GO:0005777]; 3-chloroallyl aldehyde dehydrogenase activity [GO:0004028]; aldehyde dehydrogenase (NAD+) activity [GO:0004029]; glyceraldehyde-3-phosphate dehydrogenase (NAD+) (non-phosphorylating) activity [GO:0043878]; long-chain-alcohol oxidase activity [GO:0046577]; long-chain-aldehyde dehydrogenase activity [GO:0050061]; medium-chain-aldehyde dehydrogenase activity [GO:0052814]; protein homodimerization activity [GO:0042803]; cellular aldehyde metabolic process [GO:0006081]; central nervous system development [GO:0007417]; epidermis development [GO:0008544]; fatty acid alpha-oxidation [GO:0001561]; hexadecanal metabolic process [GO:0046458]; oxidation-reduction process [GO:0055114]; peripheral nervous system development [GO:0007422]; phytol metabolic process [GO:0033306]; sesquiterpenoid metabolic process [GO:0006714]; sphingolipid biosynthetic process [GO:0030148]	3-chloroallyl aldehyde dehydrogenase activity [GO:0004028]; aldehyde dehydrogenase (NAD+) activity [GO:0004029]; glyceraldehyde-3-phosphate dehydrogenase (NAD+) (non-phosphorylating) activity [GO:0043878]; long-chain-alcohol oxidase activity [GO:0046577]; long-chain-aldehyde dehydrogenase activity [GO:0050061]; medium-chain-aldehyde dehydrogenase activity [GO:0052814]; protein homodimerization activity [GO:0042803]	ALDH3A2
ALDH3A1	P30838	AL3A1_HUMAN	reviewed	Aldehyde dehydrogenase, dimeric NADP-preferring (EC 1.2.1.5) (ALDHIII) (Aldehyde dehydrogenase 3) (Aldehyde dehydrogenase family 3 member A1)	ALDH3A1 ALDH3	Homo sapiens (Human)	453	5 out of 5	Active site (2); Beta strand (16); Chain (1); Helix (23); Initiator methionine (1); Modified residue (3); Mutagenesis (1); Natural variant (3); Nucleotide binding (1); Sequence conflict (5); Turn (4)	3D-structure;Acetylation;Complete proteome;Cytoplasm;Direct protein sequencing;NAD;NADP;Oxidoreductase;Polymorphism;Reference proteome		SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250|UniProtKB:P47739}.	Aldehyde dehydrogenase family	aging [GO:0007568]; cellular aldehyde metabolic process [GO:0006081]; oxidation-reduction process [GO:0055114]; positive regulation of cell population proliferation [GO:0008284]; response to cAMP [GO:0051591]; response to drug [GO:0042493]; response to glucocorticoid [GO:0051384]; response to hypoxia [GO:0001666]; response to nutrient [GO:0007584]; xenobiotic metabolic process [GO:0006805]	cytosol [GO:0005829]; endoplasmic reticulum [GO:0005783]; extracellular space [GO:0005615]; integral component of membrane [GO:0016021]; plasma membrane [GO:0005886]	cytosol [GO:0005829]; endoplasmic reticulum [GO:0005783]; extracellular space [GO:0005615]; integral component of membrane [GO:0016021]; plasma membrane [GO:0005886]; 3-chloroallyl aldehyde dehydrogenase activity [GO:0004028]; alcohol dehydrogenase (NADP+) activity [GO:0008106]; aldehyde dehydrogenase (NAD+) activity [GO:0004029]; aldehyde dehydrogenase [NAD(P)+] activity [GO:0004030]; benzaldehyde dehydrogenase (NAD+) activity [GO:0018479]; aging [GO:0007568]; cellular aldehyde metabolic process [GO:0006081]; oxidation-reduction process [GO:0055114]; positive regulation of cell population proliferation [GO:0008284]; response to cAMP [GO:0051591]; response to drug [GO:0042493]; response to glucocorticoid [GO:0051384]; response to hypoxia [GO:0001666]; response to nutrient [GO:0007584]; xenobiotic metabolic process [GO:0006805]	3-chloroallyl aldehyde dehydrogenase activity [GO:0004028]; alcohol dehydrogenase (NADP+) activity [GO:0008106]; aldehyde dehydrogenase (NAD+) activity [GO:0004029]; aldehyde dehydrogenase [NAD(P)+] activity [GO:0004030]; benzaldehyde dehydrogenase (NAD+) activity [GO:0018479]	ALDH3A1
ALDH2	P05091	ALDH2_HUMAN	reviewed	Aldehyde dehydrogenase, mitochondrial (EC 1.2.1.3) (ALDH class 2) (ALDH-E2) (ALDHI)	ALDH2 ALDM	Homo sapiens (Human)	517	5 out of 5	Active site (2); Alternative sequence (1); Beta strand (26); Chain (1); Frameshift (2); Helix (19); Modified residue (9); Natural variant (3); Nucleotide binding (1); Sequence caution (1); Sequence conflict (12); Site (1); Transit peptide (1); Turn (3)	3D-structure;Acetylation;Alternative splicing;Complete proteome;Direct protein sequencing;Mitochondrion;NAD;Oxidoreductase;Polymorphism;Reference proteome;Transit peptide		SUBCELLULAR LOCATION: Mitochondrion matrix.	Aldehyde dehydrogenase family	alcohol metabolic process [GO:0006066]; carbohydrate metabolic process [GO:0005975]; ethanol catabolic process [GO:0006068]; ethanol oxidation [GO:0006069]	extracellular exosome [GO:0070062]; mitochondrial matrix [GO:0005759]	extracellular exosome [GO:0070062]; mitochondrial matrix [GO:0005759]; aldehyde dehydrogenase (NAD+) activity [GO:0004029]; aldehyde dehydrogenase [NAD(P)+] activity [GO:0004030]; electron transfer activity [GO:0009055]; glyceraldehyde-3-phosphate dehydrogenase (NAD+) (non-phosphorylating) activity [GO:0043878]; NAD binding [GO:0051287]; alcohol metabolic process [GO:0006066]; carbohydrate metabolic process [GO:0005975]; ethanol catabolic process [GO:0006068]; ethanol oxidation [GO:0006069]	aldehyde dehydrogenase (NAD+) activity [GO:0004029]; aldehyde dehydrogenase [NAD(P)+] activity [GO:0004030]; electron transfer activity [GO:0009055]; glyceraldehyde-3-phosphate dehydrogenase (NAD+) (non-phosphorylating) activity [GO:0043878]; NAD binding [GO:0051287]	ALDH2
GAPDH	P04406	G3P_HUMAN	reviewed	Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (EC 1.2.1.12) (Peptidyl-cysteine S-nitrosylase GAPDH) (EC 2.6.99.-)	GAPDH GAPD CDABP0047 OK/SW-cl.12	Homo sapiens (Human)	335	5 out of 5	Active site (1); Alternative sequence (1); Beta strand (20); Binding site (6); Chain (1); Cross-link (1); Helix (13); Initiator methionine (1); Modified residue (45); Motif (1); Mutagenesis (9); Natural variant (2); Nucleotide binding (1); Region (3); Sequence conflict (1); Site (1); Turn (7)	3D-structure;ADP-ribosylation;Acetylation;Alternative splicing;Apoptosis;Complete proteome;Cytoplasm;Cytoskeleton;Direct protein sequencing;Glycolysis;Isopeptide bond;Membrane;Methylation;NAD;Nucleus;Oxidation;Oxidoreductase;Phosphoprotein;Polymorphism;Reference proteome;S-nitrosylation;Transferase;Translation regulation;Ubl conjugation		SUBCELLULAR LOCATION: Cytoplasm, cytosol {ECO:0000269|PubMed:12829261}. Nucleus {ECO:0000250}. Cytoplasm, perinuclear region {ECO:0000269|PubMed:12829261}. Membrane {ECO:0000269|PubMed:12829261}. Cytoplasm, cytoskeleton {ECO:0000250}. Note=Translocates to the nucleus following S-nitrosylation and interaction with SIAH1, which contains a nuclear localization signal (By similarity). Postnuclear and Perinuclear regions. {ECO:0000250}.	Glyceraldehyde-3-phosphate dehydrogenase family	antimicrobial humoral immune response mediated by antimicrobial peptide [GO:0061844]; canonical glycolysis [GO:0061621]; cellular response to interferon-gamma [GO:0071346]; defense response to fungus [GO:0050832]; gluconeogenesis [GO:0006094]; glycolytic process [GO:0006096]; killing by host of symbiont cells [GO:0051873]; killing of cells of other organism [GO:0031640]; microtubule cytoskeleton organization [GO:0000226]; negative regulation of endopeptidase activity [GO:0010951]; negative regulation of translation [GO:0017148]; neuron apoptotic process [GO:0051402]; peptidyl-cysteine S-trans-nitrosylation [GO:0035606]; positive regulation by organism of apoptotic process in other organism involved in symbiotic interaction [GO:0052501]; positive regulation of cytokine secretion [GO:0050715]; protein stabilization [GO:0050821]; regulation of macroautophagy [GO:0016241]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; GAIT complex [GO:0097452]; intracellular membrane-bounded organelle [GO:0043231]; lipid droplet [GO:0005811]; membrane [GO:0016020]; microtubule cytoskeleton [GO:0015630]; nuclear membrane [GO:0031965]; nucleus [GO:0005634]; perinuclear region of cytoplasm [GO:0048471]; plasma membrane [GO:0005886]; ribonucleoprotein complex [GO:1990904]; vesicle [GO:0031982]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; GAIT complex [GO:0097452]; intracellular membrane-bounded organelle [GO:0043231]; lipid droplet [GO:0005811]; membrane [GO:0016020]; microtubule cytoskeleton [GO:0015630]; nuclear membrane [GO:0031965]; nucleus [GO:0005634]; perinuclear region of cytoplasm [GO:0048471]; plasma membrane [GO:0005886]; ribonucleoprotein complex [GO:1990904]; vesicle [GO:0031982]; aspartic-type endopeptidase inhibitor activity [GO:0019828]; disordered domain specific binding [GO:0097718]; glyceraldehyde-3-phosphate dehydrogenase (NAD+) (phosphorylating) activity [GO:0004365]; identical protein binding [GO:0042802]; microtubule binding [GO:0008017]; NAD binding [GO:0051287]; NADP binding [GO:0050661]; peptidyl-cysteine S-nitrosylase activity [GO:0035605]; antimicrobial humoral immune response mediated by antimicrobial peptide [GO:0061844]; canonical glycolysis [GO:0061621]; cellular response to interferon-gamma [GO:0071346]; defense response to fungus [GO:0050832]; gluconeogenesis [GO:0006094]; glycolytic process [GO:0006096]; killing by host of symbiont cells [GO:0051873]; killing of cells of other organism [GO:0031640]; microtubule cytoskeleton organization [GO:0000226]; negative regulation of endopeptidase activity [GO:0010951]; negative regulation of translation [GO:0017148]; neuron apoptotic process [GO:0051402]; peptidyl-cysteine S-trans-nitrosylation [GO:0035606]; positive regulation by organism of apoptotic process in other organism involved in symbiotic interaction [GO:0052501]; positive regulation of cytokine secretion [GO:0050715]; protein stabilization [GO:0050821]; regulation of macroautophagy [GO:0016241]	aspartic-type endopeptidase inhibitor activity [GO:0019828]; disordered domain specific binding [GO:0097718]; glyceraldehyde-3-phosphate dehydrogenase (NAD+) (phosphorylating) activity [GO:0004365]; identical protein binding [GO:0042802]; microtubule binding [GO:0008017]; NAD binding [GO:0051287]; NADP binding [GO:0050661]; peptidyl-cysteine S-nitrosylase activity [GO:0035605]	GAPDH
ALDH5A1	P51649	SSDH_HUMAN	reviewed	Succinate-semialdehyde dehydrogenase, mitochondrial (EC 1.2.1.24) (Aldehyde dehydrogenase family 5 member A1) (NAD(+)-dependent succinic semialdehyde dehydrogenase)	ALDH5A1 SSADH	Homo sapiens (Human)	535	5 out of 5	Active site (2); Alternative sequence (1); Beta strand (23); Binding site (4); Chain (1); Disulfide bond (1); Helix (18); Modified residue (10); Mutagenesis (4); Natural variant (18); Nucleotide binding (4); Site (1); Transit peptide (1); Turn (5)	3D-structure;Acetylation;Alternative splicing;Complete proteome;Disease mutation;Disulfide bond;Mitochondrion;NAD;Oxidoreductase;Phosphoprotein;Polymorphism;Reference proteome;Transit peptide		SUBCELLULAR LOCATION: Mitochondrion.	Aldehyde dehydrogenase family	acetate metabolic process [GO:0006083]; central nervous system development [GO:0007417]; galactosylceramide metabolic process [GO:0006681]; gamma-aminobutyric acid catabolic process [GO:0009450]; glucose metabolic process [GO:0006006]; glutamate metabolic process [GO:0006536]; glutamine metabolic process [GO:0006541]; glutathione metabolic process [GO:0006749]; glycerophospholipid metabolic process [GO:0006650]; neurotransmitter catabolic process [GO:0042135]; post-embryonic development [GO:0009791]; protein homotetramerization [GO:0051289]; respiratory electron transport chain [GO:0022904]; short-chain fatty acid metabolic process [GO:0046459]; succinate metabolic process [GO:0006105]	mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]	mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]; protein homodimerization activity [GO:0042803]; succinate-semialdehyde dehydrogenase (NAD+) activity [GO:0004777]; succinate-semialdehyde dehydrogenase [NAD(P)+] activity [GO:0009013]; acetate metabolic process [GO:0006083]; central nervous system development [GO:0007417]; galactosylceramide metabolic process [GO:0006681]; gamma-aminobutyric acid catabolic process [GO:0009450]; glucose metabolic process [GO:0006006]; glutamate metabolic process [GO:0006536]; glutamine metabolic process [GO:0006541]; glutathione metabolic process [GO:0006749]; glycerophospholipid metabolic process [GO:0006650]; neurotransmitter catabolic process [GO:0042135]; post-embryonic development [GO:0009791]; protein homotetramerization [GO:0051289]; respiratory electron transport chain [GO:0022904]; short-chain fatty acid metabolic process [GO:0046459]; succinate metabolic process [GO:0006105]	protein homodimerization activity [GO:0042803]; succinate-semialdehyde dehydrogenase (NAD+) activity [GO:0004777]; succinate-semialdehyde dehydrogenase [NAD(P)+] activity [GO:0009013]	ALDH5A1
ALDH8A1	Q9H2A2	AL8A1_HUMAN	reviewed	2-aminomuconic semialdehyde dehydrogenase (EC 1.2.1.32) (Aldehyde dehydrogenase 12) (Aldehyde dehydrogenase family 8 member A1)	ALDH8A1 ALDH12	Homo sapiens (Human)	487	5 out of 5	Active site (2); Alternative sequence (4); Chain (1); Erroneous translation (1); Modified residue (1); Mutagenesis (3); Natural variant (1); Nucleotide binding (1); Sequence conflict (1); Site (1)	Alternative splicing;Complete proteome;Cytoplasm;NAD;Oxidoreductase;Phosphoprotein;Polymorphism;Reference proteome		SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}.	Aldehyde dehydrogenase family	9-cis-retinoic acid biosynthetic process [GO:0042904]; L-kynurenine catabolic process [GO:0097053]; retinal metabolic process [GO:0042574]; retinoic acid metabolic process [GO:0042573]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]; aminomuconate-semialdehyde dehydrogenase activity [GO:0047102]; retinal dehydrogenase activity [GO:0001758]; 9-cis-retinoic acid biosynthetic process [GO:0042904]; L-kynurenine catabolic process [GO:0097053]; retinal metabolic process [GO:0042574]; retinoic acid metabolic process [GO:0042573]	aminomuconate-semialdehyde dehydrogenase activity [GO:0047102]; retinal dehydrogenase activity [GO:0001758]	ALDH8A1
ALDH6A1	Q02252	MMSA_HUMAN	reviewed	Methylmalonate-semialdehyde dehydrogenase [acylating], mitochondrial (MMSDH) (Malonate-semialdehyde dehydrogenase [acylating]) (EC 1.2.1.18) (EC 1.2.1.27) (Aldehyde dehydrogenase family 6 member A1)	ALDH6A1 MMSDH	Homo sapiens (Human)	535	5 out of 5	Active site (1); Alternative sequence (1); Binding site (1); Chain (1); Modified residue (25); Natural variant (1); Nucleotide binding (2); Sequence conflict (3); Transit peptide (1)	Acetylation;Alternative splicing;Complete proteome;Disease mutation;Mitochondrion;NAD;Oxidoreductase;Phosphoprotein;Reference proteome;Transit peptide		SUBCELLULAR LOCATION: Mitochondrion.	Aldehyde dehydrogenase family	branched-chain amino acid catabolic process [GO:0009083]; brown fat cell differentiation [GO:0050873]; thymine catabolic process [GO:0006210]; thymine metabolic process [GO:0019859]; valine catabolic process [GO:0006574]; valine metabolic process [GO:0006573]	mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]; nucleoplasm [GO:0005654]	mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]; nucleoplasm [GO:0005654]; fatty-acyl-CoA binding [GO:0000062]; malonate-semialdehyde dehydrogenase (acetylating) activity [GO:0018478]; methylmalonate-semialdehyde dehydrogenase (acylating) activity [GO:0004491]; RNA binding [GO:0003723]; branched-chain amino acid catabolic process [GO:0009083]; brown fat cell differentiation [GO:0050873]; thymine catabolic process [GO:0006210]; thymine metabolic process [GO:0019859]; valine catabolic process [GO:0006574]; valine metabolic process [GO:0006573]	fatty-acyl-CoA binding [GO:0000062]; malonate-semialdehyde dehydrogenase (acetylating) activity [GO:0018478]; methylmalonate-semialdehyde dehydrogenase (acylating) activity [GO:0004491]; RNA binding [GO:0003723]	ALDH6A1
ALDH1A2	O94788	AL1A2_HUMAN	reviewed	Retinal dehydrogenase 2 (RALDH 2) (RalDH2) (EC 1.2.1.36) (Aldehyde dehydrogenase family 1 member A2) (Retinaldehyde-specific dehydrogenase type 2) (RALDH(II))	ALDH1A2 RALDH2	Homo sapiens (Human)	518	5 out of 5	Active site (2); Alternative sequence (3); Beta strand (24); Binding site (1); Chain (1); Helix (19); Modified residue (2); Natural variant (4); Nucleotide binding (4); Sequence conflict (1); Site (1); Turn (2)	3D-structure;Alternative splicing;Complete proteome;Cytoplasm;NAD;Oxidoreductase;Phosphoprotein;Polymorphism;Reference proteome		SUBCELLULAR LOCATION: Cytoplasm.	Aldehyde dehydrogenase family	9-cis-retinoic acid biosynthetic process [GO:0042904]; blood vessel development [GO:0001568]; cardiac muscle tissue development [GO:0048738]; cellular response to retinoic acid [GO:0071300]; determination of bilateral symmetry [GO:0009855]; embryonic camera-type eye development [GO:0031076]; embryonic digestive tract development [GO:0048566]; embryonic forelimb morphogenesis [GO:0035115]; face development [GO:0060324]; heart morphogenesis [GO:0003007]; hindbrain development [GO:0030902]; kidney development [GO:0001822]; liver development [GO:0001889]; lung development [GO:0030324]; midgut development [GO:0007494]; morphogenesis of embryonic epithelium [GO:0016331]; negative regulation of cell population proliferation [GO:0008285]; neural crest cell development [GO:0014032]; neural tube development [GO:0021915]; neuron differentiation [GO:0030182]; pancreas development [GO:0031016]; pituitary gland development [GO:0021983]; positive regulation of apoptotic process [GO:0043065]; positive regulation of cell population proliferation [GO:0008284]; positive regulation of gene expression [GO:0010628]; protein homotetramerization [GO:0051289]; proximal/distal pattern formation [GO:0009954]; regulation of endothelial cell proliferation [GO:0001936]; response to cytokine [GO:0034097]; response to estradiol [GO:0032355]; response to vitamin A [GO:0033189]; retinal metabolic process [GO:0042574]; retinoic acid biosynthetic process [GO:0002138]; retinoic acid metabolic process [GO:0042573]; retinoic acid receptor signaling pathway involved in somitogenesis [GO:0090242]; retinol metabolic process [GO:0042572]; ureter maturation [GO:0035799]; vitamin A metabolic process [GO:0006776]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; perinuclear region of cytoplasm [GO:0048471]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; perinuclear region of cytoplasm [GO:0048471]; 3-chloroallyl aldehyde dehydrogenase activity [GO:0004028]; aldehyde dehydrogenase (NAD+) activity [GO:0004029]; retinal binding [GO:0016918]; retinal dehydrogenase activity [GO:0001758]; 9-cis-retinoic acid biosynthetic process [GO:0042904]; blood vessel development [GO:0001568]; cardiac muscle tissue development [GO:0048738]; cellular response to retinoic acid [GO:0071300]; determination of bilateral symmetry [GO:0009855]; embryonic camera-type eye development [GO:0031076]; embryonic digestive tract development [GO:0048566]; embryonic forelimb morphogenesis [GO:0035115]; face development [GO:0060324]; heart morphogenesis [GO:0003007]; hindbrain development [GO:0030902]; kidney development [GO:0001822]; liver development [GO:0001889]; lung development [GO:0030324]; midgut development [GO:0007494]; morphogenesis of embryonic epithelium [GO:0016331]; negative regulation of cell population proliferation [GO:0008285]; neural crest cell development [GO:0014032]; neural tube development [GO:0021915]; neuron differentiation [GO:0030182]; pancreas development [GO:0031016]; pituitary gland development [GO:0021983]; positive regulation of apoptotic process [GO:0043065]; positive regulation of cell population proliferation [GO:0008284]; positive regulation of gene expression [GO:0010628]; protein homotetramerization [GO:0051289]; proximal/distal pattern formation [GO:0009954]; regulation of endothelial cell proliferation [GO:0001936]; response to cytokine [GO:0034097]; response to estradiol [GO:0032355]; response to vitamin A [GO:0033189]; retinal metabolic process [GO:0042574]; retinoic acid biosynthetic process [GO:0002138]; retinoic acid metabolic process [GO:0042573]; retinoic acid receptor signaling pathway involved in somitogenesis [GO:0090242]; retinol metabolic process [GO:0042572]; ureter maturation [GO:0035799]; vitamin A metabolic process [GO:0006776]	3-chloroallyl aldehyde dehydrogenase activity [GO:0004028]; aldehyde dehydrogenase (NAD+) activity [GO:0004029]; retinal binding [GO:0016918]; retinal dehydrogenase activity [GO:0001758]	ALDH1A2
ALDH3B2	P48448	AL3B2_HUMAN	reviewed	Aldehyde dehydrogenase family 3 member B2 (EC 1.2.1.3) (Aldehyde dehydrogenase 8)	ALDH3B2 ALDH8	Homo sapiens (Human)	385	5 out of 5	Active site (2); Chain (1); Lipidation (1); Modified residue (1); Natural variant (7); Nucleotide binding (1); Propeptide (1); Sequence conflict (6)	Complete proteome;Lipid droplet;Lipoprotein;Methylation;NAD;Oxidoreductase;Polymorphism;Prenylation;Reference proteome		SUBCELLULAR LOCATION: Lipid droplet {ECO:0000250|UniProtKB:E9Q3E1}.	Aldehyde dehydrogenase family	alcohol metabolic process [GO:0006066]; ethanol catabolic process [GO:0006068]; lipid metabolic process [GO:0006629]; sphingolipid biosynthetic process [GO:0030148]	lipid droplet [GO:0005811]	lipid droplet [GO:0005811]; 3-chloroallyl aldehyde dehydrogenase activity [GO:0004028]; aldehyde dehydrogenase (NAD+) activity [GO:0004029]; aldehyde dehydrogenase [NAD(P)+] activity [GO:0004030]; glyceraldehyde-3-phosphate dehydrogenase (NAD+) (non-phosphorylating) activity [GO:0043878]; alcohol metabolic process [GO:0006066]; ethanol catabolic process [GO:0006068]; lipid metabolic process [GO:0006629]; sphingolipid biosynthetic process [GO:0030148]	3-chloroallyl aldehyde dehydrogenase activity [GO:0004028]; aldehyde dehydrogenase (NAD+) activity [GO:0004029]; aldehyde dehydrogenase [NAD(P)+] activity [GO:0004030]; glyceraldehyde-3-phosphate dehydrogenase (NAD+) (non-phosphorylating) activity [GO:0043878]	ALDH3B2
LDHA	P00338	LDHA_HUMAN	reviewed	L-lactate dehydrogenase A chain (LDH-A) (EC 1.1.1.27) (Cell proliferation-inducing gene 19 protein) (LDH muscle subunit) (LDH-M) (Renal carcinoma antigen NY-REN-59)	LDHA PIG19	Homo sapiens (Human)	332	5 out of 5	Active site (1); Alternative sequence (6); Beta strand (14); Binding site (5); Chain (1); Cross-link (1); Helix (15); Initiator methionine (1); Modified residue (20); Natural variant (2); Nucleotide binding (1); Turn (1)	3D-structure;Acetylation;Alternative splicing;Complete proteome;Cytoplasm;Direct protein sequencing;Disease mutation;Glycogen storage disease;Isopeptide bond;NAD;Oxidoreductase;Phosphoprotein;Polymorphism;Reference proteome;Ubl conjugation		SUBCELLULAR LOCATION: Cytoplasm.	LDH/MDH superfamily, LDH family	glycolytic process [GO:0006096]; lactate metabolic process [GO:0006089]; NAD metabolic process [GO:0019674]; positive regulation of apoptotic process [GO:0043065]; post-embryonic animal organ development [GO:0048569]; pyruvate metabolic process [GO:0006090]; response to cAMP [GO:0051591]; response to estrogen [GO:0043627]; response to glucose [GO:0009749]; response to hydrogen peroxide [GO:0042542]; response to hypoxia [GO:0001666]; response to nutrient [GO:0007584]; substantia nigra development [GO:0021762]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]; membrane [GO:0016020]; nucleus [GO:0005634]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]; membrane [GO:0016020]; nucleus [GO:0005634]; cadherin binding [GO:0045296]; identical protein binding [GO:0042802]; kinase binding [GO:0019900]; L-lactate dehydrogenase activity [GO:0004459]; NAD binding [GO:0051287]; glycolytic process [GO:0006096]; lactate metabolic process [GO:0006089]; NAD metabolic process [GO:0019674]; positive regulation of apoptotic process [GO:0043065]; post-embryonic animal organ development [GO:0048569]; pyruvate metabolic process [GO:0006090]; response to cAMP [GO:0051591]; response to estrogen [GO:0043627]; response to glucose [GO:0009749]; response to hydrogen peroxide [GO:0042542]; response to hypoxia [GO:0001666]; response to nutrient [GO:0007584]; substantia nigra development [GO:0021762]	cadherin binding [GO:0045296]; identical protein binding [GO:0042802]; kinase binding [GO:0019900]; L-lactate dehydrogenase activity [GO:0004459]; NAD binding [GO:0051287]	
ALDH1L2	Q3SY69	AL1L2_HUMAN	reviewed	Mitochondrial 10-formyltetrahydrofolate dehydrogenase (Mitochondrial 10-FTHFDH) (mtFDH) (EC 1.5.1.6) (Aldehyde dehydrogenase family 1 member L2)	ALDH1L2	Homo sapiens (Human)	923	5 out of 5	Active site (3); Alternative sequence (4); Chain (1); Domain (1); Erroneous translation (1); Modified residue (8); Region (2); Sequence conflict (1); Site (1); Transit peptide (1)	Acetylation;Alternative splicing;Complete proteome;Mitochondrion;NADP;One-carbon metabolism;Oxidoreductase;Phosphopantetheine;Phosphoprotein;Reference proteome;Transit peptide		SUBCELLULAR LOCATION: Mitochondrion {ECO:0000269|PubMed:20498374}.	GART family; Aldehyde dehydrogenase family, ALDH1L subfamily	10-formyltetrahydrofolate catabolic process [GO:0009258]; biosynthetic process [GO:0009058]; folic acid metabolic process [GO:0046655]; one-carbon metabolic process [GO:0006730]	extracellular exosome [GO:0070062]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]; nucleus [GO:0005634]	extracellular exosome [GO:0070062]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]; nucleus [GO:0005634]; aldehyde dehydrogenase (NAD+) activity [GO:0004029]; formyltetrahydrofolate dehydrogenase activity [GO:0016155]; hydroxymethyl-, formyl- and related transferase activity [GO:0016742]; 10-formyltetrahydrofolate catabolic process [GO:0009258]; biosynthetic process [GO:0009058]; folic acid metabolic process [GO:0046655]; one-carbon metabolic process [GO:0006730]	aldehyde dehydrogenase (NAD+) activity [GO:0004029]; formyltetrahydrofolate dehydrogenase activity [GO:0016155]; hydroxymethyl-, formyl- and related transferase activity [GO:0016742]	ALDH1L2
ALDH1B1	P30837	AL1B1_HUMAN	reviewed	Aldehyde dehydrogenase X, mitochondrial (EC 1.2.1.3) (Aldehyde dehydrogenase 5) (Aldehyde dehydrogenase family 1 member B1)	ALDH1B1 ALDH5 ALDHX	Homo sapiens (Human)	517	5 out of 5	Active site (2); Chain (1); Modified residue (15); Natural variant (4); Nucleotide binding (1); Sequence conflict (2); Site (1); Transit peptide (1)	Acetylation;Complete proteome;Mitochondrion;NAD;Oxidoreductase;Polymorphism;Reference proteome;Transit peptide		SUBCELLULAR LOCATION: Mitochondrion matrix.	Aldehyde dehydrogenase family	carbohydrate metabolic process [GO:0005975]; ethanol catabolic process [GO:0006068]; ethanol oxidation [GO:0006069]	intracellular membrane-bounded organelle [GO:0043231]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]; nucleoplasm [GO:0005654]	intracellular membrane-bounded organelle [GO:0043231]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]; nucleoplasm [GO:0005654]; aldehyde dehydrogenase (NAD+) activity [GO:0004029]; glyceraldehyde-3-phosphate dehydrogenase (NAD+) (non-phosphorylating) activity [GO:0043878]; NAD binding [GO:0051287]; carbohydrate metabolic process [GO:0005975]; ethanol catabolic process [GO:0006068]; ethanol oxidation [GO:0006069]	aldehyde dehydrogenase (NAD+) activity [GO:0004029]; glyceraldehyde-3-phosphate dehydrogenase (NAD+) (non-phosphorylating) activity [GO:0043878]; NAD binding [GO:0051287]	ALDH1B1
ALDH9A1	P49189	AL9A1_HUMAN	reviewed	4-trimethylaminobutyraldehyde dehydrogenase (TMABA-DH) (TMABALDH) (EC 1.2.1.47) (Aldehyde dehydrogenase E3 isozyme) (Aldehyde dehydrogenase family 9 member A1) (EC 1.2.1.3) (Gamma-aminobutyraldehyde dehydrogenase) (EC 1.2.1.19) (R-aminobutyraldehyde dehydrogenase) [Cleaved into: 4-trimethylaminobutyraldehyde dehydrogenase, N-terminally processed]	ALDH9A1 ALDH4 ALDH7 ALDH9	Homo sapiens (Human)	494	5 out of 5	Active site (2); Alternative sequence (2); Beta strand (21); Binding site (2); Chain (2); Helix (19); Initiator methionine (1); Modified residue (8); Natural variant (1); Nucleotide binding (1); Sequence conflict (4); Site (1); Turn (3)	3D-structure;Acetylation;Alternative initiation;Alternative splicing;Complete proteome;Cytoplasm;Direct protein sequencing;NAD;Oxidoreductase;Polymorphism;Reference proteome		SUBCELLULAR LOCATION: Cytoplasm, cytosol {ECO:0000250|UniProtKB:Q9JLJ3}.	Aldehyde dehydrogenase family	carnitine biosynthetic process [GO:0045329]; cellular aldehyde metabolic process [GO:0006081]; hormone metabolic process [GO:0042445]; neurotransmitter biosynthetic process [GO:0042136]; oxidation-reduction process [GO:0055114]; protein homotetramerization [GO:0051289]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; 1-pyrroline dehydrogenase activity [GO:0033737]; 4-trimethylammoniobutyraldehyde dehydrogenase activity [GO:0047105]; aldehyde dehydrogenase (NAD+) activity [GO:0004029]; aminobutyraldehyde dehydrogenase activity [GO:0019145]; glyceraldehyde-3-phosphate dehydrogenase (NAD+) (non-phosphorylating) activity [GO:0043878]; carnitine biosynthetic process [GO:0045329]; cellular aldehyde metabolic process [GO:0006081]; hormone metabolic process [GO:0042445]; neurotransmitter biosynthetic process [GO:0042136]; oxidation-reduction process [GO:0055114]; protein homotetramerization [GO:0051289]	1-pyrroline dehydrogenase activity [GO:0033737]; 4-trimethylammoniobutyraldehyde dehydrogenase activity [GO:0047105]; aldehyde dehydrogenase (NAD+) activity [GO:0004029]; aminobutyraldehyde dehydrogenase activity [GO:0019145]; glyceraldehyde-3-phosphate dehydrogenase (NAD+) (non-phosphorylating) activity [GO:0043878]	ALDH9A1
ALDH1L1	O75891	AL1L1_HUMAN	reviewed	Cytosolic 10-formyltetrahydrofolate dehydrogenase (10-FTHFDH) (FDH) (EC 1.5.1.6) (Aldehyde dehydrogenase family 1 member L1)	ALDH1L1 FTHFD	Homo sapiens (Human)	902	5 out of 5	Active site (3); Alternative sequence (4); Beta strand (16); Binding site (2); Chain (1); Domain (1); Helix (15); Modified residue (10); Natural variant (10); Nucleotide binding (5); Region (3); Sequence conflict (9); Site (1); Turn (3)	3D-structure;Acetylation;Alternative splicing;Complete proteome;Cytoplasm;NADP;One-carbon metabolism;Oxidoreductase;Phosphopantetheine;Phosphoprotein;Polymorphism;Reference proteome		SUBCELLULAR LOCATION: Cytoplasm.	GART family; Aldehyde dehydrogenase family, ALDH1L subfamily	10-formyltetrahydrofolate catabolic process [GO:0009258]; biosynthetic process [GO:0009058]; folic acid metabolic process [GO:0046655]; one-carbon metabolic process [GO:0006730]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]; aldehyde dehydrogenase (NAD+) activity [GO:0004029]; catalytic activity [GO:0003824]; formyltetrahydrofolate dehydrogenase activity [GO:0016155]; hydroxymethyl-, formyl- and related transferase activity [GO:0016742]; 10-formyltetrahydrofolate catabolic process [GO:0009258]; biosynthetic process [GO:0009058]; folic acid metabolic process [GO:0046655]; one-carbon metabolic process [GO:0006730]	aldehyde dehydrogenase (NAD+) activity [GO:0004029]; catalytic activity [GO:0003824]; formyltetrahydrofolate dehydrogenase activity [GO:0016155]; hydroxymethyl-, formyl- and related transferase activity [GO:0016742]	ALDH1L1
ALDH4A1	P30038	AL4A1_HUMAN	reviewed	Delta-1-pyrroline-5-carboxylate dehydrogenase, mitochondrial (P5C dehydrogenase) (EC 1.2.1.88) (Aldehyde dehydrogenase family 4 member A1) (L-glutamate gamma-semialdehyde dehydrogenase)	ALDH4A1 ALDH4 P5CDH	Homo sapiens (Human)	563	5 out of 5	Active site (2); Alternative sequence (2); Beta strand (23); Binding site (4); Chain (1); Helix (23); Modified residue (23); Mutagenesis (1); Natural variant (4); Nucleotide binding (1); Sequence conflict (10); Site (1); Transit peptide (1); Turn (5)	3D-structure;Acetylation;Alternative splicing;Complete proteome;Direct protein sequencing;Disease mutation;Mitochondrion;NAD;Oxidoreductase;Phosphoprotein;Polymorphism;Proline metabolism;Reference proteome;Transit peptide		SUBCELLULAR LOCATION: Mitochondrion matrix.	Aldehyde dehydrogenase family	4-hydroxyproline catabolic process [GO:0019470]; glyoxylate metabolic process [GO:0046487]; proline catabolic process [GO:0006562]; proline catabolic process to glutamate [GO:0010133]; proline metabolic process [GO:0006560]	mitochondrial matrix [GO:0005759]	mitochondrial matrix [GO:0005759]; 1-pyrroline-5-carboxylate dehydrogenase activity [GO:0003842]; aldehyde dehydrogenase (NAD+) activity [GO:0004029]; electron transfer activity [GO:0009055]; identical protein binding [GO:0042802]; 4-hydroxyproline catabolic process [GO:0019470]; glyoxylate metabolic process [GO:0046487]; proline catabolic process [GO:0006562]; proline catabolic process to glutamate [GO:0010133]; proline metabolic process [GO:0006560]	1-pyrroline-5-carboxylate dehydrogenase activity [GO:0003842]; aldehyde dehydrogenase (NAD+) activity [GO:0004029]; electron transfer activity [GO:0009055]; identical protein binding [GO:0042802]	ALDH4A1
ALDH16A1	Q8IZ83	A16A1_HUMAN	reviewed	Aldehyde dehydrogenase family 16 member A1	ALDH16A1	Homo sapiens (Human)	802	3 out of 5	Alternative sequence (3); Chain (1); Erroneous initiation (1); Erroneous translation (1); Natural variant (2)	Alternative splicing;Complete proteome;Polymorphism;Reference proteome			Aldehyde dehydrogenase family		membrane [GO:0016020]	membrane [GO:0016020]; oxidoreductase activity, acting on the aldehyde or oxo group of donors, NAD or NADP as acceptor [GO:0016620]	oxidoreductase activity, acting on the aldehyde or oxo group of donors, NAD or NADP as acceptor [GO:0016620]	ALDH16A1
ALDH7A1	P49419	AL7A1_HUMAN	reviewed	Alpha-aminoadipic semialdehyde dehydrogenase (Alpha-AASA dehydrogenase) (EC 1.2.1.31) (Aldehyde dehydrogenase family 7 member A1) (EC 1.2.1.3) (Antiquitin-1) (Betaine aldehyde dehydrogenase) (EC 1.2.1.8) (Delta1-piperideine-6-carboxylate dehydrogenase) (P6c dehydrogenase)	ALDH7A1 ATQ1	Homo sapiens (Human)	539	5 out of 5	Active site (2); Alternative sequence (2); Beta strand (24); Chain (1); Erroneous initiation (5); Frameshift (1); Helix (22); Initiator methionine (1); Modified residue (6); Natural variant (10); Nucleotide binding (1); Sequence caution (1); Sequence conflict (1); Site (1); Transit peptide (1); Turn (4)	3D-structure;Acetylation;Alternative splicing;Complete proteome;Cytoplasm;Disease mutation;Epilepsy;Mitochondrion;NAD;Nucleus;Oxidoreductase;Polymorphism;Reference proteome;Transit peptide		SUBCELLULAR LOCATION: Cytoplasm, cytosol {ECO:0000269|PubMed:20207735}. Nucleus {ECO:0000269|PubMed:20207735}.; SUBCELLULAR LOCATION: Isoform 1: Mitochondrion {ECO:0000269|PubMed:20207735}.	Aldehyde dehydrogenase family	cellular aldehyde metabolic process [GO:0006081]; choline catabolic process [GO:0042426]; glycine betaine biosynthetic process from choline [GO:0019285]; lysine catabolic process [GO:0006554]; sensory perception of sound [GO:0007605]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]; nucleus [GO:0005634]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]; nucleus [GO:0005634]; aldehyde dehydrogenase (NAD+) activity [GO:0004029]; betaine-aldehyde dehydrogenase activity [GO:0008802]; glyceraldehyde-3-phosphate dehydrogenase (NAD+) (non-phosphorylating) activity [GO:0043878]; L-aminoadipate-semialdehyde dehydrogenase activity [GO:0004043]; cellular aldehyde metabolic process [GO:0006081]; choline catabolic process [GO:0042426]; glycine betaine biosynthetic process from choline [GO:0019285]; lysine catabolic process [GO:0006554]; sensory perception of sound [GO:0007605]	aldehyde dehydrogenase (NAD+) activity [GO:0004029]; betaine-aldehyde dehydrogenase activity [GO:0008802]; glyceraldehyde-3-phosphate dehydrogenase (NAD+) (non-phosphorylating) activity [GO:0043878]; L-aminoadipate-semialdehyde dehydrogenase activity [GO:0004043]	ALDH7A1
ALDH1A1	P00352	AL1A1_HUMAN	reviewed	Retinal dehydrogenase 1 (RALDH 1) (RalDH1) (EC 1.2.1.-) (EC 1.2.1.36) (ALDH-E1) (ALHDII) (Aldehyde dehydrogenase family 1 member A1) (Aldehyde dehydrogenase, cytosolic)	ALDH1A1 ALDC ALDH1 PUMB1	Homo sapiens (Human)	501	5 out of 5	Active site (2); Beta strand (22); Chain (1); Helix (20); Initiator methionine (1); Modified residue (12); Mutagenesis (2); Natural variant (3); Nucleotide binding (7); Sequence conflict (2); Site (1); Turn (2)	3D-structure;Acetylation;Complete proteome;Cytoplasm;Direct protein sequencing;NAD;Nucleotide-binding;Oxidoreductase;Phosphoprotein;Polymorphism;Reference proteome		SUBCELLULAR LOCATION: Cytoplasm, cytosol {ECO:0000250|UniProtKB:P48644}.	Aldehyde dehydrogenase family	cellular aldehyde metabolic process [GO:0006081]; ethanol oxidation [GO:0006069]; fructose catabolic process to hydroxyacetone phosphate and glyceraldehyde-3-phosphate [GO:0061624]; negative regulation of cold-induced thermogenesis [GO:0120163]; oxidation-reduction process [GO:0055114]; retinoid metabolic process [GO:0001523]; retinol metabolic process [GO:0042572]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; aldehyde dehydrogenase (NAD+) activity [GO:0004029]; androgen binding [GO:0005497]; benzaldehyde dehydrogenase (NAD+) activity [GO:0018479]; GTPase activator activity [GO:0005096]; NAD binding [GO:0051287]; retinal dehydrogenase activity [GO:0001758]; cellular aldehyde metabolic process [GO:0006081]; ethanol oxidation [GO:0006069]; fructose catabolic process to hydroxyacetone phosphate and glyceraldehyde-3-phosphate [GO:0061624]; negative regulation of cold-induced thermogenesis [GO:0120163]; oxidation-reduction process [GO:0055114]; retinoid metabolic process [GO:0001523]; retinol metabolic process [GO:0042572]	aldehyde dehydrogenase (NAD+) activity [GO:0004029]; androgen binding [GO:0005497]; benzaldehyde dehydrogenase (NAD+) activity [GO:0018479]; GTPase activator activity [GO:0005096]; NAD binding [GO:0051287]; retinal dehydrogenase activity [GO:0001758]	ALDH1A1
ALDH1A3	P47895	AL1A3_HUMAN	reviewed	Aldehyde dehydrogenase family 1 member A3 (EC 1.2.1.36) (Aldehyde dehydrogenase 6) (Retinaldehyde dehydrogenase 3) (RALDH-3) (RalDH3)	ALDH1A3 ALDH6	Homo sapiens (Human)	512	5 out of 5	Active site (2); Beta strand (23); Binding site (4); Chain (1); Helix (18); Initiator methionine (1); Modified residue (1); Natural variant (11); Nucleotide binding (1); Sequence conflict (1); Site (1); Turn (3)	3D-structure;Acetylation;Complete proteome;Cytoplasm;Direct protein sequencing;Disease mutation;Microphthalmia;NAD;Oxidoreductase;Polymorphism;Reference proteome		SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250|UniProtKB:Q9JHW9}.	Aldehyde dehydrogenase family	embryonic camera-type eye development [GO:0031076]; embryonic eye morphogenesis [GO:0048048]; face development [GO:0060324]; Harderian gland development [GO:0070384]; inner ear morphogenesis [GO:0042472]; locomotory behavior [GO:0007626]; neuromuscular process controlling balance [GO:0050885]; nucleus accumbens development [GO:0021768]; olfactory pit development [GO:0060166]; optic cup morphogenesis involved in camera-type eye development [GO:0002072]; positive regulation of apoptotic process [GO:0043065]; protein homotetramerization [GO:0051289]; retinal metabolic process [GO:0042574]; retinoic acid biosynthetic process [GO:0002138]; retinoic acid metabolic process [GO:0042573]; retinol metabolic process [GO:0042572]; righting reflex [GO:0060013]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; nucleus [GO:0005634]; plasma membrane [GO:0005886]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; nucleus [GO:0005634]; plasma membrane [GO:0005886]; aldehyde dehydrogenase (NAD+) activity [GO:0004029]; aldehyde dehydrogenase [NAD(P)+] activity [GO:0004030]; NAD+ binding [GO:0070403]; protein homodimerization activity [GO:0042803]; retinal dehydrogenase activity [GO:0001758]; thyroid hormone binding [GO:0070324]; embryonic camera-type eye development [GO:0031076]; embryonic eye morphogenesis [GO:0048048]; face development [GO:0060324]; Harderian gland development [GO:0070384]; inner ear morphogenesis [GO:0042472]; locomotory behavior [GO:0007626]; neuromuscular process controlling balance [GO:0050885]; nucleus accumbens development [GO:0021768]; olfactory pit development [GO:0060166]; optic cup morphogenesis involved in camera-type eye development [GO:0002072]; positive regulation of apoptotic process [GO:0043065]; protein homotetramerization [GO:0051289]; retinal metabolic process [GO:0042574]; retinoic acid biosynthetic process [GO:0002138]; retinoic acid metabolic process [GO:0042573]; retinol metabolic process [GO:0042572]; righting reflex [GO:0060013]	aldehyde dehydrogenase (NAD+) activity [GO:0004029]; aldehyde dehydrogenase [NAD(P)+] activity [GO:0004030]; NAD+ binding [GO:0070403]; protein homodimerization activity [GO:0042803]; retinal dehydrogenase activity [GO:0001758]; thyroid hormone binding [GO:0070324]	ALDH1A3
MDH1	P40925	MDHC_HUMAN	reviewed	Malate dehydrogenase, cytoplasmic (EC 1.1.1.37) (Cytosolic malate dehydrogenase) (Diiodophenylpyruvate reductase) (EC 1.1.1.96)	MDH1 MDHA	Homo sapiens (Human)	334	5 out of 5	Active site (1); Alternative sequence (2); Binding site (6); Chain (1); Initiator methionine (1); Modified residue (14); Nucleotide binding (2); Sequence conflict (1)	Acetylation;Alternative splicing;Complete proteome;Cytoplasm;Direct protein sequencing;Methylation;NAD;Oxidoreductase;Phosphoprotein;Reference proteome;Tricarboxylic acid cycle;Ubl conjugation		SUBCELLULAR LOCATION: Cytoplasm.	LDH/MDH superfamily, MDH type 2 family	gluconeogenesis [GO:0006094]; malate metabolic process [GO:0006108]; NADH metabolic process [GO:0006734]; NAD metabolic process [GO:0019674]; oxaloacetate metabolic process [GO:0006107]; tricarboxylic acid cycle [GO:0006099]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]; extracellular space [GO:0005615]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]; extracellular space [GO:0005615]; diiodophenylpyruvate reductase activity [GO:0047860]; L-malate dehydrogenase activity [GO:0030060]; malic enzyme activity [GO:0004470]; NAD binding [GO:0051287]; gluconeogenesis [GO:0006094]; malate metabolic process [GO:0006108]; NAD metabolic process [GO:0019674]; NADH metabolic process [GO:0006734]; oxaloacetate metabolic process [GO:0006107]; tricarboxylic acid cycle [GO:0006099]	diiodophenylpyruvate reductase activity [GO:0047860]; L-malate dehydrogenase activity [GO:0030060]; malic enzyme activity [GO:0004470]; NAD binding [GO:0051287]	MDH1
ME1	P48163	MAOX_HUMAN	reviewed	NADP-dependent malic enzyme (NADP-ME) (EC 1.1.1.40) (Malic enzyme 1)	ME1	Homo sapiens (Human)	572	5 out of 5	Active site (2); Alternative sequence (1); Beta strand (10); Binding site (3); Chain (1); Helix (34); Metal binding (3); Modified residue (2); Nucleotide binding (1); Sequence conflict (16); Site (1); Turn (7)	3D-structure;Acetylation;Alternative splicing;Complete proteome;Cytoplasm;Metal-binding;NADP;Oxidoreductase;Phosphoprotein;Reference proteome		SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:8187880}.	Malic enzymes family	carbohydrate metabolic process [GO:0005975]; malate metabolic process [GO:0006108]; nucleotide biosynthetic process [GO:0009165]; pyruvate metabolic process [GO:0006090]; regulation of lipid metabolic process [GO:0019216]; regulation of NADP metabolic process [GO:1902031]; response to carbohydrate [GO:0009743]; response to hormone [GO:0009725]	cytosol [GO:0005829]; mitochondrion [GO:0005739]	cytosol [GO:0005829]; mitochondrion [GO:0005739]; ADP binding [GO:0043531]; electron transfer activity [GO:0009055]; malate dehydrogenase (decarboxylating) (NAD+) activity [GO:0004471]; malate dehydrogenase (decarboxylating) (NADP+) activity [GO:0004473]; malic enzyme activity [GO:0004470]; manganese ion binding [GO:0030145]; NAD binding [GO:0051287]; NADP binding [GO:0050661]; oxaloacetate decarboxylase activity [GO:0008948]; carbohydrate metabolic process [GO:0005975]; malate metabolic process [GO:0006108]; nucleotide biosynthetic process [GO:0009165]; pyruvate metabolic process [GO:0006090]; regulation of lipid metabolic process [GO:0019216]; regulation of NADP metabolic process [GO:1902031]; response to carbohydrate [GO:0009743]; response to hormone [GO:0009725]	ADP binding [GO:0043531]; electron transfer activity [GO:0009055]; malate dehydrogenase (decarboxylating) (NAD+) activity [GO:0004471]; malate dehydrogenase (decarboxylating) (NADP+) activity [GO:0004473]; malic enzyme activity [GO:0004470]; manganese ion binding [GO:0030145]; NAD binding [GO:0051287]; NADP binding [GO:0050661]; oxaloacetate decarboxylase activity [GO:0008948]	ME1
ME2	P23368	MAOM_HUMAN	reviewed	NAD-dependent malic enzyme, mitochondrial (NAD-ME) (EC 1.1.1.38) (Malic enzyme 2)	ME2	Homo sapiens (Human)	584	5 out of 5	Active site (2); Alternative sequence (1); Beta strand (13); Binding site (6); Chain (1); Helix (33); Metal binding (3); Modified residue (5); Mutagenesis (2); Natural variant (2); Nucleotide binding (2); Sequence conflict (1); Site (1); Transit peptide (1); Turn (7)	3D-structure;Acetylation;Allosteric enzyme;Alternative splicing;Complete proteome;Direct protein sequencing;Metal-binding;Mitochondrion;NAD;Oxidoreductase;Polymorphism;Reference proteome;Transit peptide	MISCELLANEOUS: This isoenzyme can also use NADP(+) but is more effective with NAD(+).	SUBCELLULAR LOCATION: Mitochondrion matrix.	Malic enzymes family	malate metabolic process [GO:0006108]; pyruvate metabolic process [GO:0006090]; regulation of NADP metabolic process [GO:1902031]; tricarboxylic acid cycle [GO:0006099]	mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]	mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]; electron transfer activity [GO:0009055]; malate dehydrogenase (decarboxylating) (NAD+) activity [GO:0004471]; malate dehydrogenase (decarboxylating) (NADP+) activity [GO:0004473]; malic enzyme activity [GO:0004470]; metal ion binding [GO:0046872]; NAD binding [GO:0051287]; oxaloacetate decarboxylase activity [GO:0008948]; malate metabolic process [GO:0006108]; pyruvate metabolic process [GO:0006090]; regulation of NADP metabolic process [GO:1902031]; tricarboxylic acid cycle [GO:0006099]	electron transfer activity [GO:0009055]; malate dehydrogenase (decarboxylating) (NAD+) activity [GO:0004471]; malate dehydrogenase (decarboxylating) (NADP+) activity [GO:0004473]; malic enzyme activity [GO:0004470]; metal ion binding [GO:0046872]; NAD binding [GO:0051287]; oxaloacetate decarboxylase activity [GO:0008948]	ME2
MDH2	P40926	MDHM_HUMAN	reviewed	Malate dehydrogenase, mitochondrial (EC 1.1.1.37)	MDH2	Homo sapiens (Human)	338	5 out of 5	Active site (1); Alternative sequence (1); Beta strand (12); Binding site (7); Chain (1); Glycosylation (1); Helix (13); Modified residue (33); Mutagenesis (4); Natural variant (4); Nucleotide binding (2); Sequence conflict (1); Transit peptide (1); Turn (2)	3D-structure;Acetylation;Alternative splicing;Complete proteome;Disease mutation;Epilepsy;Glycoprotein;Mitochondrion;NAD;Oxidoreductase;Phosphoprotein;Polymorphism;Reference proteome;Transit peptide;Tricarboxylic acid cycle		SUBCELLULAR LOCATION: Mitochondrion matrix {ECO:0000250|UniProtKB:P04636}.	LDH/MDH superfamily, MDH type 1 family	aerobic respiration [GO:0009060]; gluconeogenesis [GO:0006094]; internal protein amino acid acetylation [GO:0006475]; malate metabolic process [GO:0006108]; NADH metabolic process [GO:0006734]; oxaloacetate metabolic process [GO:0006107]; tricarboxylic acid cycle [GO:0006099]	cytoplasm [GO:0005737]; extracellular exosome [GO:0070062]; membrane [GO:0016020]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]; nucleus [GO:0005634]	cytoplasm [GO:0005737]; extracellular exosome [GO:0070062]; membrane [GO:0016020]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]; nucleus [GO:0005634]; L-malate dehydrogenase activity [GO:0030060]; malate dehydrogenase (NADP+) activity [GO:0046554]; protein self-association [GO:0043621]; RNA binding [GO:0003723]; aerobic respiration [GO:0009060]; gluconeogenesis [GO:0006094]; internal protein amino acid acetylation [GO:0006475]; malate metabolic process [GO:0006108]; NADH metabolic process [GO:0006734]; oxaloacetate metabolic process [GO:0006107]; tricarboxylic acid cycle [GO:0006099]	L-malate dehydrogenase activity [GO:0030060]; malate dehydrogenase (NADP+) activity [GO:0046554]; protein self-association [GO:0043621]; RNA binding [GO:0003723]	MDH2
ME3	Q16798	MAON_HUMAN	reviewed	NADP-dependent malic enzyme, mitochondrial (NADP-ME) (EC 1.1.1.40) (Malic enzyme 3)	ME3	Homo sapiens (Human)	604	5 out of 5	Active site (2); Alternative sequence (2); Binding site (3); Chain (1); Metal binding (3); Modified residue (1); Natural variant (2); Sequence conflict (1); Site (1); Transit peptide (1)	Alternative splicing;Complete proteome;Metal-binding;Mitochondrion;NADP;Oxidoreductase;Phosphoprotein;Polymorphism;Reference proteome;Transit peptide		SUBCELLULAR LOCATION: Mitochondrion matrix.	Malic enzymes family	aerobic respiration [GO:0009060]; malate metabolic process [GO:0006108]; oxidation-reduction process [GO:0055114]; oxygen metabolic process [GO:0072592]; pyruvate metabolic process [GO:0006090]; tricarboxylic acid cycle [GO:0006099]	mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]	mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]; cofactor binding [GO:0048037]; malate dehydrogenase (decarboxylating) (NAD+) activity [GO:0004471]; malate dehydrogenase (decarboxylating) (NADP+) activity [GO:0004473]; malic enzyme activity [GO:0004470]; metal ion binding [GO:0046872]; NAD binding [GO:0051287]; oxaloacetate decarboxylase activity [GO:0008948]; aerobic respiration [GO:0009060]; malate metabolic process [GO:0006108]; oxidation-reduction process [GO:0055114]; oxygen metabolic process [GO:0072592]; pyruvate metabolic process [GO:0006090]; tricarboxylic acid cycle [GO:0006099]	cofactor binding [GO:0048037]; malate dehydrogenase (decarboxylating) (NAD+) activity [GO:0004471]; malate dehydrogenase (decarboxylating) (NADP+) activity [GO:0004473]; malic enzyme activity [GO:0004470]; metal ion binding [GO:0046872]; NAD binding [GO:0051287]; oxaloacetate decarboxylase activity [GO:0008948]	ME3
NNT	Q13423	NNTM_HUMAN	reviewed	NAD(P) transhydrogenase, mitochondrial (EC 7.1.1.1) (Nicotinamide nucleotide transhydrogenase) (Pyridine nucleotide transhydrogenase)	NNT	Homo sapiens (Human)	1086	5 out of 5	Beta strand (7); Binding site (4); Chain (1); Helix (12); Modified residue (7); Natural variant (11); Nucleotide binding (7); Sequence conflict (11); Topological domain (4); Transit peptide (1); Transmembrane (14); Turn (1)	3D-structure;Acetylation;Complete proteome;Disease mutation;Membrane;Mitochondrion;Mitochondrion inner membrane;NAD;NADP;Nucleotide-binding;Reference proteome;Transit peptide;Translocase;Transmembrane;Transmembrane helix		SUBCELLULAR LOCATION: Mitochondrion inner membrane {ECO:0000305}; Multi-pass membrane protein {ECO:0000305}; Matrix side {ECO:0000305}.	AlaDH/PNT family; PNT beta subunit family	cell redox homeostasis [GO:0045454]; cellular oxidant detoxification [GO:0098869]; NADPH regeneration [GO:0006740]; negative regulation of apoptotic process [GO:0043066]; negative regulation of protein phosphorylation [GO:0001933]; oxidation-reduction process [GO:0055114]; oxygen homeostasis [GO:0032364]; positive regulation of hydrogen peroxide catabolic process [GO:1903285]; positive regulation of mitochondrial membrane potential [GO:0010918]; proton transmembrane transport [GO:1902600]; reactive oxygen species metabolic process [GO:0072593]; response to vitamin [GO:0033273]; tricarboxylic acid cycle [GO:0006099]	integral component of membrane [GO:0016021]; membrane [GO:0016020]; mitochondrial inner membrane [GO:0005743]; mitochondrial respirasome [GO:0005746]; mitochondrion [GO:0005739]	integral component of membrane [GO:0016021]; membrane [GO:0016020]; mitochondrial inner membrane [GO:0005743]; mitochondrial respirasome [GO:0005746]; mitochondrion [GO:0005739]; NAD binding [GO:0051287]; NAD(P)+ transhydrogenase (B-specific) activity [GO:0003957]; NAD(P)+ transhydrogenase activity [GO:0008746]; NADP binding [GO:0050661]; cell redox homeostasis [GO:0045454]; cellular oxidant detoxification [GO:0098869]; NADPH regeneration [GO:0006740]; negative regulation of apoptotic process [GO:0043066]; negative regulation of protein phosphorylation [GO:0001933]; oxidation-reduction process [GO:0055114]; oxygen homeostasis [GO:0032364]; positive regulation of hydrogen peroxide catabolic process [GO:1903285]; positive regulation of mitochondrial membrane potential [GO:0010918]; proton transmembrane transport [GO:1902600]; reactive oxygen species metabolic process [GO:0072593]; response to vitamin [GO:0033273]; tricarboxylic acid cycle [GO:0006099]	NAD(P)+ transhydrogenase (B-specific) activity [GO:0003957]; NAD(P)+ transhydrogenase activity [GO:0008746]; NAD binding [GO:0051287]; NADP binding [GO:0050661]	NNT
H6PD	O95479	G6PE_HUMAN	reviewed	GDH/6PGL endoplasmic bifunctional protein [Includes: Glucose 1-dehydrogenase (EC 1.1.1.47) (Glucose-6-phosphate dehydrogenase) (EC 1.1.1.363); 6-phosphogluconolactonase (6PGL) (EC 3.1.1.31)]	H6PD GDH	Homo sapiens (Human)	791	5 out of 5	Active site (1); Binding site (4); Chain (1); Erroneous initiation (1); Glycosylation (3); Modified residue (2); Natural variant (6); Region (3); Sequence conflict (1); Signal peptide (1)	Carbohydrate metabolism;Complete proteome;Disease mutation;Endoplasmic reticulum;Glucose metabolism;Glycoprotein;Hydrolase;Multifunctional enzyme;NAD;NADP;Oxidoreductase;Polymorphism;Pyrrolidone carboxylic acid;Reference proteome;Signal		SUBCELLULAR LOCATION: Endoplasmic reticulum lumen. Note=Microsomes, endoplasmic reticulum lumen.	Glucose-6-phosphate dehydrogenase family; Glucosamine/galactosamine-6-phosphate isomerase family, 6-phosphogluconolactonase subfamily	glucose metabolic process [GO:0006006]; pentose-phosphate shunt [GO:0006098]	endoplasmic reticulum lumen [GO:0005788]	endoplasmic reticulum lumen [GO:0005788]; 6-phosphogluconolactonase activity [GO:0017057]; glucose 1-dehydrogenase [NAD(P)] activity [GO:0047936]; glucose-6-phosphate dehydrogenase activity [GO:0004345]; NADP binding [GO:0050661]; glucose metabolic process [GO:0006006]; pentose-phosphate shunt [GO:0006098]	6-phosphogluconolactonase activity [GO:0017057]; glucose 1-dehydrogenase [NAD(P)] activity [GO:0047936]; glucose-6-phosphate dehydrogenase activity [GO:0004345]; NADP binding [GO:0050661]	H6PD
IDH3G	P51553	IDH3G_HUMAN	reviewed	Isocitrate dehydrogenase [NAD] subunit gamma, mitochondrial (Isocitric dehydrogenase subunit gamma) (NAD(+)-specific ICDH subunit gamma)	IDH3G	Homo sapiens (Human)	393	5 out of 5	Alternative sequence (1); Beta strand (15); Binding site (8); Chain (1); Helix (13); Metal binding (1); Mutagenesis (16); Sequence conflict (1); Transit peptide (1); Turn (3)	3D-structure;ATP-binding;Alternative splicing;Complete proteome;Magnesium;Manganese;Metal-binding;Mitochondrion;Nucleotide-binding;Reference proteome;Transit peptide;Tricarboxylic acid cycle		SUBCELLULAR LOCATION: Mitochondrion {ECO:0000269|PubMed:11256614}.	Isocitrate and isopropylmalate dehydrogenases family	carbohydrate metabolic process [GO:0005975]; isocitrate metabolic process [GO:0006102]; tricarboxylic acid cycle [GO:0006099]	mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]; nucleolus [GO:0005730]; nucleoplasm [GO:0005654]	mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]; nucleolus [GO:0005730]; nucleoplasm [GO:0005654]; ATP binding [GO:0005524]; isocitrate dehydrogenase (NAD+) activity [GO:0004449]; magnesium ion binding [GO:0000287]; NAD binding [GO:0051287]; carbohydrate metabolic process [GO:0005975]; isocitrate metabolic process [GO:0006102]; tricarboxylic acid cycle [GO:0006099]	ATP binding [GO:0005524]; isocitrate dehydrogenase (NAD+) activity [GO:0004449]; magnesium ion binding [GO:0000287]; NAD binding [GO:0051287]	IDH3G
IDH3B	O43837	IDH3B_HUMAN	reviewed	Isocitrate dehydrogenase [NAD] subunit beta, mitochondrial (Isocitric dehydrogenase subunit beta) (NAD(+)-specific ICDH subunit beta)	IDH3B	Homo sapiens (Human)	385	5 out of 5	Alternative sequence (2); Chain (1); Modified residue (1); Natural variant (4); Sequence conflict (3); Transit peptide (1)	Acetylation;Alternative splicing;Complete proteome;Disease mutation;Mitochondrion;Polymorphism;Reference proteome;Retinitis pigmentosa;Transit peptide;Tricarboxylic acid cycle		SUBCELLULAR LOCATION: Mitochondrion.	Isocitrate and isopropylmalate dehydrogenases family	isocitrate metabolic process [GO:0006102]; tricarboxylic acid cycle [GO:0006099]	mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]; nucleus [GO:0005634]	mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]; nucleus [GO:0005634]; electron transfer activity [GO:0009055]; isocitrate dehydrogenase (NAD+) activity [GO:0004449]; magnesium ion binding [GO:0000287]; NAD binding [GO:0051287]; isocitrate metabolic process [GO:0006102]; tricarboxylic acid cycle [GO:0006099]	electron transfer activity [GO:0009055]; isocitrate dehydrogenase (NAD+) activity [GO:0004449]; magnesium ion binding [GO:0000287]; NAD binding [GO:0051287]	IDH3B
IDH1	O75874	IDHC_HUMAN	reviewed	Isocitrate dehydrogenase [NADP] cytoplasmic (IDH) (EC 1.1.1.42) (Cytosolic NADP-isocitrate dehydrogenase) (IDP) (NADP(+)-specific ICDH) (Oxalosuccinate decarboxylase)	IDH1 PICD	Homo sapiens (Human)	414	5 out of 5	Beta strand (17); Binding site (7); Chain (1); Helix (19); Initiator methionine (1); Metal binding (3); Modified residue (10); Natural variant (6); Nucleotide binding (2); Region (1); Sequence conflict (8); Site (2); Turn (3)	3D-structure;Acetylation;Complete proteome;Cytoplasm;Direct protein sequencing;Glyoxylate bypass;Magnesium;Manganese;Metal-binding;NADP;Oxidoreductase;Peroxisome;Phosphoprotein;Polymorphism;Reference proteome;Tricarboxylic acid cycle		SUBCELLULAR LOCATION: Cytoplasm, cytosol {ECO:0000269|PubMed:10521434}. Peroxisome {ECO:0000269|PubMed:10521434}.	Isocitrate and isopropylmalate dehydrogenases family	2-oxoglutarate metabolic process [GO:0006103]; female gonad development [GO:0008585]; glutathione metabolic process [GO:0006749]; glyoxylate cycle [GO:0006097]; isocitrate metabolic process [GO:0006102]; NADPH regeneration [GO:0006740]; NADP metabolic process [GO:0006739]; neutrophil degranulation [GO:0043312]; protein targeting to peroxisome [GO:0006625]; regulation of phospholipid biosynthetic process [GO:0071071]; regulation of phospholipid catabolic process [GO:0060696]; response to oxidative stress [GO:0006979]; response to steroid hormone [GO:0048545]; tricarboxylic acid cycle [GO:0006099]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; ficolin-1-rich granule lumen [GO:1904813]; mitochondrion [GO:0005739]; peroxisomal matrix [GO:0005782]; peroxisome [GO:0005777]; secretory granule lumen [GO:0034774]; tertiary granule lumen [GO:1904724]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; ficolin-1-rich granule lumen [GO:1904813]; mitochondrion [GO:0005739]; peroxisomal matrix [GO:0005782]; peroxisome [GO:0005777]; secretory granule lumen [GO:0034774]; tertiary granule lumen [GO:1904724]; cadherin binding [GO:0045296]; identical protein binding [GO:0042802]; isocitrate dehydrogenase (NADP+) activity [GO:0004450]; magnesium ion binding [GO:0000287]; NAD binding [GO:0051287]; NADP binding [GO:0050661]; protein homodimerization activity [GO:0042803]; 2-oxoglutarate metabolic process [GO:0006103]; female gonad development [GO:0008585]; glutathione metabolic process [GO:0006749]; glyoxylate cycle [GO:0006097]; isocitrate metabolic process [GO:0006102]; NADP metabolic process [GO:0006739]; NADPH regeneration [GO:0006740]; neutrophil degranulation [GO:0043312]; protein targeting to peroxisome [GO:0006625]; regulation of phospholipid biosynthetic process [GO:0071071]; regulation of phospholipid catabolic process [GO:0060696]; response to oxidative stress [GO:0006979]; response to steroid hormone [GO:0048545]; tricarboxylic acid cycle [GO:0006099]	cadherin binding [GO:0045296]; identical protein binding [GO:0042802]; isocitrate dehydrogenase (NADP+) activity [GO:0004450]; magnesium ion binding [GO:0000287]; NAD binding [GO:0051287]; NADP binding [GO:0050661]; protein homodimerization activity [GO:0042803]	IDH1
PGD	P52209	6PGD_HUMAN	reviewed	6-phosphogluconate dehydrogenase, decarboxylating (EC 1.1.1.44)	PGD PGDH	Homo sapiens (Human)	483	5 out of 5	Active site (2); Alternative sequence (1); Beta strand (12); Binding site (7); Chain (1); Helix (23); Modified residue (5); Natural variant (1); Nucleotide binding (4); Region (2); Sequence conflict (2); Turn (3)	3D-structure;Acetylation;Alternative splicing;Complete proteome;Cytoplasm;Gluconate utilization;NADP;Oxidoreductase;Pentose shunt;Phosphoprotein;Polymorphism;Reference proteome		SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}.	6-phosphogluconate dehydrogenase family	D-gluconate catabolic process [GO:0046177]; oxidation-reduction process [GO:0055114]; pentose biosynthetic process [GO:0019322]; pentose-phosphate shunt [GO:0006098]; pentose-phosphate shunt, oxidative branch [GO:0009051]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]; nucleus [GO:0005634]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]; nucleus [GO:0005634]; NADP binding [GO:0050661]; phosphogluconate dehydrogenase (decarboxylating) activity [GO:0004616]; D-gluconate catabolic process [GO:0046177]; oxidation-reduction process [GO:0055114]; pentose biosynthetic process [GO:0019322]; pentose-phosphate shunt [GO:0006098]; pentose-phosphate shunt, oxidative branch [GO:0009051]	NADP binding [GO:0050661]; phosphogluconate dehydrogenase (decarboxylating) activity [GO:0004616]	PGD
G6PD	P11413	G6PD_HUMAN	reviewed	Glucose-6-phosphate 1-dehydrogenase (G6PD) (EC 1.1.1.49)	G6PD	Homo sapiens (Human)	515	5 out of 5	Active site (1); Alternative sequence (2); Beta strand (20); Binding site (16); Chain (1); Erroneous initiation (1); Helix (26); Initiator methionine (1); Modified residue (10); Mutagenesis (6); Natural variant (71); Nucleotide binding (3); Region (1); Sequence conflict (4); Turn (8)	3D-structure;Acetylation;Alternative splicing;Carbohydrate metabolism;Complete proteome;Direct protein sequencing;Disease mutation;Glucose metabolism;Hereditary hemolytic anemia;NADP;Oxidoreductase;Phosphoprotein;Polymorphism;Reference proteome	MISCELLANEOUS: Binds two molecules of NADP. The first one is a cosubstrate (bound to the N-terminal domain), the second is bound to the C-terminal domain and functions as a structural element.		Glucose-6-phosphate dehydrogenase family	cellular response to oxidative stress [GO:0034599]; cholesterol biosynthetic process [GO:0006695]; erythrocyte maturation [GO:0043249]; glucose 6-phosphate metabolic process [GO:0051156]; glucose metabolic process [GO:0006006]; glutathione metabolic process [GO:0006749]; lipid metabolic process [GO:0006629]; NADPH regeneration [GO:0006740]; NADP metabolic process [GO:0006739]; negative regulation of cell growth involved in cardiac muscle cell development [GO:0061052]; negative regulation of protein glutathionylation [GO:0010734]; negative regulation of reactive oxygen species metabolic process [GO:2000378]; oxidation-reduction process [GO:0055114]; pentose biosynthetic process [GO:0019322]; pentose-phosphate shunt [GO:0006098]; pentose-phosphate shunt, oxidative branch [GO:0009051]; positive regulation of calcium ion transmembrane transport via high voltage-gated calcium channel [GO:1904879]; regulation of neuron apoptotic process [GO:0043523]; response to ethanol [GO:0045471]; response to food [GO:0032094]; response to iron(III) ion [GO:0010041]; response to organic cyclic compound [GO:0014070]; ribose phosphate biosynthetic process [GO:0046390]; substantia nigra development [GO:0021762]	cytoplasm [GO:0005737]; cytoplasmic side of plasma membrane [GO:0009898]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; membrane [GO:0016020]; nucleus [GO:0005634]	cytoplasm [GO:0005737]; cytoplasmic side of plasma membrane [GO:0009898]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; membrane [GO:0016020]; nucleus [GO:0005634]; glucose binding [GO:0005536]; glucose-6-phosphate dehydrogenase activity [GO:0004345]; identical protein binding [GO:0042802]; NADP binding [GO:0050661]; protein homodimerization activity [GO:0042803]; cellular response to oxidative stress [GO:0034599]; cholesterol biosynthetic process [GO:0006695]; erythrocyte maturation [GO:0043249]; glucose 6-phosphate metabolic process [GO:0051156]; glucose metabolic process [GO:0006006]; glutathione metabolic process [GO:0006749]; lipid metabolic process [GO:0006629]; NADP metabolic process [GO:0006739]; NADPH regeneration [GO:0006740]; negative regulation of cell growth involved in cardiac muscle cell development [GO:0061052]; negative regulation of protein glutathionylation [GO:0010734]; negative regulation of reactive oxygen species metabolic process [GO:2000378]; oxidation-reduction process [GO:0055114]; pentose biosynthetic process [GO:0019322]; pentose-phosphate shunt [GO:0006098]; pentose-phosphate shunt, oxidative branch [GO:0009051]; positive regulation of calcium ion transmembrane transport via high voltage-gated calcium channel [GO:1904879]; regulation of neuron apoptotic process [GO:0043523]; response to ethanol [GO:0045471]; response to food [GO:0032094]; response to iron(III) ion [GO:0010041]; response to organic cyclic compound [GO:0014070]; ribose phosphate biosynthetic process [GO:0046390]; substantia nigra development [GO:0021762]	glucose-6-phosphate dehydrogenase activity [GO:0004345]; glucose binding [GO:0005536]; identical protein binding [GO:0042802]; NADP binding [GO:0050661]; protein homodimerization activity [GO:0042803]	G6PD
IDH3A	P50213	IDH3A_HUMAN	reviewed	Isocitrate dehydrogenase [NAD] subunit alpha, mitochondrial (EC 1.1.1.41) (Isocitric dehydrogenase subunit alpha) (NAD(+)-specific ICDH subunit alpha)	IDH3A	Homo sapiens (Human)	366	5 out of 5	Alternative sequence (1); Beta strand (15); Binding site (3); Chain (1); Helix (15); Metal binding (3); Modified residue (6); Mutagenesis (7); Site (2); Transit peptide (1); Turn (2)	3D-structure;Acetylation;Alternative splicing;Complete proteome;Direct protein sequencing;Magnesium;Manganese;Metal-binding;Mitochondrion;NAD;Oxidoreductase;Phosphoprotein;Reference proteome;Transit peptide;Tricarboxylic acid cycle		SUBCELLULAR LOCATION: Mitochondrion.	Isocitrate and isopropylmalate dehydrogenases family	carbohydrate metabolic process [GO:0005975]; isocitrate metabolic process [GO:0006102]; tricarboxylic acid cycle [GO:0006099]	mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]; nucleus [GO:0005634]	mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]; nucleus [GO:0005634]; isocitrate dehydrogenase (NAD+) activity [GO:0004449]; magnesium ion binding [GO:0000287]; NAD binding [GO:0051287]; carbohydrate metabolic process [GO:0005975]; isocitrate metabolic process [GO:0006102]; tricarboxylic acid cycle [GO:0006099]	isocitrate dehydrogenase (NAD+) activity [GO:0004449]; magnesium ion binding [GO:0000287]; NAD binding [GO:0051287]	IDH3A
IDH2	P48735	IDHP_HUMAN	reviewed	Isocitrate dehydrogenase [NADP], mitochondrial (IDH) (EC 1.1.1.42) (ICD-M) (IDP) (NADP(+)-specific ICDH) (Oxalosuccinate decarboxylase)	IDH2	Homo sapiens (Human)	452	5 out of 5	Alternative sequence (1); Beta strand (14); Binding site (6); Chain (1); Helix (17); Metal binding (2); Modified residue (29); Mutagenesis (3); Natural variant (10); Nucleotide binding (2); Region (1); Sequence conflict (2); Site (2); Transit peptide (1); Turn (4)	3D-structure;Acetylation;Alternative splicing;Complete proteome;Disease mutation;Glyoxylate bypass;Magnesium;Manganese;Metal-binding;Mitochondrion;NADP;Oxidoreductase;Reference proteome;Transit peptide;Tricarboxylic acid cycle		SUBCELLULAR LOCATION: Mitochondrion.	Isocitrate and isopropylmalate dehydrogenases family	2-oxoglutarate metabolic process [GO:0006103]; carbohydrate metabolic process [GO:0005975]; glyoxylate cycle [GO:0006097]; isocitrate metabolic process [GO:0006102]; NADP biosynthetic process [GO:0006741]; NADP metabolic process [GO:0006739]; negative regulation of glial cell migration [GO:1903976]; negative regulation of glial cell proliferation [GO:0060253]; negative regulation of matrix metallopeptidase secretion [GO:1904465]; tricarboxylic acid cycle [GO:0006099]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]; peroxisome [GO:0005777]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]; peroxisome [GO:0005777]; isocitrate dehydrogenase (NADP+) activity [GO:0004450]; magnesium ion binding [GO:0000287]; NAD binding [GO:0051287]; 2-oxoglutarate metabolic process [GO:0006103]; carbohydrate metabolic process [GO:0005975]; glyoxylate cycle [GO:0006097]; isocitrate metabolic process [GO:0006102]; NADP biosynthetic process [GO:0006741]; NADP metabolic process [GO:0006739]; negative regulation of glial cell migration [GO:1903976]; negative regulation of glial cell proliferation [GO:0060253]; negative regulation of matrix metallopeptidase secretion [GO:1904465]; tricarboxylic acid cycle [GO:0006099]	isocitrate dehydrogenase (NADP+) activity [GO:0004450]; magnesium ion binding [GO:0000287]; NAD binding [GO:0051287]	IDH2
MTH1	P36639	8ODP_HUMAN	reviewed	7,8-dihydro-8-oxoguanine triphosphatase (EC 3.6.1.55) (2-hydroxy-dATP diphosphatase) (EC 3.6.1.56) (8-oxo-dGTPase) (Nucleoside diphosphate-linked moiety X motif 1) (Nudix motif 1)	NUDT1 MTH1	Homo sapiens (Human)	197	5 out of 5	Alternative sequence (3); Beta strand (11); Binding site (3); Chain (1); Domain (1); Helix (4); Metal binding (4); Motif (1); Mutagenesis (31); Natural variant (2); Region (2); Site (3); Transit peptide (1); Turn (2)	3D-structure;Alternative initiation;Complete proteome;Cytoplasm;Direct protein sequencing;Hydrolase;Magnesium;Metal-binding;Mitochondrion;Nucleus;Polymorphism;RNA-binding;Reference proteome;Transit peptide		SUBCELLULAR LOCATION: Isoform p18: Cytoplasm, cytosol {ECO:0000269|PubMed:12857738, ECO:0000269|PubMed:16607562, ECO:0000269|PubMed:7782328}. Mitochondrion matrix {ECO:0000269|PubMed:7782328, ECO:0000305|PubMed:12857738, ECO:0000305|PubMed:16607562}. Nucleus {ECO:0000269|PubMed:12857738, ECO:0000269|PubMed:7782328}. Note=Mostly present in cytosol (PubMed:7782328). A minor proportion is mitochondrial (PubMed:7782328). A very small amount of the protein is associated with nuclei (PubMed:7782328). Variant Met-124 has decreased efficiency in translocation to mitochondria (PubMed:16607562). {ECO:0000269|PubMed:16607562, ECO:0000269|PubMed:7782328}.; SUBCELLULAR LOCATION: Isoform p26: Mitochondrion matrix {ECO:0000269|PubMed:16607562}.	Nudix hydrolase family	aging [GO:0007568]; dATP catabolic process [GO:0046061]; dGTP catabolic process [GO:0006203]; DNA protection [GO:0042262]; DNA repair [GO:0006281]; male gonad development [GO:0008584]; nucleobase-containing small molecule catabolic process [GO:0034656]; purine nucleotide catabolic process [GO:0006195]; response to cadmium ion [GO:0046686]; response to oxidative stress [GO:0006979]	acrosomal vesicle [GO:0001669]; cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular space [GO:0005615]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]; nuclear membrane [GO:0031965]; nucleus [GO:0005634]; plasma membrane [GO:0005886]	acrosomal vesicle [GO:0001669]; cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular space [GO:0005615]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]; nuclear membrane [GO:0031965]; nucleus [GO:0005634]; plasma membrane [GO:0005886]; 8-oxo-7,8-dihydrodeoxyguanosine triphosphate pyrophosphatase activity [GO:0035539]; 8-oxo-7,8-dihydroguanosine triphosphate pyrophosphatase activity [GO:0008413]; ATP diphosphatase activity [GO:0047693]; GTP diphosphatase activity [GO:0036219]; GTPase activity [GO:0003924]; metal ion binding [GO:0046872]; snoRNA binding [GO:0030515]; aging [GO:0007568]; dATP catabolic process [GO:0046061]; dGTP catabolic process [GO:0006203]; DNA protection [GO:0042262]; DNA repair [GO:0006281]; male gonad development [GO:0008584]; nucleobase-containing small molecule catabolic process [GO:0034656]; purine nucleotide catabolic process [GO:0006195]; response to cadmium ion [GO:0046686]; response to oxidative stress [GO:0006979]	8-oxo-7,8-dihydrodeoxyguanosine triphosphate pyrophosphatase activity [GO:0035539]; 8-oxo-7,8-dihydroguanosine triphosphate pyrophosphatase activity [GO:0008413]; ATP diphosphatase activity [GO:0047693]; GTPase activity [GO:0003924]; GTP diphosphatase activity [GO:0036219]; metal ion binding [GO:0046872]; snoRNA binding [GO:0030515]	MTH1
PCYOX1	Q9UHG3	PCYOX_HUMAN	reviewed	Prenylcysteine oxidase 1 (EC 1.8.3.5) (Prenylcysteine lyase)	PCYOX1 KIAA0908 PCL1 UNQ597/PRO1183	Homo sapiens (Human)	505	5 out of 5	Alternative sequence (1); Chain (1); Erroneous initiation (1); Glycosylation (3); Natural variant (3); Sequence conflict (1); Signal peptide (1)	Alternative splicing;Complete proteome;Direct protein sequencing;FAD;Flavoprotein;Glycoprotein;Lysosome;Oxidoreductase;Polymorphism;Reference proteome;Signal		SUBCELLULAR LOCATION: Lysosome.	Prenylcysteine oxidase family	prenylated protein catabolic process [GO:0030327]; prenylcysteine catabolic process [GO:0030328]	extracellular exosome [GO:0070062]; lysosome [GO:0005764]; plasma membrane [GO:0005886]; very-low-density lipoprotein particle [GO:0034361]	extracellular exosome [GO:0070062]; lysosome [GO:0005764]; plasma membrane [GO:0005886]; very-low-density lipoprotein particle [GO:0034361]; ATPase-coupled chloride transmembrane transporter activity [GO:0008555]; prenylcysteine oxidase activity [GO:0001735]; prenylated protein catabolic process [GO:0030327]; prenylcysteine catabolic process [GO:0030328]	ATPase-coupled chloride transmembrane transporter activity [GO:0008555]; prenylcysteine oxidase activity [GO:0001735]	PCYOX1
TKTL1	P51854	TKTL1_HUMAN	reviewed	Transketolase-like protein 1 (EC 2.2.1.1) (Transketolase 2) (TK 2) (Transketolase-related protein)	TKTL1 TKR TKT2	Homo sapiens (Human)	596	5 out of 5	Active site (1); Alternative sequence (2); Binding site (14); Chain (1); Metal binding (3); Natural variant (2); Nucleotide binding (1); Sequence conflict (2); Site (2)	Alternative splicing;Calcium;Complete proteome;Cytoplasm;Magnesium;Metal-binding;Nucleus;Polymorphism;Reference proteome;Thiamine pyrophosphate;Transferase	MISCELLANEOUS: Strong TKTL1 protein expression has been correlated with a certain type of glucose metabolism (aerobic glycolysis; Warburg effect) and to cells which are affected by chronic complications of diabetic patients.	SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:16465194, ECO:0000269|PubMed:16969476}. Nucleus {ECO:0000269|PubMed:16465194, ECO:0000269|PubMed:16969476}. Note=Predominantly cytoplasmic and to a lesser extent also nuclear (PubMed:16969476).	Transketolase family	glucose catabolic process [GO:0006007]; thiamine metabolic process [GO:0006772]	cytoplasm [GO:0005737]; nucleus [GO:0005634]	cytoplasm [GO:0005737]; nucleus [GO:0005634]; metal ion binding [GO:0046872]; transketolase activity [GO:0004802]; glucose catabolic process [GO:0006007]; thiamine metabolic process [GO:0006772]	metal ion binding [GO:0046872]; transketolase activity [GO:0004802]	TKTL1
PGM1	P36871	PGM1_HUMAN	reviewed	Phosphoglucomutase-1 (PGM 1) (EC 5.4.2.2) (Glucose phosphomutase 1)	PGM1	Homo sapiens (Human)	562	5 out of 5	Active site (1); Alternative sequence (2); Beta strand (31); Binding site (6); Chain (1); Erroneous initiation (1); Helix (23); Metal binding (4); Modified residue (22); Natural variant (18); Region (3); Sequence conflict (1); Turn (7)	3D-structure;Acetylation;Alternative splicing;Carbohydrate metabolism;Complete proteome;Congenital disorder of glycosylation;Cytoplasm;Disease mutation;Glucose metabolism;Glycogen storage disease;Isomerase;Magnesium;Metal-binding;Phosphoprotein;Polymorphism;Reference proteome		SUBCELLULAR LOCATION: Isoform 1: Cytoplasm.	Phosphohexose mutase family	galactose catabolic process [GO:0019388]; gluconeogenesis [GO:0006094]; glucose metabolic process [GO:0006006]; glycogen biosynthetic process [GO:0005978]; glycogen catabolic process [GO:0005980]; glycolytic process [GO:0006096]; neutrophil degranulation [GO:0043312]	actin cytoskeleton [GO:0015629]; cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; ficolin-1-rich granule lumen [GO:1904813]; tertiary granule lumen [GO:1904724]	actin cytoskeleton [GO:0015629]; cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; ficolin-1-rich granule lumen [GO:1904813]; tertiary granule lumen [GO:1904724]; magnesium ion binding [GO:0000287]; phosphoglucomutase activity [GO:0004614]; galactose catabolic process [GO:0019388]; gluconeogenesis [GO:0006094]; glucose metabolic process [GO:0006006]; glycogen biosynthetic process [GO:0005978]; glycogen catabolic process [GO:0005980]; glycolytic process [GO:0006096]; neutrophil degranulation [GO:0043312]	magnesium ion binding [GO:0000287]; phosphoglucomutase activity [GO:0004614]	PGM1
PRPS2	P11908	PRPS2_HUMAN	reviewed	Ribose-phosphate pyrophosphokinase 2 (EC 2.7.6.1) (PPRibP) (Phosphoribosyl pyrophosphate synthase II) (PRS-II)	PRPS2	Homo sapiens (Human)	318	5 out of 5	Alternative sequence (1); Binding site (1); Chain (1); Erroneous initiation (1); Initiator methionine (1); Metal binding (4); Nucleotide binding (1); Region (1)	ATP-binding;Alternative splicing;Complete proteome;Direct protein sequencing;Kinase;Magnesium;Metal-binding;Nucleotide biosynthesis;Nucleotide-binding;Reference proteome;Transferase			Ribose-phosphate pyrophosphokinase family	5-phosphoribose 1-diphosphate biosynthetic process [GO:0006015]; AMP biosynthetic process [GO:0006167]; animal organ regeneration [GO:0031100]; nucleobase-containing compound metabolic process [GO:0006139]; nucleoside metabolic process [GO:0009116]; nucleotide biosynthetic process [GO:0009165]; purine nucleotide biosynthetic process [GO:0006164]	cytoplasm [GO:0005737]; ribose phosphate diphosphokinase complex [GO:0002189]	cytoplasm [GO:0005737]; ribose phosphate diphosphokinase complex [GO:0002189]; ADP binding [GO:0043531]; AMP binding [GO:0016208]; ATP binding [GO:0005524]; carbohydrate binding [GO:0030246]; GDP binding [GO:0019003]; identical protein binding [GO:0042802]; kinase activity [GO:0016301]; magnesium ion binding [GO:0000287]; protein homodimerization activity [GO:0042803]; ribose phosphate diphosphokinase activity [GO:0004749]; 5-phosphoribose 1-diphosphate biosynthetic process [GO:0006015]; AMP biosynthetic process [GO:0006167]; animal organ regeneration [GO:0031100]; nucleobase-containing compound metabolic process [GO:0006139]; nucleoside metabolic process [GO:0009116]; nucleotide biosynthetic process [GO:0009165]; purine nucleotide biosynthetic process [GO:0006164]	ADP binding [GO:0043531]; AMP binding [GO:0016208]; ATP binding [GO:0005524]; carbohydrate binding [GO:0030246]; GDP binding [GO:0019003]; identical protein binding [GO:0042802]; kinase activity [GO:0016301]; magnesium ion binding [GO:0000287]; protein homodimerization activity [GO:0042803]; ribose phosphate diphosphokinase activity [GO:0004749]	PRPS2
GPI	P06744	G6PI_HUMAN	reviewed	Glucose-6-phosphate isomerase (GPI) (EC 5.3.1.9) (Autocrine motility factor) (AMF) (Neuroleukin) (NLK) (Phosphoglucose isomerase) (PGI) (Phosphohexose isomerase) (PHI) (Sperm antigen 36) (SA-36)	GPI	Homo sapiens (Human)	558	5 out of 5	Active site (3); Alternative sequence (2); Beta strand (16); Binding site (4); Chain (1); Helix (38); Initiator methionine (1); Modified residue (11); Mutagenesis (2); Natural variant (27); Region (2); Sequence conflict (3); Turn (2)	3D-structure;Acetylation;Alternative splicing;Complete proteome;Cytokine;Cytoplasm;Direct protein sequencing;Disease mutation;Gluconeogenesis;Glycolysis;Growth factor;Hereditary hemolytic anemia;Isomerase;Phosphoprotein;Polymorphism;Reference proteome;Secreted;Ubl conjugation		SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:11437381}. Secreted {ECO:0000269|PubMed:11437381}.	GPI family	canonical glycolysis [GO:0061621]; carbohydrate metabolic process [GO:0005975]; gluconeogenesis [GO:0006094]; glucose 6-phosphate metabolic process [GO:0051156]; glycolytic process [GO:0006096]; hemostasis [GO:0007599]; humoral immune response [GO:0006959]; neutrophil degranulation [GO:0043312]; positive regulation of endothelial cell migration [GO:0010595]; positive regulation of immunoglobulin secretion [GO:0051024]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; ficolin-1-rich granule lumen [GO:1904813]; membrane [GO:0016020]; nucleoplasm [GO:0005654]; plasma membrane [GO:0005886]; secretory granule lumen [GO:0034774]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; ficolin-1-rich granule lumen [GO:1904813]; membrane [GO:0016020]; nucleoplasm [GO:0005654]; plasma membrane [GO:0005886]; secretory granule lumen [GO:0034774]; cytokine activity [GO:0005125]; glucose-6-phosphate isomerase activity [GO:0004347]; growth factor activity [GO:0008083]; intramolecular transferase activity [GO:0016866]; monosaccharide binding [GO:0048029]; ubiquitin protein ligase binding [GO:0031625]; canonical glycolysis [GO:0061621]; carbohydrate metabolic process [GO:0005975]; gluconeogenesis [GO:0006094]; glucose 6-phosphate metabolic process [GO:0051156]; glycolytic process [GO:0006096]; hemostasis [GO:0007599]; humoral immune response [GO:0006959]; neutrophil degranulation [GO:0043312]; positive regulation of endothelial cell migration [GO:0010595]; positive regulation of immunoglobulin secretion [GO:0051024]	cytokine activity [GO:0005125]; glucose-6-phosphate isomerase activity [GO:0004347]; growth factor activity [GO:0008083]; intramolecular transferase activity [GO:0016866]; monosaccharide binding [GO:0048029]; ubiquitin protein ligase binding [GO:0031625]	GPI
ALDOC	P09972	ALDOC_HUMAN	reviewed	Fructose-bisphosphate aldolase C (EC 4.1.2.13) (Brain-type aldolase)	ALDOC ALDC	Homo sapiens (Human)	364	5 out of 5	Active site (2); Beta strand (10); Binding site (2); Chain (1); Erroneous initiation (1); Helix (14); Modified residue (6); Sequence conflict (1); Site (1); Turn (4)	3D-structure;Acetylation;Complete proteome;Glycolysis;Lyase;Phosphoprotein;Reference proteome;Schiff base	MISCELLANEOUS: In vertebrates, three forms of this ubiquitous glycolytic enzyme are found, aldolase A in muscle, aldolase B in liver and aldolase C in brain.		Class I fructose-bisphosphate aldolase family	canonical glycolysis [GO:0061621]; epithelial cell differentiation [GO:0030855]; fructose 1,6-bisphosphate metabolic process [GO:0030388]; fructose metabolic process [GO:0006000]; gluconeogenesis [GO:0006094]; glycolytic process [GO:0006096]; neutrophil degranulation [GO:0043312]	cytoskeleton [GO:0005856]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; ficolin-1-rich granule lumen [GO:1904813]; secretory granule lumen [GO:0034774]; tertiary granule lumen [GO:1904724]	cytoskeleton [GO:0005856]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; ficolin-1-rich granule lumen [GO:1904813]; secretory granule lumen [GO:0034774]; tertiary granule lumen [GO:1904724]; cytoskeletal protein binding [GO:0008092]; fructose-bisphosphate aldolase activity [GO:0004332]; canonical glycolysis [GO:0061621]; epithelial cell differentiation [GO:0030855]; fructose 1,6-bisphosphate metabolic process [GO:0030388]; fructose metabolic process [GO:0006000]; gluconeogenesis [GO:0006094]; glycolytic process [GO:0006096]; neutrophil degranulation [GO:0043312]	cytoskeletal protein binding [GO:0008092]; fructose-bisphosphate aldolase activity [GO:0004332]	ALDOC
PGLS	O95336	6PGL_HUMAN	reviewed	6-phosphogluconolactonase (6PGL) (EC 3.1.1.31)	PGLS	Homo sapiens (Human)	258	4 out of 5	Chain (1); Erroneous initiation (1); Initiator methionine (1); Modified residue (3)	Acetylation;Complete proteome;Cytoplasm;Direct protein sequencing;Hydrolase;Phosphoprotein;Reference proteome		SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}.	Glucosamine/galactosamine-6-phosphate isomerase family, 6-phosphogluconolactonase subfamily	carbohydrate metabolic process [GO:0005975]; pentose-phosphate shunt [GO:0006098]; pentose-phosphate shunt, oxidative branch [GO:0009051]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]; 6-phosphogluconolactonase activity [GO:0017057]; carbohydrate metabolic process [GO:0005975]; pentose-phosphate shunt [GO:0006098]; pentose-phosphate shunt, oxidative branch [GO:0009051]	6-phosphogluconolactonase activity [GO:0017057]	PGLS
FBP2	O00757	F16P2_HUMAN	reviewed	Fructose-1,6-bisphosphatase isozyme 2 (FBPase 2) (EC 3.1.3.11) (D-fructose-1,6-bisphosphate 1-phosphohydrolase 2) (Muscle FBPase)	FBP2	Homo sapiens (Human)	339	5 out of 5	Beta strand (16); Binding site (5); Chain (1); Helix (13); Metal binding (8); Modified residue (2); Motif (1); Mutagenesis (18); Natural variant (1); Nucleotide binding (2); Region (3); Site (1); Turn (6)	3D-structure;Allosteric enzyme;Calcium;Carbohydrate metabolism;Cell junction;Complete proteome;Cytoplasm;Gluconeogenesis;Hydrolase;Magnesium;Metal-binding;Nucleus;Phosphoprotein;Polymorphism;Reference proteome	MISCELLANEOUS: Specific for the alpha-anomer of the substrate (PubMed:22120740). The Arg-33 mutant form has been shown to act on the beta-anomer (PubMed:24086250). {ECO:0000305|PubMed:22120740, ECO:0000305|PubMed:24086250}.	SUBCELLULAR LOCATION: Cell junction {ECO:0000250}. Cytoplasm. Nucleus. Cytoplasm, myofibril, sarcomere, Z line. Note=In neonatal cardiomyocytes, distributed throughout the cytosol, accumulating in the intercalated disks which occur at the Z line of cardiomyocytes and connect adjacent cells, and also located in the nucleus; dissociates from the Z line following an increase in cytosolic Ca(2+) concentration (By similarity). In muscle precursor cells, localizes predominantly to the nucleus and to a lesser extent to the cytoplasm at the proliferative phase, while mainly localizing to the cytoplasm at the differentiation phase (By similarity). Colocalizes with ALDOA and alpha-actinin on both sides of the Z line of skeletal muscle; dissociates rapidly from the Z line following an increase in cytosolic Ca(2+) concentration. {ECO:0000250}.	FBPase class 1 family	fructose 1,6-bisphosphate metabolic process [GO:0030388]; fructose 6-phosphate metabolic process [GO:0006002]; fructose metabolic process [GO:0006000]; gluconeogenesis [GO:0006094]; sucrose biosynthetic process [GO:0005986]	cell junction [GO:0030054]; cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; nucleoplasm [GO:0005654]; plasma membrane [GO:0005886]; Z disc [GO:0030018]	cell junction [GO:0030054]; cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; nucleoplasm [GO:0005654]; plasma membrane [GO:0005886]; Z disc [GO:0030018]; fructose 1,6-bisphosphate 1-phosphatase activity [GO:0042132]; identical protein binding [GO:0042802]; metal ion binding [GO:0046872]; fructose 1,6-bisphosphate metabolic process [GO:0030388]; fructose 6-phosphate metabolic process [GO:0006002]; fructose metabolic process [GO:0006000]; gluconeogenesis [GO:0006094]; sucrose biosynthetic process [GO:0005986]	fructose 1,6-bisphosphate 1-phosphatase activity [GO:0042132]; identical protein binding [GO:0042802]; metal ion binding [GO:0046872]	FBP2
FBP2	Q63HM2	PCX4_HUMAN	reviewed	Pecanex-like protein 4 (Hepatitis C virus F protein-binding protein 2) (HCV F protein-binding protein 2) (Pecanex homolog protein 4)	PCNX4 C14orf135 FBP2 PCNXL4	Homo sapiens (Human)	1172	3 out of 5	Chain (1); Erroneous initiation (4); Glycosylation (2); Natural variant (3); Sequence conflict (2); Transmembrane (15)	Complete proteome;Glycoprotein;Membrane;Polymorphism;Reference proteome;Transmembrane;Transmembrane helix		SUBCELLULAR LOCATION: Membrane {ECO:0000305}; Multi-pass membrane protein {ECO:0000305}.	Pecanex family		integral component of membrane [GO:0016021]	integral component of membrane [GO:0016021]		FBP2
ALDOB	P05062	ALDOB_HUMAN	reviewed	Fructose-bisphosphate aldolase B (EC 4.1.2.13) (Liver-type aldolase)	ALDOB ALDB	Homo sapiens (Human)	364	5 out of 5	Active site (2); Beta strand (11); Binding site (2); Chain (1); Helix (17); Initiator methionine (1); Modified residue (14); Natural variant (21); Sequence conflict (5); Site (1); Turn (4)	3D-structure;Acetylation;Complete proteome;Cytoplasm;Cytoskeleton;Direct protein sequencing;Disease mutation;Glycolysis;Lyase;Phosphoprotein;Polymorphism;Reference proteome;Schiff base	MISCELLANEOUS: In vertebrates, 3 forms of this ubiquitous glycolytic enzyme are found, aldolase A in muscle, aldolase B in liver and aldolase C in brain.	SUBCELLULAR LOCATION: Cytoplasm, cytoskeleton, microtubule organizing center, centrosome, centriolar satellite {ECO:0000269|PubMed:18000879}.	Class I fructose-bisphosphate aldolase family	canonical glycolysis [GO:0061621]; fructose 1,6-bisphosphate metabolic process [GO:0030388]; fructose catabolic process to hydroxyacetone phosphate and glyceraldehyde-3-phosphate [GO:0061624]; fructose metabolic process [GO:0006000]; gluconeogenesis [GO:0006094]; glycolytic process [GO:0006096]; NADH oxidation [GO:0006116]; positive regulation of ATPase activity [GO:0032781]; vacuolar proton-transporting V-type ATPase complex assembly [GO:0070072]	centriolar satellite [GO:0034451]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; microtubule organizing center [GO:0005815]	centriolar satellite [GO:0034451]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; microtubule organizing center [GO:0005815]; ATPase binding [GO:0051117]; cytoskeletal protein binding [GO:0008092]; fructose binding [GO:0070061]; fructose-1-phosphate aldolase activity [GO:0061609]; fructose-bisphosphate aldolase activity [GO:0004332]; identical protein binding [GO:0042802]; canonical glycolysis [GO:0061621]; fructose 1,6-bisphosphate metabolic process [GO:0030388]; fructose catabolic process to hydroxyacetone phosphate and glyceraldehyde-3-phosphate [GO:0061624]; fructose metabolic process [GO:0006000]; gluconeogenesis [GO:0006094]; glycolytic process [GO:0006096]; NADH oxidation [GO:0006116]; positive regulation of ATPase activity [GO:0032781]; vacuolar proton-transporting V-type ATPase complex assembly [GO:0070072]	ATPase binding [GO:0051117]; cytoskeletal protein binding [GO:0008092]; fructose-1-phosphate aldolase activity [GO:0061609]; fructose binding [GO:0070061]; fructose-bisphosphate aldolase activity [GO:0004332]; identical protein binding [GO:0042802]	ALDOB
PRPS1	P60891	PRPS1_HUMAN	reviewed	Ribose-phosphate pyrophosphokinase 1 (EC 2.7.6.1) (PPRibP) (Phosphoribosyl pyrophosphate synthase I) (PRS-I)	PRPS1	Homo sapiens (Human)	318	5 out of 5	Alternative sequence (1); Beta strand (16); Binding site (1); Chain (1); Helix (13); Initiator methionine (1); Metal binding (4); Mutagenesis (5); Natural variant (19); Nucleotide binding (1); Region (1); Sequence conflict (3); Turn (2)	3D-structure;ATP-binding;Alternative splicing;Charcot-Marie-Tooth disease;Complete proteome;Deafness;Direct protein sequencing;Disease mutation;Gout;Kinase;Magnesium;Mental retardation;Metal-binding;Neurodegeneration;Neuropathy;Non-syndromic deafness;Nucleotide biosynthesis;Nucleotide-binding;Polymorphism;Reference proteome;Retinitis pigmentosa;Transferase			Ribose-phosphate pyrophosphokinase family	5-phosphoribose 1-diphosphate biosynthetic process [GO:0006015]; hypoxanthine biosynthetic process [GO:0046101]; nervous system development [GO:0007399]; nucleoside metabolic process [GO:0009116]; nucleotide biosynthetic process [GO:0009165]; purine nucleobase metabolic process [GO:0006144]; purine nucleotide biosynthetic process [GO:0006164]; pyrimidine nucleotide biosynthetic process [GO:0006221]; ribonucleoside monophosphate biosynthetic process [GO:0009156]; urate biosynthetic process [GO:0034418]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; ribose phosphate diphosphokinase complex [GO:0002189]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; ribose phosphate diphosphokinase complex [GO:0002189]; ATP binding [GO:0005524]; identical protein binding [GO:0042802]; kinase activity [GO:0016301]; magnesium ion binding [GO:0000287]; protein homodimerization activity [GO:0042803]; ribose phosphate diphosphokinase activity [GO:0004749]; 5-phosphoribose 1-diphosphate biosynthetic process [GO:0006015]; hypoxanthine biosynthetic process [GO:0046101]; nervous system development [GO:0007399]; nucleoside metabolic process [GO:0009116]; nucleotide biosynthetic process [GO:0009165]; purine nucleobase metabolic process [GO:0006144]; purine nucleotide biosynthetic process [GO:0006164]; pyrimidine nucleotide biosynthetic process [GO:0006221]; ribonucleoside monophosphate biosynthetic process [GO:0009156]; urate biosynthetic process [GO:0034418]	ATP binding [GO:0005524]; identical protein binding [GO:0042802]; kinase activity [GO:0016301]; magnesium ion binding [GO:0000287]; protein homodimerization activity [GO:0042803]; ribose phosphate diphosphokinase activity [GO:0004749]	PRPS1
ALDOA	P04075	ALDOA_HUMAN	reviewed	Fructose-bisphosphate aldolase A (EC 4.1.2.13) (Lung cancer antigen NY-LU-1) (Muscle-type aldolase)	ALDOA ALDA	Homo sapiens (Human)	364	5 out of 5	Active site (2); Alternative sequence (1); Beta strand (12); Binding site (2); Chain (1); Cross-link (2); Helix (17); Initiator methionine (1); Modified residue (13); Natural variant (6); Sequence conflict (5); Site (1); Turn (2)	3D-structure;Acetylation;Alternative splicing;Complete proteome;Cytoplasm;Direct protein sequencing;Disease mutation;Glycogen storage disease;Glycolysis;Hereditary hemolytic anemia;Isopeptide bond;Lyase;Phosphoprotein;Polymorphism;Reference proteome;Schiff base;Ubl conjugation	MISCELLANEOUS: In vertebrates, three forms of this ubiquitous glycolytic enzyme are found, aldolase A in muscle, aldolase B in liver and aldolase C in brain.	SUBCELLULAR LOCATION: Cytoplasm, myofibril, sarcomere, I band. Cytoplasm, myofibril, sarcomere, M line. Note=In skeletal muscle, accumulates around the M line and within the I band, colocalizing with FBP2 on both sides of the Z line in the absence of Ca(2+). {ECO:0000250}.	Class I fructose-bisphosphate aldolase family	actin filament organization [GO:0007015]; ATP biosynthetic process [GO:0006754]; binding of sperm to zona pellucida [GO:0007339]; canonical glycolysis [GO:0061621]; fructose 1,6-bisphosphate metabolic process [GO:0030388]; fructose metabolic process [GO:0006000]; gluconeogenesis [GO:0006094]; glycolytic process [GO:0006096]; muscle cell cellular homeostasis [GO:0046716]; neutrophil degranulation [GO:0043312]; platelet degranulation [GO:0002576]; protein homotetramerization [GO:0051289]; regulation of cell shape [GO:0008360]; striated muscle contraction [GO:0006941]	actin cytoskeleton [GO:0015629]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; extracellular space [GO:0005615]; ficolin-1-rich granule lumen [GO:1904813]; I band [GO:0031674]; M band [GO:0031430]; membrane [GO:0016020]; nucleus [GO:0005634]; platelet alpha granule lumen [GO:0031093]; secretory granule lumen [GO:0034774]; sperm head [GO:0061827]; tertiary granule lumen [GO:1904724]	actin cytoskeleton [GO:0015629]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; extracellular space [GO:0005615]; ficolin-1-rich granule lumen [GO:1904813]; I band [GO:0031674]; M band [GO:0031430]; membrane [GO:0016020]; nucleus [GO:0005634]; platelet alpha granule lumen [GO:0031093]; secretory granule lumen [GO:0034774]; sperm head [GO:0061827]; tertiary granule lumen [GO:1904724]; actin binding [GO:0003779]; cadherin binding [GO:0045296]; cytoskeletal protein binding [GO:0008092]; fructose binding [GO:0070061]; fructose-bisphosphate aldolase activity [GO:0004332]; identical protein binding [GO:0042802]; RNA binding [GO:0003723]; tubulin binding [GO:0015631]; actin filament organization [GO:0007015]; ATP biosynthetic process [GO:0006754]; binding of sperm to zona pellucida [GO:0007339]; canonical glycolysis [GO:0061621]; fructose 1,6-bisphosphate metabolic process [GO:0030388]; fructose metabolic process [GO:0006000]; gluconeogenesis [GO:0006094]; glycolytic process [GO:0006096]; muscle cell cellular homeostasis [GO:0046716]; neutrophil degranulation [GO:0043312]; platelet degranulation [GO:0002576]; protein homotetramerization [GO:0051289]; regulation of cell shape [GO:0008360]; striated muscle contraction [GO:0006941]	actin binding [GO:0003779]; cadherin binding [GO:0045296]; cytoskeletal protein binding [GO:0008092]; fructose binding [GO:0070061]; fructose-bisphosphate aldolase activity [GO:0004332]; identical protein binding [GO:0042802]; RNA binding [GO:0003723]; tubulin binding [GO:0015631]	ALDOA
TKTL2	Q9H0I9	TKTL2_HUMAN	reviewed	Transketolase-like protein 2 (EC 2.2.1.1)	TKTL2	Homo sapiens (Human)	626	4 out of 5	Active site (1); Binding site (13); Chain (1); Metal binding (3); Natural variant (2); Nucleotide binding (1); Sequence conflict (4); Site (1)	Calcium;Complete proteome;Magnesium;Metal-binding;Polymorphism;Reference proteome;Thiamine pyrophosphate;Transferase			Transketolase family		cytoplasm [GO:0005737]	cytoplasm [GO:0005737]; metal ion binding [GO:0046872]; transketolase activity [GO:0004802]	metal ion binding [GO:0046872]; transketolase activity [GO:0004802]	TKTL2
RPIA	P49247	RPIA_HUMAN	reviewed	Ribose-5-phosphate isomerase (EC 5.3.1.6) (Phosphoriboisomerase)	RPIA RPI	Homo sapiens (Human)	311	5 out of 5	Chain (1); Frameshift (1); Modified residue (2); Natural variant (1); Sequence conflict (2)	Complete proteome;Disease mutation;Isomerase;Methylation;Phosphoprotein;Reference proteome			Ribose 5-phosphate isomerase family	D-ribose metabolic process [GO:0006014]; pentose-phosphate shunt [GO:0006098]; pentose-phosphate shunt, non-oxidative branch [GO:0009052]; ribose phosphate metabolic process [GO:0019693]	cytosol [GO:0005829]; intracellular membrane-bounded organelle [GO:0043231]	cytosol [GO:0005829]; intracellular membrane-bounded organelle [GO:0043231]; identical protein binding [GO:0042802]; monosaccharide binding [GO:0048029]; ribose-5-phosphate isomerase activity [GO:0004751]; D-ribose metabolic process [GO:0006014]; pentose-phosphate shunt [GO:0006098]; pentose-phosphate shunt, non-oxidative branch [GO:0009052]; ribose phosphate metabolic process [GO:0019693]	identical protein binding [GO:0042802]; monosaccharide binding [GO:0048029]; ribose-5-phosphate isomerase activity [GO:0004751]	
TKT	P29401	TKT_HUMAN	reviewed	Transketolase (TK) (EC 2.2.1.1)	TKT	Homo sapiens (Human)	623	5 out of 5	Active site (1); Alternative sequence (1); Beta strand (21); Binding site (15); Chain (1); Cross-link (1); Helix (29); Metal binding (3); Modified residue (16); Natural variant (2); Nucleotide binding (1); Sequence conflict (7); Site (2); Turn (5)	3D-structure;Acetylation;Alternative splicing;Calcium;Complete proteome;Direct protein sequencing;Disease mutation;Dwarfism;Isopeptide bond;Magnesium;Metal-binding;Phosphoprotein;Polymorphism;Reference proteome;Thiamine pyrophosphate;Transferase;Ubl conjugation			Transketolase family	glyceraldehyde-3-phosphate biosynthetic process [GO:0046166]; pentose-phosphate shunt [GO:0006098]; pentose-phosphate shunt, non-oxidative branch [GO:0009052]; regulation of growth [GO:0040008]; xylulose biosynthetic process [GO:0005999]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]; nuclear body [GO:0016604]; nuclear speck [GO:0016607]; nucleoplasm [GO:0005654]; peroxisome [GO:0005777]; vesicle [GO:0031982]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]; nuclear body [GO:0016604]; nuclear speck [GO:0016607]; nucleoplasm [GO:0005654]; peroxisome [GO:0005777]; vesicle [GO:0031982]; cofactor binding [GO:0048037]; metal ion binding [GO:0046872]; protein homodimerization activity [GO:0042803]; transketolase activity [GO:0004802]; glyceraldehyde-3-phosphate biosynthetic process [GO:0046166]; pentose-phosphate shunt [GO:0006098]; pentose-phosphate shunt, non-oxidative branch [GO:0009052]; regulation of growth [GO:0040008]; xylulose biosynthetic process [GO:0005999]	cofactor binding [GO:0048037]; metal ion binding [GO:0046872]; protein homodimerization activity [GO:0042803]; transketolase activity [GO:0004802]	TKT
TKT	Q16832	DDR2_HUMAN	reviewed	Discoidin domain-containing receptor 2 (Discoidin domain receptor 2) (EC 2.7.10.1) (CD167 antigen-like family member B) (Discoidin domain-containing receptor tyrosine kinase 2) (Neurotrophic tyrosine kinase, receptor-related 3) (Receptor protein-tyrosine kinase TKT) (Tyrosine-protein kinase TYRO10) (CD antigen CD167b)	DDR2 NTRKR3 TKT TYRO10	Homo sapiens (Human)	855	5 out of 5	Active site (1); Beta strand (21); Binding site (1); Chain (1); Disulfide bond (2); Domain (2); Glycosylation (5); Helix (17); Modified residue (4); Mutagenesis (5); Natural variant (11); Nucleotide binding (1); Sequence conflict (1); Signal peptide (1); Topological domain (2); Transmembrane (1); Turn (4)	3D-structure;ATP-binding;Cell membrane;Complete proteome;Disease mutation;Disulfide bond;Dwarfism;Glycoprotein;Kinase;Membrane;Nucleotide-binding;Osteogenesis;Phosphoprotein;Polymorphism;Receptor;Reference proteome;Signal;Transferase;Transmembrane;Transmembrane helix;Tyrosine-protein kinase		SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:18201965, ECO:0000269|PubMed:20223752, ECO:0000269|PubMed:9659899}; Single-pass type I membrane protein {ECO:0000269|PubMed:18201965, ECO:0000269|PubMed:20223752, ECO:0000269|PubMed:9659899}.	Protein kinase superfamily, Tyr protein kinase family, Insulin receptor subfamily	biomineral tissue development [GO:0031214]; cell adhesion [GO:0007155]; chondrocyte proliferation [GO:0035988]; collagen-activated tyrosine kinase receptor signaling pathway [GO:0038063]; collagen fibril organization [GO:0030199]; endochondral bone growth [GO:0003416]; extracellular matrix organization [GO:0030198]; ossification [GO:0001503]; peptidyl-tyrosine phosphorylation [GO:0018108]; positive regulation of DNA-binding transcription factor activity [GO:0051091]; positive regulation of extracellular matrix disassembly [GO:0090091]; positive regulation of fibroblast migration [GO:0010763]; positive regulation of fibroblast proliferation [GO:0048146]; positive regulation of osteoblast differentiation [GO:0045669]; positive regulation of protein kinase activity [GO:0045860]; protein autophosphorylation [GO:0046777]; regulation of bone mineralization [GO:0030500]; regulation of extracellular matrix disassembly [GO:0010715]; regulation of tissue remodeling [GO:0034103]; signal transduction [GO:0007165]; transmembrane receptor protein tyrosine kinase signaling pathway [GO:0007169]	actin cytoskeleton [GO:0015629]; apical plasma membrane [GO:0016324]; focal adhesion [GO:0005925]; integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]; receptor complex [GO:0043235]	actin cytoskeleton [GO:0015629]; apical plasma membrane [GO:0016324]; focal adhesion [GO:0005925]; integral component of plasma membrane [GO:0005887]; plasma membrane [GO:0005886]; receptor complex [GO:0043235]; ATP binding [GO:0005524]; collagen binding [GO:0005518]; protein tyrosine kinase collagen receptor activity [GO:0038062]; transmembrane receptor protein tyrosine kinase activity [GO:0004714]; biomineral tissue development [GO:0031214]; cell adhesion [GO:0007155]; chondrocyte proliferation [GO:0035988]; collagen fibril organization [GO:0030199]; collagen-activated tyrosine kinase receptor signaling pathway [GO:0038063]; endochondral bone growth [GO:0003416]; extracellular matrix organization [GO:0030198]; ossification [GO:0001503]; peptidyl-tyrosine phosphorylation [GO:0018108]; positive regulation of DNA-binding transcription factor activity [GO:0051091]; positive regulation of extracellular matrix disassembly [GO:0090091]; positive regulation of fibroblast migration [GO:0010763]; positive regulation of fibroblast proliferation [GO:0048146]; positive regulation of osteoblast differentiation [GO:0045669]; positive regulation of protein kinase activity [GO:0045860]; protein autophosphorylation [GO:0046777]; regulation of bone mineralization [GO:0030500]; regulation of extracellular matrix disassembly [GO:0010715]; regulation of tissue remodeling [GO:0034103]; signal transduction [GO:0007165]; transmembrane receptor protein tyrosine kinase signaling pathway [GO:0007169]	ATP binding [GO:0005524]; collagen binding [GO:0005518]; protein tyrosine kinase collagen receptor activity [GO:0038062]; transmembrane receptor protein tyrosine kinase activity [GO:0004714]	TKT
FBP1	P09467	F16P1_HUMAN	reviewed	Fructose-1,6-bisphosphatase 1 (FBPase 1) (EC 3.1.3.11) (D-fructose-1,6-bisphosphate 1-phosphohydrolase 1) (Liver FBPase)	FBP1 FBP	Homo sapiens (Human)	338	5 out of 5	Beta strand (15); Binding site (2); Chain (1); Erroneous gene model prediction (1); Helix (14); Initiator methionine (1); Metal binding (8); Modified residue (5); Mutagenesis (3); Natural variant (9); Nucleotide binding (3); Region (4); Sequence conflict (3); Turn (5)	3D-structure;Acetylation;Allosteric enzyme;Carbohydrate metabolism;Complete proteome;Direct protein sequencing;Disease mutation;Gluconeogenesis;Hydrolase;Magnesium;Metal-binding;Phosphoprotein;Polymorphism;Reference proteome			FBPase class 1 family	cellular response to drug [GO:0035690]; cellular response to magnesium ion [GO:0071286]; dephosphorylation [GO:0016311]; fructose 1,6-bisphosphate metabolic process [GO:0030388]; fructose 6-phosphate metabolic process [GO:0006002]; fructose metabolic process [GO:0006000]; gluconeogenesis [GO:0006094]; negative regulation of cell growth [GO:0030308]; negative regulation of glycolytic process [GO:0045820]; negative regulation of Ras protein signal transduction [GO:0046580]; negative regulation of transcription by RNA polymerase II [GO:0000122]; protein homotetramerization [GO:0051289]; regulation of gluconeogenesis [GO:0006111]; sucrose biosynthetic process [GO:0005986]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; nucleus [GO:0005634]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; nucleus [GO:0005634]; AMP binding [GO:0016208]; fructose 1,6-bisphosphate 1-phosphatase activity [GO:0042132]; identical protein binding [GO:0042802]; metal ion binding [GO:0046872]; monosaccharide binding [GO:0048029]; RNA polymerase II transcription factor binding [GO:0001085]; cellular response to drug [GO:0035690]; cellular response to magnesium ion [GO:0071286]; dephosphorylation [GO:0016311]; fructose 1,6-bisphosphate metabolic process [GO:0030388]; fructose 6-phosphate metabolic process [GO:0006002]; fructose metabolic process [GO:0006000]; gluconeogenesis [GO:0006094]; negative regulation of cell growth [GO:0030308]; negative regulation of glycolytic process [GO:0045820]; negative regulation of Ras protein signal transduction [GO:0046580]; negative regulation of transcription by RNA polymerase II [GO:0000122]; protein homotetramerization [GO:0051289]; regulation of gluconeogenesis [GO:0006111]; sucrose biosynthetic process [GO:0005986]	AMP binding [GO:0016208]; fructose 1,6-bisphosphate 1-phosphatase activity [GO:0042132]; identical protein binding [GO:0042802]; metal ion binding [GO:0046872]; monosaccharide binding [GO:0048029]; RNA polymerase II transcription factor binding [GO:0001085]	FBP1
PGM2	Q96G03	PGM2_HUMAN	reviewed	Phosphoglucomutase-2 (PGM 2) (EC 5.4.2.2) (Glucose phosphomutase 2) (Phosphodeoxyribomutase) (Phosphopentomutase) (EC 5.4.2.7)	PGM2 MSTP006	Homo sapiens (Human)	612	5 out of 5	Active site (1); Alternative sequence (4); Binding site (4); Chain (1); Initiator methionine (1); Metal binding (4); Modified residue (2); Natural variant (2); Region (3); Sequence conflict (4)	Acetylation;Alternative splicing;Carbohydrate metabolism;Complete proteome;Cytoplasm;Direct protein sequencing;Glucose metabolism;Isomerase;Magnesium;Metal-binding;Phosphoprotein;Polymorphism;Reference proteome		SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}.	Phosphohexose mutase family	deoxyribose phosphate catabolic process [GO:0046386]; galactose catabolic process [GO:0019388]; glucose metabolic process [GO:0006006]; glycogen biosynthetic process [GO:0005978]; glycogen catabolic process [GO:0005980]; neutrophil degranulation [GO:0043312]; pentose-phosphate shunt [GO:0006098]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; ficolin-1-rich granule lumen [GO:1904813]; secretory granule lumen [GO:0034774]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; ficolin-1-rich granule lumen [GO:1904813]; secretory granule lumen [GO:0034774]; magnesium ion binding [GO:0000287]; phosphoglucomutase activity [GO:0004614]; phosphopentomutase activity [GO:0008973]; deoxyribose phosphate catabolic process [GO:0046386]; galactose catabolic process [GO:0019388]; glucose metabolic process [GO:0006006]; glycogen biosynthetic process [GO:0005978]; glycogen catabolic process [GO:0005980]; neutrophil degranulation [GO:0043312]; pentose-phosphate shunt [GO:0006098]	magnesium ion binding [GO:0000287]; phosphoglucomutase activity [GO:0004614]; phosphopentomutase activity [GO:0008973]	PGM2
TALDO1	P37837	TALDO_HUMAN	reviewed	Transaldolase (EC 2.2.1.2)	TALDO1 TAL TALDO TALDOR	Homo sapiens (Human)	337	5 out of 5	Active site (1); Beta strand (8); Chain (1); Helix (19); Modified residue (7); Natural variant (1); Turn (2)	3D-structure;Acetylation;Complete proteome;Cytoplasm;Disease mutation;Pentose shunt;Phosphoprotein;Reference proteome;Schiff base;Transferase		SUBCELLULAR LOCATION: Cytoplasm {ECO:0000305}.	Transaldolase family, Type 1 subfamily	carbohydrate metabolic process [GO:0005975]; fructose 6-phosphate metabolic process [GO:0006002]; glyceraldehyde-3-phosphate metabolic process [GO:0019682]; interleukin-12-mediated signaling pathway [GO:0035722]; pentose-phosphate shunt [GO:0006098]; pentose-phosphate shunt, non-oxidative branch [GO:0009052]; xylulose biosynthetic process [GO:0005999]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; monosaccharide binding [GO:0048029]; sedoheptulose-7-phosphate:D-glyceraldehyde-3-phosphate glyceronetransferase activity [GO:0004801]; carbohydrate metabolic process [GO:0005975]; fructose 6-phosphate metabolic process [GO:0006002]; glyceraldehyde-3-phosphate metabolic process [GO:0019682]; interleukin-12-mediated signaling pathway [GO:0035722]; pentose-phosphate shunt [GO:0006098]; pentose-phosphate shunt, non-oxidative branch [GO:0009052]; xylulose biosynthetic process [GO:0005999]	monosaccharide binding [GO:0048029]; sedoheptulose-7-phosphate:D-glyceraldehyde-3-phosphate glyceronetransferase activity [GO:0004801]	TALDO1
RPE	Q96AT9	RPE_HUMAN	reviewed	Ribulose-phosphate 3-epimerase (EC 5.1.3.1) (Ribulose-5-phosphate-3-epimerase)	RPE HUSSY-17	Homo sapiens (Human)	228	5 out of 5	Active site (2); Alternative sequence (4); Beta strand (9); Binding site (2); Chain (1); Frameshift (2); Helix (14); Initiator methionine (1); Metal binding (4); Modified residue (1); Mutagenesis (9); Region (3); Sequence conflict (1); Turn (2)	3D-structure;Acetylation;Alternative splicing;Carbohydrate metabolism;Cobalt;Complete proteome;Iron;Isomerase;Manganese;Metal-binding;Reference proteome;Zinc			Ribulose-phosphate 3-epimerase family	carbohydrate metabolic process [GO:0005975]; cellular carbohydrate metabolic process [GO:0044262]; pentose catabolic process [GO:0019323]; pentose-phosphate shunt [GO:0006098]; pentose-phosphate shunt, non-oxidative branch [GO:0009052]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]; identical protein binding [GO:0042802]; metal ion binding [GO:0046872]; protein homodimerization activity [GO:0042803]; ribulose-phosphate 3-epimerase activity [GO:0004750]; carbohydrate metabolic process [GO:0005975]; cellular carbohydrate metabolic process [GO:0044262]; pentose catabolic process [GO:0019323]; pentose-phosphate shunt [GO:0006098]; pentose-phosphate shunt, non-oxidative branch [GO:0009052]	identical protein binding [GO:0042802]; metal ion binding [GO:0046872]; protein homodimerization activity [GO:0042803]; ribulose-phosphate 3-epimerase activity [GO:0004750]	RPE
PRPS1L1	P21108	PRPS3_HUMAN	reviewed	Ribose-phosphate pyrophosphokinase 3 (EC 2.7.6.1) (Phosphoribosyl pyrophosphate synthase 1-like 1) (PRPS1-like 1) (Phosphoribosyl pyrophosphate synthase III) (PRS-III)	PRPS1L1 PRPS3 PRPSL	Homo sapiens (Human)	318	5 out of 5	Binding site (1); Chain (1); Initiator methionine (1); Metal binding (4); Natural variant (1); Nucleotide binding (1); Region (1)	ATP-binding;Complete proteome;Direct protein sequencing;Kinase;Magnesium;Metal-binding;Nucleotide biosynthesis;Nucleotide-binding;Polymorphism;Reference proteome;Transferase			Ribose-phosphate pyrophosphokinase family	5-phosphoribose 1-diphosphate biosynthetic process [GO:0006015]; nucleoside metabolic process [GO:0009116]; nucleotide biosynthetic process [GO:0009165]; purine nucleotide biosynthetic process [GO:0006164]; ribonucleoside monophosphate biosynthetic process [GO:0009156]	cytoplasm [GO:0005737]; ribose phosphate diphosphokinase complex [GO:0002189]	cytoplasm [GO:0005737]; ribose phosphate diphosphokinase complex [GO:0002189]; ATP binding [GO:0005524]; kinase activity [GO:0016301]; magnesium ion binding [GO:0000287]; protein homodimerization activity [GO:0042803]; ribose phosphate diphosphokinase activity [GO:0004749]; 5-phosphoribose 1-diphosphate biosynthetic process [GO:0006015]; nucleoside metabolic process [GO:0009116]; nucleotide biosynthetic process [GO:0009165]; purine nucleotide biosynthetic process [GO:0006164]; ribonucleoside monophosphate biosynthetic process [GO:0009156]	ATP binding [GO:0005524]; kinase activity [GO:0016301]; magnesium ion binding [GO:0000287]; protein homodimerization activity [GO:0042803]; ribose phosphate diphosphokinase activity [GO:0004749]	PRPS1L1
RPEL1	Q2QD12	RPEL1_HUMAN	reviewed	Ribulose-phosphate 3-epimerase-like protein 1 (EC 5.1.3.1) (Ribulose-5-phosphate-3-epimerase-like protein 1)	RPEL1	Homo sapiens (Human)	228	4 out of 5	Active site (2); Binding site (2); Chain (1); Metal binding (4); Region (3)	Carbohydrate metabolism;Cobalt;Complete proteome;Iron;Isomerase;Manganese;Metal-binding;Reference proteome;Zinc	MISCELLANEOUS: According to some authors, RPEL1 is a RPE retrogene on chromosome 2 which is likely to be functional. {ECO:0000305|PubMed:16201836}.		Ribulose-phosphate 3-epimerase family	cellular carbohydrate metabolic process [GO:0044262]; pentose catabolic process [GO:0019323]; pentose-phosphate shunt [GO:0006098]; pentose-phosphate shunt, non-oxidative branch [GO:0009052]	cytosol [GO:0005829]	cytosol [GO:0005829]; metal ion binding [GO:0046872]; ribulose-phosphate 3-epimerase activity [GO:0004750]; cellular carbohydrate metabolic process [GO:0044262]; pentose catabolic process [GO:0019323]; pentose-phosphate shunt [GO:0006098]; pentose-phosphate shunt, non-oxidative branch [GO:0009052]	metal ion binding [GO:0046872]; ribulose-phosphate 3-epimerase activity [GO:0004750]	RPEL1
RPEL1	Q9C0D0	PHAR1_HUMAN	reviewed	Phosphatase and actin regulator 1	PHACTR1 KIAA1733 RPEL1	Homo sapiens (Human)	580	5 out of 5	Alternative sequence (2); Chain (1); Erroneous initiation (1); Modified residue (5); Motif (1); Natural variant (4); Repeat (4)	Actin-binding;Alternative splicing;Cell junction;Complete proteome;Cytoplasm;Epilepsy;Nucleus;Phosphoprotein;Polymorphism;Protein phosphatase inhibitor;Reference proteome;Repeat;Synapse		SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}. Cell junction, synapse {ECO:0000250}. Nucleus {ECO:0000250}. Note=Enriched at synapses (By similarity). Cytoplasmic in resting cells, and is imported into the nucleus upon serum stimulation. Interaction with actin prevents nuclear import (By similarity). {ECO:0000250}.	Phosphatase and actin regulator family	actin cytoskeleton reorganization [GO:0031532]; actomyosin structure organization [GO:0031032]; cell motility [GO:0048870]; cerebral cortex development [GO:0021987]; dendrite arborization [GO:0140059]; regulation of neuron migration [GO:2001222]; stress fiber assembly [GO:0043149]	cell junction [GO:0030054]; cytosol [GO:0005829]; nucleus [GO:0005634]; synapse [GO:0045202]	cell junction [GO:0030054]; cytosol [GO:0005829]; nucleus [GO:0005634]; synapse [GO:0045202]; actin binding [GO:0003779]; protein phosphatase 1 binding [GO:0008157]; protein phosphatase inhibitor activity [GO:0004864]; actin cytoskeleton reorganization [GO:0031532]; actomyosin structure organization [GO:0031032]; cell motility [GO:0048870]; cerebral cortex development [GO:0021987]; dendrite arborization [GO:0140059]; regulation of neuron migration [GO:2001222]; stress fiber assembly [GO:0043149]	actin binding [GO:0003779]; protein phosphatase 1 binding [GO:0008157]; protein phosphatase inhibitor activity [GO:0004864]	RPEL1
TXNDC3	Q8N427	TXND3_HUMAN	reviewed	Thioredoxin domain-containing protein 3 (NM23-H8) (NME/NM23 family member 8) (Spermatid-specific thioredoxin-2) (Sptrx-2)	NME8 SPTRX2 TXNDC3	Homo sapiens (Human)	588	5 out of 5	Chain (1); Disulfide bond (1); Domain (1); Natural variant (4); Region (3)	Ciliopathy;Complete proteome;Cytoplasm;Developmental protein;Differentiation;Disulfide bond;Polymorphism;Primary ciliary dyskinesia;Redox-active center;Reference proteome;Repeat;Spermatogenesis		SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:11737268}.	NDK family	cell differentiation [GO:0030154]; cell redox homeostasis [GO:0045454]; cellular response to reactive oxygen species [GO:0034614]; cilium assembly [GO:0060271]; flagellated sperm motility [GO:0030317]; multicellular organism development [GO:0007275]; spermatogenesis [GO:0007283]	outer dynein arm [GO:0036157]; sperm cytoplasmic droplet [GO:0097598]; sperm principal piece [GO:0097228]	outer dynein arm [GO:0036157]; sperm cytoplasmic droplet [GO:0097598]; sperm principal piece [GO:0097228]; microtubule binding [GO:0008017]; cell differentiation [GO:0030154]; cell redox homeostasis [GO:0045454]; cellular response to reactive oxygen species [GO:0034614]; cilium assembly [GO:0060271]; flagellated sperm motility [GO:0030317]; multicellular organism development [GO:0007275]; spermatogenesis [GO:0007283]	microtubule binding [GO:0008017]	TXNDC3
TXNDC16	Q9P2K2	TXD16_HUMAN	reviewed	Thioredoxin domain-containing protein 16	TXNDC16 ERP90 KIAA1344	Homo sapiens (Human)	825	5 out of 5	Chain (1); Disulfide bond (1); Domain (1); Erroneous initiation (1); Glycosylation (1); Motif (1); Natural variant (3); Sequence conflict (1); Signal peptide (1)	Complete proteome;Disulfide bond;Endoplasmic reticulum;Glycoprotein;Polymorphism;Reference proteome;Secreted;Signal		SUBCELLULAR LOCATION: Secreted {ECO:0000269|PubMed:25122923}. Endoplasmic reticulum lumen {ECO:0000269|PubMed:21359175, ECO:0000269|PubMed:25122923}.		cell redox homeostasis [GO:0045454]	endoplasmic reticulum lumen [GO:0005788]; extracellular exosome [GO:0070062]	endoplasmic reticulum lumen [GO:0005788]; extracellular exosome [GO:0070062]; cell redox homeostasis [GO:0045454]		TXNDC16
TXNL1	O43396	TXNL1_HUMAN	reviewed	Thioredoxin-like protein 1 (32 kDa thioredoxin-related protein)	TXNL1 TRP32 TXL TXNL	Homo sapiens (Human)	289	5 out of 5	Beta strand (13); Chain (1); Disulfide bond (1); Domain (2); Helix (7); Initiator methionine (1); Modified residue (1); Turn (5)	3D-structure;Complete proteome;Cytoplasm;Direct protein sequencing;Disulfide bond;Electron transport;Nucleus;Phosphoprotein;Proteasome;Redox-active center;Reference proteome;Transport		SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:19349277}. Nucleus {ECO:0000269|PubMed:19349277}. Note=At least 85% of the cellular TXNL1 is proteasome-associated.		cell redox homeostasis [GO:0045454]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; nucleus [GO:0005634]; proteasome complex [GO:0000502]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; nucleus [GO:0005634]; proteasome complex [GO:0000502]; disulfide oxidoreductase activity [GO:0015036]; cell redox homeostasis [GO:0045454]	disulfide oxidoreductase activity [GO:0015036]	TXNL1
TXN2	Q99757	THIOM_HUMAN	reviewed	Thioredoxin, mitochondrial (MTRX) (Mt-Trx) (Thioredoxin-2)	TXN2 TRX2	Homo sapiens (Human)	166	5 out of 5	Active site (2); Beta strand (5); Chain (1); Disulfide bond (1); Domain (1); Helix (4); Modified residue (2); Sequence conflict (2); Site (3); Transit peptide (1); Turn (3)	3D-structure;Acetylation;Complete proteome;Direct protein sequencing;Disulfide bond;Electron transport;Mitochondrion;Neurodegeneration;Primary mitochondrial disease;Redox-active center;Reference proteome;Transit peptide;Transport		SUBCELLULAR LOCATION: Mitochondrion {ECO:0000269|PubMed:12032145, ECO:0000269|PubMed:12080052}.	Thioredoxin family	cell redox homeostasis [GO:0045454]; cellular response to nutrient levels [GO:0031669]; glycerol ether metabolic process [GO:0006662]; response to axon injury [GO:0048678]; response to drug [GO:0042493]; response to glucose [GO:0009749]; response to hormone [GO:0009725]; response to hypoxia [GO:0001666]; response to organic cyclic compound [GO:0014070]; response to oxidative stress [GO:0006979]; sulfur amino acid catabolic process [GO:0000098]	dendrite [GO:0030425]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]; neuronal cell body [GO:0043025]; nucleolus [GO:0005730]	dendrite [GO:0030425]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]; neuronal cell body [GO:0043025]; nucleolus [GO:0005730]; peptide-methionine (R)-S-oxide reductase activity [GO:0033743]; peptide-methionine (S)-S-oxide reductase activity [GO:0008113]; protein disulfide oxidoreductase activity [GO:0015035]; protein-containing complex binding [GO:0044877]; cell redox homeostasis [GO:0045454]; cellular response to nutrient levels [GO:0031669]; glycerol ether metabolic process [GO:0006662]; response to axon injury [GO:0048678]; response to drug [GO:0042493]; response to glucose [GO:0009749]; response to hormone [GO:0009725]; response to hypoxia [GO:0001666]; response to organic cyclic compound [GO:0014070]; response to oxidative stress [GO:0006979]; sulfur amino acid catabolic process [GO:0000098]	peptide-methionine (R)-S-oxide reductase activity [GO:0033743]; peptide-methionine (S)-S-oxide reductase activity [GO:0008113]; protein-containing complex binding [GO:0044877]; protein disulfide oxidoreductase activity [GO:0015035]	TXN2
TXNDC15	Q96J42	TXD15_HUMAN	reviewed	Thioredoxin domain-containing protein 15	TXNDC15 C5orf14 UNQ335/PRO534	Homo sapiens (Human)	360	4 out of 5	Alternative sequence (1); Chain (1); Domain (1); Glycosylation (4); Natural variant (2); Sequence conflict (2); Signal peptide (1); Topological domain (2); Transmembrane (1)	Alternative splicing;Cell membrane;Cell projection;Ciliopathy;Cilium biogenesis/degradation;Complete proteome;Disease mutation;Glycoprotein;Meckel syndrome;Membrane;Polymorphism;Reference proteome;Signal;Transmembrane;Transmembrane helix		SUBCELLULAR LOCATION: Cell projection, cilium membrane {ECO:0000250|UniProtKB:Q6P6J9}; Single-pass type I membrane protein {ECO:0000255}.		cell redox homeostasis [GO:0045454]; cilium assembly [GO:0060271]; positive regulation of smoothened signaling pathway [GO:0045880]	cilium [GO:0005929]; integral component of membrane [GO:0016021]	cilium [GO:0005929]; integral component of membrane [GO:0016021]; cell redox homeostasis [GO:0045454]; cilium assembly [GO:0060271]; positive regulation of smoothened signaling pathway [GO:0045880]		TXNDC15
TXNDC9	O14530	TXND9_HUMAN	reviewed	Thioredoxin domain-containing protein 9 (ATP-binding protein associated with cell differentiation) (Protein 1-4)	TXNDC9 APACD	Homo sapiens (Human)	226	5 out of 5	Alternative sequence (1); Chain (1); Domain (1); Modified residue (3); Natural variant (2); Sequence conflict (3)	Alternative splicing;Complete proteome;Cytoplasm;Cytoskeleton;Nucleus;Phosphoprotein;Polymorphism;Reference proteome		SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250|UniProtKB:Q9CQ79}. Nucleus {ECO:0000250|UniProtKB:Q9CQ79}. Cytoplasm, cytoskeleton, microtubule organizing center, centrosome {ECO:0000250|UniProtKB:Q9CQ79}. Midbody {ECO:0000250|UniProtKB:Q9CQ79}. Note=Co-localizes with beta-tubulin in the centrosome. {ECO:0000250|UniProtKB:Q9CQ79}.		cell redox homeostasis [GO:0045454]	centrosome [GO:0005813]; cytosol [GO:0005829]; midbody [GO:0030496]; nucleus [GO:0005634]	centrosome [GO:0005813]; cytosol [GO:0005829]; midbody [GO:0030496]; nucleus [GO:0005634]; cadherin binding [GO:0045296]; cell redox homeostasis [GO:0045454]	cadherin binding [GO:0045296]	TXNDC9
PARK7	Q99497	PARK7_HUMAN	reviewed	Protein/nucleic acid deglycase DJ-1 (EC 3.1.2.-) (EC 3.5.1.-) (EC 3.5.1.124) (Maillard deglycase) (Oncogene DJ1) (Parkinson disease protein 7) (Parkinsonism-associated deglycase) (Protein DJ-1) (DJ-1)	PARK7	Homo sapiens (Human)	189	5 out of 5	Active site (2); Beta strand (10); Chain (1); Cross-link (1); Helix (11); Initiator methionine (1); Lipidation (3); Modified residue (5); Mutagenesis (16); Natural variant (10); Propeptide (1); Sequence conflict (1); Turn (3)	3D-structure;Acetylation;Autophagy;Cell membrane;Chaperone;Complete proteome;Copper;Cytoplasm;DNA damage;DNA repair;Direct protein sequencing;Disease mutation;Fertilization;Hydrolase;Inflammatory response;Isopeptide bond;Lipoprotein;Membrane;Mitochondrion;Neurodegeneration;Nucleus;Oxidation;Palmitate;Parkinson disease;Parkinsonism;Phosphoprotein;Polymorphism;Protease;RNA-binding;Reference proteome;Stress response;Tumor suppressor;Ubl conjugation;Zymogen		SUBCELLULAR LOCATION: Cell membrane {ECO:0000250|UniProtKB:Q99LX0}; Lipid-anchor {ECO:0000250|UniProtKB:Q99LX0}. Cytoplasm {ECO:0000269|PubMed:12851414, ECO:0000269|PubMed:14579415, ECO:0000269|PubMed:15976810, ECO:0000269|PubMed:19229105, ECO:0000269|PubMed:28596309}. Nucleus {ECO:0000269|PubMed:12851414, ECO:0000269|PubMed:14579415, ECO:0000269|PubMed:15976810, ECO:0000269|PubMed:16390825, ECO:0000269|PubMed:28596309}. Membrane raft {ECO:0000250|UniProtKB:O88767}. Mitochondrion {ECO:0000269|PubMed:15181200, ECO:0000269|PubMed:18711745, ECO:0000269|PubMed:19229105}. Note=Under normal conditions, located predominantly in the cytoplasm and, to a lesser extent, in the nucleus and mitochondrion. Translocates to the mitochondrion and subsequently to the nucleus in response to oxidative stress and exerts an increased cytoprotective effect against oxidative damage (PubMed:18711745). Detected in tau inclusions in brains from neurodegenerative disease patients (PubMed:14705119). Membrane raft localization in astrocytes and neuronal cells requires palmitoylation. {ECO:0000269|PubMed:14705119, ECO:0000269|PubMed:18711745}.	Peptidase C56 family	activation of protein kinase B activity [GO:0032148]; adult locomotory behavior [GO:0008344]; autophagy [GO:0006914]; cellular response to glyoxal [GO:0036471]; cellular response to hydrogen peroxide [GO:0070301]; cellular response to oxidative stress [GO:0034599]; detoxification of copper ion [GO:0010273]; detoxification of mercury ion [GO:0050787]; DNA repair [GO:0006281]; dopamine uptake involved in synaptic transmission [GO:0051583]; enzyme active site formation via L-cysteine sulfinic acid [GO:0018323]; glucose homeostasis [GO:0042593]; glutathione deglycation [GO:0036531]; glycolate biosynthetic process [GO:0046295]; glyoxal metabolic process [GO:1903189]; guanine deglycation [GO:0106044]; guanine deglycation, glyoxal removal [GO:0106046]; guanine deglycation, methylglyoxal removal [GO:0106045]; hydrogen peroxide metabolic process [GO:0042743]; inflammatory response [GO:0006954]; insulin secretion [GO:0030073]; lactate biosynthetic process [GO:0019249]; membrane depolarization [GO:0051899]; membrane hyperpolarization [GO:0060081]; methylglyoxal metabolic process [GO:0009438]; mitochondrion organization [GO:0007005]; negative regulation of apoptotic process [GO:0043066]; negative regulation of cell death [GO:0060548]; negative regulation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway [GO:2001268]; negative regulation of death-inducing signaling complex assembly [GO:1903073]; negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway [GO:1902236]; negative regulation of extrinsic apoptotic signaling pathway [GO:2001237]; negative regulation of gene expression [GO:0010629]; negative regulation of hydrogen peroxide-induced cell death [GO:1903206]; negative regulation of hydrogen peroxide-induced neuron death [GO:1903208]; negative regulation of hydrogen peroxide-induced neuron intrinsic apoptotic signaling pathway [GO:1903384]; negative regulation of neuron apoptotic process [GO:0043524]; negative regulation of neuron death [GO:1901215]; negative regulation of nitrosative stress-induced intrinsic apoptotic signaling pathway [GO:1905259]; negative regulation of oxidative stress-induced cell death [GO:1903202]; negative regulation of oxidative stress-induced neuron intrinsic apoptotic signaling pathway [GO:1903377]; negative regulation of proteasomal ubiquitin-dependent protein catabolic process [GO:0032435]; negative regulation of protein acetylation [GO:1901984]; negative regulation of protein binding [GO:0032091]; negative regulation of protein export from nucleus [GO:0046826]; negative regulation of protein K48-linked deubiquitination [GO:1903094]; negative regulation of protein kinase activity [GO:0006469]; negative regulation of protein phosphorylation [GO:0001933]; negative regulation of protein sumoylation [GO:0033234]; negative regulation of protein ubiquitination [GO:0031397]; negative regulation of reactive oxygen species biosynthetic process [GO:1903427]; negative regulation of TRAIL-activated apoptotic signaling pathway [GO:1903122]; negative regulation of ubiquitin-protein transferase activity [GO:0051444]; negative regulation of ubiquitin-specific protease activity [GO:2000157]; peptidyl-arginine deglycation [GO:0036527]; peptidyl-cysteine deglycation [GO:0036526]; peptidyl-lysine deglycation [GO:0036528]; positive regulation of acute inflammatory response to antigenic stimulus [GO:0002866]; positive regulation of androgen receptor activity [GO:2000825]; positive regulation of autophagy of mitochondrion [GO:1903599]; positive regulation of DNA-binding transcription factor activity [GO:0051091]; positive regulation of dopamine biosynthetic process [GO:1903181]; positive regulation of gene expression [GO:0010628]; positive regulation of interleukin-8 production [GO:0032757]; positive regulation of L-dopa biosynthetic process [GO:1903197]; positive regulation of L-dopa decarboxylase activity [GO:1903200]; positive regulation of mitochondrial electron transport, NADH to ubiquinone [GO:1902958]; positive regulation of NAD(P)H oxidase activity [GO:0033864]; positive regulation of oxidative phosphorylation uncoupler activity [GO:2000277]; positive regulation of oxidative stress-induced intrinsic apoptotic signaling pathway [GO:1902177]; positive regulation of peptidyl-serine phosphorylation [GO:0033138]; positive regulation of protein homodimerization activity [GO:0090073]; positive regulation of protein kinase B signaling [GO:0051897]; positive regulation of protein localization to nucleus [GO:1900182]; positive regulation of pyrroline-5-carboxylate reductase activity [GO:1903168]; positive regulation of reactive oxygen species biosynthetic process [GO:1903428]; positive regulation of superoxide dismutase activity [GO:1901671]; positive regulation of transcription by RNA polymerase II [GO:0045944]; positive regulation of transcription regulatory region DNA binding [GO:2000679]; positive regulation of tyrosine 3-monooxygenase activity [GO:1903178]; protein deglycation, glyoxal removal [GO:0036529]; protein deglycation, methylglyoxal removal [GO:0036530]; protein deglycosylation [GO:0006517]; protein stabilization [GO:0050821]; Ras protein signal transduction [GO:0007265]; regulation of androgen receptor signaling pathway [GO:0060765]; regulation of inflammatory response [GO:0050727]; regulation of mitochondrial membrane potential [GO:0051881]; regulation of neuron apoptotic process [GO:0043523]; regulation of supramolecular fiber organization [GO:1902903]; single fertilization [GO:0007338]	axon [GO:0030424]; cell body [GO:0044297]; cell-cell adherens junction [GO:0005913]; chromatin [GO:0000785]; cytoplasm [GO:0005737]; cytosol [GO:0005829]; endoplasmic reticulum [GO:0005783]; extracellular exosome [GO:0070062]; membrane raft [GO:0045121]; mitochondrial intermembrane space [GO:0005758]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; perinuclear region of cytoplasm [GO:0048471]; plasma membrane [GO:0005886]; PML body [GO:0016605]; presynapse [GO:0098793]	axon [GO:0030424]; cell body [GO:0044297]; cell-cell adherens junction [GO:0005913]; chromatin [GO:0000785]; cytoplasm [GO:0005737]; cytosol [GO:0005829]; endoplasmic reticulum [GO:0005783]; extracellular exosome [GO:0070062]; membrane raft [GO:0045121]; mitochondrial intermembrane space [GO:0005758]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; perinuclear region of cytoplasm [GO:0048471]; plasma membrane [GO:0005886]; PML body [GO:0016605]; presynapse [GO:0098793]; androgen receptor binding [GO:0050681]; cadherin binding [GO:0045296]; copper ion binding [GO:0005507]; cupric ion binding [GO:1903135]; cuprous ion binding [GO:1903136]; cytokine binding [GO:0019955]; enzyme binding [GO:0019899]; identical protein binding [GO:0042802]; kinase binding [GO:0019900]; L-dopa decarboxylase activator activity [GO:0036478]; mercury ion binding [GO:0045340]; mRNA binding [GO:0003729]; oxidoreductase activity, acting on peroxide as acceptor [GO:0016684]; peptidase activity [GO:0008233]; peroxiredoxin activity [GO:0051920]; protein deglycase activity [GO:0036524]; protein homodimerization activity [GO:0042803]; protein-containing complex binding [GO:0044877]; repressing transcription factor binding [GO:0070491]; scaffold protein binding [GO:0097110]; signaling receptor binding [GO:0005102]; small protein activating enzyme binding [GO:0044388]; superoxide dismutase copper chaperone activity [GO:0016532]; transcription coactivator activity [GO:0003713]; transcription factor binding [GO:0008134]; tyrosine 3-monooxygenase activator activity [GO:0036470]; ubiquitin-like protein conjugating enzyme binding [GO:0044390]; ubiquitin-specific protease binding [GO:1990381]; activation of protein kinase B activity [GO:0032148]; adult locomotory behavior [GO:0008344]; autophagy [GO:0006914]; cellular response to glyoxal [GO:0036471]; cellular response to hydrogen peroxide [GO:0070301]; cellular response to oxidative stress [GO:0034599]; detoxification of copper ion [GO:0010273]; detoxification of mercury ion [GO:0050787]; DNA repair [GO:0006281]; dopamine uptake involved in synaptic transmission [GO:0051583]; enzyme active site formation via L-cysteine sulfinic acid [GO:0018323]; glucose homeostasis [GO:0042593]; glutathione deglycation [GO:0036531]; glycolate biosynthetic process [GO:0046295]; glyoxal metabolic process [GO:1903189]; guanine deglycation [GO:0106044]; guanine deglycation, glyoxal removal [GO:0106046]; guanine deglycation, methylglyoxal removal [GO:0106045]; hydrogen peroxide metabolic process [GO:0042743]; inflammatory response [GO:0006954]; insulin secretion [GO:0030073]; lactate biosynthetic process [GO:0019249]; membrane depolarization [GO:0051899]; membrane hyperpolarization [GO:0060081]; methylglyoxal metabolic process [GO:0009438]; mitochondrion organization [GO:0007005]; negative regulation of apoptotic process [GO:0043066]; negative regulation of cell death [GO:0060548]; negative regulation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway [GO:2001268]; negative regulation of death-inducing signaling complex assembly [GO:1903073]; negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway [GO:1902236]; negative regulation of extrinsic apoptotic signaling pathway [GO:2001237]; negative regulation of gene expression [GO:0010629]; negative regulation of hydrogen peroxide-induced cell death [GO:1903206]; negative regulation of hydrogen peroxide-induced neuron death [GO:1903208]; negative regulation of hydrogen peroxide-induced neuron intrinsic apoptotic signaling pathway [GO:1903384]; negative regulation of neuron apoptotic process [GO:0043524]; negative regulation of neuron death [GO:1901215]; negative regulation of nitrosative stress-induced intrinsic apoptotic signaling pathway [GO:1905259]; negative regulation of oxidative stress-induced cell death [GO:1903202]; negative regulation of oxidative stress-induced neuron intrinsic apoptotic signaling pathway [GO:1903377]; negative regulation of proteasomal ubiquitin-dependent protein catabolic process [GO:0032435]; negative regulation of protein acetylation [GO:1901984]; negative regulation of protein binding [GO:0032091]; negative regulation of protein export from nucleus [GO:0046826]; negative regulation of protein K48-linked deubiquitination [GO:1903094]; negative regulation of protein kinase activity [GO:0006469]; negative regulation of protein phosphorylation [GO:0001933]; negative regulation of protein sumoylation [GO:0033234]; negative regulation of protein ubiquitination [GO:0031397]; negative regulation of reactive oxygen species biosynthetic process [GO:1903427]; negative regulation of TRAIL-activated apoptotic signaling pathway [GO:1903122]; negative regulation of ubiquitin-protein transferase activity [GO:0051444]; negative regulation of ubiquitin-specific protease activity [GO:2000157]; peptidyl-arginine deglycation [GO:0036527]; peptidyl-cysteine deglycation [GO:0036526]; peptidyl-lysine deglycation [GO:0036528]; positive regulation of acute inflammatory response to antigenic stimulus [GO:0002866]; positive regulation of androgen receptor activity [GO:2000825]; positive regulation of autophagy of mitochondrion [GO:1903599]; positive regulation of DNA-binding transcription factor activity [GO:0051091]; positive regulation of dopamine biosynthetic process [GO:1903181]; positive regulation of gene expression [GO:0010628]; positive regulation of interleukin-8 production [GO:0032757]; positive regulation of L-dopa biosynthetic process [GO:1903197]; positive regulation of L-dopa decarboxylase activity [GO:1903200]; positive regulation of mitochondrial electron transport, NADH to ubiquinone [GO:1902958]; positive regulation of NAD(P)H oxidase activity [GO:0033864]; positive regulation of oxidative phosphorylation uncoupler activity [GO:2000277]; positive regulation of oxidative stress-induced intrinsic apoptotic signaling pathway [GO:1902177]; positive regulation of peptidyl-serine phosphorylation [GO:0033138]; positive regulation of protein homodimerization activity [GO:0090073]; positive regulation of protein kinase B signaling [GO:0051897]; positive regulation of protein localization to nucleus [GO:1900182]; positive regulation of pyrroline-5-carboxylate reductase activity [GO:1903168]; positive regulation of reactive oxygen species biosynthetic process [GO:1903428]; positive regulation of superoxide dismutase activity [GO:1901671]; positive regulation of transcription by RNA polymerase II [GO:0045944]; positive regulation of transcription regulatory region DNA binding [GO:2000679]; positive regulation of tyrosine 3-monooxygenase activity [GO:1903178]; protein deglycation, glyoxal removal [GO:0036529]; protein deglycation, methylglyoxal removal [GO:0036530]; protein deglycosylation [GO:0006517]; protein stabilization [GO:0050821]; Ras protein signal transduction [GO:0007265]; regulation of androgen receptor signaling pathway [GO:0060765]; regulation of inflammatory response [GO:0050727]; regulation of mitochondrial membrane potential [GO:0051881]; regulation of neuron apoptotic process [GO:0043523]; regulation of supramolecular fiber organization [GO:1902903]; single fertilization [GO:0007338]	androgen receptor binding [GO:0050681]; cadherin binding [GO:0045296]; copper ion binding [GO:0005507]; cupric ion binding [GO:1903135]; cuprous ion binding [GO:1903136]; cytokine binding [GO:0019955]; enzyme binding [GO:0019899]; identical protein binding [GO:0042802]; kinase binding [GO:0019900]; L-dopa decarboxylase activator activity [GO:0036478]; mercury ion binding [GO:0045340]; mRNA binding [GO:0003729]; oxidoreductase activity, acting on peroxide as acceptor [GO:0016684]; peptidase activity [GO:0008233]; peroxiredoxin activity [GO:0051920]; protein-containing complex binding [GO:0044877]; protein deglycase activity [GO:0036524]; protein homodimerization activity [GO:0042803]; repressing transcription factor binding [GO:0070491]; scaffold protein binding [GO:0097110]; signaling receptor binding [GO:0005102]; small protein activating enzyme binding [GO:0044388]; superoxide dismutase copper chaperone activity [GO:0016532]; transcription coactivator activity [GO:0003713]; transcription factor binding [GO:0008134]; tyrosine 3-monooxygenase activator activity [GO:0036470]; ubiquitin-like protein conjugating enzyme binding [GO:0044390]; ubiquitin-specific protease binding [GO:1990381]	PARK7
PRDX1	Q06830	PRDX1_HUMAN	reviewed	Peroxiredoxin-1 (EC 1.11.1.15) (Natural killer cell-enhancing factor A) (NKEF-A) (Proliferation-associated gene protein) (PAG) (Thioredoxin peroxidase 2) (Thioredoxin-dependent peroxide reductase 2)	PRDX1 PAGA PAGB TDPX2	Homo sapiens (Human)	199	5 out of 5	Active site (1); Beta strand (10); Chain (1); Cross-link (3); Disulfide bond (2); Domain (1); Helix (9); Initiator methionine (1); Modified residue (9); Mutagenesis (2); Natural variant (1); Sequence conflict (4); Turn (1)	3D-structure;Acetylation;Antioxidant;Complete proteome;Cytoplasm;Direct protein sequencing;Disulfide bond;Isopeptide bond;Oxidoreductase;Peroxidase;Phosphoprotein;Polymorphism;Redox-active center;Reference proteome;Ubl conjugation	MISCELLANEOUS: The active site is a conserved redox-active cysteine residue, the peroxidatic cysteine (C(P)), which makes the nucleophilic attack on the peroxide substrate. The peroxide oxidizes the C(P)-SH to cysteine sulfenic acid (C(P)-SOH), which then reacts with another cysteine residue, the resolving cysteine (C(R)), to form a disulfide bridge. The disulfide is subsequently reduced by an appropriate electron donor to complete the catalytic cycle. In this typical 2-Cys peroxiredoxin, C(R) is provided by the other dimeric subunit to form an intersubunit disulfide. The disulfide is subsequently reduced by thioredoxin. {ECO:0000305|Ref.31}.	SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:17081065, ECO:0000269|PubMed:9497357}. Melanosome {ECO:0000269|PubMed:17081065}. Note=Identified by mass spectrometry in melanosome fractions from stage I to stage IV.	Peroxiredoxin family, AhpC/Prx1 subfamily	cell population proliferation [GO:0008283]; cell redox homeostasis [GO:0045454]; cellular response to oxidative stress [GO:0034599]; erythrocyte homeostasis [GO:0034101]; hydrogen peroxide catabolic process [GO:0042744]; leukocyte activation [GO:0045321]; natural killer cell activation [GO:0030101]; natural killer cell mediated cytotoxicity [GO:0042267]; regulation of NIK/NF-kappaB signaling [GO:1901222]; regulation of stress-activated MAPK cascade [GO:0032872]; removal of superoxide radicals [GO:0019430]; response to oxidative stress [GO:0006979]; retina homeostasis [GO:0001895]; skeletal system development [GO:0001501]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; extracellular space [GO:0005615]; melanosome [GO:0042470]; nucleus [GO:0005634]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; extracellular space [GO:0005615]; melanosome [GO:0042470]; nucleus [GO:0005634]; cadherin binding [GO:0045296]; identical protein binding [GO:0042802]; peroxidase activity [GO:0004601]; RNA binding [GO:0003723]; thioredoxin peroxidase activity [GO:0008379]; cell population proliferation [GO:0008283]; cell redox homeostasis [GO:0045454]; cellular response to oxidative stress [GO:0034599]; erythrocyte homeostasis [GO:0034101]; hydrogen peroxide catabolic process [GO:0042744]; leukocyte activation [GO:0045321]; natural killer cell activation [GO:0030101]; natural killer cell mediated cytotoxicity [GO:0042267]; regulation of NIK/NF-kappaB signaling [GO:1901222]; regulation of stress-activated MAPK cascade [GO:0032872]; removal of superoxide radicals [GO:0019430]; response to oxidative stress [GO:0006979]; retina homeostasis [GO:0001895]; skeletal system development [GO:0001501]	cadherin binding [GO:0045296]; identical protein binding [GO:0042802]; peroxidase activity [GO:0004601]; RNA binding [GO:0003723]; thioredoxin peroxidase activity [GO:0008379]	PRDX1
PRDX6	P30041	PRDX6_HUMAN	reviewed	Peroxiredoxin-6 (EC 1.11.1.15) (1-Cys peroxiredoxin) (1-Cys PRX) (24 kDa protein) (Acidic calcium-independent phospholipase A2) (aiPLA2) (EC 3.1.1.4) (Antioxidant protein 2) (Liver 2D page spot 40) (Non-selenium glutathione peroxidase) (NSGPx) (Red blood cells page spot 12)	PRDX6 AOP2 KIAA0106	Homo sapiens (Human)	224	5 out of 5	Active site (2); Beta strand (14); Chain (1); Domain (1); Helix (6); Initiator methionine (1); Modified residue (6); Mutagenesis (2); Region (1); Site (1); Turn (1)	3D-structure;Acetylation;Antioxidant;Complete proteome;Cytoplasm;Direct protein sequencing;Hydrolase;Lipid degradation;Lipid metabolism;Lysosome;Multifunctional enzyme;Oxidoreductase;Peroxidase;Phosphoprotein;Redox-active center;Reference proteome	MISCELLANEOUS: The active site is a conserved redox-active cysteine residue, the peroxidatic cysteine (C(P)), which makes the nucleophilic attack on the peroxide substrate. The peroxide oxidizes the C(P)-SH to cysteine sulfenic acid (C(P)-SOH), which then reacts with another cysteine residue, the resolving cysteine (C(R)), to form a disulfide bridge. The disulfide is subsequently reduced by an appropriate electron donor to complete the catalytic cycle. In this 1-Cys peroxiredoxin, no C(R) is present and C(P) instead forms a disulfide with a cysteine from another protein or with a small thiol molecule. C(P) is reactivated by glutathionylation mediated by glutathione S-transferase Pi, followed by spontaneous reduction of the enzyme with glutathione. {ECO:0000250|UniProtKB:O35244}.	SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:16186110, ECO:0000269|PubMed:19188445, ECO:0000269|PubMed:9497358}. Lysosome {ECO:0000250|UniProtKB:O35244}. Note=Also found in lung secretory organelles (lamellar bodies). {ECO:0000250|UniProtKB:O35244}.	Peroxiredoxin family, Prx6 subfamily	cell redox homeostasis [GO:0045454]; cellular oxidant detoxification [GO:0098869]; cellular response to oxidative stress [GO:0034599]; glycerophospholipid catabolic process [GO:0046475]; hydrogen peroxide catabolic process [GO:0042744]; neutrophil degranulation [GO:0043312]; positive regulation of mRNA splicing, via spliceosome [GO:0048026]; response to oxidative stress [GO:0006979]	azurophil granule lumen [GO:0035578]; cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; extracellular space [GO:0005615]; membrane [GO:0016020]; nucleus [GO:0005634]; perinuclear region of cytoplasm [GO:0048471]	azurophil granule lumen [GO:0035578]; cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; extracellular space [GO:0005615]; membrane [GO:0016020]; nucleus [GO:0005634]; perinuclear region of cytoplasm [GO:0048471]; cadherin binding [GO:0045296]; calcium-independent phospholipase A2 activity [GO:0047499]; glutathione peroxidase activity [GO:0004602]; peroxiredoxin activity [GO:0051920]; phospholipase A2 activity (consuming 1,2-dipalmitoylphosphatidylcholine) [GO:0102567]; phospholipase A2 activity consuming 1,2-dioleoylphosphatidylethanolamine) [GO:0102568]; protein homodimerization activity [GO:0042803]; ubiquitin protein ligase binding [GO:0031625]; cell redox homeostasis [GO:0045454]; cellular oxidant detoxification [GO:0098869]; cellular response to oxidative stress [GO:0034599]; glycerophospholipid catabolic process [GO:0046475]; hydrogen peroxide catabolic process [GO:0042744]; neutrophil degranulation [GO:0043312]; positive regulation of mRNA splicing, via spliceosome [GO:0048026]; response to oxidative stress [GO:0006979]	cadherin binding [GO:0045296]; calcium-independent phospholipase A2 activity [GO:0047499]; glutathione peroxidase activity [GO:0004602]; peroxiredoxin activity [GO:0051920]; phospholipase A2 activity (consuming 1,2-dipalmitoylphosphatidylcholine) [GO:0102567]; phospholipase A2 activity consuming 1,2-dioleoylphosphatidylethanolamine) [GO:0102568]; protein homodimerization activity [GO:0042803]; ubiquitin protein ligase binding [GO:0031625]	PRDX6
TXNDC12	O95881	TXD12_HUMAN	reviewed	Thioredoxin domain-containing protein 12 (EC 1.8.4.2) (Endoplasmic reticulum resident protein 18) (ER protein 18) (ERp18) (Endoplasmic reticulum resident protein 19) (ER protein 19) (ERp19) (Thioredoxin-like protein p19) (hTLP19)	TXNDC12 TLP19 UNQ713/PRO1376	Homo sapiens (Human)	172	5 out of 5	Beta strand (4); Chain (1); Disulfide bond (1); Domain (1); Helix (7); Motif (1); Mutagenesis (2); Sequence conflict (1); Signal peptide (1); Turn (2)	3D-structure;Complete proteome;Direct protein sequencing;Disulfide bond;Endoplasmic reticulum;Oxidoreductase;Redox-active center;Reference proteome;Signal		SUBCELLULAR LOCATION: Endoplasmic reticulum lumen {ECO:0000269|PubMed:12761212}.		cell redox homeostasis [GO:0045454]; negative regulation of cell death [GO:0060548]; negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway [GO:1902236]	endoplasmic reticulum [GO:0005783]; endoplasmic reticulum lumen [GO:0005788]	endoplasmic reticulum [GO:0005783]; endoplasmic reticulum lumen [GO:0005788]; peptide disulfide oxidoreductase activity [GO:0015037]; protein-disulfide reductase (glutathione) activity [GO:0019153]; cell redox homeostasis [GO:0045454]; negative regulation of cell death [GO:0060548]; negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway [GO:1902236]	peptide disulfide oxidoreductase activity [GO:0015037]; protein-disulfide reductase (glutathione) activity [GO:0019153]	TXNDC12
EPX	P11678	PERE_HUMAN	reviewed	Eosinophil peroxidase (EPO) (EC 1.11.1.7) [Cleaved into: Eosinophil peroxidase light chain; Eosinophil peroxidase heavy chain]	EPX EPER EPO EPP	Homo sapiens (Human)	715	5 out of 5	Active site (1); Binding site (2); Chain (2); Disulfide bond (6); Glycosylation (6); Metal binding (6); Modified residue (1); Natural variant (16); Propeptide (1); Sequence conflict (5); Signal peptide (1); Site (1)	Calcium;Complete proteome;Direct protein sequencing;Disease mutation;Disulfide bond;Glycoprotein;Heme;Hydrogen peroxide;Iron;Metal-binding;Nitration;Oxidoreductase;Peroxidase;Polymorphism;Reference proteome;Signal		SUBCELLULAR LOCATION: Cytoplasmic granule. Note=Cytoplasmic granules of eosinophils.	Peroxidase family, XPO subfamily	defense response to bacterium [GO:0042742]; defense response to nematode [GO:0002215]; eosinophil migration [GO:0072677]; hydrogen peroxide catabolic process [GO:0042744]; negative regulation of interleukin-10 production [GO:0032693]; negative regulation of interleukin-5 production [GO:0032714]; neutrophil degranulation [GO:0043312]; positive regulation of interleukin-4 production [GO:0032753]; response to oxidative stress [GO:0006979]	cytoplasm [GO:0005737]; extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; extracellular space [GO:0005615]; secretory granule lumen [GO:0034774]	cytoplasm [GO:0005737]; extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; extracellular space [GO:0005615]; secretory granule lumen [GO:0034774]; heme binding [GO:0020037]; metal ion binding [GO:0046872]; peroxidase activity [GO:0004601]; defense response to bacterium [GO:0042742]; defense response to nematode [GO:0002215]; eosinophil migration [GO:0072677]; hydrogen peroxide catabolic process [GO:0042744]; negative regulation of interleukin-10 production [GO:0032693]; negative regulation of interleukin-5 production [GO:0032714]; neutrophil degranulation [GO:0043312]; positive regulation of interleukin-4 production [GO:0032753]; response to oxidative stress [GO:0006979]	heme binding [GO:0020037]; metal ion binding [GO:0046872]; peroxidase activity [GO:0004601]	EPX
PRDX4	Q13162	PRDX4_HUMAN	reviewed	Peroxiredoxin-4 (EC 1.11.1.15) (Antioxidant enzyme AOE372) (AOE37-2) (Peroxiredoxin IV) (Prx-IV) (Thioredoxin peroxidase AO372) (Thioredoxin-dependent peroxide reductase A0372)	PRDX4	Homo sapiens (Human)	271	5 out of 5	Active site (1); Beta strand (10); Chain (1); Disulfide bond (2); Domain (1); Helix (8); Sequence conflict (2); Signal peptide (1); Turn (4)	3D-structure;Antioxidant;Complete proteome;Cytoplasm;Direct protein sequencing;Disulfide bond;Endoplasmic reticulum;Oxidoreductase;Peroxidase;Redox-active center;Reference proteome;Signal	MISCELLANEOUS: The active site is a conserved redox-active cysteine residue, the peroxidatic cysteine (C(P)), which makes the nucleophilic attack on the peroxide substrate. The peroxide oxidizes the C(P)-SH to cysteine sulfenic acid (C(P)-SOH), which then reacts with another cysteine residue, the resolving cysteine (C(R)), to form a disulfide bridge. The disulfide is subsequently reduced by an appropriate electron donor to complete the catalytic cycle. In this typical 2-Cys peroxiredoxin, C(R) is provided by the other dimeric subunit to form an intersubunit disulfide. The disulfide is subsequently reduced by thioredoxin. {ECO:0000305|PubMed:21994946}.	SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:18052930, ECO:0000269|PubMed:9388242}. Endoplasmic reticulum {ECO:0000269|PubMed:18052930}. Note=Cotranslationally translocated to and retained within the endoplasmic reticulum. A small fraction of the protein is cytoplasmic. {ECO:0000269|PubMed:18052930}.	Peroxiredoxin family, AhpC/Prx1 subfamily	4-hydroxyproline metabolic process [GO:0019471]; cell redox homeostasis [GO:0045454]; extracellular matrix organization [GO:0030198]; hydrogen peroxide catabolic process [GO:0042744]; I-kappaB phosphorylation [GO:0007252]; male gonad development [GO:0008584]; negative regulation of male germ cell proliferation [GO:2000255]; neutrophil degranulation [GO:0043312]; protein maturation by protein folding [GO:0022417]; response to oxidative stress [GO:0006979]; spermatogenesis [GO:0007283]	cytosol [GO:0005829]; endoplasmic reticulum [GO:0005783]; extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; ficolin-1-rich granule lumen [GO:1904813]; nucleus [GO:0005634]; secretory granule lumen [GO:0034774]; smooth endoplasmic reticulum [GO:0005790]	cytosol [GO:0005829]; endoplasmic reticulum [GO:0005783]; extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; ficolin-1-rich granule lumen [GO:1904813]; nucleus [GO:0005634]; secretory granule lumen [GO:0034774]; smooth endoplasmic reticulum [GO:0005790]; protein homodimerization activity [GO:0042803]; thioredoxin peroxidase activity [GO:0008379]; 4-hydroxyproline metabolic process [GO:0019471]; cell redox homeostasis [GO:0045454]; extracellular matrix organization [GO:0030198]; hydrogen peroxide catabolic process [GO:0042744]; I-kappaB phosphorylation [GO:0007252]; male gonad development [GO:0008584]; negative regulation of male germ cell proliferation [GO:2000255]; neutrophil degranulation [GO:0043312]; protein maturation by protein folding [GO:0022417]; response to oxidative stress [GO:0006979]; spermatogenesis [GO:0007283]	protein homodimerization activity [GO:0042803]; thioredoxin peroxidase activity [GO:0008379]	PRDX4
PRDX5	P30044	PRDX5_HUMAN	reviewed	Peroxiredoxin-5, mitochondrial (EC 1.11.1.15) (Alu corepressor 1) (Antioxidant enzyme B166) (AOEB166) (Liver tissue 2D-page spot 71B) (PLP) (Peroxiredoxin V) (Prx-V) (Peroxisomal antioxidant enzyme) (TPx type VI) (Thioredoxin peroxidase PMP20)	PRDX5 ACR1 SBBI10	Homo sapiens (Human)	214	5 out of 5	Active site (1); Alternative sequence (3); Beta strand (8); Chain (1); Disulfide bond (1); Domain (1); Frameshift (1); Helix (10); Modified residue (6); Motif (1); Mutagenesis (3); Natural variant (2); Sequence conflict (1); Transit peptide (1); Turn (3)	3D-structure;Acetylation;Alternative initiation;Alternative splicing;Antioxidant;Complete proteome;Cytoplasm;Direct protein sequencing;Disulfide bond;Mitochondrion;Oxidoreductase;Peroxidase;Peroxisome;Phosphoprotein;Polymorphism;Redox-active center;Reference proteome;Transit peptide	MISCELLANEOUS: The active site is a conserved redox-active cysteine residue, the peroxidatic cysteine (C(P)), which makes the nucleophilic attack on the peroxide substrate. The peroxide oxidizes the C(P)-SH to cysteine sulfenic acid (C(P)-SOH), which then reacts with another cysteine residue, the resolving cysteine (C(R)), to form a disulfide bridge. The disulfide is subsequently reduced by an appropriate electron donor to complete the catalytic cycle. In this atypical 2-Cys Prx, C(R) is present in the same subunit to form an intramolecular disulfide. The disulfide is subsequently reduced by thioredoxin. {ECO:0000305|PubMed:10751410, ECO:0000305|PubMed:18489898}.	SUBCELLULAR LOCATION: Isoform Mitochondrial: Mitochondrion {ECO:0000269|PubMed:10521424, ECO:0000269|PubMed:10751410}.; SUBCELLULAR LOCATION: Isoform Cytoplasmic+peroxisomal: Cytoplasm {ECO:0000269|PubMed:10514471, ECO:0000269|PubMed:10751410}. Peroxisome matrix {ECO:0000269|PubMed:10514471, ECO:0000269|PubMed:10521424, ECO:0000269|PubMed:10751410}. Note=Imported into peroxisomes via peroxisomal targeting signal 1 receptor PEX5. {ECO:0000269|PubMed:10514471}.	Peroxiredoxin family, Prx5 subfamily	cell redox homeostasis [GO:0045454]; cellular response to oxidative stress [GO:0034599]; cellular response to reactive oxygen species [GO:0034614]; hydrogen peroxide catabolic process [GO:0042744]; inflammatory response [GO:0006954]; NADPH oxidation [GO:0070995]; negative regulation of apoptotic process [GO:0043066]; negative regulation of oxidoreductase activity [GO:0051354]; negative regulation of transcription by RNA polymerase III [GO:0016480]; positive regulation of collagen biosynthetic process [GO:0032967]; reactive nitrogen species metabolic process [GO:2001057]; regulation of apoptosis involved in tissue homeostasis [GO:0060785]; response to oxidative stress [GO:0006979]	cytoplasm [GO:0005737]; cytoplasmic vesicle [GO:0031410]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; extracellular space [GO:0005615]; intracellular membrane-bounded organelle [GO:0043231]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]; nucleus [GO:0005634]; perinuclear region of cytoplasm [GO:0048471]; peroxisomal matrix [GO:0005782]; peroxisome [GO:0005777]	cytoplasm [GO:0005737]; cytoplasmic vesicle [GO:0031410]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; extracellular space [GO:0005615]; intracellular membrane-bounded organelle [GO:0043231]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]; nucleus [GO:0005634]; perinuclear region of cytoplasm [GO:0048471]; peroxisomal matrix [GO:0005782]; peroxisome [GO:0005777]; antioxidant activity [GO:0016209]; cysteine-type endopeptidase inhibitor activity involved in apoptotic process [GO:0043027]; peroxidase activity [GO:0004601]; peroxiredoxin activity [GO:0051920]; peroxynitrite reductase activity [GO:0072541]; protein dimerization activity [GO:0046983]; RNA polymerase III regulatory region DNA binding [GO:0001016]; signaling receptor binding [GO:0005102]; thioredoxin peroxidase activity [GO:0008379]; cell redox homeostasis [GO:0045454]; cellular response to oxidative stress [GO:0034599]; cellular response to reactive oxygen species [GO:0034614]; hydrogen peroxide catabolic process [GO:0042744]; inflammatory response [GO:0006954]; NADPH oxidation [GO:0070995]; negative regulation of apoptotic process [GO:0043066]; negative regulation of oxidoreductase activity [GO:0051354]; negative regulation of transcription by RNA polymerase III [GO:0016480]; positive regulation of collagen biosynthetic process [GO:0032967]; reactive nitrogen species metabolic process [GO:2001057]; regulation of apoptosis involved in tissue homeostasis [GO:0060785]; response to oxidative stress [GO:0006979]	antioxidant activity [GO:0016209]; cysteine-type endopeptidase inhibitor activity involved in apoptotic process [GO:0043027]; peroxidase activity [GO:0004601]; peroxiredoxin activity [GO:0051920]; peroxynitrite reductase activity [GO:0072541]; protein dimerization activity [GO:0046983]; RNA polymerase III regulatory region DNA binding [GO:0001016]; signaling receptor binding [GO:0005102]; thioredoxin peroxidase activity [GO:0008379]	PRDX5
TXNDC17	Q9BRA2	TXD17_HUMAN	reviewed	Thioredoxin domain-containing protein 17 (14 kDa thioredoxin-related protein) (TRP14) (Protein 42-9-9) (Thioredoxin-like protein 5)	TXNDC17 TXNL5	Homo sapiens (Human)	123	5 out of 5	Active site (2); Beta strand (5); Chain (1); Disulfide bond (1); Domain (1); Helix (7); Initiator methionine (1); Modified residue (1); Mutagenesis (2); Site (2); Turn (1)	3D-structure;Acetylation;Complete proteome;Cytoplasm;Direct protein sequencing;Disulfide bond;Redox-active center;Reference proteome		SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:14607844}.	Thioredoxin family	tumor necrosis factor-mediated signaling pathway [GO:0033209]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]; peroxidase activity [GO:0004601]; protein-disulfide reductase activity [GO:0047134]; tumor necrosis factor-mediated signaling pathway [GO:0033209]	peroxidase activity [GO:0004601]; protein-disulfide reductase activity [GO:0047134]	TXNDC17
TXN	P10599	THIO_HUMAN	reviewed	Thioredoxin (Trx) (ATL-derived factor) (ADF) (Surface-associated sulphydryl protein) (SASP)	TXN TRDX TRX TRX1	Homo sapiens (Human)	105	5 out of 5	Active site (2); Alternative sequence (1); Beta strand (6); Chain (1); Disulfide bond (2); Domain (1); Helix (4); Initiator methionine (1); Modified residue (8); Mutagenesis (10); Sequence conflict (4); Site (3); Turn (3)	3D-structure;Acetylation;Activator;Alternative splicing;Complete proteome;Cytoplasm;Direct protein sequencing;Disulfide bond;Electron transport;Nucleus;Redox-active center;Reference proteome;S-nitrosylation;Secreted;Transcription;Transcription regulation;Transport;Ubl conjugation		SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:11118054, ECO:0000269|PubMed:9108029}. Cytoplasm {ECO:0000269|PubMed:11118054, ECO:0000269|PubMed:9108029}. Secreted {ECO:0000269|PubMed:1332947}. Note=Translocates from the cytoplasm into the nucleus after phorbol 12-myristate 13-acetate induction (PMA) (PubMed:9108029). Predominantly in the cytoplasm in non irradiated cells (PubMed:11118054). Radiation induces translocation of TRX from the cytoplasm to the nucleus (PubMed:11118054). Secreted by a leaderless secretory pathway (PubMed:1332947). {ECO:0000269|PubMed:11118054, ECO:0000269|PubMed:1332947, ECO:0000269|PubMed:9108029}.	Thioredoxin family	activation of protein kinase B activity [GO:0032148]; cell redox homeostasis [GO:0045454]; glycerol ether metabolic process [GO:0006662]; negative regulation of hydrogen peroxide-induced cell death [GO:1903206]; negative regulation of protein export from nucleus [GO:0046826]; negative regulation of transcription by RNA polymerase II [GO:0000122]; oxidation-reduction process [GO:0055114]; positive regulation of DNA binding [GO:0043388]; positive regulation of peptidyl-serine phosphorylation [GO:0033138]; positive regulation of protein kinase B signaling [GO:0051897]; response to radiation [GO:0009314]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; peptide disulfide oxidoreductase activity [GO:0015037]; protein disulfide oxidoreductase activity [GO:0015035]; RNA binding [GO:0003723]; thioredoxin-disulfide reductase activity [GO:0004791]; activation of protein kinase B activity [GO:0032148]; cell redox homeostasis [GO:0045454]; glycerol ether metabolic process [GO:0006662]; negative regulation of hydrogen peroxide-induced cell death [GO:1903206]; negative regulation of protein export from nucleus [GO:0046826]; negative regulation of transcription by RNA polymerase II [GO:0000122]; oxidation-reduction process [GO:0055114]; positive regulation of DNA binding [GO:0043388]; positive regulation of peptidyl-serine phosphorylation [GO:0033138]; positive regulation of protein kinase B signaling [GO:0051897]; response to radiation [GO:0009314]	peptide disulfide oxidoreductase activity [GO:0015037]; protein disulfide oxidoreductase activity [GO:0015035]; RNA binding [GO:0003723]; thioredoxin-disulfide reductase activity [GO:0004791]	TXN
TXNL4B	Q9NX01	TXN4B_HUMAN	reviewed	Thioredoxin-like protein 4B (Dim1-like protein)	TXNL4B DIM2 DLP	Homo sapiens (Human)	149	5 out of 5	Beta strand (8); Chain (1); Helix (5); Turn (2)	3D-structure;Cell cycle;Complete proteome;Nucleus;Reference proteome;mRNA processing;mRNA splicing		SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:15161931}.	DIM1 family	cell cycle [GO:0007049]; mRNA splicing, via spliceosome [GO:0000398]	cytosol [GO:0005829]; nucleoplasm [GO:0005654]; U4/U6 x U5 tri-snRNP complex [GO:0046540]; U5 snRNP [GO:0005682]	cytosol [GO:0005829]; nucleoplasm [GO:0005654]; U4/U6 x U5 tri-snRNP complex [GO:0046540]; U5 snRNP [GO:0005682]; cell cycle [GO:0007049]; mRNA splicing, via spliceosome [GO:0000398]		TXNL4B
TXNL4A	P83876	TXN4A_HUMAN	reviewed	Thioredoxin-like protein 4A (DIM1 protein homolog) (Spliceosomal U5 snRNP-specific 15 kDa protein) (Thioredoxin-like U5 snRNP protein U5-15kD)	TXNL4A DIM1 TXNL4	Homo sapiens (Human)	142	5 out of 5	Beta strand (7); Chain (1); Disulfide bond (1); Helix (3); Modified residue (1); Mutagenesis (1); Turn (4)	3D-structure;Cell cycle;Cell division;Complete proteome;Deafness;Direct protein sequencing;Disulfide bond;Mitosis;Nucleus;Phosphoprotein;Reference proteome;Spliceosome;mRNA processing;mRNA splicing		SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:10610776, ECO:0000269|PubMed:11054566, ECO:0000269|PubMed:20858735, ECO:0000269|PubMed:26912367, ECO:0000269|PubMed:28781166}.	DIM1 family	cell cycle [GO:0007049]; cell division [GO:0051301]; mRNA splicing, via spliceosome [GO:0000398]; RNA splicing, via transesterification reactions [GO:0000375]; spliceosomal complex assembly [GO:0000245]	cytosol [GO:0005829]; nuclear membrane [GO:0031965]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; spliceosomal complex [GO:0005681]; U2-type precatalytic spliceosome [GO:0071005]; U4/U6 x U5 tri-snRNP complex [GO:0046540]; U5 snRNP [GO:0005682]	cytosol [GO:0005829]; nuclear membrane [GO:0031965]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; spliceosomal complex [GO:0005681]; U2-type precatalytic spliceosome [GO:0071005]; U4/U6 x U5 tri-snRNP complex [GO:0046540]; U5 snRNP [GO:0005682]; cell cycle [GO:0007049]; cell division [GO:0051301]; mRNA splicing, via spliceosome [GO:0000398]; RNA splicing, via transesterification reactions [GO:0000375]; spliceosomal complex assembly [GO:0000245]		TXNL4A
TXNDC11	Q6PKC3	TXD11_HUMAN	reviewed	Thioredoxin domain-containing protein 11 (EF-hand-binding protein 1)	TXNDC11 EFP1	Homo sapiens (Human)	985	5 out of 5	Alternative sequence (3); Chain (1); Coiled coil (1); Disulfide bond (2); Domain (2); Erroneous initiation (2); Frameshift (1); Modified residue (1); Natural variant (1); Sequence caution (1); Transmembrane (1)	Alternative splicing;Coiled coil;Complete proteome;Disulfide bond;Endoplasmic reticulum;Membrane;Phosphoprotein;Polymorphism;Redox-active center;Reference proteome;Repeat;Transmembrane;Transmembrane helix		SUBCELLULAR LOCATION: Endoplasmic reticulum membrane {ECO:0000305}; Single-pass membrane protein {ECO:0000305}.	Protein disulfide isomerase family	cell redox homeostasis [GO:0045454]	endoplasmic reticulum membrane [GO:0005789]; integral component of membrane [GO:0016021]	endoplasmic reticulum membrane [GO:0005789]; integral component of membrane [GO:0016021]; cell redox homeostasis [GO:0045454]		TXNDC11
PRDX3	P30048	PRDX3_HUMAN	reviewed	Thioredoxin-dependent peroxide reductase, mitochondrial (EC 1.11.1.15) (Antioxidant protein 1) (AOP-1) (HBC189) (Peroxiredoxin III) (Prx-III) (Peroxiredoxin-3) (Protein MER5 homolog)	PRDX3 AOP1	Homo sapiens (Human)	256	5 out of 5	Active site (1); Alternative sequence (1); Beta strand (8); Chain (1); Disulfide bond (2); Domain (1); Helix (8); Modified residue (4); Mutagenesis (1); Natural variant (4); Sequence conflict (1); Transit peptide (1); Turn (2)	3D-structure;Acetylation;Alternative splicing;Antioxidant;Complete proteome;Cytoplasm;Direct protein sequencing;Disulfide bond;Endosome;Mitochondrion;Oxidoreductase;Peroxidase;Phosphoprotein;Polymorphism;Redox-active center;Reference proteome;Transit peptide	MISCELLANEOUS: The active site is a conserved redox-active cysteine residue, the peroxidatic cysteine (C(P)), which makes the nucleophilic attack on the peroxide substrate. The peroxide oxidizes the C(P)-SH to cysteine sulfenic acid (C(P)-SOH), which then reacts with another cysteine residue, the resolving cysteine (C(R)), to form a disulfide bridge. The disulfide is subsequently reduced by an appropriate electron donor to complete the catalytic cycle. In this typical 2-Cys peroxiredoxin, C(R) is provided by the other dimeric subunit to form an intersubunit disulfide. The disulfide is subsequently reduced by thioredoxin. {ECO:0000305|PubMed:17707404}.	SUBCELLULAR LOCATION: Mitochondrion {ECO:0000250|UniProtKB:P35705}. Cytoplasm {ECO:0000305|PubMed:12492477}. Early endosome {ECO:0000269|PubMed:15750338}. Note=Localizes to early endosomes in a RPS6KC1-dependent manner. {ECO:0000269|PubMed:15750338}.	Peroxiredoxin family, AhpC/Prx1 subfamily	cell redox homeostasis [GO:0045454]; cellular response to oxidative stress [GO:0034599]; cellular response to reactive oxygen species [GO:0034614]; hydrogen peroxide catabolic process [GO:0042744]; maternal placenta development [GO:0001893]; mitochondrion organization [GO:0007005]; myeloid cell differentiation [GO:0030099]; negative regulation of apoptotic process [GO:0043066]; negative regulation of kinase activity [GO:0033673]; peptidyl-cysteine oxidation [GO:0018171]; positive regulation of cell population proliferation [GO:0008284]; positive regulation of NF-kappaB transcription factor activity [GO:0051092]; regulation of mitochondrial membrane potential [GO:0051881]; response to hydrogen peroxide [GO:0042542]; response to lipopolysaccharide [GO:0032496]; response to oxidative stress [GO:0006979]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; early endosome [GO:0005769]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]; protein-containing complex [GO:0032991]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; early endosome [GO:0005769]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]; protein-containing complex [GO:0032991]; alkyl hydroperoxide reductase activity [GO:0008785]; cysteine-type endopeptidase inhibitor activity involved in apoptotic process [GO:0043027]; identical protein binding [GO:0042802]; kinase binding [GO:0019900]; protein C-terminus binding [GO:0008022]; protein kinase binding [GO:0019901]; thioredoxin peroxidase activity [GO:0008379]; cell redox homeostasis [GO:0045454]; cellular response to oxidative stress [GO:0034599]; cellular response to reactive oxygen species [GO:0034614]; hydrogen peroxide catabolic process [GO:0042744]; maternal placenta development [GO:0001893]; mitochondrion organization [GO:0007005]; myeloid cell differentiation [GO:0030099]; negative regulation of apoptotic process [GO:0043066]; negative regulation of kinase activity [GO:0033673]; peptidyl-cysteine oxidation [GO:0018171]; positive regulation of cell population proliferation [GO:0008284]; positive regulation of NF-kappaB transcription factor activity [GO:0051092]; regulation of mitochondrial membrane potential [GO:0051881]; response to hydrogen peroxide [GO:0042542]; response to lipopolysaccharide [GO:0032496]; response to oxidative stress [GO:0006979]	alkyl hydroperoxide reductase activity [GO:0008785]; cysteine-type endopeptidase inhibitor activity involved in apoptotic process [GO:0043027]; identical protein binding [GO:0042802]; kinase binding [GO:0019900]; protein C-terminus binding [GO:0008022]; protein kinase binding [GO:0019901]; thioredoxin peroxidase activity [GO:0008379]	PRDX3
RRM1	P23921	RIR1_HUMAN	reviewed	Ribonucleoside-diphosphate reductase large subunit (EC 1.17.4.1) (Ribonucleoside-diphosphate reductase subunit M1) (Ribonucleotide reductase large subunit)	RRM1 RR1	Homo sapiens (Human)	792	5 out of 5	Active site (3); Beta strand (30); Binding site (5); Chain (1); Disulfide bond (1); Domain (1); Helix (41); Modified residue (3); Mutagenesis (1); Natural variant (2); Region (5); Sequence conflict (1); Site (8); Turn (7)	3D-structure;ATP-binding;Acetylation;Allosteric enzyme;Complete proteome;Cytoplasm;DNA replication;Disulfide bond;Nucleotide-binding;Oxidoreductase;Phosphoprotein;Polymorphism;Reference proteome	MISCELLANEOUS: Two distinct regulatory sites have been defined: the specificity site, which controls substrate specificity, and the activity site which regulates overall catalytic activity. A substrate-binding catalytic site, located on M1, is formed only in the presence of the second subunit M2.; MISCELLANEOUS: The level of the enzyme activity is closely correlated with the growth rate of a cell and appears to vary with the cell cycle.	SUBCELLULAR LOCATION: Cytoplasm.	Ribonucleoside diphosphate reductase large chain family	cell proliferation in forebrain [GO:0021846]; deoxyribonucleotide biosynthetic process [GO:0009263]; DNA replication [GO:0006260]; male gonad development [GO:0008584]; mitotic cell cycle [GO:0000278]; nucleobase-containing small molecule interconversion [GO:0015949]; protein heterotetramerization [GO:0051290]; pyrimidine nucleobase metabolic process [GO:0006206]; response to ionizing radiation [GO:0010212]; retina development in camera-type eye [GO:0060041]	cell projection [GO:0042995]; cytosol [GO:0005829]; neuronal cell body [GO:0043025]; nuclear envelope [GO:0005635]; ribonucleoside-diphosphate reductase complex [GO:0005971]	cell projection [GO:0042995]; cytosol [GO:0005829]; neuronal cell body [GO:0043025]; nuclear envelope [GO:0005635]; ribonucleoside-diphosphate reductase complex [GO:0005971]; ATP binding [GO:0005524]; disordered domain specific binding [GO:0097718]; identical protein binding [GO:0042802]; ribonucleoside-diphosphate reductase activity, thioredoxin disulfide as acceptor [GO:0004748]; cell proliferation in forebrain [GO:0021846]; deoxyribonucleotide biosynthetic process [GO:0009263]; DNA replication [GO:0006260]; male gonad development [GO:0008584]; mitotic cell cycle [GO:0000278]; nucleobase-containing small molecule interconversion [GO:0015949]; protein heterotetramerization [GO:0051290]; pyrimidine nucleobase metabolic process [GO:0006206]; response to ionizing radiation [GO:0010212]; retina development in camera-type eye [GO:0060041]	ATP binding [GO:0005524]; disordered domain specific binding [GO:0097718]; identical protein binding [GO:0042802]; ribonucleoside-diphosphate reductase activity, thioredoxin disulfide as acceptor [GO:0004748]	RRM1
PRDX2	P32119	PRDX2_HUMAN	reviewed	Peroxiredoxin-2 (EC 1.11.1.15) (Natural killer cell-enhancing factor B) (NKEF-B) (PRP) (Thiol-specific antioxidant protein) (TSA) (Thioredoxin peroxidase 1) (Thioredoxin-dependent peroxide reductase 1)	PRDX2 NKEFB TDPX1	Homo sapiens (Human)	198	5 out of 5	Active site (1); Alternative sequence (1); Beta strand (8); Chain (1); Disulfide bond (2); Domain (1); Helix (8); Initiator methionine (1); Modified residue (3); Natural variant (1); Sequence conflict (7); Turn (2)	3D-structure;Acetylation;Alternative splicing;Antioxidant;Complete proteome;Cytoplasm;Direct protein sequencing;Disulfide bond;Oxidoreductase;Peroxidase;Phosphoprotein;Polymorphism;Redox-active center;Reference proteome	MISCELLANEOUS: The active site is a conserved redox-active cysteine residue, the peroxidatic cysteine (C(P)), which makes the nucleophilic attack on the peroxide substrate. The peroxide oxidizes the C(P)-SH to cysteine sulfenic acid (C(P)-SOH), which then reacts with another cysteine residue, the resolving cysteine (C(R)), to form a disulfide bridge. The disulfide is subsequently reduced by an appropriate electron donor to complete the catalytic cycle. In this typical 2-Cys peroxiredoxin, C(R) is provided by the other dimeric subunit to form an intersubunit disulfide. The disulfide is subsequently reduced by thioredoxin. {ECO:0000305|PubMed:27892488}.	SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:9497357}.	Peroxiredoxin family, AhpC/Prx1 subfamily	activation of MAPK activity [GO:0000187]; cell redox homeostasis [GO:0045454]; cellular response to oxidative stress [GO:0034599]; homeostasis of number of cells [GO:0048872]; hydrogen peroxide catabolic process [GO:0042744]; leukocyte activation [GO:0045321]; negative regulation of apoptotic process [GO:0043066]; negative regulation of extrinsic apoptotic signaling pathway in absence of ligand [GO:2001240]; negative regulation of lipopolysaccharide-mediated signaling pathway [GO:0031665]; negative regulation of NF-kappaB transcription factor activity [GO:0032088]; negative regulation of T cell differentiation [GO:0045581]; positive regulation of blood coagulation [GO:0030194]; regulation of apoptotic process [GO:0042981]; regulation of hydrogen peroxide metabolic process [GO:0010310]; removal of superoxide radicals [GO:0019430]; respiratory burst involved in inflammatory response [GO:0002536]; response to lipopolysaccharide [GO:0032496]; response to oxidative stress [GO:0006979]; T cell proliferation [GO:0042098]; thymus development [GO:0048538]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; antioxidant activity [GO:0016209]; thioredoxin peroxidase activity [GO:0008379]; activation of MAPK activity [GO:0000187]; cell redox homeostasis [GO:0045454]; cellular response to oxidative stress [GO:0034599]; homeostasis of number of cells [GO:0048872]; hydrogen peroxide catabolic process [GO:0042744]; leukocyte activation [GO:0045321]; negative regulation of apoptotic process [GO:0043066]; negative regulation of extrinsic apoptotic signaling pathway in absence of ligand [GO:2001240]; negative regulation of lipopolysaccharide-mediated signaling pathway [GO:0031665]; negative regulation of NF-kappaB transcription factor activity [GO:0032088]; negative regulation of T cell differentiation [GO:0045581]; positive regulation of blood coagulation [GO:0030194]; regulation of apoptotic process [GO:0042981]; regulation of hydrogen peroxide metabolic process [GO:0010310]; removal of superoxide radicals [GO:0019430]; respiratory burst involved in inflammatory response [GO:0002536]; response to lipopolysaccharide [GO:0032496]; response to oxidative stress [GO:0006979]; T cell proliferation [GO:0042098]; thymus development [GO:0048538]	antioxidant activity [GO:0016209]; thioredoxin peroxidase activity [GO:0008379]	PRDX2
TXNDC2	Q86VQ3	TXND2_HUMAN	reviewed	Thioredoxin domain-containing protein 2 (Spermatid-specific thioredoxin-1) (Sptrx-1)	TXNDC2 SPTRX SPTRX1	Homo sapiens (Human)	553	5 out of 5	Alternative sequence (2); Chain (1); Disulfide bond (1); Domain (1); Modified residue (2); Natural variant (6); Region (1); Repeat (22)	Alternative splicing;Complete proteome;Cytoplasm;Developmental protein;Differentiation;Disulfide bond;Phosphoprotein;Polymorphism;Redox-active center;Reference proteome;Repeat;Spermatogenesis		SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:11399755}. Note=In ejaculated spermatozoa, it localizes in the caudal region of the head to the end of the principal piece.		cell differentiation [GO:0030154]; cell redox homeostasis [GO:0045454]; multicellular organism development [GO:0007275]; spermatogenesis [GO:0007283]	cytoplasm [GO:0005737]	cytoplasm [GO:0005737]; thioredoxin-disulfide reductase activity [GO:0004791]; cell differentiation [GO:0030154]; cell redox homeostasis [GO:0045454]; multicellular organism development [GO:0007275]; spermatogenesis [GO:0007283]	thioredoxin-disulfide reductase activity [GO:0004791]	TXNDC2
TXNDC6	Q86XW9	TXND6_HUMAN	reviewed	Thioredoxin domain-containing protein 6 (Thioredoxin-like protein 2) (Txl-2)	NME9 TXL2 TXNDC6	Homo sapiens (Human)	330	4 out of 5	Alternative sequence (4); Chain (1); Domain (1); Region (1); Sequence conflict (1)	Alternative splicing;Complete proteome;Cytoplasm;Cytoskeleton;Reference proteome	MISCELLANEOUS: Shows no detectable enzyme activity.	SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}. Cytoplasm, cytoskeleton {ECO:0000250}. Note=Associated with microtubules. Detected in cilia of lung epithelium, and associated with the spermatid tail and manchette (By similarity). {ECO:0000250}.	NDK family	cell redox homeostasis [GO:0045454]; CTP biosynthetic process [GO:0006241]; GTP biosynthetic process [GO:0006183]; UTP biosynthetic process [GO:0006228]	cytoplasm [GO:0005737]; cytoskeleton [GO:0005856]	cytoplasm [GO:0005737]; cytoskeleton [GO:0005856]; nucleoside diphosphate kinase activity [GO:0004550]; cell redox homeostasis [GO:0045454]; CTP biosynthetic process [GO:0006241]; GTP biosynthetic process [GO:0006183]; UTP biosynthetic process [GO:0006228]	nucleoside diphosphate kinase activity [GO:0004550]	TXNDC6
TXNRD2	Q9NNW7	TRXR2_HUMAN	reviewed	Thioredoxin reductase 2, mitochondrial (EC 1.8.1.9) (Selenoprotein Z) (SelZ) (TR-beta) (Thioredoxin reductase TR3)	TXNRD2 KIAA1652 TRXR2	Homo sapiens (Human)	524	5 out of 5	Active site (1); Alternative sequence (3); Chain (1); Cross-link (1); Disulfide bond (1); Erroneous initiation (1); Erroneous termination (1); Modified residue (2); Natural variant (5); Non-standard residue (1); Nucleotide binding (1); Sequence conflict (2); Transit peptide (1)	3D-structure;Alternative splicing;Complete proteome;Disease mutation;Disulfide bond;FAD;Flavoprotein;Mitochondrion;NADP;Oxidoreductase;Polymorphism;Redox-active center;Reference proteome;Selenocysteine;Transit peptide	MISCELLANEOUS: The active site is a redox-active disulfide bond. The selenocysteine residue is essential for enzymatic activity (By similarity). {ECO:0000250}.	SUBCELLULAR LOCATION: Mitochondrion {ECO:0000269|PubMed:10215850}.	Class-I pyridine nucleotide-disulfide oxidoreductase family	cell redox homeostasis [GO:0045454]; cellular response to oxidative stress [GO:0034599]; response to oxygen radical [GO:0000305]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]; electron transfer activity [GO:0009055]; flavin adenine dinucleotide binding [GO:0050660]; thioredoxin-disulfide reductase activity [GO:0004791]; cell redox homeostasis [GO:0045454]; cellular response to oxidative stress [GO:0034599]; response to oxygen radical [GO:0000305]	electron transfer activity [GO:0009055]; flavin adenine dinucleotide binding [GO:0050660]; thioredoxin-disulfide reductase activity [GO:0004791]	TXNRD2
TXNRD3	Q86VQ6	TRXR3_HUMAN	reviewed	Thioredoxin reductase 3 (EC 1.8.1.9) (Thioredoxin and glutathione reductase) (Thioredoxin reductase TR2)	TXNRD3 TGR TRXR3	Homo sapiens (Human)	643	5 out of 5	Active site (1); Beta strand (4); Chain (1); Cross-link (1); Disulfide bond (1); Domain (1); Erroneous termination (2); Helix (5); Modified residue (5); Non-standard residue (1); Nucleotide binding (1); Sequence caution (2); Sequence conflict (3); Turn (1)	3D-structure;Complete proteome;Cytoplasm;Developmental protein;Differentiation;Disulfide bond;Electron transport;Endoplasmic reticulum;FAD;Flavoprotein;Methylation;Microsome;NADP;Nucleus;Oxidoreductase;Phosphoprotein;Redox-active center;Reference proteome;Selenocysteine;Spermatogenesis;Transport	MISCELLANEOUS: The thioredoxin reductase active site is a redox-active disulfide bond. The selenocysteine residue is also essential for catalytic activity (By similarity). {ECO:0000250|UniProtKB:Q16881}.	SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250|UniProtKB:Q99MD6}. Nucleus {ECO:0000250|UniProtKB:Q99MD6}. Microsome {ECO:0000250|UniProtKB:Q99MD6}. Endoplasmic reticulum {ECO:0000250}. Note=Detected in cytoplasm and nucleus in late spermatids. {ECO:0000250|UniProtKB:Q99MD6}.	Class-I pyridine nucleotide-disulfide oxidoreductase family	cell differentiation [GO:0030154]; cell redox homeostasis [GO:0045454]; multicellular organism development [GO:0007275]; spermatogenesis [GO:0007283]	cytoplasm [GO:0005737]; endoplasmic reticulum [GO:0005783]; mitochondrion [GO:0005739]; nucleus [GO:0005634]	cytoplasm [GO:0005737]; endoplasmic reticulum [GO:0005783]; mitochondrion [GO:0005739]; nucleus [GO:0005634]; electron transfer activity [GO:0009055]; flavin adenine dinucleotide binding [GO:0050660]; protein disulfide oxidoreductase activity [GO:0015035]; thioredoxin-disulfide reductase activity [GO:0004791]; cell differentiation [GO:0030154]; cell redox homeostasis [GO:0045454]; multicellular organism development [GO:0007275]; spermatogenesis [GO:0007283]	electron transfer activity [GO:0009055]; flavin adenine dinucleotide binding [GO:0050660]; protein disulfide oxidoreductase activity [GO:0015035]; thioredoxin-disulfide reductase activity [GO:0004791]	TXNRD3
TXNRD1	Q16881	TRXR1_HUMAN	reviewed	Thioredoxin reductase 1, cytoplasmic (TR) (EC 1.8.1.9) (Gene associated with retinoic and interferon-induced mortality 12 protein) (GRIM-12) (Gene associated with retinoic and IFN-induced mortality 12 protein) (KM-102-derived reductase-like factor) (Thioredoxin reductase TR1)	TXNRD1 GRIM12 KDRF	Homo sapiens (Human)	649	5 out of 5	Active site (1); Alternative sequence (9); Beta strand (24); Chain (1); Cross-link (1); Disulfide bond (1); Domain (1); Erroneous termination (13); Helix (16); Modified residue (3); Natural variant (1); Non-standard residue (1); Nucleotide binding (1); Sequence conflict (15); Turn (8)	3D-structure;Acetylation;Alternative splicing;Complete proteome;Cytoplasm;Direct protein sequencing;Disulfide bond;Electron transport;FAD;Flavoprotein;NADP;Nucleus;Oxidoreductase;Phosphoprotein;Polymorphism;Redox-active center;Reference proteome;Selenocysteine;Transport;Ubl conjugation	MISCELLANEOUS: The thioredoxin reductase active site is a redox-active disulfide bond. The selenocysteine residue is also essential for catalytic activity.	SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}.; SUBCELLULAR LOCATION: Isoform 4: Cytoplasm. Nucleus.; SUBCELLULAR LOCATION: Isoform 5: Cytoplasm.	Class-I pyridine nucleotide-disulfide oxidoreductase family	cell population proliferation [GO:0008283]; cell redox homeostasis [GO:0045454]; cellular response to oxidative stress [GO:0034599]; mesoderm formation [GO:0001707]; nucleobase-containing small molecule interconversion [GO:0015949]; regulation of lipid metabolic process [GO:0019216]; selenium compound metabolic process [GO:0001887]; signal transduction [GO:0007165]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; fibrillar center [GO:0001650]; mitochondrion [GO:0005739]; nucleoplasm [GO:0005654]	cytoplasm [GO:0005737]; cytosol [GO:0005829]; extracellular exosome [GO:0070062]; fibrillar center [GO:0001650]; mitochondrion [GO:0005739]; nucleoplasm [GO:0005654]; electron transfer activity [GO:0009055]; flavin adenine dinucleotide binding [GO:0050660]; protein disulfide oxidoreductase activity [GO:0015035]; thioredoxin-disulfide reductase activity [GO:0004791]; cell population proliferation [GO:0008283]; cell redox homeostasis [GO:0045454]; cellular response to oxidative stress [GO:0034599]; mesoderm formation [GO:0001707]; nucleobase-containing small molecule interconversion [GO:0015949]; regulation of lipid metabolic process [GO:0019216]; selenium compound metabolic process [GO:0001887]; signal transduction [GO:0007165]	electron transfer activity [GO:0009055]; flavin adenine dinucleotide binding [GO:0050660]; protein disulfide oxidoreductase activity [GO:0015035]; thioredoxin-disulfide reductase activity [GO:0004791]	TXNRD1
TXNDC5	Q8NBS9	TXND5_HUMAN	reviewed	Thioredoxin domain-containing protein 5 (Endoplasmic reticulum resident protein 46) (ER protein 46) (ERp46) (Thioredoxin-like protein p46)	TXNDC5 TLP46 UNQ364/PRO700	Homo sapiens (Human)	432	5 out of 5	Alternative sequence (1); Beta strand (14); Chain (1); Disulfide bond (3); Domain (3); Erroneous initiation (1); Helix (12); Motif (1); Sequence conflict (1); Signal peptide (1); Turn (6)	3D-structure;Alternative splicing;Complete proteome;Disulfide bond;Endoplasmic reticulum;Redox-active center;Reference proteome;Repeat;Signal		SUBCELLULAR LOCATION: Endoplasmic reticulum lumen {ECO:0000255|PROSITE-ProRule:PRU10138}.	Protein disulfide isomerase family	apoptotic cell clearance [GO:0043277]; cell redox homeostasis [GO:0045454]; negative regulation of apoptotic process [GO:0043066]; neutrophil degranulation [GO:0043312]	azurophil granule lumen [GO:0035578]; endoplasmic reticulum [GO:0005783]; endoplasmic reticulum lumen [GO:0005788]; extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; lysosomal lumen [GO:0043202]	azurophil granule lumen [GO:0035578]; endoplasmic reticulum [GO:0005783]; endoplasmic reticulum lumen [GO:0005788]; extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; lysosomal lumen [GO:0043202]; isomerase activity [GO:0016853]; apoptotic cell clearance [GO:0043277]; cell redox homeostasis [GO:0045454]; negative regulation of apoptotic process [GO:0043066]; neutrophil degranulation [GO:0043312]	isomerase activity [GO:0016853]	TXNDC5
NOX1	Q9Y5S8	NOX1_HUMAN	reviewed	NADPH oxidase 1 (NOX-1) (EC 1.-.-.-) (Mitogenic oxidase 1) (MOX-1) (NADH/NADPH mitogenic oxidase subunit P65-MOX) (NOH-1)	NOX1 MOX1 NOH1	Homo sapiens (Human)	564	5 out of 5	Alternative sequence (3); Chain (1); Domain (2); Glycosylation (2); Metal binding (4); Natural variant (4); Nucleotide binding (1); Region (1); Sequence conflict (1); Topological domain (7); Transmembrane (6)	Alternative splicing;Cell junction;Cell membrane;Cell projection;Complete proteome;Electron transport;FAD;Flavoprotein;Glycoprotein;Heme;Ion channel;Ion transport;Iron;Membrane;Metal-binding;NADP;Oxidoreductase;Polymorphism;Reference proteome;Transmembrane;Transmembrane helix;Transport;Voltage-gated channel		SUBCELLULAR LOCATION: Cell projection, invadopodium membrane {ECO:0000269|PubMed:19755710}; Multi-pass membrane protein {ECO:0000269|PubMed:19755710}. Cell membrane {ECO:0000269|PubMed:26301257}.		angiogenesis [GO:0001525]; cell migration [GO:0016477]; cellular response to hyperoxia [GO:0071455]; cellular stress response to acidic pH [GO:1990451]; defense response [GO:0006952]; extracellular matrix organization [GO:0030198]; hydrogen peroxide metabolic process [GO:0042743]; inflammatory response [GO:0006954]; intracellular pH elevation [GO:0051454]; NADP metabolic process [GO:0006739]; oxidation-reduction process [GO:0055114]; oxygen metabolic process [GO:0072592]; positive regulation of cell population proliferation [GO:0008284]; positive regulation of integrin biosynthetic process [GO:0045726]; positive regulation of JNK cascade [GO:0046330]; positive regulation of oxidative stress-induced intrinsic apoptotic signaling pathway [GO:1902177]; positive regulation of smooth muscle cell proliferation [GO:0048661]; positive regulation of vascular endothelial growth factor production [GO:0010575]; regulation of blood pressure [GO:0008217]; regulation of ion transmembrane transport [GO:0034765]; regulation of systemic arterial blood pressure by renin-angiotensin [GO:0003081]; respiratory burst [GO:0045730]; signal transduction [GO:0007165]; superoxide anion generation [GO:0042554]	cell junction [GO:0030054]; early endosome [GO:0005769]; invadopodium membrane [GO:0071438]; NADPH oxidase complex [GO:0043020]; plasma membrane [GO:0005886]	cell junction [GO:0030054]; early endosome [GO:0005769]; invadopodium membrane [GO:0071438]; NADPH oxidase complex [GO:0043020]; plasma membrane [GO:0005886]; metal ion binding [GO:0046872]; NADP binding [GO:0050661]; Rac GTPase binding [GO:0048365]; superoxide-generating NADPH oxidase activity [GO:0016175]; voltage-gated ion channel activity [GO:0005244]; angiogenesis [GO:0001525]; cell migration [GO:0016477]; cellular response to hyperoxia [GO:0071455]; cellular stress response to acidic pH [GO:1990451]; defense response [GO:0006952]; extracellular matrix organization [GO:0030198]; hydrogen peroxide metabolic process [GO:0042743]; inflammatory response [GO:0006954]; intracellular pH elevation [GO:0051454]; NADP metabolic process [GO:0006739]; oxidation-reduction process [GO:0055114]; oxygen metabolic process [GO:0072592]; positive regulation of cell population proliferation [GO:0008284]; positive regulation of integrin biosynthetic process [GO:0045726]; positive regulation of JNK cascade [GO:0046330]; positive regulation of oxidative stress-induced intrinsic apoptotic signaling pathway [GO:1902177]; positive regulation of smooth muscle cell proliferation [GO:0048661]; positive regulation of vascular endothelial growth factor production [GO:0010575]; regulation of blood pressure [GO:0008217]; regulation of ion transmembrane transport [GO:0034765]; regulation of systemic arterial blood pressure by renin-angiotensin [GO:0003081]; respiratory burst [GO:0045730]; signal transduction [GO:0007165]; superoxide anion generation [GO:0042554]	metal ion binding [GO:0046872]; NADP binding [GO:0050661]; Rac GTPase binding [GO:0048365]; superoxide-generating NADPH oxidase activity [GO:0016175]; voltage-gated ion channel activity [GO:0005244]	NOX1
NOX3	Q9HBY0	NOX3_HUMAN	reviewed	NADPH oxidase 3 (EC 1.6.3.-) (Mitogenic oxidase 2) (MOX-2) (gp91phox homolog 3) (GP91-3)	NOX3 MOX2	Homo sapiens (Human)	568	5 out of 5	Chain (1); Domain (2); Glycosylation (2); Mutagenesis (1); Natural variant (1); Sequence conflict (1); Topological domain (7); Transmembrane (6)	Complete proteome;Glycoprotein;Membrane;Oxidoreductase;Polymorphism;Reference proteome;Transmembrane;Transmembrane helix		SUBCELLULAR LOCATION: Membrane {ECO:0000305}; Multi-pass membrane protein {ECO:0000305}.		defense response [GO:0006952]; detection of gravity [GO:0009590]; otolith development [GO:0048840]; oxidation-reduction process [GO:0055114]; superoxide anion generation [GO:0042554]; temperature homeostasis [GO:0001659]	cytoplasm [GO:0005737]; extracellular exosome [GO:0070062]; NADPH oxidase complex [GO:0043020]; plasma membrane [GO:0005886]	cytoplasm [GO:0005737]; extracellular exosome [GO:0070062]; NADPH oxidase complex [GO:0043020]; plasma membrane [GO:0005886]; superoxide-generating NADPH oxidase activity [GO:0016175]; defense response [GO:0006952]; detection of gravity [GO:0009590]; otolith development [GO:0048840]; oxidation-reduction process [GO:0055114]; superoxide anion generation [GO:0042554]; temperature homeostasis [GO:0001659]	superoxide-generating NADPH oxidase activity [GO:0016175]	NOX3
NOX4	Q9NPH5	NOX4_HUMAN	reviewed	NADPH oxidase 4 (EC 1.6.3.-) (Kidney oxidase-1) (KOX-1) (Kidney superoxide-producing NADPH oxidase) (Renal NAD(P)H-oxidase)	NOX4 RENOX	Homo sapiens (Human)	578	5 out of 5	Alternative sequence (8); Chain (1); Domain (2); Glycosylation (2); Mutagenesis (2); Natural variant (1); Region (1); Sequence conflict (1); Topological domain (7); Transmembrane (6)	Alternative splicing;Cell junction;Cell membrane;Complete proteome;Disulfide bond;Endoplasmic reticulum;Glycoprotein;Membrane;NADP;Nucleus;Oxidoreductase;Polymorphism;Reference proteome;Transmembrane;Transmembrane helix		SUBCELLULAR LOCATION: Endoplasmic reticulum membrane; Multi-pass membrane protein. Cell membrane {ECO:0000305}; Multi-pass membrane protein {ECO:0000305}. Cell junction, focal adhesion {ECO:0000305}. Note=May localize to plasma membrane and focal adhesions. According to PubMed:15927447, may also localize to the nucleus.; SUBCELLULAR LOCATION: Isoform 4: Nucleus {ECO:0000269|PubMed:23393389}. Nucleus, nucleolus {ECO:0000269|PubMed:23393389}.		bone resorption [GO:0045453]; cardiac muscle cell differentiation [GO:0055007]; cell aging [GO:0007569]; cell morphogenesis [GO:0000902]; cellular response to cAMP [GO:0071320]; cellular response to gamma radiation [GO:0071480]; cellular response to glucose stimulus [GO:0071333]; cellular response to oxidative stress [GO:0034599]; cellular response to transforming growth factor beta stimulus [GO:0071560]; defense response [GO:0006952]; gene expression [GO:0010467]; heart process [GO:0003015]; homocysteine metabolic process [GO:0050667]; inflammatory response [GO:0006954]; negative regulation of cell population proliferation [GO:0008285]; oxidation-reduction process [GO:0055114]; positive regulation of apoptotic process [GO:0043065]; positive regulation of DNA biosynthetic process [GO:2000573]; positive regulation of ERK1 and ERK2 cascade [GO:0070374]; positive regulation of MAP kinase activity [GO:0043406]; positive regulation of protein kinase B signaling [GO:0051897]; positive regulation of protein tyrosine kinase activity [GO:0061098]; positive regulation of reactive oxygen species metabolic process [GO:2000379]; positive regulation of smooth muscle cell migration [GO:0014911]; positive regulation of stress fiber assembly [GO:0051496]; reactive oxygen species biosynthetic process [GO:1903409]; reactive oxygen species metabolic process [GO:0072593]; response to hypoxia [GO:0001666]; superoxide anion generation [GO:0042554]; superoxide metabolic process [GO:0006801]	apical plasma membrane [GO:0016324]; endoplasmic reticulum membrane [GO:0005789]; focal adhesion [GO:0005925]; integral component of membrane [GO:0016021]; mitochondrion [GO:0005739]; NADPH oxidase complex [GO:0043020]; nucleolus [GO:0005730]; nucleus [GO:0005634]; perinuclear endoplasmic reticulum [GO:0097038]; perinuclear region of cytoplasm [GO:0048471]; plasma membrane [GO:0005886]; stress fiber [GO:0001725]	apical plasma membrane [GO:0016324]; endoplasmic reticulum membrane [GO:0005789]; focal adhesion [GO:0005925]; integral component of membrane [GO:0016021]; mitochondrion [GO:0005739]; NADPH oxidase complex [GO:0043020]; nucleolus [GO:0005730]; nucleus [GO:0005634]; perinuclear endoplasmic reticulum [GO:0097038]; perinuclear region of cytoplasm [GO:0048471]; plasma membrane [GO:0005886]; stress fiber [GO:0001725]; electron transfer activity [GO:0009055]; flavin adenine dinucleotide binding [GO:0050660]; heme binding [GO:0020037]; modified amino acid binding [GO:0072341]; NAD(P)H oxidase activity [GO:0016174]; nucleotide binding [GO:0000166]; oxygen sensor activity [GO:0019826]; protein tyrosine kinase binding [GO:1990782]; superoxide-generating NADPH oxidase activity [GO:0016175]; bone resorption [GO:0045453]; cardiac muscle cell differentiation [GO:0055007]; cell aging [GO:0007569]; cell morphogenesis [GO:0000902]; cellular response to cAMP [GO:0071320]; cellular response to gamma radiation [GO:0071480]; cellular response to glucose stimulus [GO:0071333]; cellular response to oxidative stress [GO:0034599]; cellular response to transforming growth factor beta stimulus [GO:0071560]; defense response [GO:0006952]; gene expression [GO:0010467]; heart process [GO:0003015]; homocysteine metabolic process [GO:0050667]; inflammatory response [GO:0006954]; negative regulation of cell population proliferation [GO:0008285]; oxidation-reduction process [GO:0055114]; positive regulation of apoptotic process [GO:0043065]; positive regulation of DNA biosynthetic process [GO:2000573]; positive regulation of ERK1 and ERK2 cascade [GO:0070374]; positive regulation of MAP kinase activity [GO:0043406]; positive regulation of protein kinase B signaling [GO:0051897]; positive regulation of protein tyrosine kinase activity [GO:0061098]; positive regulation of reactive oxygen species metabolic process [GO:2000379]; positive regulation of smooth muscle cell migration [GO:0014911]; positive regulation of stress fiber assembly [GO:0051496]; reactive oxygen species biosynthetic process [GO:1903409]; reactive oxygen species metabolic process [GO:0072593]; response to hypoxia [GO:0001666]; superoxide anion generation [GO:0042554]; superoxide metabolic process [GO:0006801]	electron transfer activity [GO:0009055]; flavin adenine dinucleotide binding [GO:0050660]; heme binding [GO:0020037]; modified amino acid binding [GO:0072341]; NAD(P)H oxidase activity [GO:0016174]; nucleotide binding [GO:0000166]; oxygen sensor activity [GO:0019826]; protein tyrosine kinase binding [GO:1990782]; superoxide-generating NADPH oxidase activity [GO:0016175]	NOX4
SOD3	P08294	SODE_HUMAN	reviewed	Extracellular superoxide dismutase [Cu-Zn] (EC-SOD) (EC 1.15.1.1)	SOD3	Homo sapiens (Human)	240	5 out of 5	Beta strand (10); Chain (1); Disulfide bond (2); Glycosylation (3); Helix (3); Metal binding (8); Natural variant (3); Signal peptide (1); Site (3)	3D-structure;Antioxidant;Complete proteome;Copper;Direct protein sequencing;Disulfide bond;Glycation;Glycoprotein;Heparin-binding;Metal-binding;Oxidoreductase;Polymorphism;Reference proteome;Secreted;Signal;Zinc		SUBCELLULAR LOCATION: Secreted, extracellular space. Note=99% of EC-SOD is anchored to heparan sulfate proteoglycans in the tissue interstitium, and 1% is located in the vasculature in equilibrium between the plasma and the endothelium.	Cu-Zn superoxide dismutase family	cellular response to oxidative stress [GO:0034599]; removal of superoxide radicals [GO:0019430]; response to copper ion [GO:0046688]; response to hypoxia [GO:0001666]	collagen-containing extracellular matrix [GO:0062023]; extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; extracellular space [GO:0005615]; Golgi lumen [GO:0005796]; nucleus [GO:0005634]	collagen-containing extracellular matrix [GO:0062023]; extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; extracellular space [GO:0005615]; Golgi lumen [GO:0005796]; nucleus [GO:0005634]; copper ion binding [GO:0005507]; heparin binding [GO:0008201]; superoxide dismutase activity [GO:0004784]; cellular response to oxidative stress [GO:0034599]; removal of superoxide radicals [GO:0019430]; response to copper ion [GO:0046688]; response to hypoxia [GO:0001666]	copper ion binding [GO:0005507]; heparin binding [GO:0008201]; superoxide dismutase activity [GO:0004784]	SOD3
SOD2	P04179	SODM_HUMAN	reviewed	Superoxide dismutase [Mn], mitochondrial (EC 1.15.1.1)	SOD2	Homo sapiens (Human)	222	5 out of 5	Alternative sequence (3); Beta strand (3); Chain (1); Helix (12); Metal binding (4); Modified residue (11); Mutagenesis (2); Natural variant (6); Sequence conflict (10); Transit peptide (1); Turn (2)	3D-structure;Acetylation;Alternative splicing;Complete proteome;Direct protein sequencing;Manganese;Metal-binding;Mitochondrion;Nitration;Oxidoreductase;Polymorphism;Reference proteome;Transit peptide;Ubl conjugation		SUBCELLULAR LOCATION: Mitochondrion matrix.	Iron/manganese superoxide dismutase family	acetylcholine-mediated vasodilation involved in regulation of systemic arterial blood pressure [GO:0003069]; age-dependent response to reactive oxygen species [GO:0001315]; cellular response to oxidative stress [GO:0034599]; interleukin-12-mediated signaling pathway [GO:0035722]; negative regulation of cell population proliferation [GO:0008285]; negative regulation of neuron apoptotic process [GO:0043524]; negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway [GO:1902176]; negative regulation of vascular smooth muscle cell proliferation [GO:1904706]; oxygen homeostasis [GO:0032364]; positive regulation of cell migration [GO:0030335]; positive regulation of vascular associated smooth muscle cell apoptotic process [GO:1905461]; positive regulation of vascular smooth muscle cell differentiation involved in phenotypic switching [GO:1905932]; protein homotetramerization [GO:0051289]; regulation of blood pressure [GO:0008217]; regulation of transcription by RNA polymerase II [GO:0006357]; release of cytochrome c from mitochondria [GO:0001836]; removal of superoxide radicals [GO:0019430]; response to superoxide [GO:0000303]; superoxide metabolic process [GO:0006801]	extracellular exosome [GO:0070062]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]	extracellular exosome [GO:0070062]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]; identical protein binding [GO:0042802]; manganese ion binding [GO:0030145]; metal ion binding [GO:0046872]; superoxide dismutase activity [GO:0004784]; acetylcholine-mediated vasodilation involved in regulation of systemic arterial blood pressure [GO:0003069]; age-dependent response to reactive oxygen species [GO:0001315]; cellular response to oxidative stress [GO:0034599]; interleukin-12-mediated signaling pathway [GO:0035722]; negative regulation of cell population proliferation [GO:0008285]; negative regulation of neuron apoptotic process [GO:0043524]; negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway [GO:1902176]; negative regulation of vascular smooth muscle cell proliferation [GO:1904706]; oxygen homeostasis [GO:0032364]; positive regulation of cell migration [GO:0030335]; positive regulation of vascular associated smooth muscle cell apoptotic process [GO:1905461]; positive regulation of vascular smooth muscle cell differentiation involved in phenotypic switching [GO:1905932]; protein homotetramerization [GO:0051289]; regulation of blood pressure [GO:0008217]; regulation of transcription by RNA polymerase II [GO:0006357]; release of cytochrome c from mitochondria [GO:0001836]; removal of superoxide radicals [GO:0019430]; response to superoxide [GO:0000303]; superoxide metabolic process [GO:0006801]	identical protein binding [GO:0042802]; manganese ion binding [GO:0030145]; metal ion binding [GO:0046872]; superoxide dismutase activity [GO:0004784]	SOD2
DUOX1	Q9NRD9	DUOX1_HUMAN	reviewed	Dual oxidase 1 (EC 1.11.1.-) (EC 1.6.3.1) (Large NOX 1) (Long NOX 1) (NADPH thyroid oxidase 1) (Thyroid oxidase 1)	DUOX1 DUOX LNOX1 THOX1	Homo sapiens (Human)	1551	5 out of 5	Alternative sequence (2); Calcium binding (2); Chain (1); Domain (5); Erroneous initiation (1); Erroneous termination (1); Glycosylation (5); Natural variant (3); Region (2); Sequence conflict (2); Signal peptide (1); Topological domain (8); Transmembrane (7)	Alternative splicing;Calcium;Cell membrane;Complete proteome;FAD;Flavoprotein;Glycoprotein;Hydrogen peroxide;Membrane;Metal-binding;NADP;Oxidoreductase;Peroxidase;Polymorphism;Reference proteome;Repeat;Signal;Thyroid hormones biosynthesis;Transmembrane;Transmembrane helix		SUBCELLULAR LOCATION: Apical cell membrane {ECO:0000269|PubMed:10806195, ECO:0000269|PubMed:15210697}; Multi-pass membrane protein {ECO:0000269|PubMed:10806195, ECO:0000269|PubMed:15210697}. Note=Localizes to the apical membrane of epithelial cells.	Peroxidase family	cuticle development [GO:0042335]; cytokine-mediated signaling pathway [GO:0019221]; defense response [GO:0006952]; hormone biosynthetic process [GO:0042446]; hydrogen peroxide biosynthetic process [GO:0050665]; hydrogen peroxide catabolic process [GO:0042744]; oxidation-reduction process [GO:0055114]; positive regulation of cell motility [GO:2000147]; positive regulation of wound healing [GO:0090303]; response to cAMP [GO:0051591]; response to oxidative stress [GO:0006979]; superoxide anion generation [GO:0042554]; thyroid hormone generation [GO:0006590]	apical plasma membrane [GO:0016324]; cell leading edge [GO:0031252]; cell surface [GO:0009986]; endoplasmic reticulum [GO:0005783]; NADPH oxidase complex [GO:0043020]; plasma membrane [GO:0005886]	apical plasma membrane [GO:0016324]; cell leading edge [GO:0031252]; cell surface [GO:0009986]; endoplasmic reticulum [GO:0005783]; NADPH oxidase complex [GO:0043020]; plasma membrane [GO:0005886]; calcium ion binding [GO:0005509]; heme binding [GO:0020037]; NAD(P)H oxidase activity [GO:0016174]; NADP binding [GO:0050661]; peroxidase activity [GO:0004601]; superoxide-generating NADPH oxidase activity [GO:0016175]; cuticle development [GO:0042335]; cytokine-mediated signaling pathway [GO:0019221]; defense response [GO:0006952]; hormone biosynthetic process [GO:0042446]; hydrogen peroxide biosynthetic process [GO:0050665]; hydrogen peroxide catabolic process [GO:0042744]; oxidation-reduction process [GO:0055114]; positive regulation of cell motility [GO:2000147]; positive regulation of wound healing [GO:0090303]; response to cAMP [GO:0051591]; response to oxidative stress [GO:0006979]; superoxide anion generation [GO:0042554]; thyroid hormone generation [GO:0006590]	calcium ion binding [GO:0005509]; heme binding [GO:0020037]; NAD(P)H oxidase activity [GO:0016174]; NADP binding [GO:0050661]; peroxidase activity [GO:0004601]; superoxide-generating NADPH oxidase activity [GO:0016175]	DUOX1
DUOX2	Q9NRD8	DUOX2_HUMAN	reviewed	Dual oxidase 2 (EC 1.11.1.-) (EC 1.6.3.1) (Large NOX 2) (Long NOX 2) (NADH/NADPH thyroid oxidase p138-tox) (NADPH oxidase/peroxidase DUOX2) (NADPH thyroid oxidase 2) (Thyroid oxidase 2) (p138 thyroid oxidase)	DUOX2 LNOX2 THOX2	Homo sapiens (Human)	1548	5 out of 5	Calcium binding (2); Chain (1); Disulfide bond (3); Domain (5); Glycosylation (5); Natural variant (8); Region (2); Sequence conflict (3); Signal peptide (1); Topological domain (7); Transmembrane (7)	Calcium;Cell junction;Cell membrane;Complete proteome;Congenital hypothyroidism;Disease mutation;Disulfide bond;FAD;Flavoprotein;Glycoprotein;Hydrogen peroxide;Membrane;Metal-binding;NADP;Oxidoreductase;Peroxidase;Polymorphism;Reference proteome;Repeat;Signal;Thyroid hormones biosynthesis;Transmembrane;Transmembrane helix		SUBCELLULAR LOCATION: Apical cell membrane {ECO:0000269|PubMed:15591162, ECO:0000269|PubMed:26301257}; Multi-pass membrane protein {ECO:0000269|PubMed:15591162}. Cell junction {ECO:0000269|PubMed:26301257}. Note=Localizes to the apical membrane of epithelial cells. Localizes on internal membrane structures under resting conditions, translocates to the plasma membrane and cell-cell junctions upon challenge with enteric pathogens, such as Escherichia coli. {ECO:0000269|PubMed:26301257}.	Peroxidase family	cuticle development [GO:0042335]; cytokine-mediated signaling pathway [GO:0019221]; defense response [GO:0006952]; hormone biosynthetic process [GO:0042446]; hydrogen peroxide biosynthetic process [GO:0050665]; hydrogen peroxide catabolic process [GO:0042744]; oxidation-reduction process [GO:0055114]; positive regulation of cell motility [GO:2000147]; positive regulation of wound healing [GO:0090303]; response to cAMP [GO:0051591]; response to oxidative stress [GO:0006979]; response to virus [GO:0009615]; superoxide anion generation [GO:0042554]; thyroid hormone generation [GO:0006590]	apical part of cell [GO:0045177]; apical plasma membrane [GO:0016324]; cell junction [GO:0030054]; cell leading edge [GO:0031252]; cell surface [GO:0009986]; cytosol [GO:0005829]; endoplasmic reticulum [GO:0005783]; extracellular exosome [GO:0070062]; NADPH oxidase complex [GO:0043020]; plasma membrane [GO:0005886]	apical part of cell [GO:0045177]; apical plasma membrane [GO:0016324]; cell junction [GO:0030054]; cell leading edge [GO:0031252]; cell surface [GO:0009986]; cytosol [GO:0005829]; endoplasmic reticulum [GO:0005783]; extracellular exosome [GO:0070062]; NADPH oxidase complex [GO:0043020]; plasma membrane [GO:0005886]; calcium ion binding [GO:0005509]; heme binding [GO:0020037]; NAD(P)H oxidase activity [GO:0016174]; peroxidase activity [GO:0004601]; superoxide-generating NADPH oxidase activity [GO:0016175]; cuticle development [GO:0042335]; cytokine-mediated signaling pathway [GO:0019221]; defense response [GO:0006952]; hormone biosynthetic process [GO:0042446]; hydrogen peroxide biosynthetic process [GO:0050665]; hydrogen peroxide catabolic process [GO:0042744]; oxidation-reduction process [GO:0055114]; positive regulation of cell motility [GO:2000147]; positive regulation of wound healing [GO:0090303]; response to cAMP [GO:0051591]; response to oxidative stress [GO:0006979]; response to virus [GO:0009615]; superoxide anion generation [GO:0042554]; thyroid hormone generation [GO:0006590]	calcium ion binding [GO:0005509]; heme binding [GO:0020037]; NAD(P)H oxidase activity [GO:0016174]; peroxidase activity [GO:0004601]; superoxide-generating NADPH oxidase activity [GO:0016175]	DUOX2
SOD1	P00441	SODC_HUMAN	reviewed	Superoxide dismutase [Cu-Zn] (EC 1.15.1.1) (Superoxide dismutase 1) (hSod1)	SOD1	Homo sapiens (Human)	154	5 out of 5	Beta strand (21); Chain (1); Cross-link (1); Disulfide bond (1); Helix (4); Initiator methionine (1); Lipidation (1); Metal binding (8); Modified residue (12); Mutagenesis (15); Natural variant (81); Sequence conflict (2); Turn (2)	3D-structure;Acetylation;Amyotrophic lateral sclerosis;Antioxidant;Complete proteome;Copper;Cytoplasm;Direct protein sequencing;Disease mutation;Disulfide bond;Lipoprotein;Metal-binding;Mitochondrion;Neurodegeneration;Nucleus;Oxidoreductase;Palmitate;Phosphoprotein;Reference proteome;Ubl conjugation;Zinc	MISCELLANEOUS: The protein (both wild-type and ALS1 variants) has a tendency to form fibrillar aggregates in the absence of the intramolecular disulfide bond or of bound zinc ions. These aggregates may have cytotoxic effects. Zinc binding promotes dimerization and stabilizes the native form.	SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:19741096}. Mitochondrion {ECO:0000269|PubMed:19741096}. Nucleus {ECO:0000269|PubMed:22496122}. Note=Predominantly cytoplasmic; the pathogenic variants ALS1 Arg-86 and Ala-94 gradually aggregates and accumulates in mitochondria. {ECO:0000269|PubMed:19741096}.	Cu-Zn superoxide dismutase family	activation of MAPK activity [GO:0000187]; anterograde axonal transport [GO:0008089]; auditory receptor cell stereocilium organization [GO:0060088]; cell aging [GO:0007569]; cellular iron ion homeostasis [GO:0006879]; cellular response to ATP [GO:0071318]; cellular response to cadmium ion [GO:0071276]; cellular response to oxidative stress [GO:0034599]; cellular response to potassium ion [GO:0035865]; embryo implantation [GO:0007566]; glutathione metabolic process [GO:0006749]; heart contraction [GO:0060047]; hydrogen peroxide biosynthetic process [GO:0050665]; interleukin-12-mediated signaling pathway [GO:0035722]; locomotory behavior [GO:0007626]; muscle cell cellular homeostasis [GO:0046716]; myeloid cell homeostasis [GO:0002262]; negative regulation of cholesterol biosynthetic process [GO:0045541]; negative regulation of inflammatory response [GO:0050728]; negative regulation of neuron apoptotic process [GO:0043524]; neurofilament cytoskeleton organization [GO:0060052]; ovarian follicle development [GO:0001541]; peripheral nervous system myelin maintenance [GO:0032287]; placenta development [GO:0001890]; platelet degranulation [GO:0002576]; positive regulation of apoptotic process [GO:0043065]; positive regulation of catalytic activity [GO:0043085]; positive regulation of cytokine production [GO:0001819]; positive regulation of oxidative stress-induced intrinsic apoptotic signaling pathway [GO:1902177]; positive regulation of phagocytosis [GO:0050766]; positive regulation of superoxide anion generation [GO:0032930]; reactive oxygen species metabolic process [GO:0072593]; regulation of blood pressure [GO:0008217]; regulation of GTPase activity [GO:0043087]; regulation of mitochondrial membrane potential [GO:0051881]; regulation of multicellular organism growth [GO:0040014]; regulation of organ growth [GO:0046620]; regulation of protein kinase activity [GO:0045859]; regulation of T cell differentiation in thymus [GO:0033081]; relaxation of vascular smooth muscle [GO:0060087]; removal of superoxide radicals [GO:0019430]; response to amphetamine [GO:0001975]; response to antipsychotic drug [GO:0097332]; response to axon injury [GO:0048678]; response to carbon monoxide [GO:0034465]; response to copper ion [GO:0046688]; response to drug [GO:0042493]; response to ethanol [GO:0045471]; response to heat [GO:0009408]; response to hydrogen peroxide [GO:0042542]; response to organic substance [GO:0010033]; response to superoxide [GO:0000303]; retina homeostasis [GO:0001895]; retrograde axonal transport [GO:0008090]; sensory perception of sound [GO:0007605]; spermatogenesis [GO:0007283]; superoxide anion generation [GO:0042554]; superoxide metabolic process [GO:0006801]; thymus development [GO:0048538]; transmission of nerve impulse [GO:0019226]	axon cytoplasm [GO:1904115]; cytoplasm [GO:0005737]; cytoplasmic vesicle [GO:0031410]; cytosol [GO:0005829]; dendrite cytoplasm [GO:0032839]; dense core granule [GO:0031045]; extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; extracellular space [GO:0005615]; lysosome [GO:0005764]; mitochondrial intermembrane space [GO:0005758]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]; neuronal cell body [GO:0043025]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; peroxisome [GO:0005777]; protein-containing complex [GO:0032991]	axon cytoplasm [GO:1904115]; cytoplasm [GO:0005737]; cytoplasmic vesicle [GO:0031410]; cytosol [GO:0005829]; dendrite cytoplasm [GO:0032839]; dense core granule [GO:0031045]; extracellular exosome [GO:0070062]; extracellular region [GO:0005576]; extracellular space [GO:0005615]; lysosome [GO:0005764]; mitochondrial intermembrane space [GO:0005758]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]; neuronal cell body [GO:0043025]; nucleoplasm [GO:0005654]; nucleus [GO:0005634]; peroxisome [GO:0005777]; protein-containing complex [GO:0032991]; chaperone binding [GO:0051087]; copper ion binding [GO:0005507]; identical protein binding [GO:0042802]; protein homodimerization activity [GO:0042803]; protein phosphatase 2B binding [GO:0030346]; Rac GTPase binding [GO:0048365]; superoxide dismutase activity [GO:0004784]; zinc ion binding [GO:0008270]; activation of MAPK activity [GO:0000187]; anterograde axonal transport [GO:0008089]; auditory receptor cell stereocilium organization [GO:0060088]; cell aging [GO:0007569]; cellular iron ion homeostasis [GO:0006879]; cellular response to ATP [GO:0071318]; cellular response to cadmium ion [GO:0071276]; cellular response to oxidative stress [GO:0034599]; cellular response to potassium ion [GO:0035865]; embryo implantation [GO:0007566]; glutathione metabolic process [GO:0006749]; heart contraction [GO:0060047]; hydrogen peroxide biosynthetic process [GO:0050665]; interleukin-12-mediated signaling pathway [GO:0035722]; locomotory behavior [GO:0007626]; muscle cell cellular homeostasis [GO:0046716]; myeloid cell homeostasis [GO:0002262]; negative regulation of cholesterol biosynthetic process [GO:0045541]; negative regulation of inflammatory response [GO:0050728]; negative regulation of neuron apoptotic process [GO:0043524]; neurofilament cytoskeleton organization [GO:0060052]; ovarian follicle development [GO:0001541]; peripheral nervous system myelin maintenance [GO:0032287]; placenta development [GO:0001890]; platelet degranulation [GO:0002576]; positive regulation of apoptotic process [GO:0043065]; positive regulation of catalytic activity [GO:0043085]; positive regulation of cytokine production [GO:0001819]; positive regulation of oxidative stress-induced intrinsic apoptotic signaling pathway [GO:1902177]; positive regulation of phagocytosis [GO:0050766]; positive regulation of superoxide anion generation [GO:0032930]; reactive oxygen species metabolic process [GO:0072593]; regulation of blood pressure [GO:0008217]; regulation of GTPase activity [GO:0043087]; regulation of mitochondrial membrane potential [GO:0051881]; regulation of multicellular organism growth [GO:0040014]; regulation of organ growth [GO:0046620]; regulation of protein kinase activity [GO:0045859]; regulation of T cell differentiation in thymus [GO:0033081]; relaxation of vascular smooth muscle [GO:0060087]; removal of superoxide radicals [GO:0019430]; response to amphetamine [GO:0001975]; response to antipsychotic drug [GO:0097332]; response to axon injury [GO:0048678]; response to carbon monoxide [GO:0034465]; response to copper ion [GO:0046688]; response to drug [GO:0042493]; response to ethanol [GO:0045471]; response to heat [GO:0009408]; response to hydrogen peroxide [GO:0042542]; response to organic substance [GO:0010033]; response to superoxide [GO:0000303]; retina homeostasis [GO:0001895]; retrograde axonal transport [GO:0008090]; sensory perception of sound [GO:0007605]; spermatogenesis [GO:0007283]; superoxide anion generation [GO:0042554]; superoxide metabolic process [GO:0006801]; thymus development [GO:0048538]; transmission of nerve impulse [GO:0019226]	chaperone binding [GO:0051087]; copper ion binding [GO:0005507]; identical protein binding [GO:0042802]; protein homodimerization activity [GO:0042803]; protein phosphatase 2B binding [GO:0030346]; Rac GTPase binding [GO:0048365]; superoxide dismutase activity [GO:0004784]; zinc ion binding [GO:0008270]	SOD1
CYBB	P04839	CY24B_HUMAN	reviewed	Cytochrome b-245 heavy chain (EC 1.-.-.-) (CGD91-phox) (Cytochrome b(558) subunit beta) (Cytochrome b558 subunit beta) (Heme-binding membrane glycoprotein gp91phox) (NADPH oxidase 2) (Neutrophil cytochrome b 91 kDa polypeptide) (Superoxide-generating NADPH oxidase heavy chain subunit) (gp91-1) (gp91-phox) (p22 phagocyte B-cytochrome)	CYBB NOX2	Homo sapiens (Human)	570	5 out of 5	Beta strand (6); Chain (1); Cross-link (10); Domain (2); Erroneous gene model prediction (1); Erroneous initiation (1); Glycosylation (3); Helix (6); Initiator methionine (1); Metal binding (4); Natural variant (72); Nucleotide binding (1); Sequence conflict (2); Topological domain (7); Transmembrane (6); Turn (1)	3D-structure;Cell membrane;Chronic granulomatous disease;Complete proteome;Direct protein sequencing;Disease mutation;Electron transport;FAD;Flavoprotein;Glycoprotein;Heme;Ion channel;Ion transport;Iron;Isopeptide bond;Membrane;Metal-binding;NADP;Oxidoreductase;Phosphoprotein;Polymorphism;Reference proteome;Transmembrane;Transmembrane helix;Transport;Ubl conjugation;Voltage-gated channel		SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein. Note=As unassembled monomer may localize to the endoplasmic reticulum. {ECO:0000305|PubMed:28351984}.		antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent [GO:0002479]; cell redox homeostasis [GO:0045454]; cellular response to cadmium ion [GO:0071276]; cellular response to ethanol [GO:0071361]; cellular response to L-glutamine [GO:1904845]; cellular response to oxidative stress [GO:0034599]; defense response [GO:0006952]; electron transport chain [GO:0022900]; hydrogen peroxide biosynthetic process [GO:0050665]; hypoxia-inducible factor-1alpha signaling pathway [GO:0097411]; inflammatory response [GO:0006954]; innate immune response [GO:0045087]; neutrophil degranulation [GO:0043312]; oxidation-reduction process [GO:0055114]; positive regulation of angiogenesis [GO:0045766]; positive regulation of tumor necrosis factor biosynthetic process [GO:0042535]; regulation of ion transmembrane transport [GO:0034765]; respiratory burst [GO:0045730]; response to aldosterone [GO:1904044]; response to angiotensin [GO:1990776]; superoxide anion generation [GO:0042554]; superoxide metabolic process [GO:0006801]; vascular endothelial growth factor receptor signaling pathway [GO:0048010]	dendrite [GO:0030425]; endoplasmic reticulum membrane [GO:0005789]; Golgi apparatus [GO:0005794]; integral component of plasma membrane [GO:0005887]; NADPH oxidase complex [GO:0043020]; neuronal cell body [GO:0043025]; nuclear envelope [GO:0005635]; perinuclear endoplasmic reticulum [GO:0097038]; phagocytic vesicle membrane [GO:0030670]; plasma membrane [GO:0005886]; rough endoplasmic reticulum [GO:0005791]; specific granule membrane [GO:0035579]; tertiary granule membrane [GO:0070821]	dendrite [GO:0030425]; endoplasmic reticulum membrane [GO:0005789]; Golgi apparatus [GO:0005794]; integral component of plasma membrane [GO:0005887]; NADPH oxidase complex [GO:0043020]; neuronal cell body [GO:0043025]; nuclear envelope [GO:0005635]; perinuclear endoplasmic reticulum [GO:0097038]; phagocytic vesicle membrane [GO:0030670]; plasma membrane [GO:0005886]; rough endoplasmic reticulum [GO:0005791]; specific granule membrane [GO:0035579]; tertiary granule membrane [GO:0070821]; flavin adenine dinucleotide binding [GO:0050660]; heme binding [GO:0020037]; metal ion binding [GO:0046872]; protein heterodimerization activity [GO:0046982]; superoxide-generating NADPH oxidase activity [GO:0016175]; voltage-gated ion channel activity [GO:0005244]; antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent [GO:0002479]; cell redox homeostasis [GO:0045454]; cellular response to cadmium ion [GO:0071276]; cellular response to ethanol [GO:0071361]; cellular response to L-glutamine [GO:1904845]; cellular response to oxidative stress [GO:0034599]; defense response [GO:0006952]; electron transport chain [GO:0022900]; hydrogen peroxide biosynthetic process [GO:0050665]; hypoxia-inducible factor-1alpha signaling pathway [GO:0097411]; inflammatory response [GO:0006954]; innate immune response [GO:0045087]; neutrophil degranulation [GO:0043312]; oxidation-reduction process [GO:0055114]; positive regulation of angiogenesis [GO:0045766]; positive regulation of tumor necrosis factor biosynthetic process [GO:0042535]; regulation of ion transmembrane transport [GO:0034765]; respiratory burst [GO:0045730]; response to aldosterone [GO:1904044]; response to angiotensin [GO:1990776]; superoxide anion generation [GO:0042554]; superoxide metabolic process [GO:0006801]; vascular endothelial growth factor receptor signaling pathway [GO:0048010]	flavin adenine dinucleotide binding [GO:0050660]; heme binding [GO:0020037]; metal ion binding [GO:0046872]; protein heterodimerization activity [GO:0046982]; superoxide-generating NADPH oxidase activity [GO:0016175]; voltage-gated ion channel activity [GO:0005244]	CYBB
NOX5	Q96PH1	NOX5_HUMAN	reviewed	NADPH oxidase 5 (EC 1.6.3.-)	NOX5	Homo sapiens (Human)	765	5 out of 5	Alternative sequence (4); Calcium binding (5); Chain (1); Compositional bias (1); Domain (6); Erroneous initiation (3); Mutagenesis (1); Natural variant (2); Region (2); Sequence conflict (10); Topological domain (8); Transmembrane (7)	Alternative splicing;Angiogenesis;Calcium;Complete proteome;Electron transport;Endoplasmic reticulum;FAD;Flavoprotein;Ion channel;Ion transport;Membrane;Metal-binding;NADP;Oxidoreductase;Polymorphism;Reference proteome;Repeat;Transmembrane;Transmembrane helix;Transport		SUBCELLULAR LOCATION: Membrane {ECO:0000305}; Multi-pass membrane protein {ECO:0000305}.; SUBCELLULAR LOCATION: Isoform v2: Endoplasmic reticulum.; SUBCELLULAR LOCATION: Isoform v5: Endoplasmic reticulum.		angiogenesis [GO:0001525]; apoptotic process [GO:0006915]; cell population proliferation [GO:0008283]; cellular response to oxidative stress [GO:0034599]; cytokine secretion [GO:0050663]; cytoskeleton-dependent cytokinesis [GO:0061640]; defense response [GO:0006952]; endothelial cell proliferation [GO:0001935]; oxidation-reduction process [GO:0055114]; positive regulation of reactive oxygen species metabolic process [GO:2000379]; regulation of fusion of sperm to egg plasma membrane [GO:0043012]; regulation of proton transport [GO:0010155]; superoxide anion generation [GO:0042554]	endoplasmic reticulum [GO:0005783]; endoplasmic reticulum membrane [GO:0005789]; NADPH oxidase complex [GO:0043020]; plasma membrane [GO:0005886]	endoplasmic reticulum [GO:0005783]; endoplasmic reticulum membrane [GO:0005789]; NADPH oxidase complex [GO:0043020]; plasma membrane [GO:0005886]; calcium ion binding [GO:0005509]; flavin adenine dinucleotide binding [GO:0050660]; heme binding [GO:0020037]; NADP binding [GO:0050661]; proton channel activity [GO:0015252]; superoxide-generating NADPH oxidase activity [GO:0016175]; angiogenesis [GO:0001525]; apoptotic process [GO:0006915]; cell population proliferation [GO:0008283]; cellular response to oxidative stress [GO:0034599]; cytokine secretion [GO:0050663]; cytoskeleton-dependent cytokinesis [GO:0061640]; defense response [GO:0006952]; endothelial cell proliferation [GO:0001935]; oxidation-reduction process [GO:0055114]; positive regulation of reactive oxygen species metabolic process [GO:2000379]; regulation of fusion of sperm to egg plasma membrane [GO:0043012]; regulation of proton transport [GO:0010155]; superoxide anion generation [GO:0042554]	calcium ion binding [GO:0005509]; flavin adenine dinucleotide binding [GO:0050660]; heme binding [GO:0020037]; NADP binding [GO:0050661]; proton channel activity [GO:0015252]; superoxide-generating NADPH oxidase activity [GO:0016175]	NOX5
SHMT1	P34896	GLYC_HUMAN	reviewed	Serine hydroxymethyltransferase, cytosolic (SHMT) (EC 2.1.2.1) (Glycine hydroxymethyltransferase) (Serine methylase)	SHMT1	Homo sapiens (Human)	483	5 out of 5	Alternative sequence (3); Beta strand (15); Chain (1); Helix (25); Modified residue (2); Natural variant (2); Turn (4)	3D-structure;Acetylation;Alternative splicing;Complete proteome;Cytoplasm;One-carbon metabolism;Polymorphism;Pyridoxal phosphate;Reference proteome;Transferase	MISCELLANEOUS: In eukaryotes there are two forms of the enzymes: a cytosolic one and a mitochondrial one. {ECO:0000305}.	SUBCELLULAR LOCATION: Cytoplasm.	SHMT family	carnitine biosynthetic process [GO:0045329]; cellular response to leukemia inhibitory factor [GO:1990830]; cellular response to tetrahydrofolate [GO:1904482]; dTMP biosynthetic process [GO:0006231]; folic acid metabolic process [GO:0046655]; glycine biosynthetic process from serine [GO:0019264]; glycine metabolic process [GO:0006544]; L-serine catabolic process [GO:0006565]; L-serine metabolic process [GO:0006563]; negative regulation of translation [GO:0017148]; one-carbon metabolic process [GO:0006730]; protein homotetramerization [GO:0051289]; protein tetramerization [GO:0051262]; purine nucleobase biosynthetic process [GO:0009113]; tetrahydrofolate interconversion [GO:0035999]; tetrahydrofolate metabolic process [GO:0046653]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]; nucleus [GO:0005634]	cytosol [GO:0005829]; extracellular exosome [GO:0070062]; nucleus [GO:0005634]; amino acid binding [GO:0016597]; cobalt ion binding [GO:0050897]; glycine hydroxymethyltransferase activity [GO:0004372]; identical protein binding [GO:0042802]; L-allo-threonine aldolase activity [GO:0008732]; mRNA 5'-UTR binding [GO:0048027]; protein homodimerization activity [GO:0042803]; pyridoxal phosphate binding [GO:0030170]; serine binding [GO:0070905]; translation repressor activity, mRNA regulatory element binding [GO:0000900]; zinc ion binding [GO:0008270]; carnitine biosynthetic process [GO:0045329]; cellular response to leukemia inhibitory factor [GO:1990830]; cellular response to tetrahydrofolate [GO:1904482]; dTMP biosynthetic process [GO:0006231]; folic acid metabolic process [GO:0046655]; glycine biosynthetic process from serine [GO:0019264]; glycine metabolic process [GO:0006544]; L-serine catabolic process [GO:0006565]; L-serine metabolic process [GO:0006563]; negative regulation of translation [GO:0017148]; one-carbon metabolic process [GO:0006730]; protein homotetramerization [GO:0051289]; protein tetramerization [GO:0051262]; purine nucleobase biosynthetic process [GO:0009113]; tetrahydrofolate interconversion [GO:0035999]; tetrahydrofolate metabolic process [GO:0046653]	amino acid binding [GO:0016597]; cobalt ion binding [GO:0050897]; glycine hydroxymethyltransferase activity [GO:0004372]; identical protein binding [GO:0042802]; L-allo-threonine aldolase activity [GO:0008732]; mRNA 5'-UTR binding [GO:0048027]; protein homodimerization activity [GO:0042803]; pyridoxal phosphate binding [GO:0030170]; serine binding [GO:0070905]; translation repressor activity, mRNA regulatory element binding [GO:0000900]; zinc ion binding [GO:0008270]	SHMT1
GLDC	P23378	GCSP_HUMAN	reviewed	Glycine dehydrogenase (decarboxylating), mitochondrial (EC 1.4.4.2) (Glycine cleavage system P protein) (Glycine decarboxylase) (Glycine dehydrogenase (aminomethyl-transferring))	GLDC GCSP	Homo sapiens (Human)	1020	5 out of 5	Chain (1); Modified residue (5); Natural variant (24); Sequence conflict (8); Transit peptide (1)	Acetylation;Complete proteome;Disease mutation;Mitochondrion;Oxidoreductase;Pyridoxal phosphate;Reference proteome;Transit peptide		SUBCELLULAR LOCATION: Mitochondrion {ECO:0000269|PubMed:28244183}.	GcvP family	cellular response to leukemia inhibitory factor [GO:1990830]; glycine catabolic process [GO:0006546]; glycine decarboxylation via glycine cleavage system [GO:0019464]; response to lipoic acid [GO:1903442]; response to methylamine [GO:0036255]	glycine cleavage complex [GO:0005960]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]; nucleus [GO:0005634]; plasma membrane [GO:0005886]	glycine cleavage complex [GO:0005960]; mitochondrial matrix [GO:0005759]; mitochondrion [GO:0005739]; nucleus [GO:0005634]; plasma membrane [GO:0005886]; electron transfer activity [GO:0009055]; enzyme binding [GO:0019899]; glycine binding [GO:0016594]; glycine dehydrogenase (decarboxylating) activity [GO:0004375]; lyase activity [GO:0016829]; protein homodimerization activity [GO:0042803]; pyridoxal binding [GO:0070280]; pyridoxal phosphate binding [GO:0030170]; cellular response to leukemia inhibitory factor [GO:1990830]; glycine catabolic process [GO:0006546]; glycine decarboxylation via glycine cleavage system [GO:0019464]; response to lipoic acid [GO:1903442]; response to methylamine [GO:0036255]	electron transfer activity [GO:0009055]; enzyme binding [GO:0019899]; glycine binding [GO:0016594]; glycine dehydrogenase (decarboxylating) activity [GO:0004375]; lyase activity [GO:0016829]; protein homodimerization activity [GO:0042803]; pyridoxal binding [GO:0070280]; pyridoxal phosphate binding [GO:0030170]	GLDC
SHMT2	P34897	GLYM_HUMAN	reviewed	Serine hydroxymethyltransferase, mitochondrial (SHMT) (EC 2.1.2.1) (Glycine hydroxymethyltransferase) (Serine methylase)	SHMT2	Homo sapiens (Human)	504	5 out of 5	Alternative sequence (2); Beta strand (16); Chain (1); Helix (23); Modified residue (11); Mutagenesis (10); Sequence conflict (1); Transit peptide (1); Turn (5)	3D-structure;Acetylation;Alternative splicing;Complete proteome;Cytoplasm;Membrane;Mitochondrion;Mitochondrion inner membrane;Mitochondrion nucleoid;Nucleus;One-carbon metabolism;Phosphoprotein;Pyridoxal phosphate;Reference proteome;Transferase;Transit peptide	MISCELLANEOUS: In eukaryotes there are two forms of the enzymes: a cytosolic one and a mitochondrial one.	SUBCELLULAR LOCATION: Mitochondrion {ECO:0000269|PubMed:21876188, ECO:0000269|PubMed:24075985}. Mitochondrion matrix, mitochondrion nucleoid {ECO:0000269|PubMed:18063578}. Mitochondrion inner membrane {ECO:0000269|PubMed:21876188}. Cytoplasm {ECO:0000269|PubMed:24075985}. Nucleus {ECO:0000269|PubMed:24075985}. Note=Mainly localizes in the mitochondrion. Also found in the cytoplasm and nucleus as part of the BRISC complex (PubMed:24075985). {ECO:0000269|PubMed:24075985}.	SHMT family	cellular response to tetrahydrofolate [GO:1904482]; folic acid metabolic process [GO:0046655]; glycine biosynthetic process from serine [GO:0019264]; glycine metabolic process [GO:0006544]; L-serine biosynthetic process [GO:0006564]; L-serine catabolic process [GO:0006565]; L-serine metabolic process [GO:0006563]; one-carbon metabolic process [GO:0006730]; positive regulation of cell population proliferation [GO:0008284]; protein homotetramerization [GO:0051289]; protein K63-linked deubiquitination [GO:0070536]; protein tetramerization [GO:0051262]; regulation of aerobic respiration [GO:1903715]; regulation of mitochondrial translation [GO:0070129]; regulation of oxidative phosphorylation [GO:0002082]; response to type I interferon [GO:0034340]; tetrahydrofolate interconversion [GO:0035999]; tetrahydrofolate metabolic process [GO:0046653]	BRISC complex [GO:0070552]; cytoplasm [GO:0005737]; extracellular exosome [GO:0070062]; microtubule cytoskeleton [GO:0015630]; mitochondrial inner membrane [GO:0005743]; mitochondrial intermembrane space [GO:0005758]; mitochondrial matrix [GO:0005759]; mitochondrial nucleoid [GO:0042645]; mitochondrion [GO:0005739]; nucleus [GO:0005634]	BRISC complex [GO:0070552]; cytoplasm [GO:0005737]; extracellular exosome [GO:0070062]; microtubule cytoskeleton [GO:0015630]; mitochondrial inner membrane [GO:0005743]; mitochondrial intermembrane space [GO:0005758]; mitochondrial matrix [GO:0005759]; mitochondrial nucleoid [GO:0042645]; mitochondrion [GO:0005739]; nucleus [GO:0005634]; amino acid binding [GO:0016597]; chromatin binding [GO:0003682]; cobalt ion binding [GO:0050897]; glycine hydroxymethyltransferase activity [GO:0004372]; identical protein binding [GO:0042802]; L-allo-threonine aldolase activity [GO:0008732]; pyridoxal phosphate binding [GO:0030170]; serine binding [GO:0070905]; zinc ion binding [GO:0008270]; cellular response to tetrahydrofolate [GO:1904482]; folic acid metabolic process [GO:0046655]; glycine biosynthetic process from serine [GO:0019264]; glycine metabolic process [GO:0006544]; L-serine biosynthetic process [GO:0006564]; L-serine catabolic process [GO:0006565]; L-serine metabolic process [GO:0006563]; one-carbon metabolic process [GO:0006730]; positive regulation of cell population proliferation [GO:0008284]; protein homotetramerization [GO:0051289]; protein K63-linked deubiquitination [GO:0070536]; protein tetramerization [GO:0051262]; regulation of aerobic respiration [GO:1903715]; regulation of mitochondrial translation [GO:0070129]; regulation of oxidative phosphorylation [GO:0002082]; response to type I interferon [GO:0034340]; tetrahydrofolate interconversion [GO:0035999]; tetrahydrofolate metabolic process [GO:0046653]	amino acid binding [GO:0016597]; chromatin binding [GO:0003682]; cobalt ion binding [GO:0050897]; glycine hydroxymethyltransferase activity [GO:0004372]; identical protein binding [GO:0042802]; L-allo-threonine aldolase activity [GO:0008732]; pyridoxal phosphate binding [GO:0030170]; serine binding [GO:0070905]; zinc ion binding [GO:0008270]	SHMT2
